0001193125-21-114283.txt : 20210413 0001193125-21-114283.hdr.sgml : 20210413 20210413120136 ACCESSION NUMBER: 0001193125-21-114283 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 121 CONFORMED PERIOD OF REPORT: 20210131 FILED AS OF DATE: 20210413 DATE AS OF CHANGE: 20210413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AstroNova, Inc. CENTRAL INDEX KEY: 0000008146 STANDARD INDUSTRIAL CLASSIFICATION: COMPUTER PERIPHERAL EQUIPMENT, NEC [3577] IRS NUMBER: 050318215 STATE OF INCORPORATION: RI FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-13200 FILM NUMBER: 21822467 BUSINESS ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 BUSINESS PHONE: 4018284000 MAIL ADDRESS: STREET 1: 600 E GREENWICH AVENUE CITY: WEST WARWICK STATE: RI ZIP: 02893 FORMER COMPANY: FORMER CONFORMED NAME: ASTRO MED INC /NEW/ DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: ATLAN TOL INDUSTRIES INC DATE OF NAME CHANGE: 19850220 10-K 1 d56468d10k.htm 10-K 10-K
Table of Contents
falseFY0000008146--01-31P1Yus-gaap:OperatingLeaseLiabilityCurrentus-gaap:OperatingLeaseLiabilityCurrent 0000008146 2020-02-01 2021-01-31 0000008146 2020-01-31 0000008146 2021-01-31 0000008146 2019-02-01 2020-01-31 0000008146 2018-02-01 2019-01-31 0000008146 2019-01-31 0000008146 2020-07-31 0000008146 2021-04-09 0000008146 2018-01-31 0000008146 us-gaap:CustomerContractsMember alot:MiltopeCorporationMember 2020-01-31 0000008146 us-gaap:CustomerContractsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2020-01-31 0000008146 us-gaap:NoncompeteAgreementsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2020-01-31 0000008146 alot:ExistingTechnologyMember alot:TrojanlabelApSMember 2020-01-31 0000008146 alot:DistributorRelationsMember alot:TrojanlabelApSMember 2020-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2020-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 alot:TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 alot:TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2020-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2020-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-01-31 0000008146 country:US 2020-01-31 0000008146 srt:EuropeMember 2020-01-31 0000008146 country:CA 2020-01-31 0000008146 alot:ProductIdentificationMember 2020-01-31 0000008146 alot:TestAndMeasurementMember 2020-01-31 0000008146 alot:CrossCurrencyInterestRateSwapMember alot:CashFlowHedgeMember 2020-01-31 0000008146 us-gaap:InterestRateSwapMember alot:CashFlowHedgeMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:DomesticCountryMember 2020-01-31 0000008146 us-gaap:CustomerContractsMember alot:MiltopeCorporationMember 2021-01-31 0000008146 us-gaap:CustomerContractsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2021-01-31 0000008146 us-gaap:NoncompeteAgreementsMember alot:RuggedInformationTechnologyEquipmentCorporationMember 2021-01-31 0000008146 alot:ExistingTechnologyMember alot:TrojanlabelApSMember 2021-01-31 0000008146 alot:DistributorRelationsMember alot:TrojanlabelApSMember 2021-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2021-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanMember 2021-01-31 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember 2021-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2021-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2021-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2021-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-01-31 0000008146 country:US 2021-01-31 0000008146 srt:EuropeMember 2021-01-31 0000008146 country:CA 2021-01-31 0000008146 alot:TwoThousandSevenEquityIncentivePlanMember 2021-01-31 0000008146 alot:TwoThousandFifteenEquityIncentivePlanMember 2021-01-31 0000008146 alot:TwoThousandFifteenEquityIncentivePlanMember us-gaap:RestrictedStockMember 2021-01-31 0000008146 alot:RangeThreeMember 2021-01-31 0000008146 alot:RangeFourMember 2021-01-31 0000008146 alot:RangeFiveMember 2021-01-31 0000008146 alot:TestAndMeasurementMember 2021-01-31 0000008146 alot:ProductIdentificationMember 2021-01-31 0000008146 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member 2021-01-31 0000008146 country:CN 2021-01-31 0000008146 stpr:DE 2021-01-31 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember us-gaap:RestrictedStockMember 2021-01-31 0000008146 us-gaap:EmployeeStockOptionMember 2021-01-31 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0000008146 srt:MaximumMember 2021-01-31 0000008146 srt:MinimumMember 2021-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2021-01-31 0000008146 alot:GreenWoodCreditUnionMember alot:PaycheckProtectionProgramLoanMember 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember 2021-01-31 0000008146 alot:TermLoanMember alot:BankOfAmericaMember 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember 2021-01-31 0000008146 country:US 2018-02-01 2019-01-31 0000008146 srt:EuropeMember 2018-02-01 2019-01-31 0000008146 country:CA 2018-02-01 2019-01-31 0000008146 srt:AsiaMember 2018-02-01 2019-01-31 0000008146 alot:CentralAndSouthAmericaMember 2018-02-01 2019-01-31 0000008146 alot:OthersCountriesMember 2018-02-01 2019-01-31 0000008146 alot:HardwareProductsMember 2018-02-01 2019-01-31 0000008146 alot:SuppliesMember 2018-02-01 2019-01-31 0000008146 alot:ServiceAndOtherMember 2018-02-01 2019-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2018-02-01 2019-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2018-02-01 2019-01-31 0000008146 alot:OtherCountriesMember 2018-02-01 2019-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2018-02-01 2019-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2018-02-01 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2018-02-01 2019-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2018-02-01 2019-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 2019-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-02-01 2019-01-31 0000008146 us-gaap:EmployeeStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:OperatingSegmentsMember 2018-02-01 2019-01-31 0000008146 us-gaap:TreasuryStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:CommonStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:RetainedEarningsMember 2018-02-01 2019-01-31 0000008146 country:US 2019-02-01 2020-01-31 0000008146 srt:EuropeMember 2019-02-01 2020-01-31 0000008146 country:CA 2019-02-01 2020-01-31 0000008146 srt:AsiaMember 2019-02-01 2020-01-31 0000008146 alot:CentralAndSouthAmericaMember 2019-02-01 2020-01-31 0000008146 alot:OthersCountriesMember 2019-02-01 2020-01-31 0000008146 alot:HardwareProductsMember 2019-02-01 2020-01-31 0000008146 alot:SuppliesMember 2019-02-01 2020-01-31 0000008146 alot:ServiceAndOtherMember 2019-02-01 2020-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2019-02-01 2020-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2019-02-01 2020-01-31 0000008146 alot:OtherCountriesMember 2019-02-01 2020-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2019-02-01 2020-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2019-02-01 2020-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2019-02-01 2020-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2019-02-01 2020-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-02-01 2020-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2020-01-31 0000008146 us-gaap:EmployeeStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember 2019-02-01 2020-01-31 0000008146 srt:MaximumMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-02-01 2020-01-31 0000008146 us-gaap:TreasuryStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:CommonStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:DomesticCountryMember 2019-02-01 2020-01-31 0000008146 us-gaap:RetainedEarningsMember 2019-02-01 2020-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2019-02-01 2020-01-31 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2020-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember alot:CashFlowHedgeMember 2019-02-01 2020-01-31 0000008146 alot:ProductIdenificationMember 2019-02-01 2020-01-31 0000008146 country:US 2020-02-01 2021-01-31 0000008146 srt:EuropeMember 2020-02-01 2021-01-31 0000008146 country:CA 2020-02-01 2021-01-31 0000008146 srt:AsiaMember 2020-02-01 2021-01-31 0000008146 alot:CentralAndSouthAmericaMember 2020-02-01 2021-01-31 0000008146 alot:OthersCountriesMember 2020-02-01 2021-01-31 0000008146 alot:HardwareProductsMember 2020-02-01 2021-01-31 0000008146 alot:SuppliesMember 2020-02-01 2021-01-31 0000008146 alot:ServiceAndOtherMember 2020-02-01 2021-01-31 0000008146 alot:RangeThreeMember 2020-02-01 2021-01-31 0000008146 alot:RangeFourMember 2020-02-01 2021-01-31 0000008146 alot:RangeFiveMember 2020-02-01 2021-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2020-02-01 2021-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2020-02-01 2021-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2020-02-01 2021-01-31 0000008146 alot:OtherCountriesMember 2020-02-01 2021-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-02-01 2021-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2020-02-01 2021-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2020-02-01 2021-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2020-02-01 2021-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-02-01 2021-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2021-01-31 0000008146 us-gaap:LandImprovementsMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 alot:BuildingAndLeaseholdImprovementsMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:LandImprovementsMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 alot:BuildingAndLeaseholdImprovementsMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 alot:ComputerEquipmentAndSoftwareMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 alot:ComputerEquipmentAndSoftwareMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember 2020-02-01 2021-01-31 0000008146 us-gaap:EmployeeStockMember 2020-02-01 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-02-01 2021-01-31 0000008146 us-gaap:CommonStockMember 2020-02-01 2021-01-31 0000008146 alot:AirborneProductMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 alot:AirborneProductMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:TreasuryStockMember 2020-02-01 2021-01-31 0000008146 us-gaap:RetainedEarningsMember 2020-02-01 2021-01-31 0000008146 us-gaap:EmployeeStockOptionMember 2020-02-01 2021-01-31 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2021-01-31 0000008146 alot:EmployeeStockPurchasePlanMember 2020-02-01 2021-01-31 0000008146 country:CN 2020-02-01 2021-01-31 0000008146 alot:RestrictedStockAwardMember 2020-02-01 2021-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2020-02-01 2021-01-31 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2021-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember alot:CashFlowHedgeMember 2020-02-01 2021-01-31 0000008146 us-gaap:CashFlowHedgingMember us-gaap:CrossCurrencyInterestRateContractMember 2020-02-01 2021-01-31 0000008146 alot:GreenWoodCreditUnionMember alot:PaycheckProtectionProgramLoanMember 2020-02-01 2021-01-31 0000008146 us-gaap:OtherExpenseMember alot:GreenWoodCreditUnionMember alot:PaycheckProtectionProgramLoanMember 2020-02-01 2021-01-31 0000008146 alot:BankOfAmericaMember 2020-02-01 2021-01-31 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember us-gaap:OtherExpenseMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 alot:TermLoanMember 2020-02-01 2021-01-31 0000008146 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:FederalFundsEffectiveSwapRateMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 alot:GreenwoodCreditUnionMember alot:PaycheckProtectionProgramLoanMember alot:PromissoryNoteMember 2020-02-01 2021-01-31 0000008146 alot:ProductIdenificationMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:InterestExpenseMember 2020-02-01 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:GreenWoodCreditUnionMember 2020-05-06 0000008146 us-gaap:CashFlowHedgingMember 2020-05-03 2020-08-01 0000008146 alot:TermLoanMember 2020-05-03 2020-08-01 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 0000008146 alot:ProductIdentificationMember us-gaap:OperatingSegmentsMember 2019-01-31 0000008146 alot:TestAndMeasurementMember us-gaap:OperatingSegmentsMember 2019-01-31 0000008146 alot:BankOfAmericaMember alot:ExistingCreditAgreementMember alot:TermLoanMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 alot:BankOfAmericaMember alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember 2021-03-24 2021-03-24 0000008146 us-gaap:SubsequentEventMember us-gaap:RevolvingCreditFacilityMember alot:FirstAmendmentToCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember srt:MinimumMember 2021-03-24 2021-03-24 0000008146 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:RevolvingCreditFacilityMember alot:FirstAmendmentToCreditAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 us-gaap:SubsequentEventMember us-gaap:RevolvingCreditFacilityMember alot:FirstAmendmentToCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 us-gaap:RevolvingCreditFacilityMember alot:FirstAmendmentToCreditAgreementMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 us-gaap:SubsequentEventMember alot:FirstAmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember srt:MinimumMember 2021-03-24 2021-03-24 0000008146 us-gaap:SubsequentEventMember alot:FirstAmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember srt:MaximumMember 2021-03-24 2021-03-24 0000008146 alot:BankOfAmericaMember alot:ExistingCreditAgreementMember alot:TermLoanMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 alot:BankOfAmericaMember alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 alot:BankOfAmericaMember us-gaap:RevolvingCreditFacilityMember alot:FirstAmendmentToCreditAgreementMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 alot:TermLoanMember srt:MinimumMember 2020-05-02 2020-07-31 0000008146 alot:TermLoanMember srt:MaximumMember 2020-05-02 2020-07-31 0000008146 alot:TermLoanMember 2020-08-02 2020-10-31 0000008146 alot:TermLoanMember srt:MinimumMember 2020-11-01 2021-01-31 0000008146 alot:TermLoanMember srt:MaximumMember 2020-11-01 2021-01-31 0000008146 alot:TermLoanMember srt:ScenarioForecastMember 2021-02-01 2021-04-30 0000008146 alot:TermLoanMember srt:ScenarioForecastMember 2022-02-01 2022-04-30 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2021-04-30 2021-04-30 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2021-07-31 2021-07-31 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2021-10-31 2021-10-31 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2022-01-31 2022-01-31 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2022-04-30 2022-04-30 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2022-07-31 2022-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2023-04-30 2023-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2021-04-24 2021-04-24 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2024-07-31 2024-07-31 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2024-10-31 2024-10-31 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2025-01-01 2025-01-01 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2023-07-31 2023-07-31 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2023-10-31 2023-10-31 0000008146 alot:TermLoanMember alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember 2024-01-01 2024-01-01 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2024-04-30 2024-04-30 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2025-04-30 2025-04-30 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2025-07-31 2025-07-31 0000008146 srt:ScenarioForecastMember alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2023-01-01 2023-01-01 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0000008146 us-gaap:TreasuryStockMember 2018-01-31 0000008146 us-gaap:RetainedEarningsMember 2018-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0000008146 us-gaap:CommonStockMember 2018-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-31 0000008146 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2018-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2018-01-31 0000008146 us-gaap:EmployeeStockMember 2018-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2019-01-31 0000008146 us-gaap:EmployeeStockMember 2019-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2019-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0000008146 us-gaap:RetainedEarningsMember 2019-01-31 0000008146 us-gaap:TreasuryStockMember 2019-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0000008146 us-gaap:CommonStockMember 2019-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2020-01-31 0000008146 us-gaap:EmployeeStockMember 2020-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2020-01-31 0000008146 us-gaap:CommonStockMember 2020-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0000008146 us-gaap:RetainedEarningsMember 2020-01-31 0000008146 us-gaap:TreasuryStockMember 2020-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-31 0000008146 alot:ProductIdenificationMember 2019-01-31 0000008146 alot:TMMember 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2021-01-31 0000008146 us-gaap:EmployeeStockMember 2021-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2021-01-31 0000008146 us-gaap:CommonStockMember 2021-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0000008146 us-gaap:RetainedEarningsMember 2021-01-31 0000008146 us-gaap:TreasuryStockMember 2021-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-31 0000008146 alot:ProductIdenificationMember 2020-01-31 0000008146 alot:TMMember 2020-01-31 0000008146 alot:ProductIdenificationMember 2021-01-31 0000008146 alot:TMMember 2021-01-31 iso4217:USD xbrli:shares xbrli:pure utr:Year iso4217:USD xbrli:shares alot:Segment
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-K
 
 
 
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended January 31, 2021
OR
 
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
    
    
    
to
    
    
    
    
Commission file number
0-13200
 
 
AstroNova, Inc.
(Exact name of registrant as specified in its charter)
 
Rhode Island
 
05-0318215
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer Identification No.)
   
600 East Greenwich Avenue,
West Warwick, Rhode Island
 
02893
(Address of principal executive offices)
 
(Zip Code)
Registrant’s telephone number, including area code:
(401828-4000
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading Symbol
 
Name of each exchange
on which registered
Common Stock, $.05 Par Value
 
ALOT
 
NASDAQ Global Market
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☐    No  ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer    ☐   Accelerated filer    ☐   
Non-accelerated filer    ☒
  Smaller reporting company
 
  
            
Emerging growth company
   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. 
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Act).  ☐  Yes      No
The aggregate market value of the registrant’s voting common equity held by
non-affiliates
at July 31, 2020 was approximately $47,045,000 based on the closing price on the Nasdaq Global Market on that date.
As of April 
9
, 2021, there were 7,212,977 shares of Common Stock (par value $0.05 per share) of the registrant outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Company’s definitive Proxy Statement for the 2021 Annual Meeting of Shareholders are incorporated by reference into Part III of this Annual Report on Form
10-K
where indicated.
 
 
 

ASTRONOVA, INC.
FORM
10-K
ANNUAL REPORT
TABLE OF CONTENTS
 
           
Page
PART I        
Item 1.        
3-7
Item 1A.        
8-20
Item 1B.         20
Item 2.         20-21
Item 3.         21
Item 4.         21
PART II        
Item 5.         22
Item 6.         23
Item 7.        
23-38
Item 7A.         38
Item 8.         39
Item 9.         39
Item 9A.         39
Item 9B.         39
PART III        
Item 10.         40
Item 11.         41
Item 12.         41
Item 13.         41
Item 14.         41
PART IV        
Item 15.         42
Item 16.         42
 
2

ASTRONOVA, INC.
Forward-Looking Statements
Information included in this Annual Report on Form
10-K
may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact, but rather reflect our current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “continues,” “may,” “will,” and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in this Annual Report on Form
10-K
under “Item 1A. Risk Factors.” We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The reader is cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this Annual Report on Form
10-K.
PART I
Item 1
. Business
General
Unless otherwise indicated, references to “AstroNova,” the “Company,” “we,” “our,” and “us” in this Annual Report on Form
10-K
refer to AstroNova, Inc. and its consolidated subsidiaries.
We design, develop, manufacture and distribute a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate advanced technologies to acquire, store, analyze, and present data in multiple formats. Target markets for our hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation.
Our products are distributed around the world through our own sales force, authorized dealers, and through independent dealers and representatives.
Our business consists of two segments, Product Identification (“PI”) and Test & Measurement (“T&M”). The PI segment includes specialty printing systems and related supplies sold under the QuickLabel
®
, TrojanLabel
®
and GetLabels
brand names. The T&M segment includes our line of aerospace printers and test and measurement data acquisition systems sold under the AstroNova
®
brand name. Refer to Note 17, “Nature of Operations, Segment Reporting and Geographical Information,” in our audited consolidated financial statements elsewhere in this report for financial information regarding our segments.
The following description of our business should be read in conjunction with “Management’s Discussion and Analysis of Financial Conditions and Results of Operations” on pages 23 through 28 of this Annual Report on Form
10-K.
Description of Business
Product Overview
We leverage our expertise in data visualization technologies to design, manufacture and market specialty printing systems, test and measurement systems, and related services for select growing markets on a global basis.
Product Identification products sold under the QuickLabel, TrojanLabel and GetLabels brands are used in brand owner and commercial applications to provide product packaging, marketing, tracking, branding and
 
3

labeling solutions to a wide array of industries. The PI segment offers a variety of digital color label tabletop printers, high-volume presses and specialty OEM printing systems, as well as a wide range of label, tag and flexible packaging material substrates and other supplies, including ink and toner, allowing customers to mark, track, protect and enhance the appearance of their products. In the T&M segment, we have a long history of using our technologies to provide networking systems and high-resolution light-weight flight deck and cabin printers for the aerospace market. In addition, the T&M segment includes data acquisition recorders, sold under the AstroNova brand, to enable our customers to acquire and record visual and electronic signal data from local and networked data streams and sensors. The recorded data is processed, analyzed and stored and presented in various visual output formats.
Product Identification
Our PI segment includes three brands: QuickLabel, TrojanLabel, and GetLabels. The segment provides a wide array of digital
end-to-end
product marking and identification solutions including hardware, software, and supplies for OEMs, commercial printers, and brand owners. Our customers typically label or mark products on a short to
mid-size
run basis and benefit from the efficiency, flexibility and cost-savings of digitally printing labels or packaging in their facility,
on-demand,
with the ability to accommodate multiple SKUs or variable data such as bar codes, lot numbers or expiration dates. QuickLabel brand products include tabletop printers, production-ready digital color label printers and specialty OEM printing systems for either standalone output or inline integration with existing
pre-processing
and finishing systems. Customers use our digital printing products in a wide variety of industries, including chemical, cosmetics, food and beverage, medical products, nutraceutical, pharmaceutical, and many others. TrojanLabel expands our customer market by providing a range of higher volume digital color printers, OEM printing systems and supplies that target the more demanding needs of brand owners, commercial printers, label converters, and packaging manufacturers, giving them the ability to digitally mark or encode products directly or to produce labels for post-printing applications. GetLabels brand products include a full line of media supplies, including label materials, tags, inks, toners and thermal transfer ribbons designed for optimal performance with our printing hardware, while also being compatible with a wide variety of competitive and third-party printing hardware.
Current QuickLabel models include a selection of professional tabletop digital color label printers. The high-speed
QL-120X
was built on our pioneering and successful Kiaro! platform. Introduced early in 2019, the high-performance
QL-300
was the first
5-color
toner-based electrophotographic tabletop production label printer in the market. In addition, our QuickLabel line of printers includes the
QL-850,
our next-generation wide-format inkjet color label printer, the
QL-30
and
QL-60
series, a family of
high-end
monochrome printers, and the
QLS-4100
XE, a unique solution with the ability to digitally print full-color labels and tags using thermal transfer ribbon technology.
Our TrojanLabel portfolio includes a range of products from professional digital color label mini-presses to large-scale
all-in-one
inline specialty printing systems for both brand owners, OEMs and commercial printers. The
T2-C,
a compact, digital mini-press designed for 24/7 label production, includes numerous differentiating features for several
end-use
market applications. The
T2-L
is a narrow format digital press designed specifically for flexible packaging substrates. Beyond label printing, the
T3-OPX,
introduced in late 2019, allows printing directly onto a range of flat products, including cardboard, paper bags, flat wood planks and many other items using pigment inks that are water-resistant and highly resistant to UV exposure. A professional label press and finishing system, the T4, enables print,
die-cut,
and lamination in an
all-in-one
machine with a much smaller footprint than others in the market.
GetLabels provides a broad range of high-quality supplies for both our printers and third-party printers including label and tag materials, inks, toner and thermal transfer material, all specifically designed and constructed for a wide variety of labeling applications. Label material and substrates are carefully qualified and tested in our Rhode Island Materials Research Laboratory to ensure durability and compatibility with our QuickLabel and TrojanLabel branded products, along with a variety of third-party printers.
 
4

The PI segment also develops and licenses various specialized software programs to design and manage labels, print images, manage and operate our printers and presses, and coordinate printing on an automated basis directly over networked systems. PI also provides worldwide training and support.
T&M
Products sold under our T&M segment are designed and manufactured for airborne printing solutions and data acquisition. Our aerospace products include flight deck printing solutions, networking hardware and specialized aerospace grade thermal paper. Our data acquisition systems are used in research and development, flight testing, missile/rocket telemetry production monitoring, power and maintenance applications. These products are sold to customers in a variety of industries, including aerospace & defense, automotive, commercial airline, energy, manufacturing and transportation, to meet their need to acquire and record data from local and networked data streams and sensors.
Airborne printers include our flagship ToughWriter
®
series used in the flight decks and cabins of military, commercial and business aircraft to print hard copies of data required for the safe and efficient operation of aircraft. Examples of printed data include navigation maps, arrival and departure information, flight itineraries, weather maps, performance data, passenger data, and air traffic control data. ToughSwitch
®
Ethernet switches are used primarily in military aircraft and military vehicles to connect multiple computers or Ethernet devices. The airborne printers and Ethernet switches are ruggedized to comply with rigorous military and commercial flight worthiness standards for operation under extreme environmental conditions. We are currently furnishing ToughWriter airborne printers for many aircraft made by Airbus, Boeing, Bombardier, Lockheed, Gulfstream and others. In addition to the ToughWriter products, we manufacture other flight deck printers, including the TP/NP series, the RTP80 series and the
PTA-45B
series of airborne printers. The
PTA-45B
is subject to the Asset Purchase and License Agreement with Honeywell International, Inc. (the “Honeywell Agreement”), pursuant to which in 2017 we acquired an exclusive perpetual world-wide license to manufacture and support Honeywell’s narrow-format flight deck printers for the Boeing 737 and Airbus 320 aircraft. Over time we expect customers will replace the
PTA-45B
printers with ToughWriter products because they have numerous technical features and functional advantages and significant weight savings.
Other T&M products include the TMX
®
all-in-one
high-speed data acquisition system for applications requiring high channel counts and acquisition rates; the Daxus
®
 DXS-100
distributed data acquisition platform; the SmartCorder
®
DDX-100,
a portable
all-in-one
data acquisition system for facility maintenance and field testing; and the Everest
®
EV-5000
digital strip chart recording system used mainly in telemetry applications. The Daxus
DXS-100
can be connected to the SmartCorder to increase channel count or networked as part of a distributed measurement system spanning vast distances.
Technology
Our core technologies are data visualization technologies that relate to (1) acquiring data, (2) conditioning the data, (3) displaying or printing the data on hard copy, monitor or electronic storage media and (4) analyzing the data. To service data visualization, we maintain technological core competencies and trade
know-how
concerning the subject matter peculiar to each business unit. The technological disciplines are diverse and include electronic, software, mechanical and industrial engineering aspects. Additionally, we possess engineering expertise in digital signal processing, image processing, fluidics, color theory, high-speed material handling and airworthiness design.
Patents and Copyrights
We hold several product patents in the United States and in foreign countries. We rely on a combination of copyright, patent, trademark and trade secret laws in the United States and other jurisdictions to protect our technology and brand names. We consider our intellectual property to be critical to the operation of our business. In particular, we believe that the loss of the trademarks QuickLabel, TrojanLabel, ToughWriter or ToughSwitch
 
5

or the loss of the license provided under the Honeywell Agreement could have a material adverse impact on our business taken as a whole.
Manufacturing and Supplies
We manufacture many of the products that we design and sell. Raw materials and supplies are typically available from a wide variety of sources. We manufacture many
sub-assemblies
and parts
in-house,
including certain specialty printed circuit board assemblies and harnesses, and we have extensive electronic and mechanical final assembly and test operations. Many parts not manufactured
in-house
are standard electronic items available from multiple sources. Other printers and parts are designed or modified by us and manufactured by outside vendors according to our specifications. We purchase certain components, assembled products and supplies used to manufacture our products from a single source or limited supplier sources. Although we believe the majority of these sole or limited source components, assembled products and supplies could be sourced elsewhere with appropriate changes in the design of our products, such design might not be feasible on a timely basis, and any interruption in these components, products or supplies could adversely affect our business. When circumstances cause us to anticipate that we may not be able to acquire such components, products or supplies on a timely basis, our practice is to procure a sufficient quantity in advance. In the past we have made such advance purchases primarily for aerospace products and in quantities that we anticipate will suffice for the life of the aircraft program for which those printers are designed.
Marketing and Competition
We compete worldwide in multiple markets. Through our expanding network of manufacturing, sales and support facilities, we now do business in over 150 countries.
We believe we are a market leader in tabletop digital color label printing technology in the specialty printing field, a market leader in flight deck printers, and an innovator in digital color mini-press systems. In the data acquisition area, we are one of the leaders in general-purpose portable, high-speed data acquisition systems.
Management believes that we have a market leadership position in many of the markets we serve. We retain our leadership position by virtue of our proprietary technology, product reputation, delivery, our channels to market, technical assistance and service to customers. The number of competitors varies by product line. Key competitive factors vary among our product lines, but include technology, quality, service and support, distribution network and breadth of product and service offerings.
Our Product Identification products are sold by direct field salespersons as well as independent dealers and representatives, while our Test & Measurement products are sold predominantly through direct sales and manufacturers’ representatives. In the United States, we have factory-trained direct field salespeople located throughout the country specializing in Product Identification products. We also have direct field sales or service centers in Canada, China, Denmark, France, Germany, Malaysia, Mexico, Singapore, and the United Kingdom staffed by our own employees and dedicated third party contractors. Additionally, we utilize over 200 independent dealers and representatives selling and marketing our products in over 60 countries.
No single customer accounted for 10% or more of our net revenue in any of the last three fiscal years.
Order Backlog
Our backlog varies regularly. It consists of a blend of orders for
end-user
customers, as well as original equipment manufacturer customers. Manufacturing production is designed to meet forecasted demands and
built-to-order
customer requirements. Accordingly, the amount of order backlog may not indicate future sales trends. Backlog at January 31, 2021 and 2020 was $22.5 million and $25.2 million, respectively.
Employees
As of January 31, 2021, we employed 327 people full-time employees. Of our full-time employees, 230 were in the United States, 78 in Europe, 10 in Canada, seven in Asia and two in Mexico.
 
6

None of our employees are represented by a labor union or covered by a collective bargaining agreement; except for our employees in France, where collective bargaining agreements are generally required by local regulations.
Successful execution of our business strategy depends on our ability to retain several key employees in both individual contributor and management roles. We continuously assess the risk of losing our key employees through regular communications, engagement surveys and assessments in the labor market. Our retention strategy is focused on ensuring competitive compensation packages, career and professional development, leadership coaching and other actions to improve overall engagement with our key employees.
Culture
We have ingrained a strong and definable company culture that shapes the way we operate and engage with stakeholders and employees. Our culture consists of four key components:
 
   
A powerful set of core values, including: Customer First, One Global Team, Innovation, Continuous Improvement and Building Shareholder Value.
 
   
The AstroNova Operating System (AOS), the comprehensive business management process which helps us manage the business to achieve continuous improvements in quality, delivery, cost, and growth.
 
   
A commitment to operating with integrity and compliance to ensure business is conducted in an honest, legal, and environmentally responsible manner.
 
   
A passionate commitment to quality that drives our goal to achieve zero defects and understand the changing needs and expectations of our customers.
Our core values guide our employees’ behavior and dictate the way our business is conducted. These core values are reinforced during new hire orientation, ongoing engagement surveys, leadership development, and team development activities, and are also demonstrated through teamwork, leadership, and everyday interactions.
Diversity and Inclusion
We believe that our culture and core values are strengthened through diversity and inclusion. Our diversity initiatives include—but are not limited to—our practices and policies on recruitment and selection; compensation and benefits; professional development and training; promotions; transfers; social and recreational programs; layoffs; terminations; and the ongoing development of a work environment built on the premise of gender and diversity equity. These initiatives include periodic evaluation of our workforce demographics as compared to the demographics in the workforce market, and an affirmative effort to attract, recruit, retain and train a diverse workforce that is representative of the populations in the regions in which we do business.
Other Information
Our business is not seasonal in nature. However, our revenue is impacted by the size of certain individual transactions, which can cause fluctuations in revenue from quarter to quarter.
Available Information
We make available on our website (www.astronovainc.com) our Annual Report on Form
10-K,
Quarterly Reports on Form
10-Q,
Current Reports on Form
8-K
and, if applicable, amendments to those reports filed or furnished pursuant to Sections 13(a) or 15(d) of the Securities Exchange Act of 1934 as soon as reasonably practicable after we electronically file such material with, or furnishes it to, the Securities and Exchange Commission (SEC). These filings are also accessible on the SEC’s website at http://www.sec.gov.
 
7

Item 1A.
Risk Factors
The following risk factors should be carefully considered in evaluating AstroNova, because such factors may have a significant impact on our business, operating results, liquidity and financial condition. As a result of the risk factors set forth below, actual results could differ materially from those projected in any forward-looking statements. Additional risks and uncertainties not presently known to us, or that we currently consider to be immaterial, may also impact our business operations.
Business and Industry Risks
The ongoing
COVID-19
pandemic has adversely affected and will likely continue to adversely affect our revenues, results of operations and financial condition.
Our business has been and will likely continue to be materially adversely affected by the global
COVID-19
pandemic. We operate in several regions of the world, with the largest concentration of team members in North America and Europe, and a small presence in Asia. We, and many other businesses and other organizations with which we do business directly or which otherwise impact us, have taken and are continuing to take steps to avoid or reduce infection, including limiting business travel and staying home from work when recommended by the public health authorities. These measures have disrupted and continue to disrupt our normal business operations both inside and outside of affected areas and have had significant negative impacts on our business, the businesses of our suppliers and customers, and on businesses and financial markets worldwide. Until vaccine availability and inoculation rates reach the point where public health authorities determine that the quarantines, travel restrictions, business closures, cancellations of public gatherings and other measures that national, state and local governments have implemented as a result of the pandemic are no longer necessary, we expect our business to be negatively impacted.
In response to the
COVID-19
pandemic, we have established new procedures to monitor government recommendations and regulations and made good faith efforts to comply with those regulations and the best practices recommendations issued by a variety of governmental health authorities and manufacturing industry organizations to which we belong. In addition, we have made significant modifications to our normal operations because of the
COVID-19
pandemic, including requiring most
non-production
related team members to work remotely, at least part-time. At this time, we expect that these measures will continue to remain in place for the near term, and we do not know when or if it will become practical to relax or eliminate these measures altogether. Since the start of the pandemic, we have maintained most of manufacturing operational capacity at our facilities located in West Warwick, Rhode Island, as well as our manufacturing facilities in Canada and Germany. However, there were periods when a number of team members were unable to keep work schedules due to the effects of the pandemic, which resulted in reduced production capacity that led to longer order fulfillment lead times and as a result, reduced revenues. The extent to which the COVID-19 pandemic continues to negatively impact our manufacturing production will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and any associated variants, the efficacy and timing of distribution of vaccines, and the actions to
contain COVID-19 or
treat its impact, among others. We also do not yet know to what extent our operations will be impacted permanently by remote work, increased safety protocols and the other adaptations undertaken during the pandemic.
During the
COVID-19
pandemic, we have experienced some difficulties in obtaining raw materials and components for our products. We have been able to recover from these difficulties, but we have had to incur some additional costs in expedited and express shipping fees. These difficulties have impacted our efficiency and our ability to satisfy customer requirements, but we do not believe that they have materially impacted our financial results or our relationships with our customers. We are currently monitoring the world-wide delays in transit time, as freight carriers are now experiencing significant delays in overseas shipments. We are addressing these issues through long range planning and supplementing inventories as needed. We are also monitoring the extended lead times on active electronic components and utilizing several strategies, including blanket orders,
 
8

vendor-bonded inventories, and extended commitments to our supply base. Additionally, we have taken actions to maintain regular contact with our important vendors and have increased our forecasting horizon for our products to help us better manage our supply chain. Our strategies to counteract the impact of the pandemic have tended to increase the amount of inventory we maintain, but because of the complexity of our supply chain and update our mitigation strategies as we determine to be appropriate. We will continue to monitor our supply chain a priority going forward. We are not able to predict what the full impact of the current supply chain difficulties, as it depends on how the course of the
COVID-19
pandemic continues and its impacts on the economy evolve.
The aerospace industry, which we serve through our aerospace product line, has also been significantly disrupted by the
COVID-19
pandemic, both inside and outside of the United States. The decline in air travel has had and will continue to have a material adverse impact on our financial results, the ultimate scope of which we cannot estimate at this time. Should one or more of our airplane OEM manufacturing customers or a significant number of airline customers fail to continue business as a going concern, declare bankruptcy, or otherwise permanently reduce the demand for our products as a result of the impact of the
COVID-19
pandemic, it would have a material adverse impact on our business operations and financial results.
While it is not possible at this time to estimate the full scope of the impact that
COVID-19
will have on our business, customers, suppliers or other business partners, in the long run we expect that the lasting presence of
COVID-19,
will continue to adversely impact our operational capacity and the efficiency of our team members and will continue to negatively affect our results of operations and financial condition for the near term.
Our operating results and financial condition could be harmed if the markets into which we sell our products decline or do not grow as anticipated.
Any decline in our customers’ markets or in their general economic conditions would likely result in a reduction in demand for our products. For example, the 2020 grounding, suspension and subsequent slow restart of production of the Boeing 737 MAX has reduced demand for our airborne printers that are installed on that aircraft, as well as the related repairs and supplies, which has negatively affected our results of operations. In addition, the current worldwide
COVID-19
pandemic has negatively impacted the airline industry as a whole, which could result in a reduction in orders by the airlines for new planes and reduce demand for retrofitting airplanes already in service and, therefore, a further reduction in demand for our airborne printer products. The effect of the
COVID-19
pandemic and any future action relating to the 737 MAX on our business is currently unknown, but we expect any resulting reductions in production schedules will likely have an adverse effect on our business, which could be material. Some of our customers may be reluctant to make capital equipment purchases or may defer certain of these purchases to future quarters. Some of our customers may also limit consumable product purchases to quantities necessary to satisfy immediate needs with no provisions to stock supplies for future use. Also, if our customers’ markets decline enough to impact their financial capacity, we may not be able to collect on outstanding amounts due to us. Such declines could harm our results of operations, financial position and cash flows and could limit our ability to continue to remain profitable.
Our future revenue growth depends on our ability to develop and introduce new products and services on a timely basis and achieve market acceptance of these new products and services.
The markets for our products are characterized by evolving technologies which in turn effect our product introduction cycles. Our future success depends largely upon our ability to address the rapidly changing needs of our customers by developing and supplying high-quality, cost-effective products, product enhancements and services on a timely basis and by keeping pace with technological developments and emerging industry standards. The success of our new products will also depend on our ability to differentiate our offerings from our competitors’ offerings, price our products competitively, anticipate our competitors’ development of new products, and maintain high levels of product quality and reliability. We spend a significant amount of time and effort on the development of our airborne and color printer products as well as our acquisition and data recorder products. Failure to meet our customers’ changing business needs or to further develop any of our new products and their related markets as anticipated could adversely affect our future revenue growth and operating results.
 
9

As we introduce new or enhanced products, we must also successfully manage the transition from older products to minimize disruption in customers’ ordering patterns, avoid excessive levels of older product inventories and provide sufficient supplies of new products to meet customer demands. The introduction of new or enhanced products may shorten the life cycle of our existing products, or replace sales of some of our current products, thereby offsetting the benefit of even a successful product introduction and may cause customers to defer purchasing existing products in anticipation of the new products. Additionally, when we introduce new or enhanced products, we face numerous risks relating to product transitions, including the inability to accurately forecast demand, manage excess and obsolete inventories, address new or higher product cost structures, and manage different sales and support requirements due to the type or complexity of the new products. Any customer uncertainty regarding the timeline for rolling out new products or our plans for future support of existing products may cause customers to delay purchase decisions or purchase competing products which would adversely affect our business and operating results.
Operational and Business Strategy Risks:
We are dependent upon contract manufacturers for some of our products. If these manufacturers do not meet our requirements, either in volume or quality, then we could be materially harmed.
We subcontract the manufacturing and assembly of certain of our products to independent third parties at facilities located in various countries. Relying on subcontractors involves a number of significant risks, including:
 
   
Disruptions in the global supply chain as a result of the
COVID-19
pandemic;
 
   
Limited control over the manufacturing process;
 
   
Potential absence of adequate production capacity;
 
   
Potential delays in production lead times;
 
   
Unavailability of certain process technologies; and
 
   
Reduced control over delivery schedules, manufacturing yields, quality and costs.
If one of our significant subcontractors becomes unable or unwilling to continue to manufacture or provide these products in required volumes or fails to meet our quality standards, we will have to identify qualified alternate subcontractors or take over the manufacturing ourselves. Additional qualified subcontractors may not be available or may not be available on a timely or cost competitive basis. Any interruption in the supply, increase in the cost of the products manufactured by a third party subcontractor or failure of a subcontractor to meet quality standards could have a material adverse effect on our business, operating results and financial condition.
For certain components, assembled products and supplies, we are dependent upon single or limited source suppliers. If these suppliers do not meet demand, either in volume or quality, then we could be materially harmed.
Although we use standard parts and components for our products where possible, we purchase certain components, assembled products and supplies used in the manufacture of our products from a single source or limited supplier sources. If the supply of a key component, assembled products or certain supplies were to be delayed or curtailed or, in the event a key manufacturing or sole supplier delays shipment of such components or assembled products, our ability to ship products in desired quantities and in a timely manner would be adversely affected. For example, due to the continued global
COVID-19
pandemic, there has been and likely will continue to be disruption to our supply chain due to the delays of component shipments from our vendors in China and other jurisdictions in which normal business operations are disrupted. Our business, results of operations and financial position could also be adversely affected, depending on the time required to obtain sufficient quantities from the original source or, if possible, to identify and obtain sufficient quantities from an alternative source. Additionally, if any single or limited source supplier becomes unable or unwilling to continue to supply these
 
10

components, assembled products or supplies in required volumes, we will have to identify and qualify acceptable replacements or redesign our products with different components. Alternative sources may not be available, or product redesign may not be feasible on a timely basis. Any interruption in the supply of or increase in the cost of the components, assembled products and supplies provided by single or limited source suppliers could have a material adverse effect on our business, operating results and financial condition.
We face significant competition, and our failure to compete successfully could adversely affect our results of operations and financial condition.
We operate in an environment of significant competition, especially in the markets in which we sell our PI printers and T&M data acquisition products. This competition is driven by rapid technological advances, evolving industry standards, frequent new product introductions and the demands of customers to become more efficient. Our competitors range from large international companies to relatively small firms. We compete based on technology, performance, price, quality, reliability, brand, distribution and customer service and support. Our success in future performance is largely dependent upon our ability to compete successfully in the markets we currently serve and to expand into additional market segments. Additionally, current competitors or new market entrants may develop new products or services with features that could adversely affect the competitive position of our products. To remain competitive, we must develop new products, services and applications and periodically enhance our existing offerings. If we are unable to compete successfully, our customers could seek alternative solutions from our competitors and we could lose market share, which could materially and adversely affect our business, results of operations and financial position.
Our profitability is dependent upon our ability to obtain adequate pricing for our products and to control our cost structure
.
Our success depends on our ability to obtain adequate pricing for our products and services which provides a reasonable return to our shareholders. Depending on competitive market factors, future prices we obtain for our products and services may decline from previous levels. In addition, pricing actions to offset the effect of currency devaluations may not prove sufficient to offset further devaluations or may not hold in the face of customer resistance and/or competition. If we are unable to obtain adequate pricing for our products and services, our results of operations and financial position could be materially adversely affected.
We are continually reviewing our operations with a view towards reducing our cost structure, including but not limited to reducing our labor
cost-to-revenue
ratio, improving process and system efficiencies and outsourcing certain internal functions. From time to time, we also engage in restructuring actions to reduce our cost structure. If we are unable to maintain process and systems changes resulting from cost reduction and prior restructuring actions, our results of operations and financial position could be materially adversely affected.
Our inability to adequately enforce and protect our intellectual property, defend against assertions of infringement or lose certain licenses could prevent or restrict our ability to compete.
We rely on patents, trademarks, licenses, and proprietary knowledge and technology, both internally developed and acquired, in order to maintain a competitive advantage. Our competitors may develop technologies that are similar or superior to our proprietary technologies or design technologies around the intellectual property protections or licenses that we currently own. The loss of the trademarks QuickLabel, TrojanLabel, ToughWriter and ToughSwitch or the loss of the licenses provided under the Honeywell Agreement could have a material adverse impact on our business taken as a whole. Operating outside the United States also exposes us to additional intellectual property risk. The laws and enforcement practices of certain jurisdictions in which we operate do not protect our intellectual property rights to the same extent as in the United States. Any diminution in our ability to defend against the unauthorized use of these rights and assets could have an adverse effect on our results of operations and financial condition. Litigation may be necessary to protect our intellectual property rights or defend against claims of infringement, which could result in significant costs and divert our management’s focus away from operations.
 
11

We have significant inventories on hand.
We maintain a significant amount of inventory. Although we have provided an allowance for slow-moving and obsolete inventory, any significant unanticipated changes in future product demand or market conditions, including obsolescence or the uncertainty in the global market, as well as continued reduced demand for our products if the
COVID-19
pandemic is further prolonged, could have an impact on the value of inventory and adversely affect our business, operating results and financial condition.
We could incur liabilities as a result of installed product failures due to design or manufacturing defects.
We have incurred and could incur additional liabilities as a result of installed product failures due to design or manufacturing defects. Our products may have defects despite our internal testing or testing by customers. These defects could result in among other things, a delay in recognition of sales, loss of sales, loss of market share, failure to achieve market acceptance or substantial damage to our reputation. We could be subject to material claims by customers and may incur substantial expenses to correct any product defects.
In addition, through our acquisitions, we have assumed, and may in the future assume, liabilities related to products previously developed by an acquired company that have not been subjected to the same level of product development, testing and quality control processes we employ, and may have unknown or undetected defects. Some types of defects may not be detected until the product is installed in a user environment. This may cause us to incur significant warranty, repair or
re-engineering
costs. As such, it could also divert the attention of engineering personnel from product development efforts which may result in increased costs and lower profitability.
We could experience a significant disruption in or security breach of our information technology system which could harm our business and adversely affect our results of operations.
We employ information technology systems to support our business. Any security breaches or other disruptions to our information technology infrastructure could interfere with operations, compromise our information and that of our customers and suppliers, and expose us to liability which could adversely impact our business and reputation. In the ordinary course of business, we rely on information technology networks and systems, some of which are managed by third parties, to process, transmit and store electronic proprietary or confidential information regarding our customers, employees, suppliers and others including personally identifiable information, credit card data, and other confidential information. While we continually work to safeguard our systems and mitigate potential risks, there is no assurance that such actions will be sufficient to prevent cyber-attacks or security breaches. As a result, our information technology networks and infrastructure may still be vulnerable to damage, disruptions or shutdowns due to attack by hackers or breaches, employee error, power outages, computer viruses, telecommunication or utility failures, systems failures, natural disasters, catastrophic events or other unforeseen events and in any such circumstance our system redundancy and other disaster recovery planning may be ineffective or inadequate. While we have experienced, and expect to continue to experience, these types of threats to our information technology networks and infrastructure, none of them to date has had a material impact. Any such events could result in legal claims or proceedings, liability or penalties under privacy laws, disruption in operations, and damage to our brand and reputation, which could adversely affect our business, operating results and financial condition.
We could experience disruptions related to the implementation of our new global enterprise resource planning system.
We are currently engaged in a multi-year process of conforming all our operations to one global enterprise resource planning (“ERP”) system. The ERP system is designed to improve the efficiency of our supply chain and financial transaction processes, improve the efficiency of how we accurately maintain our books and records and enhance the speed and quality of information provided to our management team for use in the operation and management of our business. The implementation of the ERP system will continue to require significant
 
12

investment of human and financial resources. As a result of the
COVID-19
pandemic, we have and will continue to experience delays and increased costs as a result of factors such as limited
on-site
availability of Company personnel and outside consultants due to travel restrictions and remote work conditions. The significant disruption in the implementation and transition to the new ERP system as a result of the
COVID-19
pandemic could delay or otherwise negatively impact our ability to obtain the benefits that the new ERP system is intended to provide. Additionally, while we have taken steps to ensure that we prevent adverse developments, any significant disruption or deficiency in the design, implementation and transition to the new ERP system could negatively impact our ability to:
 
   
record and process orders,
 
   
manufacture and ship our products in a timely manner, and
 
   
process data and electronic communications among our business locations,
any of which could have a material adverse effect on our business, consolidated financial condition or results of operations.
We also face the challenge of supporting our older systems while we implement the new ERP system. Although we have invested significant resources in planning and project management, significant unforeseen implementation issues may arise that could impact our normal business operations and have a material adverse impact on our operating results and cash flow.
We depend on our key employees and other highly qualified personnel and our ability to attract and develop new, talented professionals. Our inability to attract and retain key employees, as well as challenges with respect to the management of human capital resources could compromise our future success and our business could be harmed.
Our future success depends upon our ability to attract and retain, through competitive compensation and benefits programs, professional and executive employees, including sales, operating, marketing, and financial management personnel as well as our ability to manage human capital resources. There is substantial competition for skilled personnel, and the failure to attract, develop, retain and motivate qualified personnel could negatively impact our business, financial condition, results of operations and prospects. In order to hire new personnel or retain or replace our key personnel, we must maintain competitive compensation and benefits and we may also be required to increase compensation, which would decrease net income. Additionally, several key employees have special knowledge of customers, supplier relationships, business processes, manufacturing operations, and financial management issues. The loss of any of these employees as the result of competitive compensation pressures or ineffective management of human capital resources could harm our ability to perform efficiently and effectively until their knowledge and skills are replaced, which might be difficult to do quickly, and as a result could have a material adverse effect on our business, financial condition, and results of operations.
We may record future impairment charges, which could materially adversely impact our results of operations.
We test our goodwill balances annually, or more frequently if indicators are present or changes in circumstances suggest that impairment may exist. We assess goodwill for impairment at the reporting unit level and, in evaluating the potential for impairment of goodwill, we make assumptions regarding estimated revenue projections, growth rates, cash flows and discount rates. We monitor the key drivers of fair value to detect events or other changes that would warrant an interim impairment test of our goodwill and intangible assets. Declines in the future performance and cash flows of a reporting unit or asset group, changes in our reporting units or in the structure of our business as a result of future reorganizations, acquisitions or divestitures of assets or businesses, or changes in other key assumptions, may result in the recognition of significant asset impairment charges, which could have a material adverse impact on our results of operations.
We also review our long-lived assets including property, plant and equipment, and other intangibles assets for impairment when events or changes in circumstances indicate the carrying value may not be recoverable.
 
13

Factors we consider include significant under-performance relative to expected historical or projected future operating results, significant negative industry or economic trends and our market capitalization relative to net book value. We may be required in the future to record a significant charge to earnings in our financial statements during the period in which any impairment of our long-lived assets is determined. Such charges could have a significant adverse impact on our results of operations and our financial condition.
Financial and Economic Risks:
Economic, political and other risks associated with international sales and operations could adversely affect our results of operations and financial position.
Because we sell our products worldwide, our business is subject to risks associated with doing business internationally. Revenue from international operations, which includes both direct and indirect sales to customers outside the U.S., accounted for approximately 40% of our total revenue for fiscal year 2021, and we anticipate that international sales will continue to account for a significant portion of our revenue. In addition, we have employees, suppliers, contractors and facilities located outside the U.S. Accordingly, our business, operating results and financial condition could be harmed by a variety of factors, including:
 
   
Interruption to transportation flows for delivery of parts to us and finished goods to our customers;
 
   
Customer and vendor financial stability;
 
   
Fluctuations in foreign currency exchange rates;
 
   
Changes in a specific country’s or region’s environment including political, economic, monetary, regulatory or other conditions;
 
   
Trade protection measures and import or export licensing requirements;
 
   
Negative consequences from changes in tax laws;
 
   
Difficulty in managing and overseeing operations that are distant and remote from corporate headquarters;
 
   
Difficulty in obtaining and maintaining adequate staffing;
 
   
Differing labor regulations;
 
   
Differing protection of intellectual property;
 
   
Unexpected changes in regulatory requirements;
 
   
Uncertainty surrounding the implementation and effects of the United Kingdom’s withdrawal from the EU, commonly known as “Brexit”; and
 
   
Geopolitical turmoil, including terrorism, war and public health disruptions, such as that caused by the current
COVID-19
pandemic.
Changes in our tax rates or exposure to additional income tax liabilities or assessments could affect our profitability. In addition, audits by tax authorities could result in additional tax payments for prior periods
.
As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is based on the tax rates in effect where we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each jurisdiction. Our effective tax rate may vary as a result of numerous factors, including changes in the mix of our profitability from jurisdiction to jurisdiction, the results of examinations and audits of our tax filings, whether we secure or sustain acceptable arrangements with tax authorities, adjustments to the value of our uncertain tax positions, changes in accounting for income taxes and changes in tax laws, including the 2017 U.S. Tax Cuts and Jobs Act (the “Tax Act”). Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations.
 
14

The Tax Act significantly revised the U.S. federal corporate income tax law and included a broad range of tax reform measures affecting business including among other things, the reduction of the corporate income tax rate from 35% to 21%, the loss of certain business deductions, the acceleration of first-year expensing of certain capital expenditures and a
one-time
tax imposed on unremitted cumulative
non-U.S.
earnings of foreign subsidiaries. The Tax Act is complex and
far-reaching,
and we continue to evaluate the actual impact of its enactment on the Company. Any material adverse impact resulting from the Tax Act that has not yet been identified could have an adverse effect on our business, results of operations, financial condition and cash flow.
Further changes in the tax laws of foreign jurisdictions could arise as a result of the base erosion and profit shifting (BEPS) project undertaken by the Organisation for Economic
Co-operation
and Development (OECD), which represents a coalition of member countries. On October 5, 2015, the OECD issued a series of reports recommending changes to numerous long-standing tax principles. Many of these recommendations or similar concepts are being adopted by various countries in which we do business and may increase our taxes in these countries. Changes to these and other areas in relation to international tax reform, including future actions taken by foreign governments in response to the Tax Act, could increase uncertainty and may adversely affect our tax rate and cash flow in future years.
Changes to tax laws and regulations or changes to the interpretation thereof (including regulations and interpretations pertaining to the Tax Act), the ambiguity of tax laws and regulations, the subjectivity of factual interpretations, uncertainties regarding the geographic mix of earnings in any particular period, and other factors, could have a material impact on our estimates of our effective tax rate and our deferred tax assets and liabilities. The impact of these factors may be substantially different
from period-to-period.
In addition, the amount of income taxes we pay is subject to ongoing audits by U.S. federal, state and local tax authorities. If audits result in payments or assessments different from our reserves, our future results may include unfavorable adjustments to our tax liabilities and our financial statements could be adversely affected. Any further significant changes to the tax system in the United States or in other jurisdictions
(including changes in the taxation of international income as further described below) could adversely affect our financial statements.
We may have exposure to additional tax liabilities, which could negatively impact our income tax expense, net income and cash flow.
We are subject to income and other taxes in both the U.S. and the foreign jurisdictions in which we operate. The determination of our worldwide provision for income taxes and current and deferred tax assets and liabilities requires significant judgment and estimation. In the ordinary course of our business, there are many transactions and calculations where the ultimate tax determination is uncertain. We are subject to regular review and audit by both domestic and foreign tax authorities and to the prospective and retrospective effects of changing tax regulations and legislation. Although we believe our tax estimates are reasonable, the ultimate tax outcome may materially differ from the amounts recorded in our consolidated financial statements and may materially affect our income tax benefit or expense, net loss or income, and cash flows in the period in which such determination is made.
Deferred tax assets are recognized for the expected future tax consequences of temporary differences between the carrying amount for financial reporting purposes and the tax bases of assets and liabilities, and for net operating losses and tax credit carry forwards. In some cases, we may record a valuation allowance to reduce our deferred tax assets to estimated realizable value. We review our deferred tax assets and valuation allowance requirements quarterly. If we are unable to demonstrate that it is more likely than not that we will not be able to generate sufficient future taxable income to realize the net carrying value of deferred tax assets, we will record a valuation allowance to reduce the deferred tax assets to estimated realizable value, which could result in a material income tax charge. As part of our review, we consider positive and negative evidence, including cumulative results of recent years.
 
15

If we are unable to successfully comply with our credit agreement with Bank of America or secure alternative financing, our business and financial condition could be materially adversely affected.
Our credit agreement with Bank of America requires us, among other things, to satisfy certain financial ratios on an ongoing basis, consisting of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. We are also required to comply with other covenants and conditions, set forth in the credit agreement, including, among others, limitations on our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the credit agreement. If we were to violate the terms of the credit agreement and we were unable to renegotiate its terms at that time or secure alternative financing, it could have a material adverse impact on us.
The agreements governing our indebtedness subject us to various restrictions that limit our ability to pursue business opportunities.
The credit agreement governing our credit facility with Bank of America, N.A., as amended, contains, and any future debt agreements may include, several restrictive covenants that impose significant operating and financial restrictions on us and our subsidiaries. Such restrictive covenants may significantly limit our ability to:
 
   
Incur future indebtedness;
 
   
Place liens on assets;
 
   
Pay dividends or distributions on our and our subsidiaries’ capital stock;
 
   
Repurchase or acquire our capital stock;
 
   
Conduct mergers or acquisitions;
 
   
Sell assets; and/or
 
   
Alter our or our subsidiaries’ capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness.
In addition, the agreement governing our credit facility permits us to elect to pay interest on our term loan and revolving line of credit based on LIBOR or an alternative rate as specified in the agreement. In July 2017, the Financial Conduct Authority, the authority that regulates LIBOR, announced that it intends to stop compelling banks to submit rates for the calculation of LIBOR after 2021. The Alternative Reference Rates Committee has proposed the Secured Overnight Financing Rate (“SOFR”) as the preferred alternative to U.S. Dollar LIBOR
(“USD-LIBOR”).
Additionally, it is uncertain if applicable tenors of LIBOR will cease to exist after calendar year 2021, or whether additional reforms to LIBOR may be enacted, or whether alternative reference rates will gain market acceptance as a replacement for LIBOR. At this time, it is not possible to predict whether SOFR will attain market traction as a LIBOR replacement. Our credit facility provides for the transition to a SOFR-based alternative benchmark at such time that LIBOR rates are no longer available. We will continue to monitor the situation and address the potential reference rate changes in future debt obligations that we may incur. Accordingly, the potential effect of the
phase-out
or replacement of LIBOR on our cost of capital cannot yet be determined. Further, the use of an alternative base rate or a benchmark replacement rate as a basis for calculating interest with respect to any outstanding variable rate indebtedness could lead to an increase in the interest we pay and a corresponding increase in our costs of capital.
We may not realize the anticipated benefits of past or future acquisitions, divestitures and strategic partnerships, and integration of acquired companies or divestiture of businesses may negatively impact our overall business.
We have made strategic investments in other companies, products and technologies. We will continue to identify and pursue acquisitions of complementary companies and strategic assets, such as customer bases,
 
16

products and technology. However, there can be no assurance that we will be able to identify suitable acquisition opportunities. In any acquisition that we complete we cannot be certain that:
 
   
We will successfully integrate the operations of the acquired business with our own;
 
   
All the benefits expected from such integration will be realized;
 
   
Management’s attention will not be diverted or divided, to the detriment of current operations;
 
   
Amortization of acquired intangible assets or possible impairment of acquired intangibles will not have a negative impact on operating results or other aspects of our business;
 
   
Delays or unexpected costs related to the acquisition will not have a detrimental impact on our business, operating results and financial condition;
 
   
Customer dissatisfaction with, or performance problems at, an acquired company will not have an adverse impact on our reputation; and
 
   
Respective operations, management and personnel will be compatible.
In certain instances, as permitted by applicable law and NASDAQ rules, acquisitions may be consummated without seeking and obtaining shareholder approval, in which case shareholders will not have an opportunity to consider and vote upon the merits of such an acquisition. Although we will endeavor to evaluate the risks inherent in an acquisition, there can be no assurance that we will properly ascertain or assess such risks.
We may also divest certain businesses from time to time. Divestitures will likely involve risks, such as difficulty splitting up businesses, distracting employees, potential loss of revenue and negatively impacting margins, and potentially disrupting customer relationships. A successful divestiture depends on various factors, including our ability to:
 
   
Effectively transfer assets, liabilities, contracts, facilities and employees to the purchaser;
 
   
Identify and separate the intellectual property to be divested from the intellectual property that we wish to keep; and
 
   
Reduce fixed costs previously associated with the divested assets or business.
All of these efforts require varying levels of management resources, which may divert our attention from other business operations. Further, if market conditions or other factors lead us to change our strategic direction, we may not realize the expected value from such transactions.
If we are not able to successfully integrate or divest businesses, products, technologies or personnel that we acquire or divest, or able to realize expected benefits of our acquisitions, divestitures or strategic partnerships, our business, results of operations and financial condition could be adversely affected.
Adverse conditions in the global banking industry and credit markets could impair our liquidity or interrupt our access to capital markets, borrowings or financial transactions to hedge certain risks.
At the end of fiscal 2021, we had approximately $11.4 million of cash and cash equivalents. Our cash and cash equivalents are held in a mix of money market funds, bank demand deposit accounts and foreign bank accounts. Disruptions in the financial markets such as those caused by the current
COVID-19
pandemic may, in some cases, result in an inability to access assets such as money market funds that traditionally have been viewed as highly liquid. Any failure of our counterparty financial institutions or funds in which we have invested may adversely impact our cash and cash equivalent positions and, in turn, our financial position.
To date, we have been able to access financing that has allowed us to make investments in growth opportunities and fund working capital requirements as needed. In addition, we occasionally enter into financial transactions to hedge certain foreign exchange and interest rate risks. Our continued access to capital markets, the stability of our lenders and their willingness to support our needs, and the stability of the counter-parties to our
 
17

financial transactions that hedge risks are essential for us to meet our current and long-term obligations, fund operations, and fund our future strategic initiatives. An interruption in our access to external financing or financial transactions to hedge risk could materially and adversely affect our business and financial condition.
Inadequate self-insurance accruals or insurance coverage for employee health care benefits could have an adverse effect on our business, financial results or financial condition.
In the U.S., we maintain an employee health insurance coverage plan on a self-insured basis backed by stop-loss coverage which sets a limit on our liability for both individual and aggregate claim costs. We record expenses based on actual claims incurred and estimates of the costs of expected claims, administrative costs, and stop-loss insurance premiums.
We record a liability for our estimated cost of U.S. claims incurred and unpaid as of each balance sheet date. Our estimated liability is recorded on an undiscounted basis and is based on historical trends. Our history of claims activity is closely monitored, and liabilities are adjusted as warranted based on changing circumstances. It is possible, however, that our actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of claims that result in costs or liabilities in excess of our projections, which could cause us to record additional expenses, which could adversely impact our business, financial condition, results of operations and cash flow. We believe that the liabilities we have recorded to date will be sufficient to provide for losses we may incur due to increased
COVID-19
related employee health care insurance costs. However, the ultimate amount of these costs cannot be estimated at this time, and a prolonged period of spread of the disease could further increase our costs and liabilities, the impact of which may be material.
Legal and Regulatory Risks:
Certain of our products require certifications by customers, regulators or standards organizations, and our failure to obtain or maintain such certifications could negatively impact our business.
In certain industries and for certain products, such as those used in aircraft, we must obtain certifications for our products by customers, regulators or standards organizations. If we fail to obtain required certifications for our products, or if we fail to maintain such certifications on our products after they have been certified, our business, financial condition, results of operations and cash flows could be materially and adversely affected.
We are subject to laws and regulations; failure to address or comply with these laws and regulations could harm our business and adversely affect our results of operations.
Our operations are subject to laws, rules, regulations, including environmental regulations, government policies and other requirements in each of the jurisdictions in which we conduct business. Changes in laws, rules, regulations, policies or requirements could result in the need to modify our products and could affect the demand for our products, which may have an adverse impact on our future operating results. In addition, we must comply with regulations restricting our ability to include lead and certain other substances in our products. If we do not comply with applicable laws, rules and regulations we could be subject to costs and liabilities and our business may be adversely impacted.
Certain of our operations and products are subject to environmental, health and safety laws and regulations, which may result in substantial compliance costs or otherwise adversely affect our business.
Our operations are subject to numerous federal, state, local and foreign laws and regulations relating to protection of the environment, including those that impose limitations on the discharge of pollutants into the air and water, establish standards for the use, treatment, storage and disposal of solid and hazardous materials and wastes, and govern the cleanup of contaminated sites. We have used and continue to use various substances in our products and manufacturing operations, and have generated and continue to generate wastes, which have been or may be deemed to be hazardous or dangerous. As such, our business is subject to and may be materially
 
18

and adversely affected by compliance obligations and other liabilities under environmental, health and safety laws and regulations. These laws and regulations affect ongoing operations and require capital costs and operating expenditures in order to achieve and maintain compliance.
As the result of the
COVID-19
pandemic crisis, we have been required by U.S. federal and state governmental authorities and governmental authorities in
non-U.S.
jurisdictions, as well as our own desire to adhere to best health and safety practices, to implement a number of policies and procedures that have increased our costs and added complexity and inefficiency to our manufacturing operations and all administrative and office-based functions.
Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, and any determination that we or any of our subsidiaries has violated the Foreign Corrupt Practices Act could have a material adverse effect on our business.
The U.S. Foreign Corrupt Practices Act (FCPA), the UK Bribery Act and similar worldwide anti-corruption laws generally prohibit companies and their intermediaries from making improper payments to government officials and others for the purpose of obtaining or retaining business. Our internal policies mandate compliance with these anti-corruption laws. We operate in parts of the world that have experienced governmental corruption to some degree, and in certain circumstances, strict compliance with anti-corruption laws may conflict with local customs and practices. Despite our training and compliance programs, there can be no assurance that our internal control policies and procedures will protect us from reckless or criminal acts committed by those of our employees or agents who violate our policies.
Unauthorized access to personal data could give rise to liabilities as a result of governmental regulation, conflicting legal requirements or differing views of personal privacy rights and compliance with laws designed to prevent unauthorized access of personal data could be costly.
We collect and store certain data, including proprietary business information, and may have access to confidential or personal information that is subject to privacy and security laws, regulations and customer-imposed controls. Security breaches or other unauthorized access to, or the use or transmission of, personal user information could result in a variety of claims against us, including privacy-related claims. There are numerous federal, state, local, and international laws and regulations regarding privacy and the storage, sharing, use, processing, disclosure and protection of this kind of information, the scope of which are changing, inconsistent and conflicting and subject to differing interpretations.
We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions. For example, in 2016 the European Commission adopted the General Data Protection Regulation (GDPR), a comprehensive privacy and data protection reform that became effective in May 2018. The GDPR, which is applicable to all companies processing data of European Union residents, imposes significant fines and sanctions for violations. Similarly, the California Consumer Privacy Act of 2018, which was enacted in June 2018 and came into effect on January 1, 2020, provides a new private right of action for data breaches and requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices and allow consumers to opt out of certain data sharing with third parties.
Additionally, other jurisdictions have enacted or are enacting data localization laws that require data generated in or relating to the residents of those jurisdictions to be physically stored within those jurisdictions. In many cases, these laws and regulations apply not only to transfers between unrelated third parties but also to transfers between us and our subsidiaries. All of these evolving compliance and operational requirements impose significant costs that are likely to increase over time.
While we continue to assess these requirements and the ways they may impact the conduct of our business, we believe that we materially comply with applicable laws and industry codes of conduct relating to privacy and
 
19

data protection. There is no assurance that we will not be subject to claims that we have violated applicable laws or codes of conduct, that we will be able to successfully defend against such claims or that we will not be subject to significant fines and penalties in the event we are found not to be in compliance with such laws or codes of conduct.
Any failure or perceived failure by us (or any third parties with whom we have contracted to store such information) to comply with applicable privacy and security laws, policies or related contractual obligations or any compromise of security that results in unauthorized access to personal information may result in governmental enforcement actions, significant fines, litigation, claims of breach of contract and indemnity by third parties and adverse publicity. In the case of such an event, our reputation may be harmed, we could lose current and potential users and the competitive positions of our various brands could be diminished, any or all of which could adversely affect our business, financial condition and results of operations.
Changes in accounting standards and subjective assumptions, estimates, and judgments by management related to complex accounting matters could significantly affect our financial results or financial condition.
Generally accepted accounting principles and related accounting pronouncements, implementation guidelines, and interpretations with regard to a wide range of matters that are relevant to our business, such as revenue recognition, asset impairment and fair value determinations, inventories, business combinations and intangible asset valuations, leases, and litigation, are highly complex and involve many subjective assumptions, estimates and judgments. Changes in these rules or their interpretation or changes in underlying assumptions, estimates, or judgments could significantly change our reported or expected financial performance or financial condition.
Item 1B. Unresolved Staff Comments
None.
Item 2.
Properties
The following table sets forth information regarding our principal owned property. This property is subject to a security agreement and a mortgage in favor of the lender under our credit facility.
 
Location
 
Approximate
Square
Footage
   
Principal Use
West Warwick, Rhode Island, United States
    135,500     Corporate headquarters, research and development, manufacturing, sales and service
We also lease facilities in various other locations. The following information pertains to each location:
 
Location
 
Approximate
Square
Footage
   
Principal Use
Dietzenbach, Germany
    18,630     Manufacturing, sales and service
Copenhagen, Denmark
    4,800     R&D, sales and service
Brossard, Quebec, Canada
    4,500     Manufacturing, sales and service
Elancourt, France
    4,150     Sales and service
Schaumburg, Illinois, United States
    3,428     Sales)
Irvine, California, United States
    3,100     Sales
Shah Alam, Selangor, Malaysia
    2,067     Sales
Maidenhead, England
    1,021     Sales and service
Shanghai, China
    461     Sales
Mexico City, Mexico
    97     Sales
 
20

We believe our facilities are well maintained, in good operating condition and generally adequate to meet our needs for the foreseeable future.
Item 3.
Legal Proceedings
We are not a party to any pending, material legal proceedings. However, because of the nature of our business, we may be subject in the future to lawsuits or other claims, including those pertaining to product liability, patent infringement, commercial, employment, employee benefits, environmental and stockholder matters
.
Item 4.
Mine Safety Disclosures
Not applicable.
 
21

PART II
 
Item 5.
Market for the Registrant’s Common Stock, Related Stockholder Matters and Issuer Purchases of Equity Securities
Our common stock trades on the NASDAQ Global Market under the symbol “ALOT.”
We had approximately 270 shareholders of record as of April 9, 2021, which does not reflect shareholders with beneficial ownership in shares held in nominee name.
Stock Repurchases
During the fourth quarter of fiscal 2021, we made the following repurchases of our common stock:
 
    
Total Number
of Shares
Repurchased
   
Average
Price paid
Per Share ($)
   
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans
or Programs
    
Maximum Number
of Shares That
May Be Purchased
Under the Plans
or Programs
 
November 1 – November 30
                 —                     —                                 —                            —    
December 1 – December 31
                 —                     —                                 —                            —    
January 1 – January 31
     1,870 (a)      10.53 (a)                              —                            —    
(a) An executive of the company delivered 1,870 shares of our common stock toward the satisfaction of taxes due in connection with the vesting of restricted shares. The shares delivered were valued at a market value of $10.53 per share and are included with treasury stock in the consolidated balance sheet.
 
22

Item 6.
Selected Financial Data
Historical Financial Summary
Income Statement Data
 
(In thousands, except per share data)
  
For the Fiscal Years Ended January 31,
 
    
2021
    
2020
    
2019
    
2018
    
2017
 
Revenue
   $ 116,033      $ 133,446      $ 136,657      $ 113,401      $ 98,448  
Gross Profit
     41,360        48,758        53,999        44,002        39,489  
Operating Income
     2,433        2,433        8,720        5,412        6,281  
Income before Taxes
     2,179        1,370        7,308        5,157        6,605  
Net Income
   $ 1,284      $ 1,759      $ 5,730      $ 3,286      $ 4,228  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net Income per Common Share—Basic
   $ 0.18      $ 0.25      $ 0.83      $ 0.48      $ 0.57  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Net income per Common Share—Diluted
   $ 0.18      $ 0.24      $ 0.81      $ 0.47      $ 0.56  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Dividends Declared per Common Share
   $ 0.07      $ 0.28      $ 0.28      $ 0.28      $ 0.28  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Balance Sheet Data
 
(In thousands)
  
As of January 31,
 
    
2021
    
2020
    
2019
    
2018
    
2017
 
Cash and Marketable Securities
   $ 11,439      $ 4,249      $ 7,534      $ 11,688      $ 24,821  
Current Assets
     60,721        60,151        62,608        62,948        61,423  
Total Assets
     115,473        116,664        118,983        122,313        83,665  
Revolving Credit Facility
     —          6,500        1,500        —          —    
Current Liabilities
     20,968        26,767        24,665        25,912        11,985  
Debt, including short term portion
     12,576        13,034        18,242        23,372      —    
Shareholders’ Equity
   $ 74,683      $ 71,375      $ 69,775      $ 63,647      $ 70,537  
Item 7.
Management
s Discussion and Analysis of Financial Condition and Results of Operations
Overview
We are a multi-national enterprise that leverages its proprietary data visualization technologies to design, develop, manufacture, distribute and service a broad range of products that acquire, store, analyze and present data in multiple formats. We organize our structure around a core set of competencies, including research and development, manufacturing, service, marketing and distribution. We market and sell our products and services through the following two segments:
 
   
Product Identification (“PI”) – offers color and monochromatic digital label printers, over-printers and custom OEM printers. PI also provides software to design, manage and print labeling and packaging images locally and across networked printing systems, as well as all related printing supplies such as pressure sensitive labels, tags, inks, toners and thermal transfer ribbons used by digital printers. PI also provides
on-site
and remote service, spare parts and various service contracts.
 
   
Test and Measurement (“T&M”) – offers a suite of products and services that acquire data from local and networked data streams and sensors as well as wired and wireless networks. The T&M segment includes a line of aerospace printers used to print hard copies of data required for the safe and efficient operation of aircraft, including navigation maps, clearances, arrival and departure procedures, flight itineraries, weather maps, performance data, passenger data, and various air traffic control data. Aerospace products also include aircraft networking systems for high-speed onboard data transfer. T&M also provides repairs, service and spare parts.
 
23

We market and sell our products and services globally through a diverse distribution structure of direct sales personnel, manufacturers’ representatives and authorized dealers that deliver a full complement of branded products and services to customers in our respective markets. Our growth strategy centers on organic growth through product innovation made possible by research and development initiatives, as well as strategic acquisitions that fit into or complement existing core businesses. In fiscal 2021, 2020 and 2019, revenue from customers in various geographic areas outside the United States, primarily in Western Europe, Canada and Asia, amounted to $45.1 million, $49.8 million and $53.0 million, respectively.
We maintain an active program of product research and development. During fiscal 2021, 2020 and 2019, we spent $6.2 million, $8.1 million and $7.8 million, respectively, on Company-sponsored product development. We are committed to continuous product development as essential to our organic growth and expect to continue our focus on research and development efforts in fiscal 2021 and beyond.
We also continue to invest in sales and marketing initiatives by expanding the existing sales force and using various marketing campaigns to achieve our goals of sales growth and increased profitability notwithstanding the challenging economic environment.
In fiscal 2018, we entered into an Asset Purchase and License Agreement (“Honeywell Agreement”) with Honeywell International, Inc. (“Honeywell”) pursuant to which, we acquired the exclusive perpetual world-wide license to manufacture Honeywell’s narrow format flight deck printers for the Boeing 737 and Airbus 320 aircraft.
COVID-19
Update—Overview
Our business has been materially adversely affected by the global
COVID-19
pandemic, and will likely continue to be negatively impacted until the vaccine availability and inoculation rates reach the point where public health authorities conclude that the quarantines, travel restrictions, business closures, cancellations of public gatherings and other similar measures are no longer necessary. We operate in several regions of the world, with the largest concentration of team members in North America and Europe, and a small presence in Asia. Due to the
COVID-19
pandemic, we and many other businesses and organizations with which we do business directly or which otherwise impact us have taken and are continuing to take steps to avoid or reduce infection, including limiting business travel and working from home as advised by the public health authorities. These measures have been and continue to be disrupting normal business operations both inside and outside of affected areas and have had significant negative impacts on our business, the businesses of our suppliers and customers, and on businesses and financial markets worldwide.
Since the
COVID-19
pandemic began to impact us in early March 2020, we have closely monitored the government and health authority recommendations applicable to us and have made modifications to our operations based on that guidance and on our growing experience and knowledge of the situation. We responded by reducing our staffing levels and reducing other costs.
In response to the pandemic, we have established new procedures to monitor government recommendations and regulations and made good faith efforts to comply with both those regulations and the best practices recommendations issued by a variety of governmental health authorities and manufacturing industry organizations to which we belong. In addition, we have made significant modifications to our normal operations, including requiring most
non-production
related team members to work remotely, for at least part-time. At this time, we expect that these measures will continue to remain in place for the near term, and we do not know when or if it will become practical to relax or eliminate them altogether. Since the start of the pandemic, we have maintained most of manufacturing operational capacity at our facilities located in West Warwick, Rhode Island, as well as our manufacturing facilities in Canada and Germany. However, there have been periods when a number of team members were unable to keep work schedules due to the effect of the COVID
-19
pandemic, resulting in reduced production capacity and longer order fulfillment lead times and as a result, reduced revenues. The extent to which COVID-19 impacts our manufacturing production in the future will depend on future
 
24

COVID-19
developments, which are uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19 and any associated variants, the efficacy and distribution of vaccines, and the actions to
contain COVID-19 or
treat its impact, among others. We also do not yet know to what extent our operations will be impacted permanently by remote work, increased safety protocols and the other temporary adaptations undertaken during the pandemic.
During the
COVID-19
pandemic, we have experienced some difficulties in obtaining raw materials and components for our products. We have been able to recover from these difficulties, but we have had to incur some additional costs in expedited and express shipping fees. These difficulties have impacted our efficiency and our ability to satisfy customer requirements, but we have been able to keep these impacts to a minimum. We are currently monitoring the world-wide delays in transit time, as freight carriers are now experiencing significant delays in overseas shipments. We are addressing these issues through long range planning and supplementing inventories as needed. We are also monitoring the extended lead times on active electronic components and utilizing several strategies, including blanket orders, vendor bonded inventories, and extended commitments to our supply base. Additionally, we have taken actions to maintain regular contact with our important vendors and have increased our forecasting horizon for our products to help us better manage our supply chain. Our strategies to counteract the impact of the pandemic have tended to increase the amount of inventory we have had to maintain, but because of the complexity of our supply chain it is impossible to isolate the exact impact. We will continue to monitor our supply chain.
While it is not possible at this time to estimate the full scope of the impact that
COVID-19
will have on our business, customers, suppliers or other business partners in the long run, we expect that the lasting presence of
COVID-19
will continue to adversely impact our operational capacity and the efficiency of our team members and will continue to negatively affect our results of operations and financial condition for the near term.
Product Identification Update
The global
COVID-19
pandemic has also negatively impacted sales of our Product Identification hardware products primarily as a result of the impact of travel restrictions on our sales efforts, as most customers historically have preferred
in-person
demonstrations of these printers at their production sites prior to placing orders with us and those visits have been severely limited. Additionally, the widespread cancellation of trade shows, which traditionally provided an effective forum for customers to consider our products, has also had an adverse impact on traditional methods of sales lead generation. However, we believe we have been able to ameliorate these negative impacts by placing a greater reliance on various forms of digital advertising and internet-based marketing techniques, including remote video demonstrations and support, which has proven effective in obtaining sales. Despite favorable market reception to our recently refreshed and expanded product lines, the degree to which we will be able to maintain or grow the level of hardware revenues through the changes we have made to our
go-to-market
strategies remains unclear. When the
COVID-19
pandemic abates, and it is possible again for our direct sales force and distributors to travel to visit customers and attend and present products at trade shows (if they are even offered) it is likely that some reversion to those historical sales methods will occur, but some of the
COVID-19
induced adaptations are also likely to become permanent. We do not know how that mix of sales strategies will evolve and how they will impact the results of operations for this segment.
Despite the pandemic, underlying overall demand remained strong through this period and in general, we believe that the diversified nature of our end markets and the relative concentration of business in consumer
non-durable
market related applications impart a greater degree of near- and longer-term stability to our Product Identification segment.
Test & Measurement Update
Our sales of flight deck printers for Boeing 737 aircraft have been severely impacted by the chain of events that occurred after two 737 MAX aircraft crashed. In March 2019, all major civil aviation authorities worldwide grounded the Boeing 737 MAX aircraft for safety reasons. In April 2019, Boeing reduced the number of 737
 
25

MAX aircraft produced per month from 52 to 42, and in January 2020, Boeing ceased production of the 737 MAX completely. On May 27, 2020, in anticipation of an eventual certification, Boeing announced that it would
re-start
production at low initial rates and gradually increase production in the future.
On August 3, 2020, the United States Federal Aviation Administration (the “FAA”) issued a notice of proposed rulemaking for a Boeing 737 MAX airworthiness directive, and on November 18, 2020 the FAA certified the model for return to service in the United States. On January 27, 2021, the European Union Aviation Safety Agency (EASA) approved the return to service of the Boeing 737 MAX in Europe. The exact timing of
re-certification
by other worldwide civil aviation authorities is unknown but we expect that most will permit a return to service later in 2021. Before any individual 737 MAX aircraft can return to commercial service, all civilian aviation authority agency certification requirements relevant to each carrier must be met. As these requirements vary, and can be quite extensive, the exact timing of the recertification and return to service of the 737 MAX fleet in each geographical area is unclear at this time and will depend on the ability of Boeing and each airline to complete the required steps.
Aircraft manufacturing rather than aircraft deliveries drives demand for our airborne printer products. We have experienced very low levels of 737 MAX new printer orders and shipments since the production halt, as Boeing is now producing a small number of new aircraft per month. The majority of our future 737 MAX printer sales volume will be tied to the pace of Boeing’s manufacturing dates and delivery schedules, and the recovery is expected to be prolonged. We believe that Boeing has already installed our printers in most of the airplanes that it has completed and that require our printers to be installed prior to delivery. Further, due to the
COVID-19
pandemic, global air travel demand precipitously declined, and the number of flights scheduled by airlines declined sharply. As a result, order demand from airlines for new deliveries of most aircraft models has declined. The demand for air travel and the demand for new airplanes from the airlines is expected to remain lower for an unknown period due to the unpredictable course of the pandemic and the perceived infection risk of air travel. Aircraft manufacturers have reduced their projected production rates across most or all of their product lines. As the
COVID-19
pandemic impact on the air travel industry continues, the financial health of the airlines and airframe manufacturers may become further stressed, and the ultimate impact on the structure of the industry and the individual companies that comprise it is unknown. Because we are the primary source for aircraft cabin printers to the airframe manufacturers for a majority of aircraft models produced in the world, the longer-term demand for our products is defined less by the impact of
COVID-19
on particular airlines within the industry than the health of the industry as a whole. Although we do not know what the timing and rate of recovery will be, we do expect that the industry, and hence the demand for our products, will continue to recover slowly after effective vaccines and treatments for
COVID-19
become both widely available and accepted, and as demand for air travel recovers.
Demand for aerospace spare products, paper, parts and repairs has also been significantly impacted by the decline in air travel, as requirements for these products and services are based primarily upon aircraft usage. Although we have experienced modest increases in demand for spare products, paper, parts and repairs as flight hours have increased since the second quarter of fiscal 2021, it is unknown whether this will continue or increase, or at what pace.
The decline in demand for our aerospace products has had a material adverse impact on our revenues and results of operations, which we expect will continue until demand recovers.
While we have reduced and plan to continue to reduce our costs as much as we are prudently able to, our strategy and operational plans are to maintain sufficient capabilities and staffing to fully support our customers and meet the stringent quality requirements the market requires, and to be able to rapidly increase production as demand returns, the decline in revenue has adversely impacted our profitability.
 
26

Results of Operations
Fiscal 2021 compared to Fiscal 2020
The following table presents the revenue of each of our segments, as well as the percentage of total revenue and change from the prior year.
 
($ in thousands)   
2021
   
2020
 
    
Revenue
    
As a % of
Total Revenue
   
% Change
Over Prior Year
   
Revenue
    
As a % of
Total Revenue
 
Product Identification
   $ 90,268        77.8     2.4   $ 88,116        66.0
T&M
     25,765        22.2     (43.2 )%      45,330        34.0
  
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Total
   $ 116,033        100.0     (13.0 )%    $ 133,446        100.0
  
 
 
    
 
 
   
 
 
   
 
 
    
 
 
 
Net revenue in fiscal 2021 was $116.0 million, a 13.0% decrease compared to net revenue of $133.4 million for fiscal 2020. Current year revenue through domestic channels was $70.9 million, a decline of 15.3% from prior year domestic revenue of $83.7 million. International revenue of $45.1 million for fiscal 2021 decreased 9.4% compared to prior year international revenue of $49.8 million. Fiscal 2021 international revenue reflects a favorable foreign exchange rate impact of $0.8 million, compared to an unfavorable impact of $1.4 million in fiscal 2020. International revenue declined primarily due to lower international sales of aerospace printers in Europe.
Hardware revenue in fiscal 2021 was $34.1 million, a $14.8 million, or 30.3%, decrease compared to fiscal 2020 hardware revenue of $49.0 million. The current year decrease in hardware revenue is primarily due to the decline in revenue in the T&M segment resulting from lower aerospace printer product lines sales as a result of the effects of the Boeing 737 MAX grounding and the impact of the sharp decline in air travel due to
COVID-19.
T&M hardware revenue for the current year was also impacted by a decline in sales of data recorders. Also contributing to the overall decline in hardware revenue for the current year was a more modest the decline in sales in the PI segment of certain QuickLabel model printers which was entirely offset by sales related to printers in the TrojanLabel product group.
Revenue from supplies in fiscal 2021 was $71.8 million, which was consistent with the fiscal 2020 supplies revenue. The PI segment recognized an increase in current year supply revenue primarily due to increased demand for Trojan Label product supplies due to increased market penetration of these printers, offset somewhat by lower sales of QuickLabel supplies compared to a very strong prior year. This increase was offset to a large extent by a decline in sales supplies for the aerospace product group due to the declines in commercial aircraft flight hours within the T&M segment.
Service and other revenue in fiscal 2021 was $10.1 million, a 19.8% decrease compared to fiscal 2020 service and other revenue of $12.6 million. The current year decrease is due primarily to declines in repair and part revenue related to the aerospace printer product line in the T&M segment as the result of declines in commercial aircraft flight hours.
Gross profit was $41.4 million for fiscal 2021, reflecting a 15.2% decline compared to fiscal 2020 gross profit of $48.8 million. Our gross profit margin of 35.6% in fiscal 2021 reflects a decrease compared to fiscal 2020 gross profit margin of 36.5%. The lower gross profit for the current year compared to the prior year is primarily attributable to the adverse effects of the decline in revenue in the aerospace printer product line and related product mix, which were slightly offset by the favorable impact of reductions on our manufacturing and period costs.
Operating expenses for the current year were $38.9 million, representing a 16.0% decrease from the prior year’s operating expenses of $46.3 million. Specifically, selling and marketing expenses of $23.3 million in fiscal 2021 decreased 13.3% from the prior year amount of $26.9 million. The decrease in selling and marketing expenses for the current year is primarily due to decreased travel and entertainment, advertising trade shows and commission expenses. Selling and marketing expenses represent 20.1% of net revenue for both fiscal 2021 and
 
27

2020. Current year general and administrative (“G&A”) expenses of $9.4 million decreased by 17.1% from the prior year amount of $11.4 million, primarily as a result of decreased IT costs, a decline in employee fees and lower travel and entertainment expenses due to the impact of
COVID-19.
G&A expenses represented 8.1% of net revenue for fiscal 2021, compared to 8.5% in fiscal 2020. The decline in G&A expenses in the current year is partially offset by an increase in expenses for outside services fees. Research & development (“R&D”) costs in fiscal 2021 of $6.2 million decreased 23.2% from $8.1 million in fiscal 2020, primarily due to a decrease in wages, benefits and outside services. The R&D spending level for fiscal 2021 represents 5.3% of net revenue, a decrease compared to the prior year level of 6.1%.
Other expense in fiscal 2021 was $0.3 million compared to $1.1 million in fiscal 2020. Current year other expense includes $1.0 million of interest expense on debt and revolving line of credit, offset by a net foreign exchange gain of $0.6 million and other income of $0.1 million. Other expense in fiscal 2020 includes interest expense on debt of $0.7 million and a foreign exchange loss of $0.5 million, which were partially offset by investment and other income of $0.1 million.
Net income for fiscal 2021 was $1.3 million, or $0.18 per diluted share, a decrease compared to $1.8 million, or $0.24 per diluted share in fiscal 2020. During fiscal 2021 we recognized a $0.9 million income tax expense, or a 41.1% effective tax rate compared to an income tax benefit of $0.4 million, or a 28.4% negative effective tax rate for fiscal 2020. The increase in the effective tax rate in 2021 from 2020 is primarily related to the change in mix of income between relevant jurisdictions in which we are subject to income taxes. Specific items increasing the fiscal 2021 effective tax rate include foreign rate differential, Denmark statutory audit adjustments, stock-based compensation, and Canada withholding taxes. This increase was offset by the foreign derived intangible income deduction, the release of a valuation allowance in China, and R&D tax credits expected to be utilized.
Fiscal 2020 compared to Fiscal 2019
For a comparison of our results of operations for the fiscal years ended January 31, 2020 and January 31, 2019, see “Part II, Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our annual report on Form
10-K
for the fiscal year ended January 31, 2020, filed with the SEC on April 10, 2020.
Segment Analysis
We report two segments consistent with our product revenue groups: PI and T&M. Segment performance is evaluated based on the operating segment’s profit (loss) before corporate and financial administration expenses. The following table summarizes selected financial information by segment.
 
($ in thousands)  
Revenue
   
Segment Operating Profit (Loss)
   
Segment Operating Profit
(Loss) as a % of Revenue
 
   
2021
   
2020
   
2019
   
2021
   
2020
   
2019
   
 2021 
   
 2020 
   
 2019 
 
PI
  $ 90,268     $ 88,116     $ 86,786     $ 12,885     $ 7,509     $ 7,910       14.3     8.5     9.1
T&M
    25,765       45,330       49,871       (1,032     6,281       11,933       (4.0 )%      13.9     23.9
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total
  $ 116,033     $ 133,446     $ 136,657       11,853       13,790       19,843       (10.2 )%      10.3     14.5
 
 
 
   
 
 
   
 
 
         
 
 
   
 
 
   
 
 
 
Corporate Expenses
          9,420       11,357       11,123        
       
 
 
   
 
 
   
 
 
       
Operating Income
          2,433       2,433       8,720        
Other Expense, Net
          (254     (1,063     (1,412      
       
 
 
   
 
 
   
 
 
       
Income Before Income Taxes
          2,179       1,370       7,308        
Income Tax Provision (Benefit)
          895       (389     1,578        
       
 
 
   
 
 
   
 
 
       
Net Income
        $ 1,284     $ 1,759     $ 5,730        
       
 
 
   
 
 
   
 
 
       
 
28

Product Identification
Revenue from the PI segment increased 2.4% in fiscal 2021, with revenue of $90.3 million compared to revenue of $88.1 million in the prior year. The current year increase is primarily attributable to growth in demand for ink jet and media supplies for the Trojan Label product line and to a lesser degree, the increase in current year sales of QuickLabel’s electrophotographic printer supplies. Also contributing to the increase in revenue for the current year was an increase in hardware sales in the Trojan Label product group, including contributions from the launch of new products such as the
T3-OPX
label press. PI current year segment operating profit was $12.9 million with a profit margin of 14.3%, compared to the prior year segment operating profit of $7.5 million and related profit margin of 8.5%. The increase in current year segment operating profit and margin is primarily due to increased revenue and lower operating and period costs.
Test & Measurement
Revenue from the T&M product group was $25.8 million for fiscal 2021, a 43.2% decrease compared to revenue of $45.3 million in the prior year. The decrease in revenue for the current year is primarily attributable to the decline in the aerospace printer product lines impacted by the Boeing 737 MAX grounding and the dramatic drop in air travel due to the impact of
COVID-19.
To a lesser degree, the decrease in the current year revenue was also impacted by the declines in certain T&M’s data acquisition hardware sales, as well as a decline in supplies, service and other revenue in the aerospace product lines, due to
Covid-19
induced declines in commercial airline flights. T&M current year segment operating loss was $1.0 million resulting in a negative 4.0% profit margin compared to the
prior year segment operating profit of $6.3 million and related operating margin of 13.9%. Despite lower manufacturing and period costs, the segment operating loss and related margin for the current year is primarily due to the decline in current year revenue.
Liquidity and Capital Resources
Overview
Historically, our primary sources of short-term liquidity have been cash generated from operating activities and borrowings under our revolving credit facility. These sources have also funded a portion of our capital expenditures and contractual contingent consideration obligations. We have typically funded acquisitions by borrowing under bank term loan facilities.
The onset of the
COVID-19
pandemic and the decline in revenues in the T&M segment due to the decline in aerospace printer sales, combined with the period of
COVID-19
pandemic induced credit risk avoidance in the capital markets, led to a period of liquidity concerns for us through the second quarter of fiscal 2021 despite our efforts to reduce expenses as rapidly as possible and preserve liquidity. As a result of the availability of the PPP loan during our fiscal second quarter of 2021discussed below, we were able, despite a pending default on our credit facility, to secure an amendment at the end of the second quarter of fiscal 2021 that provided additional liquidity. Those two sources of capital allowed us the time necessary to retain employment levels and focus on continuing efforts to reduce costs, and as those cost reductions took hold, to improve operating profit and cash flow. Based on improved conditions in the credit market and in recognition of the substantial cost and working capital reductions we accomplished, we were able to reduce our debt, and, subsequent to the end of fiscal year 2021, renegotiate the amendment to the credit agreement we had signed in the second quarter of fiscal 2021, which, together with our improved performance, restored us to a solid liquidity position.
On May 6, 2020, we entered into a loan agreement (the “Loan Agreement”) with and executed a promissory note (the “Promissory Note”) in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”) from Greenwood pursuant to the Paycheck Protection Program (the “PPP”) administered by the United States Small Business Administration (the “SBA”) and authorized by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), enacted on March 27, 2020. The terms
 
29

of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020 (the “PPP Flexibility Act”), which was enacted on June 5, 2020. We believe that our obtaining the PPP Loan and suspending the payment of dividends on our common stock were instrumental in our ability to successfully negotiate the A&R Credit Agreement, as defined below.
At the end of the first quarter of fiscal 2021, the deterioration of our financial condition and operating results due to the decline in 737
MAX-related
revenue and
COVID-19
impacts caused us to violate the financial covenants in our Credit Agreement dated February 28, 2017 (the “Prior Credit Agreement”) with Bank of America, N.A. (the “Lender”). On June 22, 2020, we entered into a letter agreement with the Lender wherein it agreed to waive compliance with those financial covenants for the measurement period ended May 2, 2020.
On July 30, 2020, we entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with the Lender, our wholly owned subsidiary ANI ApS, a Danish private limited liability company and ANI ApS’s wholly-owned subsidiary TrojanLabel ApS, a Danish private limited liability company (“TrojanLabel”). The A&R Credit Agreement amended and restated the Prior Credit Agreement. In connection with our entry into the A&R Credit Agreement, we entered into an Amended and Restated Security and Pledge Agreement and a mortgage in favor of the Lender with respect to our owned real property in West Warwick, Rhode Island. Under the A&R Credit Agreement, AstroNova, Inc. is the sole borrower, and, prior to the effectiveness of the Amendment (as defined below), its obligations were guaranteed by ANI ApS and TrojanLabel.
Immediately prior to the closing of the A&R Credit Agreement, we repaid $1.5 million in principal amount of term loans outstanding under the Prior Credit Agreement.
The A&R Credit Agreement provided for (i) a term loan in the principal amount of $15.2 million, which we used to refinance the outstanding term loans borrowed by us and ANI ApS under the Prior Credit Agreement and a portion of the outstanding revolving loans borrowed by us under the Prior Credit Agreement, and (ii) a $10.0 million revolving credit facility available to us for general corporate purposes. Revolving credit loans may be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
At January 31, 2021, our cash and cash equivalents were $11.4 million. There was no outstanding balance on our revolving line of credit at January 31, 2021 and we had $10.0 million available for borrowing under the A&R Credit Agreement.
On March 24, 2021, subsequent to year end, we entered into a First Amendment to Credit Agreement (the “Amendment”) to our A&R Credit Agreement (the “A&R Credit Agreement amended by the Amendment, the “Amended Credit Agreement”) with the Lender, ANI ApS and TrojanLabel. Immediately prior to the closing of the Amendment, we repaid $ 2.6 million in principal amount of the term loan outstanding under the A&R Credit Agreement, resulting in an outstanding balance of the term loan of $10.0 million and no amount drawn and outstanding under the revolving credit facility under the Amended Credit Agreement.
The Amended Credit Agreement expires on September 30, 2025, a significant extension of tenor. It also eliminated a minimum adjusted EBITDA covenant, an asset coverage covenant and a minimum liquidity covenant, and, subject to ongoing covenant compliance, significantly reduced limitations on restricted payments such as dividends, eliminated restrictions on capital expenditures and increased operating flexibility with respect to funding our global operations.
The Amended Credit Agreement provides for (i) a term loan in the principal amount of $10.0 million, and (ii) a $22.5 million revolving credit facility available for general corporate purposes. At the closing of the Amended Credit Agreement, we borrowed the entire $10.0 million term loan which was used to refinance in full the outstanding term loan under the A&R Credit Agreement. Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
 
30

While we expected that as a result of the impact of the
COVID-19
pandemic, some of our customers would experience liquidity pressure and be unable to pay us for products on a timely basis, in general our recent receivables collection experience has been consistent with our historical experience and a significant deterioration in receivables collection has not occurred through the end of fiscal year. We believe that this favorable result in T&M was due in part to the terms of the contractual relationships with our customers, and in part due to the critical nature of the nature of repairs and supplies relationships. In Product Identification it was due to the critical nature of our relationships with our customers and the general resilience of the markets we generally serve. For both segments, we have experienced improved collections efforts. During the first quarter of fiscal 2021, we experienced a limited number of cases in which certain of our aerospace customers failed to pay us on a timely basis and we increased our reserves for potential losses on those accounts. In the second quarter of fiscal 2021, two small airlines with whom we had small receivable balances for which we had previously fully reserved, entered bankruptcy, but in general, in the following quarters, the aerospace customer problems abated such that we did not increase our reserves. If the impact of the
COVID-19
pandemic continues for a prolonged period or worsens, we may experience further adverse impacts of delayed aerospace receivable collections.
In response to the
COVID-19
pandemic and related economic dislocation, we have implemented and will continue to implement a variety of expense reduction and cash preservation initiatives. On April 27, 2020, our board of directors suspended our quarterly cash dividend beginning with the second quarter of our fiscal year 2021.
We currently have $22.5 million available for borrowing under our Amended Credit Agreement and we believe that our available cash and credit facilities combined with our cash generated from operations will be sufficient to support our operating requirements, so long as the impact of
COVID-19
does not worsen.
Indebtedness
Term Loan
The Amended Credit Agreement requires that the term loan be paid as follows: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2021 through January 31, 2022 is $187,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2022 through January 31, 2023 is $250,000; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2023 through January 31, 2025 is $312,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2025 and July 31, 2025 is $500,000; and the entire remaining principal balance of the term loan is required to be paid on September 30, 2025. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than September 30, 2025, at which time any outstanding revolving loans will be due and payable in full, and the revolving credit facility will terminate. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
The Amended Credit Agreement includes an uncommitted accordion provision under which the term loan and/or revolving credit facility commitments may be increased in an aggregate principal amount not exceeding $10,000,000, subject to obtaining the agreement of the Lender and the satisfaction of certain other conditions.
As under the A&R Credit Agreement, the loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
 
31

Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
The interest rates under the A&R Credit Agreement were modified in the Amended Credit Agreement as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the LIBOR Rate as defined in the A&R Credit Agreement (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.30% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.30% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.30% based on our consolidated leverage ratio.
We must comply with various customary financial and
non-financial
covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. The minimum EBITDA, minimum consolidated asset coverage ratio, minimum liquidity and maximum capital expenditures covenants with which we were required to comply under the A&R Credit Agreement were eliminated by the Amendment. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Amendment.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.
Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests held by us in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island. Pursuant to the Amendment, the guarantees of our obligations under the A&R Credit Agreement that were previously provided by ANI ApS and TrojanLabel were released.
PPP Loan
The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date and is payable monthly. No payments are due on the PPP Loan at this time, but interest accrues during the deferral period. Interest accrued in the amount of $33,000 is included in other expense for the period ended January 31, 2021.
The PPP Loan may be prepaid at any time without penalty. The Loan Agreement and Promissory Note include customary provisions for a loan of this type, including prohibitions on our payment of dividends or repurchase of shares of our stock while the PPP Loan remains outstanding and events of default relating to, among other things, payment defaults, breaches of the provisions of the Loan Agreement or the Promissory Note and cross-defaults on other loans.
 
32

Subject to the limitations and conditions set forth in the CARES Act, the PPP Flexibility Act and the regulations and guidance provided by the SBA with respect to the PPP, a portion of the PPP Loan may be forgiven in an amount up to the amount of the PPP Loan proceeds we spent on payroll, rent, utilities and interest on certain debt during the twenty-four week period following incurrence of the PPP Loan; interest accrued on the forgiven portion of the principal amount of the PPP Loan is also forgiven. The amount of the PPP Loan to be forgiven in respect of rent, utilities and interest on certain debt will be capped at 40% of the forgiven amount, with the remaining forgiven amount allocated to payroll costs. We fully utilized the PPP Loan proceeds for qualifying expenses and have applied for forgiveness of the PPP Loan (including all associated accrued interest) subsequent to year end. Whether our application for forgiveness will be granted and in what amount is subject to an application to, and approval by, the SBA and may also be subject to further requirements in any regulations and guidelines the SBA may adopt.
Cash Flow
The statements of cash flows for the years ended January 31, 2021, 2020 and 2019 are included on page 53 of this Form
10-K.
Net cash provided by operating activities was $15.5 million in fiscal 2021 compared to net cash provided by operating activities of $3.2 million in the previous year. The increase in net cash provided by operations for the current year is primarily due to an increase in cash provided by working capital of $12.4 million from fiscal 2020. The changes in accounts receivable, inventory, income taxes, accounts payable and accrued expenses for the current year increased cash by $7.4 million in fiscal 2021 compared to a decrease to cash of $5.0 million in the prior year.
The accounts receivable balance decreased to $17.4 million at January 31, 2021, compared to $19.8 at January 31, 2020. The $2.4 million decrease in the accounts receivable balance is directly related to lower full year revenues in fiscal 2021 compared to the prior year. The days sales outstanding dropped to 51 days at year end compared to 55 days at the end of fiscal 2020 contributing to the lower receivables balance at January 31, 2021. The days sales outstanding decrease in the current year is due to customer mix, as aerospace receivables typically take longer to collect, and these revenues were down significantly in fiscal 2021.
The
year-end
inventory balance decreased to $30.1 million at January 31, 2021 versus $33.9 million at January 31, 2020 and the days inventory on hand decreased to 147 days at the end of fiscal 2021 as compared to 151 days at the end of the fiscal 2020. The current period decrease in inventory is due to lower production demand, particularly in the Test & Measurement segment and the related days on hand decline is a reflection of improved procurement strategies and production scheduling.
Net cash used by investing activities for fiscal 2021 was $2.6 million for capital expenditures, consisting of $0.1 million for land and building improvements; $2.4 million for information technology; and $0.1 million for tools and dies.
Net cash used by financing activities for fiscal 2021 was $5.1 million, consisting primarily of $6.5 million net cash decrease on the revolving line of credit, $4.0 million of principal payments of long-term debt, $2.0 million payment on the guaranteed royalty obligation payment, and $0.5 million of dividends, offset by $4.4 million of proceeds received from the PPP loan and a net of $3.5 million of proceeds received in the second quarter of fiscal 2021 related to the refinance of long-term debt..
Fiscal 2020 compared to Fiscal 2019
For a comparison of our cash flow for the fiscal years ended January 31, 2020 and January 31, 2019, see “Part II, Item 7. Management’s Discussion and Analysis of Liquidity and Capital Resources” in our annual report on Form
10-K
for the fiscal year ended January 31, 2020, filed with the SEC on April 10, 2020.
 
33

Contractual Obligations, Commitments and Contingencies
At January 31, 2021, our contractual obligations with initial remaining terms in excess of one year were as follows:
 
(In thousands)   
Total
    
Less than
1 Year
    
1-3

Years
    
3-5

Years
    
More than
5 Years
 
Purchase Commitments (1)
   $ 15,250      $ 14,959      $ 291      $ —      $ —  
Debt (2)
     12,576        5,326        7,250        —          —    
Interest on Debt (3)
     648        496        152        —          —    
Royalty Obligation (4)
     8,161        1,300        3,652        1,959        1,250  
Excess Royalty Obligation (5)
     177      177      —          —          —    
Operating Lease Obligations
     1,599        372        610        347        270  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
   $ 38,411      $ 22,630      $ 11,955      $ 2,306      $ 1,520  
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
(1)
Purchase obligations include undiscounted amounts committed under legally enforceable contracts or purchase orders for goods and services with defined terms as to price, quantity and delivery dates.
(2)
Based on the term loan balance outstanding under the A&R Credit Agreement as of January 31, 2021.
(3)
Interest rate on variable rate debt is based on the LIBOR Rate, plus a margin that varies within a range of 2.15% to 3.65% based on our consolidated leverage ratio for the outstanding loan under the A&R Credit Agreement as of January 31, 2021.
(4)
We are subject to a guaranteed minimum royalty payment obligation over the next seven years pursuant to the Honeywell Asset Purchase and License Agreement. Refer to Note 11, “Royalty Obligation” in the audited consolidated financial statements included elsewhere in this report for further details.
(5)
We are subject to excess royalty payments beyond the guaranteed minimum royalty obligation pursuant to the Honeywell Asset Purchase & License Agreement. Refer to Note 11, “Royalty Obligation,” in the audited consolidated financial statements included elsewhere in this report for further details.
We are also subject to contingencies, including legal proceedings and claims arising out of its businesses that cover a wide range of matters, such as: contract and employment claims; workers compensation claims; product liability claims; warranty claims; and claims related to modification, adjustment or replacement of component parts of units sold. While it is impossible to ascertain the ultimate legal and financial liability with respect to contingent liabilities, including lawsuits, we believe that the aggregate amount of such liabilities, if any, in excess of amounts provided, or covered by insurance, will not have a material adverse effect on our consolidated financial position or results of operations. It is possible, however, that results of operations for any future period could be materially affected by changes in our assumptions or strategies related to these contingencies or changes out of our control.
Critical Accounting Policies and Estimates
Our discussion and analysis of financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. Certain of our accounting policies require the application of judgment in selecting the appropriate assumptions for calculating financial estimates. By their nature, these judgments are subject to an inherent degree of uncertainty. We periodically evaluate the judgments and estimates used for our critical accounting policies to ensure that such judgments and estimates are reasonable for our interim and
year-end
reporting requirements. These judgments and estimates are based on our historical experience, current trends and information available from other sources, as appropriate. If actual conditions differ from the assumptions used in our judgments, our financial results could be materially different from our estimates. We believe the following critical accounting policies require significant judgments and estimates in the preparation of our consolidated financial statements:
 
34

Revenue Recognition
: We recognize revenue in accordance with Accounting Standards Update
(ASU) 2014-9, Revenue
from Contracts with Customers (also referred to as Topic 606). Under Topic 606, based on the nature of our contracts and consistent with prior practice, we recognize most of our revenue upon shipment, which is when the performance obligation has been satisfied.
Our accounting policies relating to the recognition of revenue under Topic 606 require management to make estimates, determinations and judgments based on historical experience and on various other assumptions, which include (i) the existence of a contract with the customer, (ii) the identification of the performance obligations in the contract, (iii) the value of any variable consideration in the contract, (iv) the stand alone selling price of multiple obligations in the contract, for the purpose of allocating the consideration in the contract, and (v) determining when a performance obligation has been met. Recognition of revenue based on incorrect judgments, including the identification of performance obligation arrangements as well as the pattern of delivery for those services, could result in inappropriate recognition of revenue, or incorrect timing of revenue recognition, which could have a material effect on our financial condition and results of operations.
We recognize revenue for
non-recurring
engineering (NRE) fees, as necessary, for product modification orders upon completion of agreed-upon milestones. Revenue is deferred for any amounts received prior to completion of milestones. Certain of our NRE arrangements include formal customer acceptance provisions. In such cases, we determine whether we have obtained customer acceptance for the specific milestone before recognizing revenue.
Infrequently, we receive requests from customers to hold product being purchased from us for the customers’ convenience. We recognize revenue for such bill and hold arrangements in accordance with the guidance provided by Topic 606, which requires the transaction to meet the following criteria in order to determine that the customer has obtained control: (a) the reason for the bill and hold is substantive, (b) the product has separately been identified as belonging to the customer, (c) the product is currently ready for physical transfer to the customer, and (d) we do not have the ability to use the product or direct it to another customer.
Allowance for Doubtful Accounts:
Accounts receivable consists primarily of receivables from our customers arising from the sale of our products. We actively monitor our exposure to credit risk through the use of credit approvals and credit limits. Accounts receivable is presented net of reserves for doubtful accounts.
We estimate the collectability of our receivables and establish allowances for accounts receivable that we estimate to be uncollectible. We base these allowances on our historical collection experience, the length of time our accounts receivable are outstanding and the financial condition of individual customers. In situations where we are aware of a specific customer’s inability to meet its financial obligation, such as in the case of a bankruptcy filing, we assess the need for a specific reserve for bad debts. We believe that our procedure for estimating such amounts is reasonable and historically have not resulted in material adjustments in subsequent periods. Bad debt expense was less than 1% of net sales in each of fiscal 2021 and 2020.
Warranty Claims:
We offer warranties on some of our products. We establish a reserve for estimated costs of warranties at the time the product revenue is recognized. This reserve requires us to make estimates regarding the amounts necessary to settle future and existing claims using historical data on products sold as of the balance sheet date. The length of the warranty period, the product’s failure rates, and the customer’s usage affect estimated warranty cost. If actual warranty costs differ from our estimated amounts, future results of operations could be affected adversely. Warranty cost is recorded as cost of revenue, and the reserve balance recorded as an accrued expense. While we maintain product quality programs and processes, our warranty obligation is affected by product failure rates and the related corrective costs. If actual product failure rates and/or corrective costs differ from the estimates, we revise our estimated warranty liability accordingly.
Inventories:
Inventories are stated at the lower of cost
(first-in,
first-out)
or net realizable value. The process for evaluating and recording obsolete and excess inventory provisions consists of analyzing the inventory supply on hand and estimating the net realizable value of the inventory based on historical experience, current business
 
35

conditions and anticipated future revenue. We believe that our procedures for estimating such amounts are reasonable and historically have not resulted in material adjustments in subsequent periods when the estimates are adjusted to actual experience.
Income Taxes:
A valuation allowance is established when it is
“more-likely-than-not”
that all or a portion of deferred tax assets will not be realized. A review of all available positive and negative evidence must be considered, including our performance, the market environment in which we operate, length of carryforward periods, existing revenue backlog and future revenue projections. If actual factors and conditions differ materially from the estimates made by management, the actual realization of the net deferred tax assets or liabilities could vary materially from the amounts previously recorded. At January 31, 2021, we had provided valuation allowances for future tax benefits resulting from certain domestic R&D tax credits and foreign tax credit carryforwards, both of which could expire unused.
The calculation of tax liabilities involves significant judgment in estimating the impact of uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions. Although guidance on the accounting for uncertain income taxes prescribes the use of a recognition and measurement model, the determination of whether an uncertain tax position has met those thresholds will continue to require significant judgment by management. If the ultimate resolution of tax uncertainties is different from what we have estimated, our income tax expense could be materially impacted.
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law in the U.S. and the new legislation contains several key tax provisions that affected us, including a
one-time
mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and subsequent to year end have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return.
Intangible and Long-Lived Assets:
Long-lived assets, such as definite-lived intangible assets and property, plant and equipment, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, which is determined by the discounting of future cash flows.
Goodwill:
Goodwill is tested for impairment at the reporting unit. A reporting unit is an operating segment or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment
 
36

are aggregated as a single reporting unit if they have similar economic characteristics. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate, indicate that the carrying value of an asset might be impaired. Goodwill is first qualitatively assessed to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using the income approach based upon a discounted cash flow model. We believe that this approach is appropriate because it provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. In addition, we use the market approach, which compares the reporting unit to publicly traded companies and transactions involving similar business, to support the conclusions based upon the income approach. The income approach requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference.
Due to the consideration of the impact of the decline in the global economy due to the global
COVID-19
pandemic, coupled with the grounding of the 737 MAX in March, 2019 and the 737 MAX production halt in January, 2020 which negatively impacted revenues and margins in fiscal 2020 and 2021, we elected to forgo the qualitative assessment and perform a quantitative goodwill impairment test to determine whether the carrying values of the reporting units are greater than the fair values. We utilized a blended income and market approach. The income approach was based upon a discounted cash flow model which we believe provides a fair values estimate of the reporting unit’s expected long-term operating performance. The market approach compares the reporting units to similar publicly traded companies. Based on our quantitative impairment assessment as of January 31, 2021, we determined that the fair value of the reporting units were in excess of their carrying values and therefore, no goodwill impairment has occurred.
Self-Insurance Liability Accrual:
We maintain self-insured group medical and dental programs for qualifying employees in the United States and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Our assumptions are closely monitored and adjusted when warranted by changing circumstances. Should claims occur or medical costs increase in greater amounts than we have expected, accruals may not be sufficient, and we may record additional expenses.
Share-Based Compensation:
Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted-average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grants and assessed the expected risk tolerance of different option groups. The risk-free interest rate used in the model is based on the actual
 
37

U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (“RSAs”) and restricted stock units (“RSUs”) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the date of grant. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience.
Recent Accounting Pronouncements
Reference is made to Note 1 of our audited consolidated financial statements included elsewhere in this report.
Item 7A.
Quantitative and Qualitative Disclosures about Market Risk
Our primary financial market risks consists of foreign currency exchange rates risk and the impact of changes in interest rates that fluctuate with the market on our variable rate credit borrowings under our existing credit agreement.
Financial Exchange Risk
The functional currencies of our foreign subsidiaries and branches are the local currencies—the British Pound in the U.K., the Canadian Dollar in Canada, the Danish Kroner in Denmark, the Chinese Yuan in China, and the Euro in France and Germany. We are exposed to foreign currency exchange risk as the functional currency financial statements of foreign subsidiaries are translated to U.S. dollars. The assets and liabilities of our foreign subsidiaries having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at an average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. The reported results of our foreign subsidiaries will be influenced by their translation into U.S. dollars by currency movements against the U.S. dollar. Our primary currency translation exposure is related to our subsidiaries that have functional currencies denominated in Danish Kroner and the Euro. A hypothetical 10% change in the rates used to translate the results of our foreign subsidiaries would result in an increase or decrease in our consolidated net income of approximately $0.3 million for the year ended January 31, 2021.
Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and losses are reported as foreign exchange gain (loss) in the consolidated statements of income. Foreign exchange gains resulting from transactional exposure were $0.6 million for the year ended January 31, 2021.
Interest Rate Risk
At January 31, 2021, our total indebtedness included $12.6 million of term loan variable-rate debt. At January 31, 2021, the term loan under the A&R Credit Agreement bears interest at the LIBOR rate plus a margin that varies within a range of 2.15% to 3.65% based on our consolidated leverage ratio. The impact on our results of operations of a 100basis point change in the interest rate on the outstanding balance of our variable-rate debt at January 31, 2021, would be approximately $0.1 million annually.
 
38

Item 8.
Financial Statements and Supplementary Data
The consolidated financial statements required under this item are submitted as a separate section of this report on the pages indicated at Item 15(a)(1).
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A.
Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management has evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Annual Report on Form
10-K
pursuant to Rules
13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934, as amended (Exchange Act). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective at January 31, 2021 to ensure that the information required to be disclosed in our Exchange Act reports is (1) recorded, processed, summarized and reported in a timely manner and (2) accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as such term is defined in Rules
13a-15(f)
and
15d-15(f)
under the Exchange Act). Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of its financial reporting and the preparation of published financial statements in accordance with generally accepted accounting principles.
Because of the inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to risk that controls may become inadequate because of changes in conditions, or the degree of compliance may deteriorate.
Management conducted its evaluation of the effectiveness of its internal control over financial reporting as of January 31, 2021. In making this assessment, management used the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment, the principal executive officer and principal financial officer believe that as of January 31, 2021, our internal control over financial reporting was effective based on criteria set forth by COSO in “Internal Control-Integrated Framework.”
Changes in Internal Controls over Financial Reporting
There have been no changes in our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Item 9B.
Other Information
None.
 
39

PART III
Item 10.
Directors, Executive Officers and Corporate Governance
The information required by this item is incorporated herein by reference to our definitive proxy statement to be filed for our 2021 Annual Meeting of Shareholders.
The following sets forth certain information with respect to all executive officers of the Company. All officers serve at the pleasure of the Board of Directors.
 
Name
  
Age
    
Position
Gregory A. Woods
     62     
President, Chief Executive Officer and Director
David S. Smith
     64     
Vice President, Chief Financial Officer and Treasurer
Stephen M. Petrarca
     58     
Vice President—Operations
Michael J. Natalizia
     57     
Chief Technology Officer and Vice President of Strategic Technical Alliances
Tom Carll
     54     
Vice President and General Manager—Aerospace
Mr. Woods has served as Chief Executive Officer of the Company since February 1, 2014. Mr. Woods joined the Company in September 2012 as Executive Vice President and Chief Operating Officer and was appointed President and Chief Operating Officer on August 29, 2013. Prior to joining the Company, Mr. Woods served from January 2010 to August 2012 as Managing Director of Medfield Advisors, LLC, an advisory firm located in Medfield, Massachusetts focused on providing corporate development and strategy guidance to technology driven manufacturing firms. From 2008 to 2010, Mr. Woods served as President of Performance Motion Devices, a specialty semiconductor and electronics manufacturer located in Lincoln, Massachusetts.
Mr. Smith was appointed Vice President, Chief Financial Officer and Treasurer of the Company effective January 22, 2018. Prior to joining the Company, Mr. Smith served as Managing Partner of S.C. Advisors LLC, a financial management consultancy firm from 2008 through January 2018. Mr. Smith has also held a variety of senior finance positions at semiconductor and manufacturing companies, including Senior Vice President and Chief Financial Officer of Standard Microsystems Corporation, a global semiconductor company, from 2005 to 2008 and Vice President, Finance and Chief Financial Officer of both Dover Corporation, a diversified global manufacturing company, from 2000 to 2002 and Crane Company, a diversified manufacturing company from 1994 to 2000.
Mr. Petrarca was appointed Vice President—Operations in 1998. He has previously held positions as General Manager of Manufacturing, Manager of Grass Operations and Manager of Grass Sales. He has been with the Company since 1980.
Mr. Natalizia was appointed Vice President and Chief Technology Officer of the Company on March 9, 2012. Prior to this appointment, Mr. Natalizia held the position of Director of Product Development of the Company since 2005.
Mr. Carll joined the Company in 1989 and has held the position of Vice President and General Manager—Aerospace since 2011. Previously, Mr. Carll was Product Manager and National Sales Manager of the AstroNova Test & Measurement product group and from its formation in 2004, the AstroNova Aerospace business group.
Code of Ethics
We have adopted a Code of Conduct which applies to all of our directors, officers and employees of the Company, including our Chief Executive Officer (“CEO”), Chief Financial Officer (“CFO”) and principal accounting officer which meets the requirements of a “code of ethics” as defined in Item 406 of Regulation
S-K.
A copy of the Code of Conduct will be provided to shareholders, without charge, upon request directed to Investor Relations or can be obtained on our website,
(www.astronovainc.com)
, under the heading “Investors—Corporate Governance—Governance Documents.” We intend to disclose any amendment to, or waiver of, a provision of the Code of Conduct for the CEO, CFO, principal accounting officer, or persons performing similar functions by posting such information on our website.
 
40

Item 11.
Executive Compensation
The information required by this item is incorporated herein by reference to our definitive Proxy Statement to be filed for our 2021 Annual Meeting of Shareholders.
The information set forth under the heading “Compensation Committee Report” in our definitive Proxy Statement is furnished and shall not be deemed filed for purposes of Section 18 of the Exchange Act, nor be incorporated by reference in any filing under the Securities Act of 1933, as amended.
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated herein by reference to our definitive Proxy Statement to be filed for our 2021 Annual Meeting of Shareholders.
Equity Compensation Plan Information
The following table sets forth information about our equity compensation plans as of January 31, 2021:
 
Plan Category
  
Number of Securities to
be Issued Upon Exercise
of Outstanding Options,
Warrants and Rights
   
Weighted-
Average Exercise
Price of
Outstanding
Options,
Warrants and
Rights
   
Number of Securities
Remaining Available for
Future Issuance Under
Equity Compensation Plans
 
Equity Compensation Plans Approved by Shareholders
     771,496 (1)    $ 14.63 (2)      538,853 (3) 
Equity Compensation Plans Not Approved by Shareholders
     —         —         —    
  
 
 
   
 
 
   
 
 
 
Total
     771,496 (1)    $ 14.63 (2)      538,853 (3) 
  
 
 
   
 
 
   
 
 
 
 
(1)
Includes 337,958 shares issuable upon exercise of outstanding options granted under our 2007 Equity Incentive Plan; 148,625 shares issuable upon exercise of outstanding options granted and 10,833 restricted stock units outstanding under our 2015 Equity Incentive Plan; and 135,500 shares issuable upon exercise of outstanding options granted and 138,580 restricted stock units outstanding under our 2018 Equity Incentive Plan. This balance does not include 48,000 of unvested restricted stock which are subject to forfeiture.
(2)
Does not include restricted stock units.
(3)
Represents 528,479 shares available for grant under the AstroNova, Inc. 2018 Equity Incentive Plan and 10,374 shares available for purchase under the Employee Stock Purchase Plan.
Additional information regarding these equity compensation plans is contained in Note 15, “Share-Based Compensation,” in our Consolidated Financial Statements included in Item 15 hereto.
Item 13.
Certain Relationships, Related Transactions and Director Independence
The information required by this item is incorporated herein by reference to our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders.
Item 14.
Principal Accountant Fees and Services
The information required by this item is incorporated herein by reference to our definitive Proxy Statement for our 2021 Annual Meeting of Shareholders.
 
41

PART IV
Item 15. Exhibits and Financial Statement Schedule
(a)(1) Financial Statements:
The following documents are included as part of this Annual Report filed on Form
10-K:
 
    
Page
   47-48
   49
   50
   51
   52
   53
  
54-81
(a)(2) Financial Statement Schedule:
  
   83
All other schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission are not required under the related instructions or are inapplicable, and therefore, have been omitted.
Item 16. Form
10-K
Summary
Not Applicable.
(a)(3) Exhibits:
 
Exhibit
Number
   
    (2.1)   Share Purchase Agreement, dated January 7, 2017, as amended, by and among ANI ApS, Trojan Holding ApS, as a Seller and as the Sellers’ Representative, and Li Wei Chong filed as Exhibit 2.1 to our Annual Report on Form 10-K for the year ended January 31, 2017 and incorporated by reference herein*
    (3A)   Restated Articles of Incorporation of the Company and all amendments thereto filed as Exhibit 3A to our Quarterly Report on Form 10-Q for the quarter ended April 30, 2016 and incorporated by reference herein.
    (3B)   By-laws of the Company as amended to date filed as Exhibit 3B to our Annual Report on Form 10-K for the fiscal year ended January 31, 2008 (File No. 000-13200) and incorporated by reference herein.
    (4.1)   Specimen form of common stock certificate of the Company filed as Exhibit 4 to our Quarterly Report on Form 10-Q for the quarter ended April 30, 2016 and incorporated by reference herein.
    (4.2)   Description of securities registered pursuant to Section 12 of the Exchange Act filed as Exhibit 4.2 to our Annual Report on Form 10-K for the fiscal year ended January 31, 2020 (File No. 000-13200) and incorporated by reference herein.
  (10.1)   We , Inc. 2007 Equity Incentive Plan as filed as Appendix A to the Definitive Proxy Statement filed on April 25, 2007 on Schedule 14A (File No. 000-13200) for the 2007 annual shareholders meeting and incorporated by reference herein.**
 
42

Exhibit
Number
   
  (10.2)   Equity Incentive Award Agreement dated as of November 24, 2014 by and between the Company and Gregory A. Woods filed as Exhibit 10.12 to our Annual Report on Form 10-K for the year ended January 31, 2015 and incorporated by reference herein.**
  (10.3)   Change in Control Agreement dated as of November 24, 2014 by and between the Company and Gregory A. Woods filed as Exhibit 10.13 to our Annual Report on Form 10-K for the year ended January 31, 2015 and incorporated by reference herein.**
  (10.4)   AstroNova Inc. 2015 Equity Incentive Plan filed as Exhibit A to the Definitive Proxy Statement filed on April 21, 2015 (File No. 000-13200) for the 2015 annual shareholders meeting and incorporated by reference herein.**
  (10.5)   Form of Indemnification Agreement for directors and officers filed as Exhibit 10.1 to our Quarterly Report on Form 10-Q for the period ended October 31, 2015 and incorporated by reference herein.**
  (10.6)   Form of Restricted Stock Agreement granted under the Amended and Restated Non-Employee Director Annual Compensation Program filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.7)   Form of Incentive Stock Option Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.8)   Form of Non-Statutory Stock Option Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.9)   Form of Non-Employee Director Non-Statutory Stock Option Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.10)   Form of Restricted Stock Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.11)   Form of Non-Employee Director Restricted Stock Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.12)   Form of Time-Based Restricted Stock Unit Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.8 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.13)   Form of Performance Restricted Stock Unit Agreement granted under the 2015 Equity Incentive Plan filed as Exhibit 10.9 to the Company’s Quarterly Report on Form 10-Q for the period ended July 30, 2016 and incorporated by reference herein.**
  (10.14)   Asset Purchase and License Agreement, dated September 28, 2017, by and between AstroNova, Inc. and Honeywell International, Inc. filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, event date September 28, 2017, filed with the SEC on October 4, 2017 and incorporated by reference herein.
  (10.15)   Amended and Restated AstroNova, Inc. Employee Stock Purchase Plan filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K/A, event date November 20, 2017, filed with the SEC on December 28, 2017 and incorporated by reference herein.
 
43

Exhibit
Number
   
  (10.16)   Letter Agreement dated January 12, 2018 between the Company and David Smith filed as Exhibit 10.30 to the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2018 and incorporated by reference herein.**
  (10.17)   Form of Performance-based Restricted Stock Unit Award Agreement filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.18)   Form of Restricted Stock Unit Agreement (time-based vesting) filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.19)   Form of Incentive Stock Option filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.20)   Form of Non-statutory Stock Option filed as Exhibit 10.4 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.21)   Form of Non-statutory Stock Option (Non-employee Director) filed as Exhibit 10.5 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.22)   Form of Restricted Stock Agreement filed as Exhibit 10.6 to the Company’s Current Report on Form 8-K, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.23)   Form of Non-employee Director Restricted Stock Agreement filed as Exhibit 10.7 to the Company’s Current Report on Form 8-K filed, event date June 4, 2018, filed with the SEC on June 4, 2018 and incorporated by reference herein.**
  (10.24)   AstroNova, Inc. Amended and Restated Non-Employee Director Annual Compensation Program filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed, event date January 31, 2019, filed with the SEC on February 4, 2019 and incorporated by reference herein.**
  (10.25)   AstroNova, Inc. 2018 Equity Incentive Plan Non-Employee Director Restricted Stock Agreement filed as Exhibit 10.41 to the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2019 and incorporated by reference to herein.*
  (10.26)   AstroNova, Inc. 2018 Equity Incentive Plan, as amended, filed as Appendix A to the Company’s Definitive Proxy Statement filed with the SEC on May 25, 2019 on Schedule 14A and incorporated by reference herein.*
  (10.27)   Loan Agreement effective as of May 6, 2020, by and between AstroNova, Inc. and Greenwood Credit Union, filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 2, 2020 and incorporated by reference herein.
  (10.28)   Promissory Note dated May 6, 2020, by and between AstroNova, Inc. and Greenwood Credit Union, filed as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 2, 2020 and incorporated by reference herein.
  (10.29)   Letter of Agreement dated June 22, 2020 between AstroNova, Inc. and Bank of America, N.A. , filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q for the quarter ended May 2, 2020 and incorporated by reference herein.
 
44

Exhibit
Number
   
  (10.30)   Amended and Restated Credit Agreement dated as of July 30, 2020 among AstroNova, Inc., ANI ApS, TrojanLabel ApS, and Bank of America, N.A. filed as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q for the quarter ended August 1, 2020 and incorporated by reference herein.
  (10.31)   Amended and Restated Security and Pledge Agreement dated as of July 30, 2020 among AstroNova, Inc. and Bank of America, N.A. , filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K, event date July 30, 2020, and incorporated by reference herein.
  (10.32)   Open-End Mortgage Deed to Secure Present and Future Loans under Chapter 25 of Title 34 of the Rhode Island General Laws, Assignment of Leases and Rents, Security Agreement and Fixture Filing dated as of July 30, 2020 among AstroNova, Inc. and Bank of America, N.A. , filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K, event date July 30, 2020, and incorporated by reference herein.
  (10.33)   Change in Control Agreement dated September 8, 2020 by and between AstroNova, Inc. and David S. Smith. filed as Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q for the quarter ended August 1, 2020 and incorporated by reference herein.**
  (10.34)   First Amendment to Credit Agreement dated as of March 24, 2021 among AstroNova, Inc. ANI ApS, TrojanLabel ApS and Bank of America, N.A.
  (10.35)   First Amendment to Open-End Mortgage Deed to Secure Present and Future Loans under Chapter 25 of Title 34 of the Rhode Island General Laws, Assignment of Leases and Rents, Security Agreement and Fixture Filing dated as of March 24, 2021 among AstroNova, Inc. and Bank of America, N.A.
  (21)   List of Subsidiaries of the Company.
  (23.1)   Consent of Wolf & Company, P.C.
  (31.1)   Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  (31.2)   Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
  (32.1)   Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  (32.2)   Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
  (101.INS)   XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
  (101.SCH)   Inline XBRL Taxonomy Extension Schema Document
  (101.CAL)   Inline XBRL Taxonomy Extension Calculation Linkbase Document
  (101.DEF)   Inline XBRL Taxonomy Extension Definition Linkbase Document
  (101.LAB)   Inline XBRL Taxonomy Extension Label Linkbase Document
  (101.PRE)   Inline XBRL Taxonomy Extension Presentation Linkbase Document
  (104)   Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
*
Schedules to this Exhibit have been omitted in reliance on Item 601(b)(2) of Regulation
S-K.
The Company will furnish copies of any such schedules to the SEC upon request.
**
Management contract or compensatory plan or arrangement.
 
45

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
   
ASTRONOVA, INC.
(Registrant)
Date: April 13, 2021     By:  
/S/    GREGORY A. WOODS        
      (Gregory A. Woods, Chief Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.
 
Name
  
Title
 
Date
/s/    GREGORY A. WOODS
Gregory A. Woods
  
President, Chief Executive Officer and Director (Principal Executive Officer)
 
April 13, 2021
/s/    DAVID S. SMITH
David S. Smith
  
Vice President, Chief Financial Officer and Treasurer (Principal Accounting and Financial Officer)
 
April 13, 2021
/s/    JEAN A. BUA
Jean A. Bua
  
Director
 
April 13, 2021
/s/    MITCHELL I. QUAIN
Mitchell I. Quain
  
Director
 
April 13, 2021
/s/    YVONNE E. SCHLAEPPI
Yvonne E. Schlaeppi
  
Director
 
April 13, 2021
/s/    HAROLD SCHOFIELD
Harold Schofield
  
Director
 
April 13, 2021
/s/    RICHARD S. WARZALA
Richard S. Warzala
  
Director
 
April 13, 2021
 
46

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Shareholders and Board of Directors and Shareholders of
AstroNova, Inc.
Opinions on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of AstroNova, Inc. (the “Company”) as of January 31, 2021 and 2020, and the related consolidated statements of income, comprehensive income, changes in shareholders’ equity and cash flows for each of the years in the three-year period ended January 31, 2021 and the related notes and the financial statement schedule listed in Item 15(a)(2)(collectively, the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of January 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended January 31, 2021 in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Goodwill Impairment Assessment
As discussed in Note 3 to the financial statements, the Company’s consolidated goodwill balance was approximately $12.8 million as of January 31, 2021. Company management tests goodwill for impairment at the reporting unit level, at least annually, at the end of the fiscal year. As a result of the decline in revenues and
 
47

margins in the current year, management performed a quantitative goodwill impairment test as of January 31, 2021. The quantitative assessment utilizes a combination of the income approach and market approach to estimate the fair value of each reporting unit.
We have identified the evaluation of goodwill for impairment as a critical audit matter as a result of (i) the significant judgment by management when developing the fair value measurements and; (ii) a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to financial projections.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included, among others (i) evaluating the qualifications of the third-party expert engaged by management; (ii) testing management’s, and the third-party expert’s, process for developing the fair value estimates, including consideration of the appropriateness of the methods used; (iii) testing the completeness and accuracy of underlying data used in the fair value estimates; and (iv) evaluating the significant assumptions used in developing financial projections. In evaluating management’s assumptions used in the development of financial projections we considered (i) the current and past performance of the reporting units; (ii) whether these assumptions were consistent with evidence obtained in other areas of the audit and (iii) the sensitivity to change of the assumptions used.
/s/ Wolf & Company, P.C.
We have served as the Company’s auditor since 2013.
Boston, Massachusetts
April 13, 2021
 
48

ASTRONOVA, INC.
CONSOLIDATED BALANCE SHEETS
As of January 31
(In Thousands, Except Share Data)
 
    
2021
   
2020
 
ASSETS
                
CURRENT ASSETS
                
Cash and Cash Equivalents
   $ 11,439     $ 4,249  
Accounts Receivable, net of reserves of $1,054 in 2021 and $856 in 2020
     17,415       19,784  
Inventories
     30,060       33,925  
Prepaid Expenses and Other Current Assets
     1,807       2,193  
    
 
 
   
 
 
 
Total Current Assets
     60,721       60,151  
 
 
 
 
 
 
 
 
 
Property, Plant and Equipment, net
     12,011       11,268  
Identifiable Intangibles, net
     21,502       25,383  
Goodwill
     12,806       12,034  
Deferred Tax Assets, net
     5,941       5,079  
Right of Use Asset
     1,389       1,661  
Other
     1,103       1,088  
    
 
 
   
 
 
 
TOTAL ASSETS
   $ 115,473     $ 116,664  
    
 
 
   
 
 
 
LIABILITIES AND SHAREHOLDERS’ EQUITY
                
CURRENT LIABILITIES
                
Accounts Payable
   $ 5,734     $ 4,409  
Accrued Compensation
     2,852       2,700  
Other Accrued Expenses
     3,939       4,711  
Revolving Credit Facility
     —         6,500  
Current Portion of Long-Term Debt
     5,326       5,208  
Current Liability—Royalty Obligation
     2,000       2,000  
Current Liability—Excess Royalty Payment Due
     177       773  
Income Taxes Payable
     655       —    
Deferred Revenue
     285       466  
    
 
 
   
 
 
 
Total Current Liabilities
     20,968       26,767  
NON CURRENT LIABILITIES
                
Long-Term Debt, net of current portion
     7,109       7,715  
Royalty Obligation, net of current portion
     6,161       8,012  
Long-Term Debt—PPP Loan
     4,422       —    
Lease Liabilities, net of current portion
     1,065       1,279  
Income Taxes Payable
     681       1,081  
Deferred Tax Liabilities
     384       435  
    
 
 
   
 
 
 
TOTAL LIABILITIES
     40,790       45,289  
Commitments and Contingencies (See Note 21)
                
SHAREHOLDERS’ EQUITY
                
Preferred Stock, $10 Par Value, Authorized 100,000 shares, None Issued
     —         —    
Common Stock, $0.05 Par Value, Authorized 13,000,000 shares; Issued 10,425,094 shares in 2021 and 10,343,610 shares in 2020
     521       517  
Additional
Paid-in
Capital
     58,049       56,130  
Retained Earnings
     50,085       49,298  
Treasury Stock, at Cost, 3,297,058 shares in 2021 and 3,281,701 shares in 2020
     (33,588     (33,477
Accumulated Other Comprehensive Loss, net of tax
     (384     (1,093
    
 
 
   
 
 
 
TOTAL SHAREHOLDERS’ EQUITY
     74,683       71,375  
    
 
 
   
 
 
 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
   $ 115,473     $ 116,664  
    
 
 
   
 
 
 
See Notes to the Consolidated Financial Statements.
 
49

ASTRONOVA, INC.
CONSOLIDATED STATEMENTS OF INCOME
For the years ended January 31
(In Thousands, Except Per Share Data)
 
    
2021
   
2020
   
2019
 
Revenue
   $ 116,033     $ 133,446     $ 136,657  
Cost of Revenue
     74,673       84,688       82,658  
    
 
 
   
 
 
   
 
 
 
Gross Profit
     41,360       48,758       53,999  
Costs and Expenses:
                        
Selling and Marketing
     23,301       26,884       26,343  
Research and Development
     6,206       8,084       7,813  
General and Administrative
     9,420       11,357       11,123  
    
 
 
   
 
 
   
 
 
 
Operating Expenses
     38,927       46,325       45,279  
    
 
 
   
 
 
   
 
 
 
Operating Income
     2,433       2,433       8,720  
Other Expense:
                        
Interest Income (Expense), net
     (955     (682     (731
Gain (Loss) on Foreign Currency Transactions
     590       (448     (745
Other, net
     111       67       64  
    
 
 
   
 
 
   
 
 
 
       (254     (1,063     (1,412
    
 
 
   
 
 
   
 
 
 
Income before Income Taxes
     2,179       1,370       7,308  
Income Tax Provision (Benefit)
     895       (389     1,578  
    
 
 
   
 
 
   
 
 
 
Net Income
   $ 1,284     $ 1,759     $ 5,730  
    
 
 
   
 
 
   
 
 
 
Net Income Per Common Share—Basic
   $ 0.18     $ 0.25     $ 0.83  
    
 
 
   
 
 
   
 
 
 
Net Income Per Common Share—Diluted
   $ 0.18     $ 0.24     $ 0.81  
    
 
 
   
 
 
   
 
 
 
Weighted Average Number of Common Shares Outstanding—Basic
     7,104       7,024       6,881  
Dilutive Effect of Common Stock Equivalents
     62       214       203  
    
 
 
   
 
 
   
 
 
 
Weighted Average Number of Common Shares Outstanding—Diluted
     7,166       7,238       7,084  
    
 
 
   
 
 
   
 
 
 
See Notes to the Consolidated Financial Statements.
 
50

ASTRONOVA, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the years ended January 31
(In Thousands)
 
    
2021
   
2020
   
2019
 
Net Income
   $ 1,284     $ 1,759     $ 5,730  
Other Comprehensive Income (Loss), net of taxes and reclassification adjustments:
                        
Foreign Currency Translation Adjustments
     710       (133     (671
Change in Value of Derivatives Designated as Cash Flow Hedge
     (239     122       622  
(Gains) Losses from Cash Flow Hedges Reclassified to Income Statement
     193       (264     (600
Cross-Currency Interest Rate Swap Terminations
     45       —         —    
Realized Gain on Securities Available for Sale Reclassified to Income Statement
     —         —         3  
    
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     709       (275     (646
    
 
 
   
 
 
   
 
 
 
Comprehensive Income
   $ 1,993     $ 1,484     $ 5,084  
    
 
 
   
 
 
   
 
 
 
See Notes to the Consolidated Financial Statements.
 
5
1

ASTRONOVA, INC.
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
($ In Thousands)
 
 
 
 
Common Stock
 
 
Additional
Paid-in

Capital
 
 
Retained
Earnings
 
 
Treasury
Stock
 
 
Accumulated
Other
Comprehensive
Income (Loss)
 
 
Total
Shareholders’
Equity
 
 
 
Shares
 
 
Amount
 
Balance January 31, 2018
    9,996,120     $ 500     $ 50,016     $ 45,700     $ (32,397   $ (172   $ 63,647  
Share-based compensation
    —         —         1,886       —         —         —         1,886  
Employee option exercises
    154,992       7       1,669       —         (366     —         1,310  
Restricted stock awards vested, net
    67,447       4       (3     —         (234     —         (233
Reclassification due to adoption of ASU
2018-02
    —         —         —         14       —         —         14  
Common Stock—cash dividend—$0.28 per share
    —         —         —         (1,933     —         —         (1,933
Net income
    —         —         —         5,730       —         —         5,730  
Other comprehensive loss
    —         —         —         —         —         (646     (646
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance January 31, 2019
    10,218,559     $ 511     $ 53,568     $ 49,511     $ (32,997   $ (818   $ 69,775  
Share-based compensation
    —         —         1,775       —         —         —         1,775  
Employee option exercises
    65,121       3       790       —         (11     —         782  
Restricted stock awards vested, net
    59,930       3       (3     —         (469     —         (469
Common Stock—cash dividend—$0.28 per share
    —         —         —         (1,972     —         —         (1,972
Net income
    —         —         —         1,759       —         —         1,759  
Other comprehensive loss
    —         —         —         —         —         (275     (275
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance January 31, 2020
    10,343,610     $ 517     $ 56,130     $ 49,298     $ (33,477   $ (1,093   $ 71,375  
Share-based compensation
    —         —         1,819       —         —         —         1,819  
Employee option exercises
    16,487       1       103       —         —         —         104  
Restricted stock awards vested, net
    64,997       3       (3     —         (111     —         (111
Common Stock—cash dividend—$0.07 per share
    —         —         —         (497     —         —         (497
Net income
    —         —         —         1,284       —         —         1,284  
Other comprehensive income
    —         —         —         —         —         709       709  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance January 31, 2021
    10,425,094     $ 521     $ 58,049     $ 50,085     $ (33,588   $ (384   $ 74,683  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
See Notes to the Consolidated Financial Statements.
 
52
ASTRONOVA, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
For the years ended January 31
(In Thousands)
 
 
  
2021
 
 
2020
 
 
2019
 
Cash Flows from Operating Activities:
  
     
 
     
 
     
Net Income
   $ 1,284     $ 1,759     $ 5,730  
Adjustments to Reconcile Net Income to Net Cash Provided By Operating Activities:
                        
Depreciation and Amortization
     5,983       6,284       6,152  
Amortization of Debt Issuance Costs
     75       49       51  
Share-Based Compensation
     1,819       1,775       1,886  
Deferred Income Tax Provision (Benefit)
     (1,021     (1,638     (1,638
Changes in Assets and Liabilities:
                        
Accounts Receivable
     2,702       3,594       (1,493
Inventories
     4,247       (3,938     (2,872
Accounts Payable and Accrued Expenses
     (57     (2,732     (2,342
Income Taxes Payable
     1,482       (1,773     (151
Other
     (970     (156     (318
    
 
 
   
 
 
   
 
 
 
Net Cash Provided by Operating Activities
     15,544       3,224       5,005  
    
 
 
   
 
 
   
 
 
 
Cash Flows from Investing Activities:
                        
Proceeds from Sales/Maturities of Securities Available for Sale
     —         —         1,511  
Cash Paid for Honeywell Asset Purchase and License Agreement
     —         —         (400
Additions to Property, Plant and Equipment
     (2,587     (2,906     (2,645
    
 
 
   
 
 
   
 
 
 
Net Cash Used by Investing Activities
     (2,587     (2,906     (1,534
    
 
 
   
 
 
   
 
 
 
Cash Flows from Financing Activities:
                        
Net Proceeds Employee Stock Option Plans
     9       654       1,228  
Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan
     95       128       82  
Net Cash Used for Payment of Taxes Related to Vested Restricted Stock
     (111     (469     (233
Net
(
Repayments
)
/Borrowing
s
 under Revolving Credit Facility
     (6,500     5,000       1,500  
Payment of Minimum Guarantee Royalty Obligation
     (2,000     (1,875     (1,625
Proceeds from Long-Term Debt – PPP Loan
     4,422       —         —    
Proceeds from Long-Term Debt Borrowings
     15,232       —         —    
Payoff of Long-Term Debt
     (11,732     —         —    
Principal Payments on Long-Term Debt
     (3,958     (5,208     (5,130
Payments of Debt Issuance Costs
     (100     —         —    
Dividends Paid
     (497     (1,972     (1,933
    
 
 
   
 
 
   
 
 
 
Net Cash Used by Financing Activities
     (5,140     (3,742     (6,111
    
 
 
   
 
 
   
 
 
 
Effect of Foreign Exchange Rate Changes on Cash and Cash Equivalents
     (627     139       (3
    
 
 
   
 
 
   
 
 
 
Net Increase (Decrease) in Cash and Cash Equivalents
     7,190       (3,285     (2,643
Cash and Cash Equivalents, Beginning of Year
     4,249       7,534       10,177  
    
 
 
   
 
 
   
 
 
 
Cash and Cash Equivalents, End of Year
   $ 11,439     $ 4,249     $ 7,534  
    
 
 
   
 
 
   
 
 
 
Supplemental Information:
                        
Cash Paid During the Period for:
                        
Interest
   $ 677     $ 531     $ 636  
Income Taxes, Net of Refunds
   $ 446     $ 2,913     $ 3,472  
Schedule of
non-cash
financing activities:
                        
Value of Shares Received in Satisfaction of Option Exercise Price
   $ —       $ 11     $ 366  
See Notes to the Consolidated Financial Statements.
 
53
ASTRONOVA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
January 31, 2021, 2020 and 2019
Note 1—Summary of Significant Accounting Policies
Basis of Presentation:
The accompanying financial statements and accompanying notes have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Our fiscal year end is January 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation:
The consolidated financial statements include the accounts of AstroNova, Inc. and its subsidiaries. All material intercompany accounts and transactions are eliminated in consolidation.
Reclassification:
Certain amounts in prior year’s financial statements have been reclassified to conform to the current year’s presentation.
Use of Estimates:
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect these financial statements and accompanying notes. Some of the more significant estimates relate to the allowances for doubtful accounts, inventory valuation, valuation and estimated lives of intangible assets, impairment of long-lived assets, goodwill, income taxes, share-based compensation and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters. Consequently, actual results could differ from those estimates.
Cash and Cash Equivalents:
Highly liquid investments with an original maturity of 90 days or less are considered to be cash equivalents. Similar investments with original maturities beyond three months are classified as securities available for sale. At January 31, 2021 and 2020, $4.6 million and $3.4 million, respectively, was held in foreign bank accounts.
Inventories:
Inventories are stated at the lower of cost
(first-in,
first-out)
or net realizable value and include material, labor and manufacturing overhead.
Property, Plant and Equipment:
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets (land improvements—10 to 20 years; buildings and leasehold improvements—10 to 45 years; machinery and equipment—3 to 10 years and computer equipment and software—3 to 10 years).
Revenue Recognition:
We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Topic 606 defines a five step process to recognize revenue and requires more judgment and estimates within the revenue recognition process than required under previous U.S. GAAP, including identifying contracts with customers, identifying performance obligations in the contract, determining and estimating the amount of any variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and recognizing revenue when the entity satisfies each performance obligation. 
The vast majority of our revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration we expect to receive in exchange for such products, which is generally at the contractually stated prices, and is recognized when we satisfy a performance obligation by transferring control of a product to a customer. The transfer of control generally occurs at one point in time, upon shipment, when title and risk of loss pass to the customer. Returns and customer credits are infrequent and are recorded as a reduction to revenue. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.
 
5
4

Many of the contracts entered into with customers are commonly comprised of a combination of equipment, supplies, installation and/or training services. We determine performance obligations by assessing whether the products or services are distinct from other elements of the contract. In order to be distinct, the product must perform either on its own or with readily available resources and must be separate within the context of the contract.
Most of our hardware products contain embedded operating systems and data management software which is included in the purchase price of the equipment. The software is deemed incidental to the systems as a whole, as it is not sold or marketed separately, and its production costs are minor compared to those of the hardware system. Hardware and software elements are typically delivered at the same time and are accounted for as a single performance obligation for which revenue is recognized at the point in time when ownership is transferred to the customer.
Installation and training services vary based on certain factors such as the complexity of the equipment, staffing availability in a geographic location and customer preferences, and can range from a few days to a few months. The delivery of installation and training services are not assessed to determine whether they are separate performance obligations, as the amounts are not material to the contract.
Shipping and handling activities that occur after control over a product has transferred to a customer are accounted for as fulfillment activities rather than performance obligations, as allowed under a practical expedient provided by Topic 606. The shipping and handling fees charged to customers are recognized as revenue and the related costs are included in cost of revenue at the point in time when ownership of the product is transferred to the customer.
We may perform service at the request of the customer, generally for the repair and maintenance of products previously sold. These services are short in duration and total less than 10% of revenue for the years ended January 31, 2021 and 2020. Revenue is recognized as services are rendered and accepted by the customer. We also provide service agreements on certain of our Product Identification equipment. Service agreements are purchased separately from the equipment and provide for the right to obtain service and maintenance on the equipment for a period of typically one to two years. Accordingly, revenue on these agreements is recognized over the term of the agreements. The portion of service agreement contracts that are uncompleted at the end of any reporting period are included in deferred revenue.
We generally provide warranties for our products. The standard warranty period is typically 12 months for most hardware products except for airborne printers, which typically have warranties that extend for
3-5
years, consistent with industry practice. Such assurance-type warranties are not deemed to be separate performance obligations from the hardware product and costs associated with providing the warranties are accrued in accordance with ASC 450, “Contingencies,” as we have the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. Our estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that our experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue. On occasion, customers request a warranty period longer than our standard warranty. In those instances, in which extended warranty services are separately quoted to the customer, an additional performance obligation is created, and the associated revenue is deferred and recognized as service revenue ratably over the term of the extended warranty period. The portion of service contracts and extended warranty services agreements that are uncompleted at the end of any reporting period are included in deferred revenue.
We recognize an asset for the incremental direct costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. Costs related to obtaining sales contracts for our aerospace printer products have been capitalized and are being amortized based on the forecasted number of units sold over the estimated benefit term. We apply the practical expedient to expense costs incurred for costs to obtain a contract when the amortization period would have been less than a year. These costs include sales commissions paid to the internal direct sales team as well as to third-party representatives and distributors. Contractual
 
5
5

agreements with each of these parties outline commission structures and rates to be paid. Generally speaking, the contracts are all individual procurement decisions by the customers and do not include renewal provisions and as such the majority of the contracts have an economic life of significantly less than a year.
Accounts Receivables and Allowance for Doubtful Accounts:
Standard payment terms are typically 30 days after shipment but vary by type and geographic location of our customer. Credit is extended based upon an evaluation of the customer’s financial condition. In circumstances where we are aware of a customer’s inability to meet its financial obligations, an allowance is established. The remainder of the allowance established is based on a variety of factors, including the age of amounts outstanding relative to their contractual due date, historical
write-off
experience and current market assessments. Accounts receivable are stated at their estimated net realizable value.
Research and Development Costs:
We charge costs to expense in the period incurred, and these expenses are presented in the consolidated statement of income. The following costs are included in research and development expense: salaries and benefits, external engineering service costs, engineering related information costs and supplies.
Foreign Currency Translation:
The financial statements of foreign subsidiaries and branches are measured using the local currency as the functional currency. Foreign currency-denominated assets and liabilities are translated into U.S. dollars at
year-end
exchange rates with the translation adjustment recorded as a component of accumulated comprehensive income (loss) in shareholders’ equity. Revenues and expenses are translated at the average monthly exchange rates in effect during the related period. We do not provide for U.S. income taxes on foreign currency translation adjustments associated with our subsidiaries in Germany, Denmark and China since their undistributed earnings are considered to be permanently invested. Included in our consolidated statements of income was a net transactional foreign exchange gain of $0.6 million in fiscal 2021, and a net transaction foreign exchange loss of $0.4 million in fiscal 2020 and $0.7 million for fiscal 2019.
Advertising:
We
expense advertising costs as incurred. Advertising costs including advertising production, trade shows and other activities are designed to enhance demand for our products and amounted to approximately $0.9 million; $1.8 million and $1.9 million in fiscal 2021, 2020 and 2019, respectively.
Long-Lived Assets:
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, as determined by the discounting of future cash flows. There were no impairment charges for our long-lived assets in fiscal years 2021, 2020 or 2019.
Intangible Assets:
Intangible assets include the value of customer and distributor relationships, existing technology and
non-competition
agreements acquired in connection with business and asset acquisitions and are stated at cost (fair value at acquisition) less accumulated amortization. These intangible assets have a definite life and are amortized over the assets’ useful lives using a systematic and rational basis which is representative of the assets’ use. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. If necessary, an impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the asset. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. There were no impairment charges for our intangible assets in fiscal years 2021, 2020 or 2019.
Goodwill:
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate indicate that the carrying value of an asset might be
 
5
6

impaired. Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment, or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment are aggregated as a single reporting unit if they have similar economic characteristics. We determined that each of our operating segments (Product Identification and T&M) represents a reporting unit for purposes of goodwill impairment testing.
The accounting guidance related to goodwill impairment testing allows for the performance of an optional qualitative assessment of whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this qualitative assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. Additionally, we can elect to forgo the qualitative assessment and perform the quantitative test. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using a blended income and market approach. The income approach is based on a discounted cash flow model and provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. The market approach, compares the reporting unit to publicly traded companies and transactions involving similar business, and requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference. We performed a quantitative analysis of the reporting units as of January 31, 2021 and determined that the fair value was in excess of our carrying value and therefore, no goodwill impairment has occurred. See Note 3, “Goodwill,” for further details.
Leases:
On February 1, 2019 we adopted ASC 842, Leases. This guidance requires a lessee to recognize assets and liabilities on the balance sheet for all leases, with the result being the recognition of a right of use (ROU) asset and a lease liability. The lease liability is equal to the present value of the minimum lease payments for the term of the lease, including any optional renewal periods determined to be reasonably certain to be exercised, using a discount rate determined at lease commencement. This discount rate is the rate implicit in the lease, if known; otherwise, the incremental borrowing rate for the expected lease term is used. Our incremental borrowing rate approximates the rate we would have to pay to borrow on a collateralized basis over a similar term at lease inception. The value of the ROU asset is equal to the initial measurement of the lease liability plus any lease payments made to the lessor at or before the commencement date and any unamortized initial direct costs incurred by the lessee, less any unamortized lease incentives received. Several of our lease contracts include options to extend the lease term and we include the renewal options for these leases in the determination of the ROU asset and lease liability when the likelihood of renewal is determined to be reasonably certain.
We enter into lease contracts for certain of our facilities at various locations worldwide. At inception of a contract, we determine whether the contract is or contains a lease. If we have a right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the asset, then the contract contains a lease.
There are two types of leases, operating leases and finance leases. Lease classification is determined at lease commencement. We have made an accounting policy election to apply the short-term exception, which does not require the capitalization of leases with terms of 12 months or less. All of our leases are classified as operating leases. Operating lease expense is recognized on a straight-line basis over the lease term and included in general and administrative expense on the consolidated statement of income. ROU assets are classified in other long-term assets, short-term lease liabilities are classified in other current liabilities, and long-term lease liabilities are classified in other long-term liabilities in the consolidated balance sheet. In the statement of cash flow, payments for operating leases are classified as operating activities.
 
5
7

 
In addition, several of our lease agreements include
non-lease
components for items such as common area maintenance and utilities which are accounted for separately from the lease component.
 
Income Taxes:
We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and tax basis of the assets and liabilities and are measured using statutory tax rates that will be in effect when the differences are expected to reverse. Our deferred taxes are presented as
non-current
in the accompanying consolidated balance sheet. An allowance against deferred tax assets is recognized when it is
more-likely-than-not
that some portion or all of the deferred tax assets will not be realized. At January 31, 2021 and 2020, a valuation allowance was provided for deferred tax assets attributable to certain domestic R&D credit carryforwards. In addition, during fiscal 2021, we provided a valuation allowance for deferred tax assets attributable to foreign tax credit carryforwards which would expire unused.
We account for uncertain tax positions in accordance with the guidance provided in ASC 740, “Accounting for Income Taxes.” This guidance describes a recognition threshold and measurement attribute for the financial statement disclosure of tax positions taken or expected to be taken in a tax return and requires recognition of tax benefits that satisfy a
more-likely-than-not
threshold. ASC 740 also provides guidance on
de-recognition,
classification, interest and penalties, accounting in interim periods and disclosure.
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a
one-time
mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and, subsequent to year end, have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return.
Net Income Per Common Share:
Basic net income per share is based on the weighted average number of shares outstanding during the period. Diluted net income per share is based on the basic weighted average number of shares and potential common equivalent shares for stock options, restricted stock awards and restricted stock units outstanding during the period using the treasury stock method. In fiscal years 2021, 2020 and 2019, there were 642,623; 202,187 and 326,275, respectively, of common equivalent shares that were not included in the computation of diluted net income per common share because their inclusion would be anti-dilutive.
Fair Value Measurement:
We measure our financial assets at fair value on a recurring basis in accordance with the guidance provided in ASC 820, “Fair Value Measurement and Disclosures,” which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
 
58

market participants at the measurement date. In addition, ASC 820 establishes a three-tiered hierarchy for inputs used in management’s determination of fair value of financial instruments that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect management’s belief about the assumptions market participants would use in pricing a financial instrument based on the best information available in the circumstances.
The fair value hierarchy is summarized as follows:
 
 
 
Level 1—Quoted prices in active markets for identical assets or liabilities;
 
 
 
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
 
 
 
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities
Cash and cash equivalents, accounts receivable, accounts payable, accrued compensation, other accrued expenses and income tax payable are reflected in the consolidated balance sheet at carrying value, which approximates fair value due to the short-term nature of these instruments.
Self-Insurance:
We are self-insured for U.S. medical and dental benefits for qualifying employees and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Assumptions are closely monitored and adjusted when warranted by changing circumstances. Our liability for self-insured claims is included within accrued compensation in our consolidated balance sheets and was $0.2 million and $0.6 million, as of January 31, 2021 and 2020.
Share-Based Compensation:
Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grant and has assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (RSA) and restricted stock units (RSU) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the grant date. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience.
Cash flow from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified with other income tax cash flows as an operating activity.
Share-based compensation becomes deductible for determining income taxes when the related award vests, is exercised, or is forfeited depending on the type of share-based award and subject to relevant tax law.
 
59

Derivative Financial Instruments:
We occasionally uses derivative instruments as part of its overall strategy to manage its exposure to market risks primarily associated with fluctuations in foreign currency exchange rates and interest rates. Derivative instruments are recognized as either assets or liabilities in the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the statement of income during the current period. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.
For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) (OCI) and reclassified into earnings in the same line item associated with the forecasted transaction, and in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest Expense” when the hedged transactions are interest cash flows associated with floating-rate debt, or “Other, Net” for portions reclassified relating to the remeasurement of the debt). The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any, are recognized in the statement of income during the current period.
Recent Accounting Pronouncements
Recently Adopted:
Fair Value Measurement
In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”)
2018-13,
“Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” ASU
2018-13
modifies the disclosure requirements for fair value measurements by removing, modifying or adding certain disclosures. The provisions of ASU
2018-13
relating to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. The remaining provisions should be applied retrospectively to all periods presented upon their effective date. We adopted the provisions of this guidance effective February 1, 2020. The adoption of this guidance did not have a material impact on our consolidated financial statements and accompanying disclosures.
Recent Accounting Standards Not Yet Adopted:
Income Taxes
In December 2019, the FASB issued an ASU
2019-12,
“Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU
2019-12
is effective for fiscal years beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are not electing to early adopt and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and accompanying disclosures.
No other new accounting pronouncements, issued or effective during fiscal 2021, have had or are expected to have a material impact on our consolidated financial statements.
 
6
0

Note 2—Revenue Recognition
We derive revenue from the sale of (i) hardware including, digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers used in the flight deck and in the cabin of military, commercial and business aircraft, (ii) related consumable supplies including paper, labels, tags, inks, toners and ribbons, (iii) repairs and maintenance of equipment and (iv) service agreements.
Revenues disaggregated by primary geographic markets and major product types are as follows:
Primary geographical markets:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
United States
   $ 70,911      $ 83,671      $ 83,668  
Europe
     29,029        29,617        31,574  
Canada
     5,574        5,719        6,692  
Asia
     5,105        8,316        8,207  
Central and South America
     3,950        4,145        4,147  
Other
     1,464        1,978        2,369  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
Major product types:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
Hardware
   $ 34,111      $ 48,959      $ 53,207  
Supplies
     71,772        71,838        71,178  
Service and Other
     10,150        12,649        12,272  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
Contract Assets and Liabilities
We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time.
Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $285,000 and $466,000 at January 31, 2021 and January 31, 2020, respectively, and are recorded as deferred revenue in the consolidated balance sheet. The decrease in the deferred revenue balance during the period ended January 31, 2021 is primarily due to $466,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2020 offset by cash payments received in advance of satisfying performance obligations.
Contract Costs
We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized based on the forecasted number of units sold over the estimated benefit term. The balance of these contract assets at January 31, 2020 was $944,000, of which $59,000 was reported in other current assets and $885,000 was reported in other assets in the consolidated balance sheet. Amortization of incremental direct costs was $26,940 for the period ended
 
6
1

January 31, 2021. The balance of the deferred incremental direct contract costs net of accumulated amortization at January 31, 202
1
is $
917,000
, of which $
36,000
was reported in other current assets and $
881,000
was reported in other assets in the consolidated balance sheet. The contract costs are expected to be amortized over the estimated remaining period of benefit, which we currently estimate to be approximately
5
 years.
Note 3—Goodwill
Goodwill by reporting unit is as follows:
 
(In thousands)
  
Product
Identification
 
 
T&M
 
  
Total
 
Balance at January 31, 2019
   $ 7,807     $ 4,522      $ 12,329  
Foreign currency translation
     (295     —          (295
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2020
   $ 7,512     $ 4,522      $ 12,034
Foreign currency translation
     772       —          772  
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2021
   $ 8,284     $ 4,522      $ 12,806  
  
 
 
   
 
 
    
 
 
 
 
After consideration of the impact of the decline in the global economy due to the COVID-19 pandemic, coupled with the grounding of the 737 MAX in March, 2019 and the production halt in January, 2020 which negatively impacted revenues and margins in fiscal 2020 and 2021, we elected to forgo the qualitative assessment and instead performed a quantitative goodwill impairment test to determine if the carrying values of the reporting units are greater than the fair values. We utilized a blended income and market approach. The income approach was based upon a discounted cash flow model which we believe provides a fair value estimate of the reporting unit’s expected long-term operating performance. The market approach compares the reporting units to similar publicly traded companies. Based on our quantitative impairment assessment as of January 31, 2021, we determined that the fair value of the reporting units were in excess of their carrying values and therefore, no goodwill impairment had occurred.
 
Note 4—Intangible Assets
Intangible assets are as follows:
 
   
January 31, 2021
   
January 31, 2020
 
(In thousands)
 
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
   
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
 
Miltope:
                                                               
Customer Contract Relationships
  $ 3,100     $ (2,284   $ —       $ 816     $ 3,100     $ (2,021   $ —       $ 1,079  
RITEC:
                                                               
Customer Contract Relationships
    2,830       (1,423     —         1,407       2,830       (1,076     —         1,754  
Non-Competition
Agreement
    950       (950     —                  950       (871     —         79  
TrojanLabel:
                                                               
Existing Technology
    2,327       (1,405     196       1,118       2,327       (1,053     78       1,352  
Distributor Relations
    937       (396     89       630       937       (297     27       667  
Honeywell:
                                                               
Customer Contract Relationships
    27,243       (9,712     —         17,531       27,243       (6,791     —         20,452  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Intangible Assets, net
  $ 37,387     $ (16,170   $       285     $ 21,502     $ 37,387     $ (12,109   $       105     $ 25,383  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
62

There were no impairments to intangible assets during the periods ended January 31, 2021 and 2020. Amortization expense of $4.1 million; $4.2 million and $4.1 million with regard to acquired intangibles has been included in the consolidated statements of income for years ended January 31, 2021, 2020 and 2019, respectively.
Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
2022
 
  
2023
 
  
2024
 
  
2025
 
  
2026
 
Estimated amortization expense
   $ 3,938      $ 3,956      $ 4,055      $ 3,416      $ 3,021  
Note 5—Inventories
The components of inventories are as follows:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)              
Materials and Supplies
   $ 20,265      $ 20,151  
Work-in-Progress
     2,076        1,408  
Finished Goods
     16,371        17,992  
    
 
 
    
 
 
 
       38,712        39,551  
Inventory Reserve
     (8,652      (5,626
    
 
 
    
 
 
 
     $ 30,060      $ 33,925  
    
 
 
    
 
 
 
Finished goods inventory includes $4.0 million and $3.4 million of demonstration equipment at January 31, 2021 and 2020, respectively.
Note 6—Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
  
  
1,004     
967  
Buildings and Leasehold Improvements
     12,642        12,524  
Machinery and Equipment
     23,346        23,167  
Computer Equipment and Software
     13,847        11,388  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     50,839        48,046  
Accumulated Depreciation
     (38,828      (36,778
    
 
 
    
 
 
 
Net Property Plant and Equipment
  
12,011     
11,268  
    
 
 
    
 
 
 
Depreciation expense on property, plant and equipment was $1.9 million for the year ended January 31, 2021 and $2.0 million for both of the years ended January 31, 2020 and 2019.
 
63

Note 7—Accrued Expenses
Accrued expenses consisted of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Warranty
   $ 730      $ 850  
Professional Fees
     546        697  
Lease Liability
     372        416  
Accrued Payroll & Sales Tax
     292        193  
Stockholder Relation Fees
     91        194  
Dealer Commissions
     57        236  
Other Accrued Expenses
     1,851        2,125  
    
 
 
    
 
 
 
     $ 3,939      $ 4,711  
    
 
 
    
 
 
 
Note 8—Credit Agreement and Long-
 
Term Debt
Credit Agreement
On July 30, 2020, we entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), our wholly owned subsidiary, ANI ApS, a Danish private limited liability company and TrojanLabel ApS, a Danish private limited liability company and wholly-owned subsidiary of ANI ApS (“TrojanLabel”). The A&R Credit Agreement amended and restated the Credit Agreement dated as of February 28, 2017 (the “Prior Credit Agreement”) by and among us, ANI ApS, TrojanLabel and the Lender. In connection with the A&R Credit Agreement, we entered into an Amended and Restated Security and Pledge Agreement and a mortgage in favor of the Lender with respect to our owned real property in West Warwick, Rhode Island. Under the A&R Credit Agreement, AstroNova, Inc. is the sole borrower, and at January 31, 2021, its obligations are guaranteed by ANI ApS and TrojanLabel.
Immediately prior to the closing of the A&R Credit Agreement, we repaid $1.5 million in principal amount of term loans outstanding under the 
Prior
 
Credit Agreement.
The A&R Credit Agreement provides for (i) a term loan in the principal amount of $15.2 million, which we used to refinance the outstanding term loans borrowed by us and ANI ApS under the 
Prior
Credit Agreement
 
and a portion of the outstanding revolving loans borrowed by us under the
Pr
i
or
 Credit Agreement, and (ii) a $10.0 million revolving credit facility available to us for general corporate purposes. Revolving credit loans may be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
During the third quarter of fiscal year 2021, we repaid the entire outstanding balance under the revolving line of credit. Balances outstanding under the revolving line of credit during the year ended January 31, 2021 bore interest at a weighted average annual rate of 3.41%, and $188,000 of interest was incurred and is included in other income (expense) in the accompanying condensed consolidated income statement for the year ended January 31, 2021. At January 31, 2021, there was no balance outstanding under the revolving line of credit and $10.0 million was available for borrowing under the revolving credit facility.
The A&R Credit Agreement was accounted for as a debt modification in a
non-
troubled
debt restructuring. We incurred $0.2 million of new debt issuance costs related to the term loan, of which $0.1 million of new lender fees were recorded against the debt as debt issuance costs and will be amortized over the term of the loan and $0.1 million of third party fees that were expensed as incurred. Additionally, $0.1 million of unamortized debt issuance costs related to the prior term debt will be amortized over the remaining life of the new term loan. We also incurred $0.1 million of new debt issuance fees in connection with the revolving line of credit which are included as a component of prepaid expenses and other current assets and will be amortized over the remaining life of the A&R Credit Agreement.
64

Under the A&R Credit Agreement, the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about July 31, 2020 and October 31, 2020 was $0.8 million; the principal amount of the quarterly installment required to be paid on the last day of our fiscal quarter ending January 31, 2021 was $1.1 million; the principal amount of the quarterly installment required to be paid on the last day of the our fiscal quarter ending on or about April 30, 2021 will be $1.1 million; the principal amount of each quarterly installment required to be paid on the last day of each of the our fiscal quarters ending on or about July 31, 2021, October 31, 2021, January 31, 2022 and April 30, 2022 is $1.4 million, and the entire remaining principal balance of the term loan is required to be paid on June 15, 2022. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than June 15, 2022, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
Under the A&R Credit Agreement the term loan and revolving credit loans bear interest at a rate per annum equal to, at the our option, either (a) the LIBOR Rate (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 2.15% to 3.65% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 1.00%, plus a margin that varies within a range of 1.15% to 2.65% based on our consolidated leverage ratio. We are also required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.25% and 0.675% based on our consolidated leverage ratio.
The loans under the A&R Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the A&R Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
Under the A&R Credit Agreement, we must comply with various customary financial and
non-financial
covenants including a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio, a minimum level of EBITDA, a consolidated asset coverage ratio and a minimum level of liquidity. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on capital stock, to repurchase or acquire capital stock, to conduct mergers or acquisitions, to sell assets, to alter the capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the A&R Credit Agreement.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the A&R Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or our undergoing a change of control.
In addition to the guarantees by ANI ApS and TrojanLabel, our obligations under the A&R Credit Agreement are also secured by substantially all of AstroNova, Inc.’s personal property assets (including a pledge of the equity interests it holds in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island.
 
65

Long-Term Debt
Long-term debt in the accompanying condensed consolidated balance sheets under the A&R Credit Agreement is as follows:
 
 
  
January 31
 
(In thousands)
  
2021
 
  
2020
 
USD Term Loan (4.65% as of January 31, 2021); maturity date of June 15, 2022
   $ 12,576      $     
USD Term Loan (3.03% as of January 31, 2021); maturity date November 30, 2022
               8,250  
USD Term Loan (3.03% as of January 31, 2021); maturity date of January 31, 2022
               4,784  
    
 
 
    
 
 
 
       12,576        13,034  
Debt Issuance Costs, net of accumulated amortization
     (141      (111
Current Portion of Term Loan
     (5,326      (5,208
    
 
 
    
 
 
 
Long-Term Debt
   $ 7,109      $ 7,715  
    
 
 
    
 
 
 
During the years ended January 31, 2021, 2020 and 2019, we recognized $0.5 million, $0.4 million and $0.6 million of interest expense, respectively, which was included in other income (expense) in the accompanying consolidated income statement.
The schedule of required principal payments remaining under the A&R Credit Agreement on long-term debt outstanding as of January 31, 2021 is as follows:
 
(In thousands)
  
 
 
Fiscal 2022
   $ 5,326  
Fiscal 2023
     7,250  
    
 
 
 
     $ 12,576  
    
 
 
 
Refer to Note 23, “Subsequent Event” for details regarding the First Amendment to Credit Agreement to our A&R Credit Agreement, which was entered into subsequent to year end on March 24, 2021.
Note 9—Paycheck Protection Program Loan
On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”) from Greenwood pursuant to the Paycheck Protection Program (“PPP”) administered by the United States Small Business Administration (the “SBA”) and authorized by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), enacted on March 27, 2020. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020 (the “PPP Flexibility Act”) which was enacted on June 5, 2020.
The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date, and is payable monthly. No payments are due on the PPP Loan until the date on which the SBA determines the amount of the PPP Loan that is eligible for forgiveness, so long as we apply for forgiveness within the ten months from the end of the twenty-four week period following the date of loan disbursement, but interest will continue to accrue during the deferral period. We accrued interest for the PPP Loan in the amount of $33,000, which is included in other income (expense) in the accompanying consolidated statements of income for the year ended January 31, 2021.
The PPP Loan may be prepaid at any time without penalty. The loan agreement and promissory note include customary provisions for a loan of this type, including prohibitions on our payment of dividends or repurchase of
 
66

shares of our stock while the PPP Loan remains outstanding. The loan agreement and promissory note also include events of default relating to, among other things, payment defaults, breaches of the provisions of the loan agreement or the promissory note, and cross-defaults on other loans.
Subject to the limitations and conditions set forth in the CARES Act, the PPP Flexibility Act, and the regulations and guidance provided by the SBA with respect to the PPP, a portion of the PPP Loan may be forgiven in an amount up to the amount of the PPP Loan proceeds that we spent on payroll, rent, utilities and interest on certain debt during the twenty-four-week period following incurrence of the PPP Loan. Interest accrued on the forgiven portion of the principal amount of the PPP Loan is also forgiven. The amount of the PPP Loan to be forgiven in respect of rent, utilities and interest on certain debt will be capped at 40% of the forgiven amount, with the remaining forgiven amount allocated to payroll costs. We have fully utilized the PPP Loan proceeds for qualifying expenses during fiscal year 2021 and subsequent to year end we applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Whether our application for forgiveness will be granted and in what amount is subject to approval by the SBA and may also be subject to further requirements in any regulations and guidelines the SBA may adopt. The PPP Loan is classified as long-term debt in the condensed consolidated balance sheet until the forgiveness determination has been made by the SBA.
Note 10—Derivative Financial Instruments and Risk Management
On February 28, 2017, as part of the Prior Credit Agreement, we entered into a cross-currency interest rate swap to manage the interest rate risk and foreign currency exchange risk associated with the floating-rate foreign currency-denominated term loan borrowing by ANI ApS and an interest rate swap to manage the interest rate risk associated with our variable rate term loan borrowing (the “Swaps”). Both Swaps were designated as cash flow hedges of floating-rate borrowings.
Our cross-currency interest rate swap agreement effectively modified our exposure to interest rate risk and foreign currency exchange rate risk by converting our floating-rate debt denominated in U.S. Dollars on ANI ApS’s books to a fixed-rate debt denominated in Danish Kroner for the term of the loan, thus reducing the impact of interest-rate and foreign currency exchange rate changes on future interest expense and principal repayments. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed-rate interest payments in Danish Kroner, as well as exchanges of principal at the inception spot rate, over the life of the term loan.
Subsequently, concurrent with our borrowings to fund the payments for the Asset Purchase and License Agreement with Honeywell International, we entered into an interest rate swap agreement to modify our exposure to interest rate risk by effectively converting our floating-rate borrowings to fixed-rate debt over the term of the loan, thus reducing the impact of interest-rate changes on future interest expense. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed interest rate payments in U.S. dollars over the life of the term loan.
As a direct result of the terms of the Lender’s conditions for entry into the A&R Credit Agreement, on July 30, 2020, we terminated the two Swaps that we used to manage the interest rate and foreign currency exchange risks associated with our prior borrowings under the
Prior
Credit Agreement. The terms of the A&R Credit Agreement caused those swaps to cease to be effective hedges of the underlying exposures. The termination of the Swaps was contracted immediately prior to the end of the second quarter of fiscal 2021 at a cash cost of approximately $0.7 million, which was settled in the third quarter. Upon termination, the remaining balance of $58,000 in accumulated other comprehensive loss related to the cross-currency interest rate swap was reclassified into earnings as the forecasted foreign currency interest payments will not occur and such balance is included in other expense in the accompanying consolidated statements of income for the period ended January 31, 2021. The remaining balance in accumulated other comprehensive loss related to the interest rate swap of $ 0.1 million is being amortized into earnings through the original term of the hedge relationship as the underlying floating interest rate debt still exists.
 
67

The following table summarizes the notional amount and fair value of our derivative instruments:
 
Cash Flow Hedges
(In thousands)
  
January 31, 2021
 
  
January 31, 2020
 
  
Notional Amount
 
  
Fair Value Derivatives
 
  
Notional Amount
 
  
Fair Value Derivatives
 
 
  
Asset
 
  
Liability
 
  
Asset
 
  
Liability
 
Cross-currency Interest Rate Swap
   $      $      $      $ 4,489      $      $ 250  
Interest Rate Swap
   $      $      $      $ 8,250      $      $ 96  
The following tables present the impact of the derivative instruments in our consolidated financial statements for the years ended January 31, 2021 and 2020:
 
 
  
Years Ended
 
Cash Flow Hedge
(In thousands)
  
Amount of Gain(Loss)
Recognized in OCI
on
Derivative
 
  
Location of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
January 31,
2021
 
 
January 31,
2020
 
  
January 31,
2021
 
 
January 31,
2020
 
Swap contracts
   $ (301   $ 159        Other Income      $ (248   $ 338  
    
 
 
   
 
 
             
 
 
   
 
 
 
At January 31, 2021, we expect to reclassify approximately $0.1 million of net gains on the swap contracts from accumulated other comprehensive loss to earnings during the next 12 months due to changes in foreign exchange rates and the payment of variable interest associated with the floating-rate debt.
 
Note 11—Royalty Obligation
In fiscal 2018, AstroNova, Inc. entered into an Asset Purchase and License Agreement with Honeywell International, Inc. to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid in quarterly installments over a
ten-year
period. Royalty payments are based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue.
The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments using a present value factor of 2.8%, which is based on the estimated
after-tax
cost of debt for similar companies. As of January 31, 2021, we had paid an aggregate of $5.5 million of the guaranteed minimum royalty obligation. At January 31, 2021, the current portion of the outstanding guaranteed minimum royalty obligation of $2.0 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $6.1 million is reported as a long-term liability on our consolidated balance sheet. In addition to the guaranteed minimum royalty payments, for the periods ended January 31, 2021 and January 31, 2020, we also incurred excess royalty expense of $31 thousand and $1.2 million, respectively, which is included in cost of revenue in our consolidated statements of income. A total of $0.2 million of excess royalty is payable and reported as a current liability on our consolidated balance sheet at January 31, 2021.
Note 12—Leases
We enter into lease contracts for certain of its facilities at various locations worldwide. Our leases have remaining lease terms of one to eight years, some of which include options to extend the lease term for periods of up to five years when it is reasonably certain the Company will exercise such options.
 
68

We lease office space from an affiliate. This lease is classified as an operating lease with annual rental payments of $63,000 for both January 31, 2021 and January 31, 2020.
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
  
January 31,
2021
    
January 31,
2020
 
Lease Assets
   Right of Use Assets   
$
1,389
 
 
$ 1,661  
Lease Liabilities
Current
   Other Accrued Expenses   
 
372
 
 
  416  
Lease Liabilities
Long Term
   Lease Liabilities   
$
1,065
 
 
$ 1,279  
Lease cost information is as follows:
 
Operating Leases
(In thousands)
  
Statement of Income Classification
    
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Operating Lease Costs
       General and Administrative Expense        $ 485      $ 449  
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
January 31,
2021
 
2022
   $ 372  
2023
     318  
2024
     292  
2025
     184  
2026
     163  
Thereafter
     270  
    
 
 
 
Total Lease Payments
     1,599  
Less: Imputed Interest
     (162
    
 
 
 
Total Lease Liabilities
   $ 1,437  
    
 
 
 
As of January 31, 2021, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 5.2 years and 4.00%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term.
Supplemental cash flow information related to leases is as follows:
 
(In thousands)
  
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Cash paid for operating lease liabilities
   $ 429      $ 406  
 
 
69

Note 13—Accumulated Other Comprehensive Income (Loss)
The changes in the balance of accumulated other comprehensive income (loss) by component are as follows:
 
(In thousands)   
Foreign Currency
Translation
Adjustments
   
Unrealized
Holding
Gain (Loss)
on Available
for Sale
Securities
   
Net
Unrealized
Gain (Losses)
on Cash Flow
Hedges
   
Total
 
Balance at January 31, 2018
   $ (181   $ (3   $ 12     $ (172
Other Comprehensive Income (Loss) before reclassification
     (671     —         622       (49
Amounts reclassified from AOCI to Earnings
     —         3       (600     (597
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (671     3       22       (646
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2019
   $ (852   $ —       $ 34     $ (818
Other Comprehensive Income (Loss) before reclassification
     (133     —         122       (11
Amounts reclassified from AOCI to Earnings
     —         —         (264     (264
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (133     —         (142     (275
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2020
   $ (985   $ —       $ (108   $ (1,093
Other Comprehensive Income (Loss) before reclassification
     710       —         (239     471  
Amounts Reclassified from AOCI to Earnings
     —         —         193       193  
Cross-Currency Interest Rate Swap Termination
     —         —         45       45  
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     710       —         (1     709  
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2021
   $ (275   $ —       $ (109   $ (384
    
 
 
   
 
 
   
 
 
   
 
 
 
The amounts presented above in other comprehensive income (loss) are net of taxes except for translation adjustments associated with our German and Danish subsidiaries.
Note 14—Shareholders’ Equity
During fiscal 2021, 2020 and 2019, certain of our employees delivered a total of 15,357, 20,329 and 33,430 shares, respectively, of our common stock to satisfy the exercise price and related taxes for stock options exercised and restricted stock vesting. The shares delivered were valued at a total of $0.1 million; $0.5 million and $0.6 million, respectively, and are included in treasury stock in the accompanying consolidated balance sheets at January 31, 2021, 2020 and 2019. These transactions did not impact the number of shares authorized for repurchase under our current repurchase program.
Note 15—Share-Based Compensation
The Company maintains the following share-based compensation plans:
Stock Plans:
We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options,
non-qualified
stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (RSAs). The 2018 Plan authorizes the issuance of up to 950,000 shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under the previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or, for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more
 
70

than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, 186,500 unvested shares of restricted stock and options to purchase an aggregate of 135,500 shares were outstanding as of January 31, 2021.
In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 or 2015 Plans, but outstanding awards will continue to be governed by those plans. As of January 31, 2021, options to purchase an aggregate of 337,958 shares were outstanding under the 2007 Plan and 10,833 unvested shares of restricted stock and options to purchase an aggregate of 148,625 shares were outstanding under the 2015 Plan.
We also have a
Non-Employee
Director Annual Compensation Program (the “Program”), under which each of our
non-employee
directors automatically receives a grant of restricted stock on the date of their
re-election
to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2021 was $60,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date.
Share-Based Compensation:
Share-based compensation expense has been recognized as follows:
 
 
 
Years Ended January 31
 
 
 
    2021    
 
  
    2020    
 
  
    2019    
 
(In thousands)
 
 
 
  
 
 
  
 
 
Stock Options
   $ 517      $ 616      $ 783  
Restricted Stock Awards and Restricted Stock Units
     1,285        1,136        1,088  
Employee Stock Purchase Plan
     17        23        15  
    
 
 
    
 
 
    
 
 
 
Total
   $ 1,819      $ 1,775      $ 1,886  
    
 
 
    
 
 
    
 
 
 
71
Stock Options:
Aggregated information regarding stock options granted under the plans is summarized below:
 
    
Number
of Shares
   
Weighted-
Average
Exercise
Price Per
Share
 
Options Outstanding, January 31, 2018
     745,270     $ 12.52  
Options Granted
     196,000       18.21  
Options Exercised
     (150,125     10.62  
Options Forfeited
     (16,300     15.10  
Options Cancelled
     (3,700     8.95  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2019
     771,145     $ 14.30  
Options Granted
                  
Options Exercised
     (57,175     11.60  
Options Forfeited
     (34,526     15.73  
Options Cancelled
     (400     6.22  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2020
     679,044     $ 14.46  
Options Granted
              —    
Options Exercised
     (1,200     7.60  
Options Forfeited
     (54,361     12.89  
Options Cancelled
     (1,400     7.36  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2021
     622,083     $ 14.63  
    
 
 
   
 
 
 
Set forth below is a summary of options outstanding at January 31, 2021:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
     41,044      $ 7.97        1.3        41,044      $ 7.97        1.3  
$10.01-15.00
     359,314        13.63        4.9        326,741        13.65        4.7  
$15.01-20.00
     221,725        17.48            6.8        167,367        17.22        6.7  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       622,083      $ 14.63            5.3        535,152      $ 14.33        5.1  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
No options were granted during fiscal 2021 or
fis
cal
2020. The weighted-average estimated fair value of options granted during fiscal 2019 was $7.43. As of January 31, 2021, there was $0.2 million of unrecognized compensation expense related to the unvested stock options granted under the plans. This expense is expected to be recognized over a weighted-average period of 0.8 years.
As of January 31, 2021, the aggregate intrinsic value (the aggregate difference between the closing stock price of our common stock on January 31, 2021, and the exercise price of the outstanding options) that would have been received by the option holders if all options had been exercised was $0.1 million for all exercisable options and $0.1 million for all options outstanding. The total aggregate intrinsic value of options exercised during 2021, 2020 and 2019 was $4,000, $0.5 million and $1.1 million, respectively.
 
7
2

Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs):
Aggregated information regarding RSUs and RSAs granted under the Plan is summarized below:
 
 
  
RSAs & RSUs
 
  
Weighted-Average
Grant Date Fair Value
 
Outstanding at January 31, 2018
  
 
177,347
 
  
$
13.99
 
Granted
  
 
108,790
 
  
 
17.85
 
Vested
  
 
(67,447
  
 
14.26
 
Forfeited
  
 
(85,023
  
 
14.17
 
 
  
 
 
 
  
 
 
 
Outstanding at January 31, 2019
     133,667      $ 16.90  
Granted
     119,522        19.86  
Vested
     (59,930      14.50  
Forfeited
     (58,625      19.00  
    
 
 
    
 
 
 
Outstanding at January 31, 2020
     134,634      $ 16.79  
    
 
 
    
 
 
 
Granted
     245,131        7.61  
Vested
     (64,997      17.28  
Forfeited
     (117,355      8.83  
    
 
 
    
 
 
 
Outstanding at January 31, 2021
     197,413      $ 9.96  
    
 
 
    
 
 
 
As of January 31, 2021, there was $1.1 million of unrecognized compensation expense related to unvested RSUs and RSAs. This expense is expected to be recognized over a weighted average period of 0.8 years.
Employee Stock Purchase Plan (ESPP):
Our
 ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair market value on the date of purchase. A total of 247,500 shares were initially reserved for issuance under this plan. Summarized plan activity is as follows:
 
    
Years Ended January 31
 
    
    2021    
    
    2020    
    
    2019    
 
Shares Reserved, Beginning
     24,974        33,853        39,207  
Shares Purchased
     (14,600      (8,879      (5,354
    
 
 
    
 
 
    
 
 
 
Shares Reserved, Ending
     10,374        24,974        33,853  
    
 
 
    
 
 
    
 
 
 
Note 16—Income Taxes
The components of income (loss) before income taxes are as follows:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Domestic
   $ (1,193   $ 1,930     $ 6,859  
Foreign
     3,372       (560     449  
    
 
 
   
 
 
   
 
 
 
     $ 2,179     $ 1,370     $ 7,308  
    
 
 
   
 
 
   
 
 
 
 
73

The components of the provision/(benefit) for income taxes are as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Current:
  
     
 
     
 
     
Federal
   $ 1,272      $ 660      $ 1,807  
State
     224        221        457  
Foreign
     420        368        952  
    
 
 
    
 
 
    
 
 
 
     1,916        1,249        3,216
 
    
 
 
    
 
 
    
 
 
 
 
Deferred:
                        
Federal
   $ (910   $ (1,364   $ (843
State
     (189     (282     (170
Foreign
     78       8       (625
    
 
 
   
 
 
   
 
 
 
       (1,021     (1,638     (1,638
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Total income tax provision/(benefit)
 
differs from the expected tax provision/(benefit) as a result of the following:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Income Tax Provision at Statutory Rate
   $ 458     $ 288     $ 1,534  
Denmark Statutory Audit
     341       —         —    
Foreign Rate Deferential
     197       315       558  
Share Based Compensation
     171       (145     (127
Canada Withholding Taxes
     62       —         —    
State Taxes, Net of Federal Tax Effect
     28       (48     226  
Global Intangible Low Taxed Incom
e
     14       107       —    
Meals and Entertainment
     11       31       56  
U.S. Corporate Rate Change
     —         —         52  
Transition Tax on Repatriated Earnings
     —         —         14  
Return to Provision Adjustment
     (2     (207     58  
Change in Reserves Related to ASC 740 Liability
     (10     (352     (34
Change in Valuation Allowance
     (81     256       —    
R&D Credits
     (157     (209     (218
Foreign Derived Intangible Income
     (150     (107     (53
Foreign Tax Credits
     —         (344     (477
Other
     13       26       (11
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Our effective tax rate for 2021 was 41.1% compared to negative 28.4% in 2020 and 21.6% in 2019. The increase in the effective tax rate in 2021 from 2020 is primarily related to the change in mix of income between relevant jurisdictions in which
 
we
are
subject to income taxes. Specific items increasing the effective tax rate include foreign rate differential, Denmark statutory audit adjustments, stock-based compensation, and Canada withholding taxes. This increase was offset by the foreign derived intangible income (“FDII”) deduction, the release of a valuation allowance in China, and R&D tax credits expected to be utilized.
The decrease in the effective tax rate in 2020 from 2019 is primarily related to lower
pre-tax
income in 2020 compared to 2019.. Specific items decreasing the effective tax rate include FDII, the release of ASC 740 liabilities, R&D credit utilization, and return to provision adjustments. This decrease was offset by valuation
 
74

allowances recorded on unbenefited losses in China and on carryforward foreign tax credits expected to expire unused.
The components of deferred income tax expense arise from various temporary differences and relate to items included in the statement of income. The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities are as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
(In thousands)
  
 
 
 
 
 
Deferred Tax Assets:
  
     
 
     
Inventory
   $ 2,700     $ 2,094  
Honeywell Royalty Liability
     2,590       2,583  
State R&D Credits
     1,546       1,496  
Share-Based Compensation
     600       582  
Bad Debt
     245       165  
Warranty Reserve
     176       205  
Compensation Accrual
     159       159  
Net Operating Loss
     154       443  
ASU 842 Adjustment—Lease Liability
     125       —    
Unrecognized State Tax Benefits
     101       116  
Foreign Tax Credit
     83       113  
Deferred Service Contract Revenue
     68       111  
Other
     308       295  
    
 
 
   
 
 
 
       8,855       8,362  
Deferred Tax Liabilities:
                
Accumulated Tax Depreciation in Excess of Book Depreciation
     752       1,002  
Intangibles
     399       776  
ASU 842 Adjustment – Lease Liability
     119           
Other
     307       188  
    
 
 
   
 
 
 
       1,577       1,966  
    
 
 
   
 
 
 
Subtotal
     7,278       6,396  
Valuation Allowance
     (1,721     (1,752
    
 
 
   
 
 
 
Net Deferred Tax Assets
   $ 5,557     $ 4,644  
    
 
 
   
 
 
 
The valuation allowance of $1.7 million at January 31, 2021 relate
s
to domestic research and development tax credit carryforwards and foreign tax credit carryforwards which are expected to expire unused. The valuation allowance of $1.8 million at January 31, 2020 included a valuation allowance on China net operating losses, which was released during 2021.    
At January 31, 2021, we had net operating loss carryforwards of $0.4 million in China, which expire in 2022 through 2026. We have net operating loss carryforwards of $0.2 million in Germany, which can be carried forward indefinitely. We expect to utilize the net operating loss carryforwards in China and Germany before expiration.
At January 31, 2021, we had state research credit carryforwards of approximately $1.5 million which expire in 2021 through 2028. We maintain a full valuation allowance against these credits as we expect these credits to expire unused.
75

We believe that it is reasonably possible that some unrecognized tax benefits, accrued interest and penalties could decrease income tax expense in the next year due to either the review of previously filed tax returns or the expiration of certain statutes of limitation. The changes in the balances of unrecognized tax benefits, excluding interest and penalties are as
follows:
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance at February 1
  
$
362
 
 
$
618
 
 
$
665
 
Increases in prior period tax position
s
  
 
59
 
 
 
—  
 
 
 
—  
 
Increases in current period tax positions
  
 
5
 
 
 
2
 
 
 
7
 
Reductions related to lapse of statutes of limitations
  
 
(42
 
 
(26
 
 
(54
Reductions related to settlement with tax authorities
  
 
—  
 
 
 
(232
 
 
—  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Balance at January 31
  
$
384
 
 
$
362
 
 
$
618
 
 
  
 
 
 
 
 
 
 
 
 
 
 
During fiscal 2021 and 2020, we released $50,000 and $114,000, respectively, of accrued interest and penalties relating to a change in various unrecognized tax positions. During fiscal 2019, we recognized $8,000 of expense related to a change in interest and penalties, which are included as a component of income tax expense in the accompanying statements of income for the period ended January 31, 2019. The Company has accrued potential interest and penalties of $0.3 million included in Income Taxes Payable in the consolidated balance sheet at the end of both January 31, 2021 and 2020.
The Company and its subsidiaries file income tax returns in U.S. federal jurisdictions, various state jurisdictions, and various foreign jurisdictions. The Company was previously under audit by the IRS for the tax years ended January 31, 2015, 2016, and 2017, but on June 6, 2019, we received formal communication regarding the close of the audit with no additional changes made by the IRS. Therefore, the reserves for federal uncertain tax positions relating to the years in question have been released. In fiscal 2020, we released $232,000 relating to the federal tax exposure for the years previously under audit and $74,000 of related interest (net of federal benefit) and penalties.
The Company was also notified of an income tax audit from the state of Rhode Island, but no significant items have been raised at this time other than information requests. No assessments have been made as of January 31, 2021.
U.S. income taxes have not been provided on $5.7 million of undistributed earnings of our foreign subsidiaries since it is our intention to permanently reinvest such earnings offshore. If the earnings were distributed in the form of dividends, the Company would not be subject to U.S. tax as a result of the Tax Act but could be subject to foreign income and withholding taxes. Determination of the amount of this unrecognized deferred income tax liability is not practical.
Note 17—Nature of Operations, Segment Reporting and Geographical Information
Our operations consist of the design, development, manufacture and sale of specialty printers and data acquisition and analysis systems, including both hardware and software and related consumable supplies. We organize and manage our business as a portfolio of products and services designed around a common theme of data acquisition and information output. We have two reporting segments consistent with our revenue product groups: Product Identification (“PI”) and Test & Measurement (“T&M”).
Our PI segment produces an array of high-technology digital color and monochrome label printers and mini presses, labeling software and supplies for a variety of commercial industries worldwide. AstroNova’s T&M segment produces data acquisition systems used worldwide for a variety of recording, monitoring and troubleshooting applications for many industries including aerospace, automotive, defense, rail, energy, industrial and general manufacturing. The T&M segment also includes our line of aerospace flight deck and cabin printers.
 
7
6

Business is conducted in the United States and through foreign branch offices and subsidiaries in Canada, Europe, China, Southeast Asia and Mexico. Manufacturing activities are primarily conducted in the United States. Revenue and service activities outside the United States are conducted through wholly-owned entities and, to a lesser extent, through authorized distributors and agents. Transfer prices are intended to produce gross profit margins as would be associated with an arms-length transaction.
The accounting policies of the reporting segments are the same as those described in the summary of significant accounting policies herein. We evaluate segment performance based on the segment profit before corporate and financial administration expenses.
Summarized below are the revenue and segment operating profit (loss) (both in dollars and as a percentage of revenue) for each reporting segment:
 
($ in thousands)
 
Revenue
 
 
Segment Operating Profit (Loss)
 
 
Segment Operating Profit (Loss)
as a % of Revenue
 
 
 
2021
 
 
2020
 
 
2019
 
 
    2021    
 
 
    2020    
 
 
    2019    
 
 
  2021  
 
 
  2019  
 
 
  2018  
 
Product Identification
  $ 90,268     $ 88,116     $ 86,786     $ 12,885     $ 7,509     $ 7,910       14.3     8.5     9.1
T&M
    25,765       45,330       49,871       (1,032     6,281       11,933       (4.0 )%      13.9     23.9
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total
  $ 116,033     $ 133,446     $ 136,657       11,853       13,790       19,843       (10.3 )%      10.3     14.5
   
 
 
   
 
 
   
 
 
                           
 
 
   
 
 
   
 
 
 
Corporate Expenses
                            9,420       11,357       11,123                          
                           
 
 
   
 
 
   
 
 
                         
Operating Income
                            2,433       2,433       8,720                          
Other Expense, Net
                            (254     (1,063     (1,412                        
                           
 
 
   
 
 
   
 
 
                         
Income Before Income Taxes
                            2,179       1,370       7,308                          
Income Tax Provision (Benefit)
                            895       (389     1,578                          
                           
 
 
   
 
 
   
 
 
                         
Net Income
                          $ 1,284     $ 1,759     $ 5,730                          
                           
 
 
   
 
 
   
 
 
                         
No customer accounted for greater than 10% of net revenue in fiscal 2021, 2020 or 2019.
Other information by segment is presented below:
 
(In thousands)
  
Assets
 
 
  
2021
 
  
2020
 
Product Identification
   $ 50,047      $ 51,439  
T&M
     51,262        57,050  
Corporate*
     14,164        8,175  
    
 
 
    
 
 
 
Total
   $ 115,473      $ 116,664  
    
 
 
    
 
 
 
 
*
Corporate assets consist principally of cash, cash equivalents, deferred tax assets and refunds, and certain prepaid corporate assets.
 
(In thousands)   
Depreciation and
Amortization
    
Capital Expenditures
 
    
2021
    
2020
    
2019
    
2021
    
2020
    
2019
 
Product Identification
   $ 1,835      $ 1,928      $ 1,888      $ 1,563      $ 2,001      $ 1,935  
T&M
     4,148        4,356        4,264        1,024        905        710  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 5,983      $ 6,284      $ 6,152      $ 2,587      $ 2,906      $ 2,645  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
77

Geographical Data
Presented below is selected financial information by geographic area:
 
(In thousands)
  
Revenue
 
  
Long-Lived Assets*
 
 
  
2021
 
  
2020
 
  
2019
 
  
2021
 
  
2020
 
United States
   $ 70,911      $ 83,671      $ 83,668      $ 31,226      $ 34,072  
Europe
     29,029        29,617        31,574        2,274        2,544  
Canada
     5,574        5,719        6,692        13        35  
Asia
     5,105        8,316        8,207        —          —    
Central and South America
     3,950        4,145        4,147        —          —    
Other
     1,464        1,978        2,369        —          —    
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 116,033      $ 133,446      $ 136,657      $ 33,513      $ 36,651  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
*
Long-lived assets exclude goodwill assigned to the T&M segment of $4.5 million at both January 31, 2021 and 2020 and $8.3 million and $7.5 million assigned to the PI segment at January 31, 2021 and 2020, respectively.
 
Note 18—Employee Benefit Plans
We sponsor a Profit-Sharing Plan (the “Plan”) which provides retirement benefits to all eligible domestic employees. The Plan allows participants to defer a portion of their cash compensation and contribute such deferral to the Plan through payroll deductions. The Company makes matching contributions up to specified levels. The deferrals are made within the limits prescribed by Section 401(k) of the Internal Revenue Code.
All contributions are deposited into trust funds. It
 is
our
 policy
to fund any
contributions accrued. Our annual contribution amounts are determined by the Board of Directors. Contributions paid or accrued amounted to $0.4 million in fiscal 2021 and $0.5 million in both fiscal 2020 and 2019.
Note 19—Product Warranty Liability
We offer a manufacturer’s warranty for the majority of our hardware products. The specific terms and conditions of warranty vary depending upon the products sold and country in which we do business. We estimate the warranty costs based on historical claims experience and record a liability in the amount of such estimates at the time product revenue is recognized. We regularly assess the adequacy of our recorded warranty liabilities and adjusts the amounts as necessary. Activity in the product warranty liability, which is included in other accrued expenses in the accompanying consolidated balance sheet, is as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance, beginning of the year
   $ 850     $ 832     $ 575  
Provision for Warranty Expense
     855       1,733       1,680  
Cost of Warranty Repair
s
     (975     (1,715     (1,423
    
 
 
   
 
 
   
 
 
 
Balance, end of the year
   $ 730     $ 850     $ 832  
    
 
 
   
 
 
   
 
 
 
Note 20—Concentration of Risk
Credit is generally extended on an uncollateralized basis to almost all customers after review of credit worthiness. Concentration of credit and geographic risk with respect to accounts receivable is limited due to the large number and general dispersion of accounts which constitute our customer base. We periodically perform
on-going
credit evaluations of our customers. We have not historically experienced significant credit losses on collection of our accounts receivable.
 
78

 
During the years ended January 31, 2021, 2020 and 2019, one vendor accounted for 23.2%, 21.2% and 21.6% of purchases, and 23.8%, 28.0% and 28.7% of accounts payable, respectively, as of January 31, 2021, 2020 and 2019.
Note 21—Commitments and Contingencies
We are subject to contingencies, including legal proceedings and claims arising in the normal course of business that cover a wide range of matters including, among others, contract and employment claims; workers compensation claims; product liability; warranty and modification; and adjustment or replacement of component parts of units sold.
Direct costs associated with the estimated resolution of contingencies are accrued at the earliest date at which it is deemed probable that a liability has been incurred and the amount of such liability can be reasonably estimated. While it is impossible to ascertain the ultimate legal and financial liability with respect to contingent liabilities, including lawsuits, we believe that the aggregate amount of such liabilities, if any, in excess of amounts provided or covered by insurance, will not have a material adverse effect on the consolidated financial position or results of operations. It is possible, however, that future results of operations for any particular future period could be materially affected by changes in our assumptions or strategies related to these contingencies or changes out of our control.
Note 22—Fair Value Measurements
Assets and Liabilities Recorded at Fair Value on a Recurring Basis
The following tables provide a summary of the financial liabilities that are measured at fair value:
 
Liabilities measured at fair value:
  
Fair value measurement at
January 31, 2021
 
  
Fair value measurement at
January 31, 2020
 
(in thousands)
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)
   $ —        $ —        $ —        $ —        $ —        $ 250      $ —        $ 250  
Interest Rate Swap Contract (included in Other Long-Term Liabilities)
     —          —          —          —          —          96        —          96  
Earnout Liability (included in Other Liabilities)
     —          —          —          —          —          —          14        14  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $
    
—        $
    
—        $
    
—        $
    
—        $
 
 
—        $
 
 
346      $
 
 
14      $
 
 
360  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
We used the market approach to measure fair value of our derivative instruments. These derivative instruments were measured at fair value using readily observable market inputs, such as quotations on interest rates and foreign exchange rates and are classified as Level 2 because they are
over-the-counter
contracts with a bank counterparty that are not traded in an active market.
 
79

Assets and Liabilities Not Recorded at Fair Value on the Consolidated Balance Sheet
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
Fair Value Measurement at
January 31, 2021
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $   —        $   —        $ 12,586      $ 12,586      $ 12,576  
     
    
Fair Value Measurement at
January 31, 2020
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $ —        $ —        $ 13,258      $ 13,258      $ 13,034  
The above table does not include the PPP loan, as the fair value of the PPP loan approximates its carrying value.
The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar borrowings with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3.
Note 2
3
—Subsequent Event
On March 24, 2021, we entered into a First Amendment to Credit Agreement (the “Amendment”) to the A&R Credit Agreement
 
(the “A&R Credit Agreement,”
 as
amended by the Amendment; the “Amended Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), ANI ApS and TrojanLabel. Immediately prior to the closing of the Amendment, we repaid $2.6 million in principal amount of the term loan outstanding under the A&R Credit Agreement, resulting in an outstanding balance of the term loan of $10.0 million and no amount drawn and outstanding under the revolving credit facility under the A&R Credit Agreement.
The Amended Credit Agreement provides for (i) a term loan in the principal amount of $10.0 million, and (ii) a $22.5 million revolving credit facility available for general corporate purposes. At the closing of the Amend
ment
,
w
e
borrowed the entire $10.0 million term loan which was used to refinance, in full, the outstanding term loan under the A&R Credit Agreement. Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
The Amended Credit Agreement requires that the term loan be paid as follows: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2021 through January 31, 2022 is $187,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2022 through January 31, 2023 is $250,000; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2023 through January 31, 2025 is $312,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2025 and July 31, 2025 is $500,000; and the entire remaining principal balance of the term loan is required to be paid on September 30, 2025. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than September 30, 2025, at which time any outstanding revolving loans will be due and payable in full, and the revolving credit facility will terminate. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
 
8
0

The Amended Credit Agreement includes an uncommitted accordion provision under which the term loan and/or revolving credit facility commitments may be increased in an aggregate principal amount not exceeding $10.0 million, subject to obtaining the agreement of the Lender and the satisfaction of certain other conditions.
The interest rates under the
Prior
Credit Agreement were modified in the Amended Credit Agreement as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the LIBOR Rate as de
fin
ed
 in the Amended Credit Agreement (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.30% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.30% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.30% based on our consolidated leverage ratio. The commitment fee paid on the undrawn portion of the revolving credit facility was $28,000 for fiscal year 2021 and is included in the interest expense line in the consolidated income statement for the period ended January 31, 2021.
As under the Prior Credit Agreement, the loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
We must comply with various customary financial and
non-financial
covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. The minimum EBITDA, minimum consolidated asset coverage ratio, minimum liquidity and maximum capital expenditures covenants with which we were required to comply under the Prior Credit Agreement were eliminated by the Amendment. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Amendment.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.
Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests held in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island. Pursuant to the Amendment, the guarantees of our obligations under the Prior Credit Agreement that were previously provided by ANI ApS and TrojanLabel were released.
 
8
1

SUPPLEMENTARY DATA
Quarterly Financial Information (Unaudited)
 
  
 
2021
 
 
  
 
 
2020
 
 
  
 
(In
 thousands,
 except
 per
 share
 data)
 
Q1
 
 
Q2
 
 
Q3
 
 
Q4
 
 
  
 
 
Q1
 
 
Q2
 
 
Q3
 
 
Q4
 
 
  
 
Revenue
 
$
30,919
 
 
$
27,658
 
 
$
28,017
 
 
$
29,438
 
 
   
 
 
$
36,181
 
 
$
33,468
 
 
$
33,318
 
 
$
30,479
 
 
     
Cost of Revenue
 
 
20,064
 
 
 
17,871
 
 
 
18,282
 
 
 
18,456
 
 
   
 
 
 
21,942
 
 
 
21,491
 
 
 
21,021
 
 
 
20,234
 
 
     
Gross Profit
 
 
10,855
 
 
 
9,787
 
 
 
9,735
 
 
 
10,982
 
 
   
 
 
 
14,239
 
 
 
11,977
 
 
 
12,297
 
 
 
10,245
 
 
     
 
 
 
35.1
 
 
35.4
 
 
34.7
 
 
37.3
 
   
 
 
 
39.4
 
 
35.8
 
 
36.9
 
 
33.6
 
     
Operating Expenses (1):
 
     
 
     
 
     
 
     
 
   
 
 
     
 
     
 
     
 
     
 
     
Selling & Marketing
 
$
5,925
 
 
$
5,555
 
 
$
5,553
 
 
$
6,267
 
 
   
 
 
$
6,765
 
 
$
6,413
 
 
$
6,944
 
 
$
6,762
 
 
     
Research & Development
 
 
1,940
 
 
 
1,493
 
 
 
1,412
 
 
 
1,361
 
 
   
 
 
 
2,007
 
 
 
1,785
 
 
 
2,076
 
 
 
2,216
 
 
     
General & Administrative
 
 
2,327
 
 
 
2,535
 
 
 
2,353
 
 
 
2,206
 
 
 
 
 
 
 
2,999
 
 
 
2,616
 
 
 
2,830
 
 
 
2,912
 
 
 
 
 
Total Operating Expenses
 
 
10,192
 
 
 
9,583
 
 
 
9,318
 
 
 
9,834
 
 
 
 
 
 
 
11,771
 
 
 
10,814
 
 
 
11,850
 
 
 
11,890
 
 
 
 
 
Operating Income (Loss)
 
 
663
 
 
 
204
 
 
 
417
 
 
 
1,148
 
 
   
 
 
 
2,468
 
 
 
1,163
 
 
 
447
 
 
 
(1,645
 
     
 
 
 
2.1
 
 
0.7
 
 
1.5
 
 
3.9
 
   
 
 
 
6.8
 
 
3.5
 
 
1.3
 
 
(5.4
)% 
 
     
Other Income (Expense), Net
 
 
(349
 
 
328
 
 
 
(437
 
 
204
 
 
   
 
 
 
(368
 
 
(183
 
 
(238
 
 
(275
 
     
Income (Loss) Before Taxes
 
 
314
 
 
 
532
 
 
 
(20
 
 
1,352
 
 
   
 
 
 
2,100
 
 
 
980
 
 
 
209
 
 
 
(1,920
 
     
Income Tax Provision (Benefit)
 
 
(118
 
 
529
 
 
 
(32
 
 
516
 
 
 
 
 
 
 
400
 
 
 
29
 
 
 
(247
 
 
(572
 
 
 
 
Net Income (Loss)
 
$
432
 
 
$
3
 
 
$
12
 
 
$
836
 
 
 
 
 
 
$
1,700
 
 
$
951
 
 
$
456
 
 
$
(1,348
 
 
 
 
Net Income (Loss) per Common Share—Basic
 
$
0.06
 
 
$
0.00
 
 
$
0.00
 
 
$
0.12
 
 
 
 
 
 
$
0.24
 
 
$
0.14
 
 
$
0.06
 
 
$
(0.19
 
 
 
 
Net Income (Loss) per Common Share—Diluted
 
$
0.06
 
 
$
0.00
 
 
$
0.00
 
 
$
0.12
 
 
 
 
 
 
$
0.23
 
 
$
0.13
 
 
$
0.06
 
 
$
(0.19
 
 
 
 
Annual totals may not agree to the summation of quarterly information due to insignificant rounding and the required calculation conventions.
 
(1)
Certain amounts reported in the prior quarters may have been reclassified to conform to our current presentation at
year-end.
 
82

ASTRONOVA, INC.
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
 
Description
  
Balance at
Beginning
of Year
    
Provision/
(Benefit)
Charged to
Operations
    
Deductions(2)
   
Balance
at End
of Year
 
Allowance for Doubtful Accounts(1):
                                  
(In thousands)                           
Year Ended January 31,
                                  
2021
   $ 856      $ 194      $ 4     $ 1,054  
2020
   $ 521      $ 546      $ (211   $ 856  
2019
   $ 377      $ 310      $ (166   $ 521  
 
(1)
The allowance for doubtful accounts has been netted against accounts receivable in the balance sheets as of the respective balance sheet dates.
(2)
Uncollectible accounts written off, net of recoveries.
 
8
3
EX-10.34 2 d56468dex1034.htm EX-10.34 EX-10.34

Exhibit 10.34

Execution Version

FIRST AMENDMENT TO CREDIT AGREEMENT

This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of March 24, 2021 (this “First Amendment”), is among the following: (i) AstroNova, Inc., a Rhode Island corporation (the “Borrower”); (ii) ANI APS, a Danish private liability company (“ANI APS”); (iii) Trojan Label APS, a Danish private liability company (“Trojan Label”, and together with ANI APS, individually, each a “Guarantor” and, collectively, the “Guarantors”); and (iv) Bank of America, N.A. (the “Lender”). Capitalized terms used but not defined in this First Amendment shall have the meanings assigned to such terms in the Credit Agreement (as defined below).

RECITALS:

WHEREAS, reference is hereby made to the Amended and Restated Credit Agreement, dated as of July 30, 2020 (the “Existing Credit Agreement”), by and among the Borrower, the Guarantors, and the Lender;

WHEREAS, the Borrower, the Guarantors, and the Lender wish to amend the Existing Credit Agreement as set forth herein (the Existing Credit Agreement, as so amended, the “Credit Agreement”);

NOW, THEREFORE, in consideration of the premises, agreements, provisions and covenants herein contained, the parties hereto agree as follows:

Section 1. Amendments to the Existing Credit Agreement.

(a) The following definitions are hereby amended and restated in Section 1.01 of the Existing Credit Agreement to read in their entirety as follows:

Applicable Rate” means, (i) for any day on or prior to the First Amendment Effective Date, the rate per annum set forth below for Level 4:

 

Applicable Rate

 

Level

   Consolidated
Leverage Ratio
     Eurocurrency
Rate
     Letter of
Credit Fees
     Base Rate      Commitment Fee  

1

     < 1.00:1        215 bps        215 bps        115 bps        25 bps  

2

   ³

 

 1.00:1 but

< 2.00:1

 

 

     265 bps        265 bps        165 bps        37.5 bps  

3

     > 2.00:1        315 bps        315 bps        215 bps        50 bps  

4

     N/A        365 bps        365 bps        265 bps        67.5 bps  

and (ii) commencing on the First Amendment Effective Date and thereafter, (x) for any day on or prior to the date on which the Compliance Certificate for the Fiscal Quarter ending on January 31, 2021 has been delivered to the Lender, the rate per annum set forth below for Level 3 and (y) thereafter, the rate per annum set forth below opposite the applicable Level then in effect (based on the Consolidated Leverage Ratio):


Applicable Rate

 

Level

   Consolidated
Leverage Ratio
     Eurocurrency
Rate
     Letter of
Credit Fees
     Base Rate      Commitment Fee  

1

     < 0.50:1        160 bps        160 bps        60 bps        15 bps  

2

   ³

 

0.50:1 but

< 1.25:1

 

 

     185 bps        185 bps        85 bps        20 bps  

3

   ³

 

1.25:1 but

< 2.00:1

 

 

     210 bps        210 bps        110 bps        25 bps  

4

     > 2.00:1        230 bps        230 bps        130 bps        30 bps  

Any increase or decrease in the Applicable Rate resulting from a change in the Consolidated Leverage Ratio shall become effective as of the first Business Day immediately following the date a Compliance Certificate is delivered pursuant to Section 6.02(a); provided, however, that if a Compliance Certificate is not delivered when due in accordance with such Section, then, Pricing Level 4 shall apply unless otherwise agreed to by the Lender, in each case as of the first Business Day after the date on which such Compliance Certificate was required to have been delivered and in each case shall remain in effect until the first Business Day following the date on which such Compliance Certificate is delivered.

Notwithstanding anything to the contrary contained in this definition, the determination of the Applicable Rate for any period shall be subject to the provisions of Section 2.10(b). Any adjustment in the Applicable Rate shall be applicable to all Credit Extensions then existing or subsequently made or issued.

Consolidated Fixed Charge Coverage Ratio” means, as of any date of determination, the ratio of (a) (i) Consolidated EBITDA, less (ii) the aggregate amount of all non-financed cash Consolidated Capital Expenditures, provided that, Capital Expenditures of the Borrower and its Subsidiaries incurred in connection with the implementation of new enterprise resource planning software and systems not to exceed an aggregate amount of $2,500,000 shall be excluded from the deduction in this clause (a)(ii), less (iii) Restricted Payments paid in cash, less (iv) the aggregate amount of all federal, state, local and foreign income taxes paid in cash less (v) Royalty Payments to (b) the sum of (i) Consolidated Interest Charges to the extent paid in cash, and (ii) the aggregate principal amount of all redemptions or similar acquisitions for value of outstanding Consolidated Funded Indebtedness or regularly scheduled principal payments on Consolidated Funded Indebtedness, but for purposes of this clause (b), the following shall be excluded: (x) any such payments to the extent refinanced through the incurrence of additional Indebtedness otherwise expressly permitted under Section 7.02, in each case, of or by the Borrower and its Subsidiaries for the most recently completed Measurement Period and (y) for avoidance of doubt, (A) any such intercompany payments made in connection with the closing of this Agreement to refinance the Existing Danish Term Loan or in respect of the termination of hedging arrangements previously entered into by the Borrower or any of its Subsidiaries with respect to the Existing Term Loans, (B) the Closing Date Prepayment, and (C) payments by the Borrower and its Subsidiaries to the Lender or its affiliates in respect of the termination of hedging arrangements previously entered into by the Borrower or any of its Subsidiaries with respect to the Existing Term Loans, and (2) for the first 12 months following the First Amendment Effective Date, with respect to the Term Facility, clause (b)(ii) above shall be determined based on the amount of regularly scheduled principal payments on Consolidated Funded Indebtedness due in the 12 month period following the Measurement Period including the modifications to Section 2.07(a) herein.

 

- 2 -


Maturity Date” means (a) with respect to the Revolving Facility, September 30, 2025 and (b) with respect to the Term Facility, September 30, 2025; provided, however, that, in each case, if such date is not a Business Day, the Maturity Date shall be the next preceding Business Day.

Revolving Commitment” means the Lender’s obligation to (a) make Revolving Loans to the Borrower pursuant to Section 2.01(b) and (b) issue Letters of Credit for the account of the Borrower pursuant to Section 2.03. The Revolving Commitment for the period from the Closing Date until the First Amendment Effective Date shall be $10,000,000, and the Revolving Commitment for the period commencing on the First Amendment Effective Date and thereafter shall be $22,500,000, in each case during the Availability Period.

(b) The definition of “Base Rate” appearing in Section 1.01 of the Existing Credit Agreement is hereby amended by deleting the text “if the Base Rate shall be less than one percent (1.00%), such rate shall be deemed one percent (1.00%) for purposes of this Agreement” and inserting in lieu thereof the text “if the Base Rate shall be less than one half of one percent (0.50%), such rate shall be deemed one half of one percent (0.50%) for purposes of this Agreement”.

(c) The definition of “Eurocurrency Rate” appearing in Section 1.01 of the Existing Credit Agreement is hereby amended by deleting the text “(ii) if the Eurocurrency Rate shall be less than one percent (1.00%), such rate shall be deemed one percent (1.00%) for purposes of this Agreement” and inserting in lieu thereof the text “(ii) if the Eurocurrency Rate shall be less than one half of one percent (0.50%), such rate shall be deemed one half of one percent (0.50%) for purposes of this Agreement”.

(d) The definition of “Fiscal Quarter” appearing in Section 1.01 of the Existing Credit Agreement is hereby amended by adding the text “, as it may be updated from time to time in any Compliance Certificate” immediately before the period at the end thereof.

(e) The definition of “Pro Forma Basis” and “Pro Forma Effect” appearing in Section 1.01 of the Existing Credit Agreement is hereby amended by deleting the text “or for any Restricted Payment” and inserting in lieu thereof the text “, for any Restricted Payment or for any Incremental Increase pursuant to Section 2.13”.

(f) The following definitions are hereby added to Section 1.01 of the Existing Credit Agreement in the appropriate alphabetical order:

First Amendment Effective Date” means March 24, 2021.

Incremental Increase” is defined in Section 2.13.

Incremental Conditions” means, for any Incremental Increase, that (a) no Default has occurred and is continuing, (b) after giving Pro Forma Effect to such Revolving Commitment increase or term loan borrowing, as applicable, the Consolidated Leverage Ratio is no greater than 2.75 to 1.00 and the Consolidated Fixed Charge Coverage Ratio is no less than 1.25 to 1.00 and (c) Liquidity plus Availability is equal to at least $5,000,000.

ISDA Definitions” means the 2006 ISDA Definitions published by the International Swaps and Derivatives Association, Inc. or any successor thereto, as amended or supplemented from time to time, or any successor definitional booklet for interest rate derivatives published from time to time by the International Swaps and Derivatives Association, Inc. or such successor thereto.

 

- 3 -


LIBOR Replacement Date” has the meaning specified in Section 3.03.

LIBOR Successor Rate” has the meaning specified in Section 3.03.

LIBOR Successor Rate Conforming Changes” means, with respect to any proposed LIBOR Successor Rate, any conforming changes to the definition of Base Rate, Interest Period, timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters (including, for the avoidance of doubt, the definition of Business Day, timing of borrowing requests or prepayment, conversion or continuation notices and length of lookback periods) as may be appropriate, in the discretion of the Lender, to reflect the adoption and implementation of such LIBOR Successor Rate and to permit the administration thereof by the Lender in a manner substantially consistent with market practice (or, if the Lender determines that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such LIBOR Successor Rate exists, in such other manner of administration as the Lender determines is reasonably necessary in connection with the administration of this Agreement and any other Loan Document).

Pre-Adjustment Successor Rate” has the meaning specified in Section 3.03.

Related Adjustment” means, in determining any LIBOR Successor Rate, the first relevant available alternative set forth in the order below that can be determined by the Lender applicable to such LIBOR Successor Rate:

(a) the spread adjustment, or method for calculating or determining such spread adjustment, that has been selected or recommended by the Relevant Governmental Body for the relevant Pre-Adjustment Successor Rate (taking into account the interest period, interest payment date or payment period for interest calculated and/or tenor thereto) and which adjustment or method (x) is published on an information service as selected by the Lender from time to time in its reasonable discretion or (y) solely with respect to Term SOFR, if not currently published, which was previously so recommended for Term SOFR and published on an information service acceptable to the Lender; or

(b) the spread adjustment that would apply (or has previously been applied) to the fallback rate for a derivative transaction referencing the ISDA Definitions (taking into account the interest period, interest payment date or payment period for interest calculated and/or tenor thereto).

Relevant Governmental Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York.

Royalty Payments” means the sum of (a) the amounts of royalty payments to Honeywell International, Inc. or its affiliates as indicated in respect of the relevant Measurement Period on Schedule 7.11(b), and (b) any other similar royalty payments which have not been otherwise deducted in the determination of Net Income due during the relevant Measurement Period.

SOFR” with respect to any Business Day means the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark (or a successor administrator) on the Federal Reserve Bank of New York’s website (or any successor source) at approximately 8:00 a.m. (New York City time) on the immediately succeeding Business Day and, in each case, that has been selected or recommended by the Relevant Governmental Body.

 

- 4 -


Term SOFR” means the forward-looking term rate for any period that is approximately (as determined by Lender) as long as any of the Interest Period options set forth in the definition of “Interest Period” and that is based on SOFR and that has been selected or recommended by the Relevant Governmental Body, in each case as published on an information service as selected by the Lender from time to time in its reasonable discretion.

(g) The following definitions are hereby deleted from Section 1.01 of the Existing Credit Agreement: “Capital Expenditure Testing Termination Date”, “Consolidated Assets”, “Consolidated Asset Coverage Ratio”, “Foreign Subsidiary Accounts” and “Restricted Payments Milestone”.

(h) The portion of Section 2.07(a) of the Existing Credit Agreement preceding the proviso therein is hereby amended and restated in its entirety to read as follows:

(a) Term Loans. From and after the First Amendment Effective Date, the Borrower shall repay to the Lender the aggregate principal amount of the Term Loan outstanding as of immediately following the effectiveness of the First Amendment in installments, with each payment of the Term Facility to be due and payable on the last day of each Fiscal Quarter of the Borrower (commencing with the Fiscal Quarter ending April 30, 2021) in the applicable amount in accordance with the following schedule (which amount shall be reduced as a result of the application of prepayments in accordance with the order of priority set forth in Section 2.05), unless accelerated sooner pursuant to Section 8.02:

 

Fiscal Quarter Ending

   Installment Amount  

April 30, 2021

   $ 187,500  

July 31, 2021

   $ 187,500  

October 31, 2021

   $ 187,500  

January 31, 2022

   $ 187,500  

April 30, 2022

   $ 250,000  

July 31, 2022

   $ 250,000  

October 31, 2022

   $ 250,000  

January 31, 2023

   $ 250,000  

April 30, 2023

   $ 250,000  

July 31, 2023

   $ 250,000  

October 31, 2023

   $ 250,000  

January 31, 2023

   $ 250000  

April 30, 2024

   $ 312,500  

July 31, 2024

   $ 312,500  

October 31, 2024

   $ 312,500  

January 31, 2025

   $ 312,500  

April 30, 2025

   $ 500,000  

July, 31 2025

   $ 500,000  

Maturity Date

    
Aggregate Principal Amount
Outstanding
 
 

(i) Section 2.13 of the Existing Credit Agreement is hereby amended and restated to read in its entirety as follows:

 

- 5 -


2.13 Increase in Commitments.

(a) Request for Increase. Provided that the Incremental Conditions are satisfied at the time of the request, the Borrower may, by at least thirty (30) days’ written notice to the Lender, request an increase in the Revolving Commitments or a new term loan tranche (each, an “Incremental Increase”) in an aggregate amount (for all such requests) not exceeding $10,000,000; provided that (i) any such request for an increase shall be in a minimum amount of $5,000,000, and (ii) the Borrower may make a maximum of three such requests.

(b) Effective Date and Allocations. If an Incremental Increase is extended in accordance with this Section, the Lender and the Borrower shall determine the effective date (the “Increase Effective Date”) of such increase.

(c) Conditions to Effectiveness of Increase. The effectiveness of any Incremental Increase pursuant to this Section 2.13 shall be subject to completion of business and legal due diligence satisfactory to the Lender, the satisfaction (or waiver) on the date thereof of each of the conditions set forth in the definitive documentation giving effect to such increase, including, without limitation, (i) the delivery of an amendment to this Agreement reflecting the agreed terms of the Incremental Increase, (ii) the delivery of an acknowledgement in form and substance satisfactory to the Lender and executed by each Guarantor acknowledging that the Incremental Increase shall constitute Obligations hereunder, (iii) a certificate of dated as of the Increase Effective Date signed by a Responsible Officer (x) certifying and attaching the resolutions adopted by the Borrower approving or consenting to such Incremental Increase, and (y) certifying that, before and after giving effect to such increase, (A) the representations and warranties contained in Article V and the other Loan Documents are true and correct on and as of the Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct as of such earlier date, and except that for purposes of this Section 2.13, the representations and warranties contained in subsections (a) and (b) of Section 5.05 shall be deemed to refer to the most recent statements furnished pursuant to subsections (a) and (b), respectively, of Section 6.01, and (B) no Default exists; and (iv) the delivery of such other customary documents, legal opinion(s) and officer’s certificates as the Lender may request, in each case, in form and substance satisfactory to the Lender.

(j) Section 3.03 of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:

3.03 Inability to Determine Rates.

(a) Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Lender determines (which determination shall be conclusive absent manifest error), or the Borrower notifies the Lender that the Borrower has determined, that:

(i) adequate and reasonable means do not exist for ascertaining LIBOR for any Interest Period hereunder or any other tenors of LIBOR, including, without limitation, because the LIBOR Rate is not available or published on a current basis and such circumstances are unlikely to be temporary; or

(ii) the administrator of the LIBOR Rate or a Governmental Authority having jurisdiction over the Lender or such administrator has made a public statement identifying a specific date after which LIBOR or the LIBOR Rate shall no longer be made available, or used for determining the interest rate of loans, provided that, at the time of such statement, there is no successor administrator that is satisfactory to the Lender, that will continue to provide LIBOR after such specific date (such specific date, the “Scheduled Unavailability Date”); or

 

- 6 -


(iii) the administrator of the LIBOR Rate or a Governmental Authority having jurisdiction over such administrator has made a public statement announcing that all Interest Periods and other tenors of LIBOR are no longer representative; or

(iv) syndicated loans currently being executed, or that include language similar to that contained in this Section 3.03, are being executed or amended (as applicable) to incorporate or adopt a new benchmark interest rate to replace LIBOR;

then, in the case of clauses (i)-(iii) above, on a date and time determined by the Lender (any such date, the “LIBOR Replacement Date”), which date shall be at the end of an Interest Period or on the relevant interest payment date, as applicable, for interest calculated and within a reasonable period of time after the occurrence of any of the events or circumstances under clauses (i), (ii) or (iii) above and, solely with respect to clause (ii) above, no later than the Scheduled Unavailability Date, LIBOR will be replaced hereunder and under any Loan Document with, subject to the proviso below, the first available alternative set forth in the order below for any payment period for interest calculated that can be determined by the Lender, in each case, without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document (the “LIBOR Successor Rate”; and any such rate before giving effect to the Related Adjustment, the “Pre-Adjustment Successor Rate”):

(x) Term SOFR plus the Related Adjustment; and

(y) SOFR plus the Related Adjustment;

and in the case of clause (iv) above, the Borrower and Lender may amend this Agreement solely for the purpose of replacing LIBOR under this Agreement and under any other Loan Document in accordance with the definition of “LIBOR Successor Rate”;

provided that, if the Lender determines that Term SOFR has become available, is administratively feasible for the Lender and would have been identified as the Pre-Adjustment Successor Rate in accordance with the foregoing if it had been so available at the time that the LIBOR Successor Rate then in effect was so identified, and the Lender notifies the Borrower of such availability, then from and after the beginning of the Interest Period, relevant interest payment date or payment period for interest calculated, in each case, commencing no less than thirty (30) days after the date of such notice, the Pre-Adjustment Successor Rate shall be Term SOFR and the LIBOR Successor Rate shall be Term SOFR plus the relevant Related Adjustment.

The Lender will promptly (in one or more notices) notify the Borrower of (x) any occurrence of any of the events, periods or circumstances under clauses (i) through (iii) above, (y) a LIBOR Replacement Date and (z) the LIBOR Successor Rate.

Any LIBOR Successor Rate shall be applied in a manner consistent with market practice; provided that to the extent such market practice is not administratively feasible for the Lender, such LIBOR Successor Rate shall be applied in a manner as otherwise reasonably determined by the Lender.

 

- 7 -


Notwithstanding anything else herein, if at any time any LIBOR Successor Rate as so determined would otherwise be less than 0.50%, the LIBOR Successor Rate will be deemed to be 0.50% for the purposes of this Agreement and the other Loan Documents.

In connection with the implementation of a LIBOR Successor Rate, the Lender will have the right to make LIBOR Successor Rate Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such LIBOR Successor Rate Conforming Changes will become effective without any further action or consent of any other party to this Agreement; provided that, with respect to any such amendment effected, the Lender shall post each such amendment implementing such LIBOR Successor Rate Conforming Changes to the Borrower reasonably promptly after such amendment becomes effective.

If the events or circumstances of the type described in 3.03(a)(i)-(iii) have occurred with respect to the LIBOR Successor Rate then in effect, then the successor rate thereto shall be determined in accordance with the definition of “LIBOR Successor Rate.”

(b) Notwithstanding anything to the contrary herein, (i) after any such determination by the Lender or receipt by the Lender of any such notice described under Section 3.03(a)(i)-(iii), as applicable, if the Lender determines that none of the LIBOR Successor Rates is available on or prior to the LIBOR Replacement Date, (ii) if the events or circumstances described in Section 3.03(a)(iv) have occurred but none of the LIBOR Successor Rates is available, or (iii) if the events or circumstances of the type described in Section 3.03(a)(i)-(iii) have occurred with respect to the LIBOR Successor Rate then in effect and the Lender determines that none of the LIBOR Successor Rates is available, then in each case, the Lender and the Borrower may amend this Agreement solely for the purpose of replacing LIBOR or any then current LIBOR Successor Rate in accordance with this Section 3.03 at the end of any Interest Period, relevant interest payment date or payment period for interest calculated, as applicable, with another alternate benchmark rate giving due consideration to any evolving or then existing convention for similar U.S. dollar denominated syndicated credit facilities for such alternative benchmarks and, in each case, including any Related Adjustments and any other mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar U.S. dollar denominated syndicated credit facilities for such benchmarks, which adjustment or method for calculating such adjustment shall be published on an information service as selected by the Lender from time to time in its reasonable discretion and may be periodically updated. For the avoidance of doubt, any such proposed rate and adjustments shall constitute a LIBOR Successor Rate.

(c) If, at the end of any Interest Period, relevant interest payment date or payment period for interest calculated, no LIBOR Successor Rate has been determined in accordance with clauses (a) or (b) of this Section 3.03 and the circumstances under clauses (a)(i) or (a)(iii) above exist or the Scheduled Unavailability Date has occurred (as applicable), the Lender will promptly so notify the Borrower. Thereafter, (x) the obligation of the Lender to make or maintain Eurocurrency Rate Loans shall be suspended, (to the extent of the affected Eurocurrency Rate Loans, Interest Periods, interest payment dates or payment periods), and (y) the Eurocurrency Rate component shall no longer be utilized in determining the Base Rate, until the LIBOR Successor Rate has been determined in accordance with clauses (a) or (b). Upon receipt of such notice, the Borrower may revoke any pending request for a Borrowing of, conversion to or continuation of Eurocurrency Rate Loans (to the extent of the affected Eurocurrency Rate Loans, Interest Periods, interest payment dates or payment periods) or, failing that, will be deemed to have converted such request into a request for a Borrowing of Base Rate Loans (subject to the foregoing clause (y)) in the amount specified therein.

 

- 8 -


(k) Section 6.01(c) of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:

(c) [Reserved.]

(l) Section 6.14(d) of the Existing Credit Agreement is hereby amended and restated to read in its entirety as follows:

(a) Deposit Accounts and Securities Accounts. Neither the Borrower nor any of the Guarantors that are Domestic Subsidiaries shall open, maintain or otherwise have any deposit or other accounts (including securities accounts) at any bank or other financial institution other than the Lender, or any other account where money or securities are or may be deposited or maintained with any Person, other than (i) the Borrower’s account with Greenwood Credit Union, identified on Schedule 6.14 hereto, provided that such account contain only the proceeds of the Indebtedness described in Section 7.02(g) hereof; (ii) the Borrower’s accounts set forth on Schedule 6.14 and designated as unrestricted accounts or Foreign Accounts; provided that at all times the aggregate balance of all Foreign Accounts shall not exceed the Dollar Equivalent of $5,000,000, (iii) deposit accounts that are maintained at all times with depository institutions as to which the Lender shall have received a Qualifying Control Agreement, or at any time prior to the occurrence and during the continuance of an Event of Default, with respect to the Excluded Accounts and (iv) solely with respect to securities accounts, securities accounts that are maintained at all times with financial institutions as to which the Lender shall have received a Qualifying Control Agreement. For avoidance of doubt, accounts described in clauses (i) and (ii) of the preceding sentence shall not be required to be subject to a Qualifying Control Agreement.

(m) Section 6.02(a) of the Existing Credit Agreement is hereby amended by deleting the text “Concurrently with the delivery of the financial statements referred to in Sections 6.01(a), (b) and (c)” appearing therein and inserting in lieu thereof the text “Concurrently with the delivery of the financial statements referred to in Sections 6.01(a) and (b)”.

(n) Section 7.03(c) of the Existing Credit Agreement is hereby amended by amending and restating clauses (iv) and (v) thereof in their entirety and inserting in lieu thereof the following:

(iv) [reserved], (v) so long as no Default has occurred and is continuing or would result from making such Investment at the time of the making of such Investment, additional Investments by the Borrower and its Subsidiaries in wholly owned Foreign Subsidiaries in an aggregate amount invested from the Closing Date not to exceed $5,000,000 outstanding at any time calculated after giving effect to any returns or distributions of, or with respect to, capital or repayment of principal against Indebtedness constituting Investments actually received by the Borrower or such Subsidiary, as applicable, provided in each case, the provisions of Section 7.02(d) shall be met with respect to Intercompany Debt and

(o) Section 7.06 of the Existing Credit Agreement is hereby amended by (i) deleting the text “(x)” appearing therein and (ii) deleting the text “and (y) with respect to each clause (d) through (f) below, the Borrower has achieved the Restricted Payments Milestone” appearing therein.

(p) Sections 7.11(c), (d) and (e) of the Existing Credit Agreement are hereby deleted in their entirety.

 

- 9 -


(q) Section 7.12 of the Existing Credit Agreement is hereby amended and restated in its entirety to read as follows:

7.12 [Reserved.]

(r) Schedule 1.01(c) of the Existing Credit Agreement is hereby amended and restated in its entirety to read as Schedule 1.01(c) attached hereto as Exhibit A.

(s) The Existing Credit Agreement is amended by inserting the attached Schedule 7.11(b) as Schedule 7.11(b) thereof.

(t) Exhibit A to the Existing Credit Agreement is amended by inserting the following to appear as a new paragraph 7 of the Compliance Certificate:

[ 7. Attached hereto as Schedule 1.01(c) are updates to the Borrower’s and its Subsidiaries’ Fiscal Quarter end dates.]

Section 2. Release of Guarantors.

Upon satisfaction of all conditions precedent to the effectiveness of this First Amendment, ANI APS and Trojan Label shall be released from their respective Obligations under the Credit Agreement and the other Loan Documents and neither ANI APS nor Trojan Label shall be a “Guarantor” under the Credit Agreement or any of the other Loan Documents. Borrower or its authorized representative(s) may file, or cause to be filed, all appropriate assignment, termination or release statements with respect to the Credit Agreement and the other Loan Documents consistent with the terms of this First Amendment, which documents shall be prepared and filed at the Borrower’s sole cost and expense. The Lender shall execute and deliver such further guaranty and/or lien releases, discharges and such other documents, including any such documents as may be required under any U.S. or Danish law, as reasonably necessary to discharge or release each of ANI APS and Trojan Label from their respective Obligations consistent with the terms of this First Amendment at the Borrower’s sole cost and expense.

Section 3. Conditions to Effectiveness.

This First Amendment shall become effective on the first Business Day on which the following conditions are satisfied (the “Effective Date”):

(a) The Lender’s receipt of each of the following:

(i) the properly executed First Amendment, which shall be an original or facsimile or electronic copy (followed promptly by an original) unless otherwise specified;

(ii) the properly executed Amended and Restated Revolving Note, which shall be an original or facsimile or electronic copy (followed promptly by an original) unless otherwise specified;

(iii) the properly executed and notarized First Amendment to Open-End Mortgage Deed to Secure Present and Future Loans under Chapter 25 of Title 34 of the Rhode Island General Laws, Assignment of Leases and Rents, Security Agreement and Fixture Filing, which shall be an original or facsimile or electronic copy (followed promptly by an original) unless otherwise specified;

 

- 10 -


(iv) (x) an opinion of Foley Hoag LLP, as counsel for the Borrower, in form and substance reasonably satisfactory to the Lender and (y) an opinion of Nixon Peabody LLP, as special Rhode Island counsel for the Borrower, in form and substance reasonably satisfactory to the Lender

(v) a certificate of a Responsible Officer dated the Closing Date, certifying as to the Organization Documents of each Loan Party (which, to the extent filed with a Governmental Authority, shall be certified as of a recent date by such Governmental Authority), the resolutions of the governing body of each Loan Party, the good standing, existence or its equivalent of each Loan Party and of the incumbency (including specimen signatures) of the Responsible Officers of each Loan Party;

(vi) a Solvency Certificate signed by a Responsible Officer of the Borrower as to the financial condition, solvency and related matters of the Borrower and its Subsidiaries, taken together as a group on a Consolidated basis and each Loan Party, after giving effect this First Amendment and the other transactions contemplated hereby;

(vii) a Loan Notice with respect to the Loans to be made on the First Amendment Effective Date;

(viii) a closing certificate from a Responsible Officer certifying as to the conditions set forth in subsections (d), (f) and (g) and as to such other matters the Lender requires.

(b) Immediately prior to the effectiveness of this First Amendment, the Borrower shall repay an aggregate principal amount of the Term Loans equal to $2,576,000.

(c) The Lender shall have received copies of the financial statements as may be reasonably requested by the Lender prior to the Effective Date, each in form and substance satisfactory to the Lender.

(d) The Lender shall have received satisfactory evidence that all members, boards of directors, governmental, shareholder and material third party consents and approvals necessary in connection with the entering into of this First Amendment have been obtained.

(e) The Borrower shall have paid in full all reasonable out-of-pocket costs and expenses (including the reasonable fees, charges and expenses of Jones Day) incurred in connection with the transactions contemplated hereby;

(f) Before and after giving effect to this First Amendment, no Default shall exist;

(g) Each of the representations and warranties set forth in Section 4 of this First Amendment, in the Credit Agreement and in the other Loan Documents shall be true and correct in all material respects on and as of the date of this First Amendment; provided that, to the extent that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided further, that any representation or warranty that is qualified as to “materiality”, “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) without duplication of such materiality qualifiers as of such date or such earlier date, as applicable.

 

- 11 -


(h) The Lender shall have received, in form and substance satisfactory to the Lender (i) as to the Borrower (A) searches of UCC filings in the jurisdiction of incorporation of the Borrower and each jurisdiction where a filing would need to be made in order to perfect the Lender’s security interest in the Collateral, copies of the financing statements on file in such jurisdictions and evidence that no Liens exist other than Permitted Liens and (B) tax lien, judgment and bankruptcy searches.

(i) All other documents and legal matters, including all due diligence, whether related to legal, insurance, tax, flood, or otherwise, in connection with the transactions contemplated by this First Amendment shall be reasonably satisfactory in form and substance to Lender and its counsel.

Section 4. Representations and Warranties. Each of the Loan Parties represents and warrants as follows:

(a) It has taken all necessary action to authorize the execution, delivery and performance of this First Amendment.

(b) This First Amendment has been duly executed and delivered by such Person and constitutes such Person’s legal, valid and binding obligation, enforceable in accordance with its terms, except as such enforceability may be subject to (i) bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting creditors’ rights generally and (ii) general principles of equity (regardless of whether such enforceability is considered in a proceeding at law or in equity).

(c) The Lender shall be satisfied that no consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental authority or third party is required in connection with the execution, delivery or performance the Loan Parties of this First Amendment.

(d) Each of the representations and warranties set forth in the Credit Agreement and in the other Loan Documents are true and correct in all material respects on and as of the date of this First Amendment; provided that, to the extent that such representations and warranties specifically refer to an earlier date, they were true and correct in all material respects as of such earlier date; provided further, that any representation or warranty that is qualified as to “materiality”, “Material Adverse Effect” or similar language is true and correct (after giving effect to any qualification therein) without duplication of such materiality qualifiers as of such date or such earlier date, as applicable.

(e) No event has occurred and is continuing which constitutes a Default.

(f) The Collateral Documents continue to create a valid security interest in, and Lien upon, the Collateral, in favor of the Lender, which security interests and Liens are perfected in accordance with the terms of the Collateral Documents and prior to all Liens other than Permitted Liens.

Section 5. Acknowledgments and Affirmations of the Loan Parties. Each Loan Party hereby ratifies the Credit Agreement and expressly acknowledges the terms of this First Amendment and confirms and reaffirms, as of the date hereof, (i) the covenants and agreements contained in each Loan Document to which it is a party, including, in each case, such covenants and agreements as in effect immediately after giving effect to this First Amendment and the transactions contemplated hereby and thereby, and agrees it is bound by all terms of the Credit Agreement applicable to it and agrees to observe and fully perform its respective Obligations, (ii) its respective guarantee, if any, pursuant to Article IX of the Credit Agreement and (iii) in the case of the Borrower, its grant of Liens on the Collateral to secure its Secured Obligations pursuant to the Collateral Documents.

 

- 12 -


Section 6. Other. This First Amendment, the Credit Agreement and the other Loan Documents constitute the entire agreement among the parties hereto with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties hereto with respect to the subject matter hereof. Except as expressly set forth herein, this First Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of any party under, the Credit Agreement, nor alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. It is understood and agreed (a) that each reference in each Loan Document to the Credit Agreement, whether direct or indirect, shall hereafter be deemed to be a reference to the Credit Agreement as amended by this First Amendment and (b) that this First Amendment is a Loan Document.

Section 7. Governing Law; Submission to Jurisdiction; Venue; Waiver of Jury Trial. THIS FIRST AMENDMENT AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER SHALL BE GOVERNED BY, CONSTRUED AND INTERPRETED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. THE JURISDICTION, SERVICE OF PROCESS AND WAIVER OF JURY TRIAL PROVISIONS SET FORTH IN SECTIONS 10.13 AND 10.14 OF THE CREDIT AGREEMENT ARE HEREBY INCORPORATED BY REFERENCE INTO THIS FIRST AMENDMENT AND SHALL APPLY MUTATIS MUTANDIS HERETO.

Section 8. Severability. Any term or provision of this First Amendment which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction, be ineffective to the extent of such invalidity or unenforceability without rendering invalid or unenforceable the remaining terms and provisions of this First Amendment or affecting the validity or enforceability of any of the terms or provisions of this First Amendment in any other jurisdiction. If any provision of this First Amendment is so broad as to be unenforceable, the provision shall be interpreted to be only so broad as would be enforceable.

Section 9. Counterparts. This First Amendment may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this First Amendment by telecopy or e-mail (including in a “.pdf” format) shall be effective as delivery of a manually executed counterpart of this First Amendment and shall be followed by such manually executed counterpart.

Section 10. Further Assurances. The Loan Parties agree to promptly take such action, upon the request of Lender, as is necessary to carry out the intent of this First Amendment.

Section 11. No Actions, Claims, etc. As of the date hereof, each of the Loan Parties hereby acknowledges and confirms that it has no knowledge of any actions, causes of action, claims, demands, damages and liabilities of whatever kind or nature, in law or in equity, against the Lender or the Lender’s respective officers, employees, representatives, agents, counsel or directors arising from any action by such Persons, or failure of such Persons to act under the Existing Credit Agreement on or prior to the date hereof.

[Signature pages follow]

 

- 13 -


IN WITNESS WHEREOF the parties hereto have caused this First Amendment to be duly executed under seal on the date first above written.

 

BORROWER:     ASTRONOVA, INC.
    By:  

David S. Smith

      Name: David S. Smith
      Title: Vice President and Chief Financial Officer

[Signature Page to First Amendment]


GUARANTORS:     ANI APS
    By:  

Gregory A. Woods

      Name: Gregory A. Woods
      Title: Chief Executive Officer and Chairman of the Board
    TROJAN LABEL APS
    By:  

Gregory A. Woods

      Name: Gregory A. Woods
      Title: Chairman of the Board

[Signature Page to First Amendment]


LENDER:     BANK OF AMERICA, N.A., as Lender
    By:  

Nicholas Storti

      Name: Nicholas Storti
      Title: Senior Vice President

[Signature Page to First Amendment]


Exhibit A

Schedule 1.01(c)

Fiscal Quarters

 

Fiscal Year 2020

  

Fiscal Quarter 1

   February 1, 2019 – April 29, 2019

Fiscal Quarter 2

   April 30, 2019 – July 29, 2019

Fiscal Quarter 3

   July 30, 2019 – November 2, 2019

Fiscal Quarter 4

   November 3, 2019—January 31, 2020

Fiscal Year 2021

  

Fiscal Quarter 1

   February 1, 2020 – May 2, 2020

Fiscal Quarter 2

   May 3, 2020 – August 1, 2020

Fiscal Quarter 3

   August 2, 2020 – October 31, 2020

Fiscal Quarter 4

   November 1, 2020 – January 31, 2021

Fiscal Year 2022

  

Fiscal Quarter 1

   February 1, 2021 – May 1, 2021

Fiscal Quarter 2

   May 2, 2021 – July 31, 2021

Fiscal Quarter 3

   August 1, 2021—October 30, 2021

Fiscal Quarter 4

   October 31, 2021 – January 31, 2022

Fiscal Year 2023

  

Fiscal Quarter 1

   February 1, 2022 – May 1, 2022

Fiscal Quarter 2

   May 2, 2022 – July 31, 2022

Fiscal Quarter 3

   August 1, 2022—October 30, 2022

Fiscal Quarter 4

   October 31, 2022 – January 31, 2023

Fiscal Year 2024

  

Fiscal Quarter 1

   February 1, 2023 – May 1, 2023

Fiscal Quarter 2

   May 2, 2023 – July 31, 2023

Fiscal Quarter 3

   August 1, 2023—October 30, 2023

Fiscal Quarter 4

   October 31, 2023 – January 31, 2024

Fiscal Year 2025

  

Fiscal Quarter 1

   February 1, 2024 – May 1, 2024

Fiscal Quarter 2

   May 2, 2024 – July 31, 2024

Fiscal Quarter 3

   August 1, 2024—October 30, 2024

Fiscal Quarter 4

   October 31, 2024 – January 31, 2025

Fiscal Year 2026

  

Fiscal Quarter 1

   February 1, 2025 – May 1, 2025

Fiscal Quarter 2

   May 2, 2024 – July 31, 2025

Fiscal Quarter 3

   August 1, 2025-October 30, 2025

Fiscal Quarter 4

   October 31, 2025-January 31, 2026


Schedule 7.02(b)

Royalty Payments

 

Measurement Period

Ending

  

Applicable clause (a)

Royalty Payment

May 1, 2021

   $2,000,000

July 31, 2021

   $2,000,000

October 30, 2021

   $2,000,000

January 31, 2022

   $2,000,000

May 1, 2022

   $1,875,000

July 31, 2022

   $1,750,000

October 30, 2022

   $1,625,000

January 31, 2023

   $1,500,000

May 1, 2023

   $1,500,000

July 31, 2023

   $1,500,000

October 30, 2023

   $1,500,000

January 31, 2024

   $1,500,000

May 1, 2024

   $1,375,000

July 31, 2024

   $1,250,000

October 30, 2024

   $1,125,000

January 31, 2025

   $1,000,000

May 1, 2025

   $1,000,000

July 31, 2025

   $1,000,000
EX-10.35 3 d56468dex1035.htm EX-10.35 EX-10.35

Exhibit 10.35

FIRST AMENDMENT TO OPEN-END MORTGAGE DEED TO SECURE PRESENT

AND FUTURE LOANS UNDER CHAPTER 25 OF TITLE 34

OF THE RHODE ISLAND GENERAL LAWS,

ASSIGNMENT OF LEASES AND RENTS,

SECURITY AGREEMENT AND

FIXTURE FILING

by

ASTRONOVA, INC.,

a Rhode Island corporation,

as Mortgagor

and

BANK OF AMERICA, N.A.,

a national banking association,

as Mortgagee

This document serves as a Fixture Filing under the Rhode Island Uniform Commercial Code.

Mortgagor’s Organizational Identification Number is 000001534.

Property Commonly Known As: 600 East Greenwich Avenue

(a/k/a Assessor’s Plat 30, Lots 46, 40, 48, 24, 64 and 37)

City/County: West Warwick, Kent County

State: Rhode Island


FIRST AMENDMENT TO OPEN-END MORTGAGE DEED TO SECURE PRESENT AND

FUTURE LOANS UNDER CHAPTER 25 OF TITLE 34 OF THE RHODE ISLAND

GENERAL LAWS, ASSIGNMENT OF LEASES AND RENTS, SECURITY AGREEMENT

AND FIXTURE FILING

This FIRST AMENDMENT TO OPEN-END MORTGAGE DEED TO SECURE PRESENT AND FUTURE LOANS UNDER CHAPTER 25 OF TITLE 34 OF THE RHODE ISLAND GENERAL LAWS, ASSIGNMENT OF LEASES AND RENTS, SECURITY AGREEMENT AND FIXTURE FILING (this “Agreement”) is made as of the 24th day of March, 2021 (the “Effective Date”), by ASTRONOVA, INC., a Rhode Island corporation (herein referred to as “Mortgagor”), whose address is 600 East Greenwich Avenue, West Warwick, Rhode Island 02893, to BANK OF AMERICA, N.A., a national banking association (“Mortgagee”), whose address is 100 Westminster Street, RI-536-10-01, Providence, RI 02903.

Recitals

WHEREAS, Mortgagor delivered that certain Open-End Mortgage Deed To Secure Present And Future Loans Under Chapter 25 Of Title 34 Of The Rhode Island General Laws, Assignment Of Leases And Rents, Security Agreement And Fixture Filing, with an Effective Date of July 30, 2020, to Mortgagee, and recorded in the Land Evidence Records in the Town of West Warwick, Rhode Island in Book 2485, Page 3313 (the “Mortgage”), to secure, singly and collectively: (i) that certain Term Note of even date therewith made by Mortgagor payable to the order of Mortgagee in the principal face amount of Sixteen Million Seven Hundred Thirty-Two Thousand and No/100 Dollars ($16,732,000.00); and, (ii) that certain Revolving Note of even date therewith made by Mortgagor, payable to the order of Mortgagee in the principal face amount of Ten Million and No/100 Dollars ($10,000,000.00), as the same may from time to time be extended, renewed, amended, restated, replaced, supplemented or otherwise modified.

WHEREAS, Mortgagor and Mortgagee have agreed to certain amendments to the Loan, as that term is defined by the Mortgage (collectively, the “Amendment”) and as a condition precedent to amending the Loan, Mortgagee has required that Mortgagor execute and deliver this First Amendment to Open-End Mortgage Deed to Secure Present and Future Loans Under Chapter 25 of Title 34 of The Rhode Island General Laws, Assignment of Leases and Rents, Security Agreement and Fixture Filing

WHEREAS, all things necessary to make this Agreement the valid and legally binding obligation of Mortgagor in accordance with its terms, for the uses and purposes herein set forth, have been done and performed.

WHEREAS, capitalized terms used in this Agreement without definition shall have the respective meanings attributed thereto in the Loan Agreement.

Grants and Agreements

Now, therefore, for good and valuable consideration, the receipt and adequacy of which are hereby acknowledged by Mortgagor, and in order to induce Mortgagee to amend the Loan to Mortgagor and enter into the Amendment, Mortgagor agrees as follows:

 

Page 1


1. Amendments to Mortgage. The Mortgage is hereby amended as follows:

A. Article I is hereby amended by deleting the following definitions in their entirety and replacing them with the following:

Loan Agreement” means the Amended and Restated Credit Agreement dated as of July 30, 2020 between Mortgagor and Mortgagee as amended by that certain First Amendment to the Credit Agreement dated as of March ____, 2021 between Mortgagor, Mortgagee, ANI APS, a Danish private liability company; and, Trojan Label APS, a Danish private liability company, which amends certain of the terms and conditions regarding the Loan, as the same may from time to time be extended, amended, restated, supplemented or otherwise modified.

Note” means, singly and collectively, (i) that certain Term Note dated as of July 30, 2020 made by Mortgagor payable to the order of Mortgagee in the principal face amount of Sixteen Million Two Hundred Thirty-Two Thousand and No/100 Dollars ($16,232,000.00)(the “Original Term Note”), the principal balance of which as of the Effective Date is Ten Million and No/100 Dollars ($10,000,000.00) and (ii) that certain Revolving Note dated as of July 30, 2020 made by Mortgagor payable to the order of Mortgagee in the principal face amount of Ten Million and No/100 Dollars ($10,000,000.00)(the “Original Revolving Note”), as amended and restated in its entirety by that certain Amended and Restated Revolving Note dated as of March _____, 2021 made by Mortgagor payable to the order of Mortgagee in the principal face amount of Twenty-Two Million Five Hundred Thousand and No/100 Dollars ($22,500,000.00), as the same may from time to time be extended, renewed, amended, restated, replaced, supplemented or otherwise modified.

B. Section 8.16(c) of the Mortgage shall be deleted in its entirety and replaced with the following:

Future Advances; Rhode Island Open-End Mortgage. This Mortgage permits and secures any and all current and future advances to Mortgagor evidenced by (or pursuant to) any one or more of the following: the Note, the Loan Agreement, and the other Loan Documents, such other note or notes as may be signed by Mortgagor payable to Lender and such other agreement(s) as may be entered into by Mortgagor with Lender, and signed by Borrower. The unpaid principal balance of indebtedness outstanding under this Mortgage shall at no time exceed Thirty-Two Million Five Hundred Thousand and 00/100 Dollars ($32,500,000.00). Borrower will accept notices pursuant to R.I.G.L. §34-25-10(B) and §34-25-11 at the address and in the manner specified in Section 8.8 of this Mortgage.

C. The Mortgage is further amended so that the term “Mortgage” shall collectively refer to the Mortgage and this Agreement, “Loan Agreement” shall refer collectively to the Loan Agreement as defined by this Agreement, and the term “Note” shall refer to the Note as defined by this Agreement.

2. Ratification. With the amendments thereto made hereby, the Mortgage and all of the terms, covenants and conditions and other provisions thereof are hereby ratified, reconfirmed and readopted. All references to the Mortgage in the other Loan Documents shall be deemed to refer to the Mortgage as amended hereby. To the extent the terms of this Agreement are inconsistent with the other Loan Documents, the terms hereunder shall control.

 

Page 2


3. No Novation. Mortgagor further agrees that this Agreement and the other documents executed in connection with the Amendment are not intended to be, nor shall they be construed to create, a novation or accord and satisfaction of any of the Original Term Note (as defined in this Agreement), the Original Revolving Note (as defined in this Agreement), or the indebtedness evidenced thereby.

4. General Provisions.

4.1 Changes: This Agreement may not be changed orally but only by a writing signed by the parties hereto and dated subsequent to the date hereof.

4.2 Governing Law: This Agreement shall be governed by, and construed, interpreted and enforced in accordance with the provisions of Section 8.11 of the Mortgage without reference to its principles of conflicts of law.

4.3 Binding Effect: This Agreement shall be binding upon and inure to the benefit of the parties and their respective administrators, executors, personal representatives, heirs, successors and assigns.

4.4 Entire Agreement. This Agreement constitutes the entire agreement of the parties pertaining to the subject matter hereof and all prior negotiations and representations relating thereto are merged herein. The terms and conditions set forth in this Agreement are the product of joint draftsmanship by all parties, each being represented or having the opportunity to be represented by counsel, and any ambiguities in this Agreement or any documentation prepared pursuant to or in connection with this Agreement shall not be construed against any of the parties because of draftsmanship. This Agreement is not intended to modify and does not modify the rights, remedies and obligations of the parties pursuant to any loan or security agreement, guaranty or debt instrument, except to the extent expressly set forth herein. This Agreement shall inure to the benefit of, and be binding upon, the representatives, successors and assigns of the parties hereto, respectively. The parties each acknowledge that they have read and understand this Agreement, that they have had the ability to consult with an attorney of their own choosing, and that they execute this Agreement voluntarily.

[Remainder of Page Intentionally Blank; Signatures Follow]

 

Page 3


IN WITNESS WHEREOF, Mortgagor has caused this Mortgage to be executed as of the date first written above.

 

MORTGAGOR:

ASTRONOVA, INC.,

a Rhode Island corporation

By:  

/s/ David S. Smith

Name:   David S. Smith
Title:   VP, CFO

STATE OF NEW YORK

COUNTY OF   Westchester    

In Harrison, NY, on this 23rd day of March, 2021, before me personally appeared David S. Smith, the V.P., CFO of AstroNova, Inc., a Rhode Island corporation, to me known and known by me to be the party executing the foregoing instrument on behalf of said corporation, and acknowledged said instrument and the execution thereof to be his/her free act and deed in said capacity and the free act and deed of said corporation.

 

/s/ Philip M. Smith                

Notary Public
Print Name Philip M. Smith
My Commission Expires                                                                 
[SEAL]


MORTGAGEE:
BANK OF AMERICA, N.A.
By:  

/s/ Nicholas Storti

Name:   Nicholas Storti
Title:   Senior Vice President

STATE OF RHODE ISLAND

COUNTY OF   Providence        

In Johnston, on this 24 day of March, 2021, before me personally appeared Nicholas Storti, the Senior Vice President of Bank of America, N.A., to me known and known by me to be the party executing the foregoing instrument on behalf of said corporation, and acknowledged said instrument and the execution thereof to be his/her free act and deed in said capacity and the free act and deed of said corporation.

 

/s/ Sandugash Yedgeyeva                

Notary Public
Print Name Sandugash Yedgeyeva
My Commission Expires 06/17/2023
[SEAL]
EX-21 4 d56468dex21.htm EX-21 EX-21

Exhibit 21

LIST OF SUBSIDIARIES OF THE COMPANY

 

Name

   Jurisdiction of Organization

AstroNova GmbH

   Germany

AstroNova (Shanghai) Trading Co., Ltd

   China

AstroNova Aerospace, Inc.

   Delaware

ANI ApS

   Denmark

AstroNova Scandinavia ApS (formally TrojanLabel ApS)

   Denmark

AstroNova SAS

   France

AstroDigital Data de México, S.A. de C.V.

   Mexico
EX-23.1 5 d56468dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statements (Nos. 333-231953, 333-143854, 333-204619, 333-225404 and 2-81081) on Form S-8 of AstroNova, Inc. of our report dated April 13, 2021, related to our audit of the consolidated financial statements, and the financial statement schedule, which appear in this Annual Report on Form 10-K for the year ended January 31, 2021.

 

/s/ Wolf & Company, P.C.

Boston, Massachusetts

April 13, 2021

EX-31.1 6 d56468dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Gregory A. Woods certify that:

1. I have reviewed this annual report on Form 10-K of AstroNova, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on our evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date April 13, 2021

 

/s/ GREGORY A. WOODS

Gregory A. Woods

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 7 d56468dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, David S. Smith, certify that:

1. I have reviewed this annual report on Form 10-K of AstroNova, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on our evaluation; and

(d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date April 13, 2021

 

/s/ David S. Smith
David S. Smith
Vice President, Chief Financial Officer and
Treasurer (Principal Financial Officer and
Principal Accounting Officer)
EX-32.1 8 d56468dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

AstroNova Inc.

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of AstroNova, Inc. (the “Company”) on Form 10-K for the year ended January 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregory A. Woods, Chief Executive Officer, hereby certify, pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 13th day of April, 2021

 

/s/ GREGORY A. WOODS
Gregory A. Woods

President and Chief Executive Officer

(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to AstroNova, Inc. and will be retained by AstroNova, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 9 d56468dex322.htm EX-32.2 EX-32.2

Exhibit 32.2

AstroNova Inc.

CERTIFICATION OF THE CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of AstroNova , Inc. (the “Company”) on Form 10-K for the year ended January 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David S. Smith, Vice President, Chief Financial Officer and Treasurer, hereby certify, pursuant to Rule 13a-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated this 13th day of April, 2021

 

/s/ David S. Smith
David S. Smith
Vice President, Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer)

A signed original of this written statement required by Section 906 has been provided to AstroNova, Inc. and will be retained by AstroNova, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.SCH 10 alot-20210131.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Consolidated Statements of Income link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Consolidated Statements of Comprehensive Income link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Revenue Recognition link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Goodwill link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Property, Plant and Equipment link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Accrued Expenses link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Credit Agreement and Long- Term Debt link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Paycheck Protection Program Loan link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Derivative Financial Instruments and Risk Management link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Royalty Obligation link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Leases link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Employee Benefit Plans link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Product Warranty Liability link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Concentration of Risk link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Fair Value Measurements link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Subsequent Event link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Goodwill (Tables) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Credit Agreement and Long- Term Debt (Tables) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Derivative Financial Instruments and Risk Management (Tables) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Leases (Tables) link:presentationLink link:definitionLink link:calculationLink 1043 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:definitionLink link:calculationLink 1044 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1045 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 1046 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information (Tables) link:presentationLink link:definitionLink link:calculationLink 1047 - Disclosure - Product Warranty Liability (Tables) link:presentationLink link:definitionLink link:calculationLink 1048 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:definitionLink link:calculationLink 1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1050 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) link:presentationLink link:definitionLink link:calculationLink 1051 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) link:presentationLink link:definitionLink link:calculationLink 1052 - Disclosure - Revenue Recognition - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1053 - Disclosure - Goodwill - Summary of Goodwill by reporting unit (Detail) link:presentationLink link:definitionLink link:calculationLink 1054 - Disclosure - Goodwill - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1055 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) link:presentationLink link:definitionLink link:calculationLink 1056 - Disclosure - Intangible Assets - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1057 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1058 - Disclosure - Inventories - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1059 - Disclosure - Inventories - Components of Inventories (Detail) link:presentationLink link:definitionLink link:calculationLink 1060 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1061 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1062 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) link:presentationLink link:definitionLink link:calculationLink 1063 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) link:presentationLink link:definitionLink link:calculationLink 1064 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail) link:presentationLink link:definitionLink link:calculationLink 1065 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 1066 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1067 - Disclosure - Paycheck Protection Program Loan - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1068 - Disclosure - Derivative Financial Instruments and Risk Management - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1069 - Disclosure - Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail) link:presentationLink link:definitionLink link:calculationLink 1070 - Disclosure - Royalty Obligation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1071 - Disclosure - Leases - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1072 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1073 - Disclosure - Leases - Lease Cost Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1074 - Disclosure - Leases - Maturities of lease liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1075 - Disclosure - Leases - Supplemental cash flow information (Detail) link:presentationLink link:definitionLink link:calculationLink 1076 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) link:presentationLink link:definitionLink link:calculationLink 1077 - Disclosure - Shareholders' Equity - Additional information (Detail) link:presentationLink link:definitionLink link:calculationLink 1078 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1079 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1080 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1081 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail) link:presentationLink link:definitionLink link:calculationLink 1082 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1083 - Disclosure - Share-Based Compensation - Summarized Plan Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1084 - Disclosure - Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail) link:presentationLink link:definitionLink link:calculationLink 1085 - Disclosure - Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail) link:presentationLink link:definitionLink link:calculationLink 1086 - Disclosure - Income Taxes - Components of Income before Income Taxes (Detail) link:presentationLink link:definitionLink link:calculationLink 1087 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Detail) link:presentationLink link:definitionLink link:calculationLink 1088 - Disclosure - Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) link:presentationLink link:definitionLink link:calculationLink 1089 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1090 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1091 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail) link:presentationLink link:definitionLink link:calculationLink 1092 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail) link:presentationLink link:definitionLink link:calculationLink 1093 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail) link:presentationLink link:definitionLink link:calculationLink 1094 - Disclosure - Employee Benefit Plans - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1095 - Disclosure - Product Warranty Liability - Activity in Product Warranty Liability (Detail) link:presentationLink link:definitionLink link:calculationLink 1096 - Disclosure - Concentration of Risk - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1097 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 1098 - Disclosure - Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) link:presentationLink link:definitionLink link:calculationLink 1099 - Disclosure - Subsequent Event - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1100 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 11 alot-20210131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 12 alot-20210131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 13 alot-20210131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 14 alot-20210131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 15 d56468d10k_htm.xml IDEA: XBRL DOCUMENT 0000008146 2020-02-01 2021-01-31 0000008146 2020-01-31 0000008146 2021-01-31 0000008146 2019-02-01 2020-01-31 0000008146 2018-02-01 2019-01-31 0000008146 2019-01-31 0000008146 2020-07-31 0000008146 2021-04-09 0000008146 2018-01-31 0000008146 alot:MiltopeCorporationMember us-gaap:CustomerContractsMember 2020-01-31 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:CustomerContractsMember 2020-01-31 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:NoncompeteAgreementsMember 2020-01-31 0000008146 alot:TrojanlabelApSMember alot:ExistingTechnologyMember 2020-01-31 0000008146 alot:TrojanlabelApSMember alot:DistributorRelationsMember 2020-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2020-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 alot:TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 alot:TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2020-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2020-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2020-01-31 0000008146 country:US 2020-01-31 0000008146 srt:EuropeMember 2020-01-31 0000008146 country:CA 2020-01-31 0000008146 alot:ProductIdentificationMember 2020-01-31 0000008146 alot:TestAndMeasurementMember 2020-01-31 0000008146 alot:CrossCurrencyInterestRateSwapMember alot:CashFlowHedgeMember 2020-01-31 0000008146 us-gaap:InterestRateSwapMember alot:CashFlowHedgeMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-01-31 0000008146 us-gaap:DomesticCountryMember 2020-01-31 0000008146 alot:MiltopeCorporationMember us-gaap:CustomerContractsMember 2021-01-31 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:CustomerContractsMember 2021-01-31 0000008146 alot:RuggedInformationTechnologyEquipmentCorporationMember us-gaap:NoncompeteAgreementsMember 2021-01-31 0000008146 alot:TrojanlabelApSMember alot:ExistingTechnologyMember 2021-01-31 0000008146 alot:TrojanlabelApSMember alot:DistributorRelationsMember 2021-01-31 0000008146 us-gaap:CustomerContractsMember alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2021-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember 2021-01-31 0000008146 alot:TermLoanMember 2021-01-31 0000008146 alot:TwoThousandEighteenEquityIncentivePlanMember 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2021-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2021-01-31 0000008146 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-31 0000008146 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-01-31 0000008146 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-01-31 0000008146 country:US 2021-01-31 0000008146 srt:EuropeMember 2021-01-31 0000008146 country:CA 2021-01-31 0000008146 alot:TwoThousandSevenEquityIncentivePlanMember 2021-01-31 0000008146 alot:TwoThousandFifteenEquityIncentivePlanMember 2021-01-31 0000008146 us-gaap:RestrictedStockMember alot:TwoThousandFifteenEquityIncentivePlanMember 2021-01-31 0000008146 alot:RangeThreeMember 2021-01-31 0000008146 alot:RangeFourMember 2021-01-31 0000008146 alot:RangeFiveMember 2021-01-31 0000008146 alot:TestAndMeasurementMember 2021-01-31 0000008146 alot:ProductIdentificationMember 2021-01-31 0000008146 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-01-31 0000008146 country:CN 2021-01-31 0000008146 stpr:DE 2021-01-31 0000008146 us-gaap:RestrictedStockMember alot:TwoThousandEighteenEquityIncentivePlanMember 2021-01-31 0000008146 us-gaap:EmployeeStockOptionMember 2021-01-31 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2021-01-31 0000008146 srt:MaximumMember 2021-01-31 0000008146 srt:MinimumMember 2021-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:GreenWoodCreditUnionMember 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember 2021-01-31 0000008146 alot:TermLoanMember alot:BankOfAmericaMember 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember 2021-01-31 0000008146 country:US 2018-02-01 2019-01-31 0000008146 srt:EuropeMember 2018-02-01 2019-01-31 0000008146 country:CA 2018-02-01 2019-01-31 0000008146 srt:AsiaMember 2018-02-01 2019-01-31 0000008146 alot:CentralAndSouthAmericaMember 2018-02-01 2019-01-31 0000008146 alot:OthersCountriesMember 2018-02-01 2019-01-31 0000008146 alot:HardwareProductsMember 2018-02-01 2019-01-31 0000008146 alot:SuppliesMember 2018-02-01 2019-01-31 0000008146 alot:ServiceAndOtherMember 2018-02-01 2019-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2018-02-01 2019-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2018-02-01 2019-01-31 0000008146 alot:OtherCountriesMember 2018-02-01 2019-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2018-02-01 2019-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2018-02-01 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2018-02-01 2019-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2018-02-01 2019-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-02-01 2019-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2018-02-01 2019-01-31 0000008146 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-02-01 2019-01-31 0000008146 us-gaap:EmployeeStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:OperatingSegmentsMember 2018-02-01 2019-01-31 0000008146 us-gaap:TreasuryStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:CommonStockMember 2018-02-01 2019-01-31 0000008146 us-gaap:RetainedEarningsMember 2018-02-01 2019-01-31 0000008146 country:US 2019-02-01 2020-01-31 0000008146 srt:EuropeMember 2019-02-01 2020-01-31 0000008146 country:CA 2019-02-01 2020-01-31 0000008146 srt:AsiaMember 2019-02-01 2020-01-31 0000008146 alot:CentralAndSouthAmericaMember 2019-02-01 2020-01-31 0000008146 alot:OthersCountriesMember 2019-02-01 2020-01-31 0000008146 alot:HardwareProductsMember 2019-02-01 2020-01-31 0000008146 alot:SuppliesMember 2019-02-01 2020-01-31 0000008146 alot:ServiceAndOtherMember 2019-02-01 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2019-02-01 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2019-02-01 2020-01-31 0000008146 alot:OtherCountriesMember 2019-02-01 2020-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2019-02-01 2020-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2019-02-01 2020-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2019-02-01 2020-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2019-02-01 2020-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-02-01 2020-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-02-01 2020-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2019-02-01 2020-01-31 0000008146 us-gaap:EmployeeStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:OperatingSegmentsMember 2019-02-01 2020-01-31 0000008146 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-02-01 2020-01-31 0000008146 us-gaap:TreasuryStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:CommonStockMember 2019-02-01 2020-01-31 0000008146 us-gaap:DomesticCountryMember 2019-02-01 2020-01-31 0000008146 us-gaap:RetainedEarningsMember 2019-02-01 2020-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2019-02-01 2020-01-31 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2019-02-01 2020-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember alot:CashFlowHedgeMember 2019-02-01 2020-01-31 0000008146 alot:ProductIdenificationMember 2019-02-01 2020-01-31 0000008146 country:US 2020-02-01 2021-01-31 0000008146 srt:EuropeMember 2020-02-01 2021-01-31 0000008146 country:CA 2020-02-01 2021-01-31 0000008146 srt:AsiaMember 2020-02-01 2021-01-31 0000008146 alot:CentralAndSouthAmericaMember 2020-02-01 2021-01-31 0000008146 alot:OthersCountriesMember 2020-02-01 2021-01-31 0000008146 alot:HardwareProductsMember 2020-02-01 2021-01-31 0000008146 alot:SuppliesMember 2020-02-01 2021-01-31 0000008146 alot:ServiceAndOtherMember 2020-02-01 2021-01-31 0000008146 alot:RangeThreeMember 2020-02-01 2021-01-31 0000008146 alot:RangeFourMember 2020-02-01 2021-01-31 0000008146 alot:RangeFiveMember 2020-02-01 2021-01-31 0000008146 alot:TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember 2020-02-01 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2020-02-01 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2020-02-01 2021-01-31 0000008146 alot:OtherCountriesMember 2020-02-01 2021-01-31 0000008146 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2020-02-01 2021-01-31 0000008146 alot:TradeAccountsPayablesMember us-gaap:SupplierConcentrationRiskMember 2020-02-01 2021-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2020-02-01 2021-01-31 0000008146 us-gaap:CorporateNonSegmentMember 2020-02-01 2021-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-02-01 2021-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-02-01 2021-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:LandImprovementsMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember alot:BuildingAndLeaseholdImprovementsMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember us-gaap:LandImprovementsMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember alot:BuildingAndLeaseholdImprovementsMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember alot:ComputerEquipmentAndSoftwareMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember alot:ComputerEquipmentAndSoftwareMember 2020-02-01 2021-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember 2020-02-01 2021-01-31 0000008146 us-gaap:EmployeeStockMember 2020-02-01 2021-01-31 0000008146 us-gaap:OperatingSegmentsMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-02-01 2021-01-31 0000008146 us-gaap:CommonStockMember 2020-02-01 2021-01-31 0000008146 alot:AirborneProductMember srt:MinimumMember 2020-02-01 2021-01-31 0000008146 alot:AirborneProductMember srt:MaximumMember 2020-02-01 2021-01-31 0000008146 us-gaap:TreasuryStockMember 2020-02-01 2021-01-31 0000008146 us-gaap:RetainedEarningsMember 2020-02-01 2021-01-31 0000008146 us-gaap:EmployeeStockOptionMember 2020-02-01 2021-01-31 0000008146 us-gaap:RestrictedStockUnitsRSUMember 2020-02-01 2021-01-31 0000008146 alot:EmployeeStockPurchasePlanMember 2020-02-01 2021-01-31 0000008146 country:CN 2020-02-01 2021-01-31 0000008146 alot:RestrictedStockAwardMember 2020-02-01 2021-01-31 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2020-02-01 2021-01-31 0000008146 us-gaap:GeneralAndAdministrativeExpenseMember 2020-02-01 2021-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember alot:CashFlowHedgeMember 2020-02-01 2021-01-31 0000008146 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2020-02-01 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:GreenWoodCreditUnionMember 2020-02-01 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:GreenWoodCreditUnionMember us-gaap:OtherExpenseMember 2020-02-01 2021-01-31 0000008146 alot:BankOfAmericaMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:OtherExpenseMember alot:BankOfAmericaMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 alot:TermLoanMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:FederalFundsEffectiveSwapRateMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-02-01 2021-01-31 0000008146 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember 2020-02-01 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:PromissoryNoteMember alot:GreenwoodCreditUnionMember 2020-02-01 2021-01-31 0000008146 alot:ProductIdenificationMember 2020-02-01 2021-01-31 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:InterestExpenseMember 2020-02-01 2021-01-31 0000008146 alot:PaycheckProtectionProgramLoanMember alot:GreenWoodCreditUnionMember 2020-05-06 0000008146 us-gaap:CashFlowHedgingMember 2020-05-03 2020-08-01 0000008146 alot:TermLoanMember 2020-05-03 2020-08-01 0000008146 alot:HoneywellAssetPurchaseAndLicenseAgreementMember 2018-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:ProductIdentificationMember 2019-01-31 0000008146 us-gaap:OperatingSegmentsMember alot:TestAndMeasurementMember 2019-01-31 0000008146 alot:ExistingCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:SubsequentEventMember 2021-03-24 2021-03-24 0000008146 alot:ExistingCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember alot:BankOfAmericaMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 alot:FirstAmendmentToCreditAgreementMember us-gaap:RevolvingCreditFacilityMember alot:BankOfAmericaMember us-gaap:SubsequentEventMember 2021-03-24 0000008146 srt:MinimumMember alot:TermLoanMember 2020-05-02 2020-07-31 0000008146 srt:MaximumMember alot:TermLoanMember 2020-05-02 2020-07-31 0000008146 alot:TermLoanMember 2020-08-02 2020-10-31 0000008146 srt:MinimumMember alot:TermLoanMember 2020-11-01 2021-01-31 0000008146 srt:MaximumMember alot:TermLoanMember 2020-11-01 2021-01-31 0000008146 srt:ScenarioForecastMember alot:TermLoanMember 2021-02-01 2021-04-30 0000008146 srt:ScenarioForecastMember alot:TermLoanMember 2022-02-01 2022-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2021-04-30 2021-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2021-07-31 2021-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2021-10-31 2021-10-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2022-01-31 2022-01-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2022-04-30 2022-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2022-07-31 2022-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2023-04-30 2023-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember alot:TermLoanMember 2021-04-24 2021-04-24 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2024-07-31 2024-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2024-10-31 2024-10-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2025-01-01 2025-01-01 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2023-07-31 2023-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2023-10-31 2023-10-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2024-01-01 2024-01-01 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2024-04-30 2024-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2025-04-30 2025-04-30 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2025-07-31 2025-07-31 0000008146 alot:FirstAmendmentToCreditAgreementMember srt:ScenarioForecastMember alot:TermLoanMember 2023-01-01 2023-01-01 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-31 0000008146 us-gaap:TreasuryStockMember 2018-01-31 0000008146 us-gaap:RetainedEarningsMember 2018-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0000008146 us-gaap:CommonStockMember 2018-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-31 0000008146 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2018-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2018-01-31 0000008146 us-gaap:EmployeeStockMember 2018-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2019-01-31 0000008146 us-gaap:EmployeeStockMember 2019-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2019-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0000008146 us-gaap:RetainedEarningsMember 2019-01-31 0000008146 us-gaap:TreasuryStockMember 2019-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-31 0000008146 us-gaap:CommonStockMember 2019-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2020-01-31 0000008146 us-gaap:EmployeeStockMember 2020-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2020-01-31 0000008146 us-gaap:CommonStockMember 2020-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2020-01-31 0000008146 us-gaap:RetainedEarningsMember 2020-01-31 0000008146 us-gaap:TreasuryStockMember 2020-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-01-31 0000008146 alot:ProductIdenificationMember 2019-01-31 0000008146 alot:TMMember 2019-01-31 0000008146 us-gaap:AllowanceForCreditLossMember 2021-01-31 0000008146 us-gaap:EmployeeStockMember 2021-01-31 0000008146 alot:RestrictedStockAwardAndRestrictedStockUnitMember 2021-01-31 0000008146 us-gaap:CommonStockMember 2021-01-31 0000008146 us-gaap:AdditionalPaidInCapitalMember 2021-01-31 0000008146 us-gaap:RetainedEarningsMember 2021-01-31 0000008146 us-gaap:TreasuryStockMember 2021-01-31 0000008146 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-31 0000008146 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-31 0000008146 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-01-31 0000008146 alot:ProductIdenificationMember 2020-01-31 0000008146 alot:TMMember 2020-01-31 0000008146 alot:ProductIdenificationMember 2021-01-31 0000008146 alot:TMMember 2021-01-31 iso4217:USD shares pure utr:Year iso4217:USD shares alot:Segment false FY 0000008146 --01-31 P1Y us-gaap:OperatingLeaseLiabilityCurrent us-gaap:OperatingLeaseLiabilityCurrent 10-K true 2021-01-31 2021 false 0-13200 AstroNova, Inc. RI 05-0318215 600 East Greenwich Avenue West Warwick RI 02893 401 828-4000 Common Stock ALOT NASDAQ No No Yes Yes Non-accelerated Filer true false false false 47045000 7212977 11439000 4249000 1054000 856000 17415000 19784000 30060000 33925000 1807000 2193000 60721000 60151000 12011000 11268000 21502000 25383000 12806000 12034000 5941000 5079000 1389000 1661000 1103000 1088000 115473000 116664000 5734000 4409000 2852000 2700000 3939000 4711000 6500000 5326000 5208000 2000000 2000000 177000 773000 655000 285000 466000 20968000 26767000 7109000 7715000 6161000 8012000 4422000 1065000 1279000 681000 1081000 384000 435000 40790000 45289000 10 10 100000 100000 0 0 0.05 0.05 13000000 13000000 10425094 10343610 521000 517000 58049000 56130000 50085000 49298000 3297058 3281701 33588000 33477000 -384000 -1093000 74683000 71375000 115473000 116664000 116033000 133446000 136657000 74673000 84688000 82658000 41360000 48758000 53999000 23301000 26884000 26343000 6206000 8084000 7813000 9420000 11357000 11123000 38927000 46325000 45279000 2433000 2433000 8720000 -955000 -682000 -731000 590000 -448000 -745000 111000 67000 64000 -254000 -1063000 -1412000 2179000 1370000 7308000 895000 -389000 1578000 1284000 1759000 5730000 0.18 0.25 0.83 0.18 0.24 0.81 7104000 7024000 6881000 62000 214000 203000 7166000 7238000 7084000 1284000 1759000 5730000 710000 -133000 -671000 -239000 122000 622000 -193000 264000 600000 45000 -3000 709000 -275000 -646000 1993000 1484000 5084000 9996120 500000 50016000 45700000 -32397000 -172000 63647000 1886000 1886000 154992 7000 1669000 -366000 1310000 67447 4000 -3000 -234000 -233000 14000 14000 0.28 1933000 1933000 5730000 5730000 -646000 -646000 10218559 511000 53568000 49511000 -32997000 -818000 69775000 1775000 1775000 65121 3000 790000 -11000 782000 59930 3000 -3000 -469000 -469000 0.28 1972000 1972000 1759000 1759000 -275000 -275000 10343610 517000 56130000 49298000 -33477000 -1093000 71375000 1819000 1819000 16487 1000 103000 104000 64997 3000 -3000 -111000 -111000 0.07 497000 497000 1284000 1284000 709000 709000 10425094 521000 58049000 50085000 -33588000 -384000 74683000 1284000 1759000 5730000 5983000 6284000 6152000 75000 49000 51000 1819000 1775000 1886000 -1021000 -1638000 -1638000 -2702000 -3594000 1493000 -4247000 3938000 2872000 -57000 -2732000 -2342000 1482000 -1773000 -151000 970000 156000 318000 15544000 3224000 5005000 1511000 400000 2587000 2906000 2645000 -2587000 -2906000 -1534000 9000 654000 1228000 95000 128000 82000 111000 469000 233000 -6500000 5000000 1500000 2000000 1875000 1625000 4422000 15232000 11732000 3958000 5208000 5130000 100000 497000 1972000 1933000 -5140000 -3742000 -6111000 -627000 139000 -3000 7190000 -3285000 -2643000 4249000 7534000 10177000 11439000 4249000 7534000 677000 531000 636000 446000 2913000 3472000 11000 366000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1—Summary of Significant Accounting Policies </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation:</div></div> The accompanying financial statements and accompanying notes have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Our fiscal year end is January 31. Unless otherwise stated, all years and dates refer to our fiscal year. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation: </div></div>The consolidated financial statements include the accounts of AstroNova, Inc. and its subsidiaries. All material intercompany accounts and transactions are eliminated in consolidation. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassification: </div></div>Certain amounts in prior year’s financial statements have been reclassified to conform to the current year’s presentation. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates: </div></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect these financial statements and accompanying notes. Some of the more significant estimates relate to the allowances for doubtful accounts, inventory valuation, valuation and estimated lives of intangible assets, impairment of long-lived assets, goodwill, income taxes, share-based compensation and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters. Consequently, actual results could differ from those estimates. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents: </div></div>Highly liquid investments with an original maturity of 90 days or less are considered to be cash equivalents. Similar investments with original maturities beyond three months are classified as securities available for sale. At January 31, 2021 and 2020, $4.6 million and $3.4 million, respectively, was held in foreign bank accounts. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories:</div></div> Inventories are stated at the lower of cost <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out)</div> or net realizable value and include material, labor and manufacturing overhead. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment: </div></div>Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets (land improvements—10 to 20 years; buildings and leasehold improvements—10 to 45 years; machinery and equipment—3 to 10 years and computer equipment and software—3 to 10 years). </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition:</div> We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Topic 606 defines a five step process to recognize revenue and requires more judgment and estimates within the revenue recognition process than required under previous U.S. GAAP, including identifying contracts with customers, identifying performance obligations in the contract, determining and estimating the amount of any variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and recognizing revenue when the entity satisfies each performance obligation. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The vast majority of our revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration we expect to receive in exchange for such products, which is generally at the contractually stated prices, and is recognized when we satisfy a performance obligation by transferring control of a product to a customer. The transfer of control generally occurs at one point in time, upon shipment, when title and risk of loss pass to the customer. Returns and customer credits are infrequent and are recorded as a reduction to revenue. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the contracts entered into with customers are commonly comprised of a combination of equipment, supplies, installation and/or training services. We determine performance obligations by assessing whether the products or services are distinct from other elements of the contract. In order to be distinct, the product must perform either on its own or with readily available resources and must be separate within the context of the contract. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of our hardware products contain embedded operating systems and data management software which is included in the purchase price of the equipment. The software is deemed incidental to the systems as a whole, as it is not sold or marketed separately, and its production costs are minor compared to those of the hardware system. Hardware and software elements are typically delivered at the same time and are accounted for as a single performance obligation for which revenue is recognized at the point in time when ownership is transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Installation and training services vary based on certain factors such as the complexity of the equipment, staffing availability in a geographic location and customer preferences, and can range from a few days to a few months. The delivery of installation and training services are not assessed to determine whether they are separate performance obligations, as the amounts are not material to the contract. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling activities that occur after control over a product has transferred to a customer are accounted for as fulfillment activities rather than performance obligations, as allowed under a practical expedient provided by Topic 606. The shipping and handling fees charged to customers are recognized as revenue and the related costs are included in cost of revenue at the point in time when ownership of the product is transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may perform service at the request of the customer, generally for the repair and maintenance of products previously sold. These services are short in duration and total less than 10% of revenue for the years ended January 31, 2021 and 2020. Revenue is recognized as services are rendered and accepted by the customer. We also provide service agreements on certain of our Product Identification equipment. Service agreements are purchased separately from the equipment and provide for the right to obtain service and maintenance on the equipment for a period of typically one to two years. Accordingly, revenue on these agreements is recognized over the term of the agreements. The portion of service agreement contracts that are uncompleted at the end of any reporting period are included in deferred revenue. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;">We generally provide warranties for our products. The standard warranty period is typically 12 months for most hardware products except for airborne printers, which typically have warranties that extend for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years, consistent with industry practice. Such assurance-type warranties are not deemed to be separate performance obligations from the hardware product and costs associated with providing the warranties are accrued in accordance with ASC 450, “Contingencies,” as we have the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. Our estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that our experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue. On occasion, customers request a warranty period longer than our standard warranty. In those instances, in which extended warranty services are separately quoted to the customer, an additional performance obligation is created, and the associated revenue is deferred and recognized as service revenue ratably over the term of the extended warranty period. The portion of service contracts and extended warranty services agreements that are uncompleted at the end of any reporting period are included in deferred revenue. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize an asset for the incremental direct costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. Costs related to obtaining sales contracts for our aerospace printer products have been capitalized and are being amortized based on the forecasted number of units sold over the estimated benefit term. We apply the practical expedient to expense costs incurred for costs to obtain a contract when the amortization period would have been less than a year. These costs include sales commissions paid to the internal direct sales team as well as to third-party representatives and distributors. Contractual </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">agreements with each of these parties outline commission structures and rates to be paid. Generally speaking, the contracts are all individual procurement decisions by the customers and do not include renewal provisions and as such the majority of the contracts have an economic life of significantly less than a year. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivables and Allowance for Doubtful Accounts: </div></div>Standard payment terms are typically 30 days after shipment but vary by type and geographic location of our customer. Credit is extended based upon an evaluation of the customer’s financial condition. In circumstances where we are aware of a customer’s inability to meet its financial obligations, an allowance is established. The remainder of the allowance established is based on a variety of factors, including the age of amounts outstanding relative to their contractual due date, historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience and current market assessments. Accounts receivable are stated at their estimated net realizable value. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs: </div></div>We charge costs to expense in the period incurred, and these expenses are presented in the consolidated statement of income. The following costs are included in research and development expense: salaries and benefits, external engineering service costs, engineering related information costs and supplies. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation: </div></div>The financial statements of foreign subsidiaries and branches are measured using the local currency as the functional currency. Foreign currency-denominated assets and liabilities are translated into U.S. dollars at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates with the translation adjustment recorded as a component of accumulated comprehensive income (loss) in shareholders’ equity. Revenues and expenses are translated at the average monthly exchange rates in effect during the related period. We do not provide for U.S. income taxes on foreign currency translation adjustments associated with our subsidiaries in Germany, Denmark and China since their undistributed earnings are considered to be permanently invested. Included in our consolidated statements of income was a net transactional foreign exchange gain of $0.6 million in fiscal 2021, and a net transaction foreign exchange loss of $0.4 million in fiscal 2020 and $0.7 million for fiscal 2019. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advertising: </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">We</div><div style="background: none;;font-style:italic;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div>expense advertising costs as incurred. Advertising costs including advertising production, trade shows and other activities are designed to enhance demand for our products and amounted to approximately $0.9 million; $1.8 million and $1.9 million in fiscal 2021, 2020 and 2019, respectively. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-Lived Assets: </div></div>Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, as determined by the discounting of future cash flows. There were no impairment charges for our long-lived assets in fiscal years 2021, 2020 or 2019. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible Assets: </div></div>Intangible assets include the value of customer and distributor relationships, existing technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> agreements acquired in connection with business and asset acquisitions and are stated at cost (fair value at acquisition) less accumulated amortization. These intangible assets have a definite life and are amortized over the assets’ useful lives using a systematic and rational basis which is representative of the assets’ use. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. If necessary, an impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the asset. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. There were no impairment charges for our intangible assets in fiscal years 2021, 2020 or 2019. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill: </div></div>Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate indicate that the carrying value of an asset might be </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impaired. Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment, or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment are aggregated as a single reporting unit if they have similar economic characteristics. We determined that each of our operating segments (Product Identification and T&amp;M) represents a reporting unit for purposes of goodwill impairment testing. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance related to goodwill impairment testing allows for the performance of an optional qualitative assessment of whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this qualitative assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. Additionally, we can elect to forgo the qualitative assessment and perform the quantitative test. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using a blended income and market approach. The income approach is based on a discounted cash flow model and provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. The market approach, compares the reporting unit to publicly traded companies and transactions involving similar business, and requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference. We performed a quantitative analysis of the reporting units as of January 31, 2021 and determined that the fair value was in excess of our carrying value and therefore, no goodwill impairment has occurred. See Note 3, “Goodwill,” for further details. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases: </div></div>On February 1, 2019 we adopted ASC 842, Leases. This guidance requires a lessee to recognize assets and liabilities on the balance sheet for all leases, with the result being the recognition of a right of use (ROU) asset and a lease liability. The lease liability is equal to the present value of the minimum lease payments for the term of the lease, including any optional renewal periods determined to be reasonably certain to be exercised, using a discount rate determined at lease commencement. This discount rate is the rate implicit in the lease, if known; otherwise, the incremental borrowing rate for the expected lease term is used. Our incremental borrowing rate approximates the rate we would have to pay to borrow on a collateralized basis over a similar term at lease inception. The value of the ROU asset is equal to the initial measurement of the lease liability plus any lease payments made to the lessor at or before the commencement date and any unamortized initial direct costs incurred by the lessee, less any unamortized lease incentives received. Several of our lease contracts include options to extend the lease term and we include the renewal options for these leases in the determination of the ROU asset and lease liability when the likelihood of renewal is determined to be reasonably certain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into lease contracts for certain of our facilities at various locations worldwide. At inception of a contract, we determine whether the contract is or contains a lease. If we have a right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the asset, then the contract contains a lease. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are two types of leases, operating leases and finance leases. Lease classification is determined at lease commencement. We have made an accounting policy election to apply the short-term exception, which does not require the capitalization of leases with terms of 12 months or less. All of our leases are classified as operating leases. Operating lease expense is recognized on a straight-line basis over the lease term and included in general and administrative expense on the consolidated statement of income. ROU assets are classified in other long-term assets, short-term lease liabilities are classified in other current liabilities, and long-term lease liabilities are classified in other long-term liabilities in the consolidated balance sheet. In the statement of cash flow, payments for operating leases are classified as operating activities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In addition, several of our lease agreements include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components for items such as common area maintenance and utilities which are accounted for separately from the lease component.</div></div><div> </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes: </div></div>We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and tax basis of the assets and liabilities and are measured using statutory tax rates that will be in effect when the differences are expected to reverse. Our deferred taxes are presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> in the accompanying consolidated balance sheet. An allowance against deferred tax assets is recognized when it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that some portion or all of the deferred tax assets will not be realized. At January 31, 2021 and 2020, a valuation allowance was provided for deferred tax assets attributable to certain domestic R&amp;D credit carryforwards. In addition, during fiscal 2021, we provided a valuation allowance for deferred tax assets attributable to foreign tax credit carryforwards which would expire unused. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;">We account for uncertain tax positions in accordance with the guidance provided in ASC 740, “Accounting for Income Taxes.” This guidance describes a recognition threshold and measurement attribute for the financial statement disclosure of tax positions taken or expected to be taken in a tax return and requires recognition of tax benefits that satisfy a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold. ASC 740 also provides guidance on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-recognition,</div> classification, interest and penalties, accounting in interim periods and disclosure. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;">On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and, subsequent to year end, have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income Per Common Share: </div></div>Basic net income per share is based on the weighted average number of shares outstanding during the period. Diluted net income per share is based on the basic weighted average number of shares and potential common equivalent shares for stock options, restricted stock awards and restricted stock units outstanding during the period using the treasury stock method. In fiscal years 2021, 2020 and 2019, there were 642,623; 202,187 and 326,275, respectively, of common equivalent shares that were not included in the computation of diluted net income per common share because their inclusion would be anti-dilutive. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement: </div></div>We measure our financial assets at fair value on a recurring basis in accordance with the guidance provided in ASC 820, “Fair Value Measurement and Disclosures,” which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market participants at the measurement date. In addition, ASC 820 establishes a three-tiered hierarchy for inputs used in management’s determination of fair value of financial instruments that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect management’s belief about the assumptions market participants would use in pricing a financial instrument based on the best information available in the circumstances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value hierarchy is summarized as follows: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Quoted prices in active markets for identical assets or liabilities; </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, accounts receivable, accounts payable, accrued compensation, other accrued expenses and income tax payable are reflected in the consolidated balance sheet at carrying value, which approximates fair value due to the short-term nature of these instruments. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Self-Insurance:</div></div> We are self-insured for U.S. medical and dental benefits for qualifying employees and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Assumptions are closely monitored and adjusted when warranted by changing circumstances. Our liability for self-insured claims is included within accrued compensation in our consolidated balance sheets and was $0.2 million and $0.6 million, as of January 31, 2021 and 2020. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation:</div></div> Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grant and has assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (RSA) and restricted stock units (RSU) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the grant date. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified with other income tax cash flows as an operating activity. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation becomes deductible for determining income taxes when the related award vests, is exercised, or is forfeited depending on the type of share-based award and subject to relevant tax law. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments:</div></div> We occasionally uses derivative instruments as part of its overall strategy to manage its exposure to market risks primarily associated with fluctuations in foreign currency exchange rates and interest rates. Derivative instruments are recognized as either assets or liabilities in the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the statement of income during the current period. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) (OCI) and reclassified into earnings in the same line item associated with the forecasted transaction, and in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest Expense” when the hedged transactions are interest cash flows associated with floating-rate debt, or “Other, Net” for portions reclassified relating to the remeasurement of the debt). The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any, are recognized in the statement of income during the current period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13,</div> “Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> modifies the disclosure requirements for fair value measurements by removing, modifying or adding certain disclosures. The provisions of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> relating to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. The remaining provisions should be applied retrospectively to all periods presented upon their effective date. We adopted the provisions of this guidance effective February 1, 2020. The adoption of this guidance did not have a material impact on our consolidated financial statements and accompanying disclosures. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards Not Yet Adopted: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued an ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> “Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is effective for fiscal years beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are not electing to early adopt and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and accompanying disclosures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No other new accounting pronouncements, issued or effective during fiscal 2021, have had or are expected to have a material impact on our consolidated financial statements. </div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation:</div></div> The accompanying financial statements and accompanying notes have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Our fiscal year end is January 31. Unless otherwise stated, all years and dates refer to our fiscal year. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Principles of Consolidation: </div></div>The consolidated financial statements include the accounts of AstroNova, Inc. and its subsidiaries. All material intercompany accounts and transactions are eliminated in consolidation. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reclassification: </div></div>Certain amounts in prior year’s financial statements have been reclassified to conform to the current year’s presentation. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates: </div></div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect these financial statements and accompanying notes. Some of the more significant estimates relate to the allowances for doubtful accounts, inventory valuation, valuation and estimated lives of intangible assets, impairment of long-lived assets, goodwill, income taxes, share-based compensation and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters. Consequently, actual results could differ from those estimates. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents: </div></div>Highly liquid investments with an original maturity of 90 days or less are considered to be cash equivalents. Similar investments with original maturities beyond three months are classified as securities available for sale. At January 31, 2021 and 2020, $4.6 million and $3.4 million, respectively, was held in foreign bank accounts. 90 days or less 4600000 3400000 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inventories:</div></div> Inventories are stated at the lower of cost <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out)</div> or net realizable value and include material, labor and manufacturing overhead. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment: </div></div>Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets (land improvements—10 to 20 years; buildings and leasehold improvements—10 to 45 years; machinery and equipment—3 to 10 years and computer equipment and software—3 to 10 years). P10Y P20Y P10Y P45Y P3Y P10Y P3Y P10Y <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue Recognition:</div> We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Topic 606 defines a five step process to recognize revenue and requires more judgment and estimates within the revenue recognition process than required under previous U.S. GAAP, including identifying contracts with customers, identifying performance obligations in the contract, determining and estimating the amount of any variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and recognizing revenue when the entity satisfies each performance obligation. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The vast majority of our revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration we expect to receive in exchange for such products, which is generally at the contractually stated prices, and is recognized when we satisfy a performance obligation by transferring control of a product to a customer. The transfer of control generally occurs at one point in time, upon shipment, when title and risk of loss pass to the customer. Returns and customer credits are infrequent and are recorded as a reduction to revenue. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many of the contracts entered into with customers are commonly comprised of a combination of equipment, supplies, installation and/or training services. We determine performance obligations by assessing whether the products or services are distinct from other elements of the contract. In order to be distinct, the product must perform either on its own or with readily available resources and must be separate within the context of the contract. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most of our hardware products contain embedded operating systems and data management software which is included in the purchase price of the equipment. The software is deemed incidental to the systems as a whole, as it is not sold or marketed separately, and its production costs are minor compared to those of the hardware system. Hardware and software elements are typically delivered at the same time and are accounted for as a single performance obligation for which revenue is recognized at the point in time when ownership is transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Installation and training services vary based on certain factors such as the complexity of the equipment, staffing availability in a geographic location and customer preferences, and can range from a few days to a few months. The delivery of installation and training services are not assessed to determine whether they are separate performance obligations, as the amounts are not material to the contract. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling activities that occur after control over a product has transferred to a customer are accounted for as fulfillment activities rather than performance obligations, as allowed under a practical expedient provided by Topic 606. The shipping and handling fees charged to customers are recognized as revenue and the related costs are included in cost of revenue at the point in time when ownership of the product is transferred to the customer. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may perform service at the request of the customer, generally for the repair and maintenance of products previously sold. These services are short in duration and total less than 10% of revenue for the years ended January 31, 2021 and 2020. Revenue is recognized as services are rendered and accepted by the customer. We also provide service agreements on certain of our Product Identification equipment. Service agreements are purchased separately from the equipment and provide for the right to obtain service and maintenance on the equipment for a period of typically one to two years. Accordingly, revenue on these agreements is recognized over the term of the agreements. The portion of service agreement contracts that are uncompleted at the end of any reporting period are included in deferred revenue. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;">We generally provide warranties for our products. The standard warranty period is typically 12 months for most hardware products except for airborne printers, which typically have warranties that extend for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years, consistent with industry practice. Such assurance-type warranties are not deemed to be separate performance obligations from the hardware product and costs associated with providing the warranties are accrued in accordance with ASC 450, “Contingencies,” as we have the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. Our estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that our experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue. On occasion, customers request a warranty period longer than our standard warranty. In those instances, in which extended warranty services are separately quoted to the customer, an additional performance obligation is created, and the associated revenue is deferred and recognized as service revenue ratably over the term of the extended warranty period. The portion of service contracts and extended warranty services agreements that are uncompleted at the end of any reporting period are included in deferred revenue. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We recognize an asset for the incremental direct costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. Costs related to obtaining sales contracts for our aerospace printer products have been capitalized and are being amortized based on the forecasted number of units sold over the estimated benefit term. We apply the practical expedient to expense costs incurred for costs to obtain a contract when the amortization period would have been less than a year. These costs include sales commissions paid to the internal direct sales team as well as to third-party representatives and distributors. Contractual </div></div> agreements with each of these parties outline commission structures and rates to be paid. Generally speaking, the contracts are all individual procurement decisions by the customers and do not include renewal provisions and as such the majority of the contracts have an economic life of significantly less than a year. 0.10 0.10 P3Y P5Y <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounts Receivables and Allowance for Doubtful Accounts: </div></div>Standard payment terms are typically 30 days after shipment but vary by type and geographic location of our customer. Credit is extended based upon an evaluation of the customer’s financial condition. In circumstances where we are aware of a customer’s inability to meet its financial obligations, an allowance is established. The remainder of the allowance established is based on a variety of factors, including the age of amounts outstanding relative to their contractual due date, historical <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">write-off</div> experience and current market assessments. Accounts receivable are stated at their estimated net realizable value. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Costs: </div></div>We charge costs to expense in the period incurred, and these expenses are presented in the consolidated statement of income. The following costs are included in research and development expense: salaries and benefits, external engineering service costs, engineering related information costs and supplies. <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Currency Translation: </div></div>The financial statements of foreign subsidiaries and branches are measured using the local currency as the functional currency. Foreign currency-denominated assets and liabilities are translated into U.S. dollars at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> exchange rates with the translation adjustment recorded as a component of accumulated comprehensive income (loss) in shareholders’ equity. Revenues and expenses are translated at the average monthly exchange rates in effect during the related period. We do not provide for U.S. income taxes on foreign currency translation adjustments associated with our subsidiaries in Germany, Denmark and China since their undistributed earnings are considered to be permanently invested. Included in our consolidated statements of income was a net transactional foreign exchange gain of $0.6 million in fiscal 2021, and a net transaction foreign exchange loss of $0.4 million in fiscal 2020 and $0.7 million for fiscal 2019. 600000 400000 700000 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advertising: </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">We</div><div style="background: none;;font-style:italic;display:inline;"><div style="background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div>expense advertising costs as incurred. Advertising costs including advertising production, trade shows and other activities are designed to enhance demand for our products and amounted to approximately $0.9 million; $1.8 million and $1.9 million in fiscal 2021, 2020 and 2019, respectively. 900000 1800000 1900000 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-Lived Assets: </div></div>Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, as determined by the discounting of future cash flows. There were no impairment charges for our long-lived assets in fiscal years 2021, 2020 or 2019. 0 0 0 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Intangible Assets: </div></div>Intangible assets include the value of customer and distributor relationships, existing technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-competition</div> agreements acquired in connection with business and asset acquisitions and are stated at cost (fair value at acquisition) less accumulated amortization. These intangible assets have a definite life and are amortized over the assets’ useful lives using a systematic and rational basis which is representative of the assets’ use. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. If necessary, an impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the asset. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. There were no impairment charges for our intangible assets in fiscal years 2021, 2020 or 2019. 0 0 0 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Goodwill: </div></div>Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate indicate that the carrying value of an asset might be <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">impaired. Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment, or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment are aggregated as a single reporting unit if they have similar economic characteristics. We determined that each of our operating segments (Product Identification and T&amp;M) represents a reporting unit for purposes of goodwill impairment testing. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting guidance related to goodwill impairment testing allows for the performance of an optional qualitative assessment of whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this qualitative assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. Additionally, we can elect to forgo the qualitative assessment and perform the quantitative test. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using a blended income and market approach. The income approach is based on a discounted cash flow model and provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. The market approach, compares the reporting unit to publicly traded companies and transactions involving similar business, and requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference. We performed a quantitative analysis of the reporting units as of January 31, 2021 and determined that the fair value was in excess of our carrying value and therefore, no goodwill impairment has occurred. See Note 3, “Goodwill,” for further details. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases: </div></div>On February 1, 2019 we adopted ASC 842, Leases. This guidance requires a lessee to recognize assets and liabilities on the balance sheet for all leases, with the result being the recognition of a right of use (ROU) asset and a lease liability. The lease liability is equal to the present value of the minimum lease payments for the term of the lease, including any optional renewal periods determined to be reasonably certain to be exercised, using a discount rate determined at lease commencement. This discount rate is the rate implicit in the lease, if known; otherwise, the incremental borrowing rate for the expected lease term is used. Our incremental borrowing rate approximates the rate we would have to pay to borrow on a collateralized basis over a similar term at lease inception. The value of the ROU asset is equal to the initial measurement of the lease liability plus any lease payments made to the lessor at or before the commencement date and any unamortized initial direct costs incurred by the lessee, less any unamortized lease incentives received. Several of our lease contracts include options to extend the lease term and we include the renewal options for these leases in the determination of the ROU asset and lease liability when the likelihood of renewal is determined to be reasonably certain. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into lease contracts for certain of our facilities at various locations worldwide. At inception of a contract, we determine whether the contract is or contains a lease. If we have a right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the asset, then the contract contains a lease. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are two types of leases, operating leases and finance leases. Lease classification is determined at lease commencement. We have made an accounting policy election to apply the short-term exception, which does not require the capitalization of leases with terms of 12 months or less. All of our leases are classified as operating leases. Operating lease expense is recognized on a straight-line basis over the lease term and included in general and administrative expense on the consolidated statement of income. ROU assets are classified in other long-term assets, short-term lease liabilities are classified in other current liabilities, and long-term lease liabilities are classified in other long-term liabilities in the consolidated balance sheet. In the statement of cash flow, payments for operating leases are classified as operating activities. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes: </div></div>We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and tax basis of the assets and liabilities and are measured using statutory tax rates that will be in effect when the differences are expected to reverse. Our deferred taxes are presented as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-current</div> in the accompanying consolidated balance sheet. An allowance against deferred tax assets is recognized when it is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> that some portion or all of the deferred tax assets will not be realized. At January 31, 2021 and 2020, a valuation allowance was provided for deferred tax assets attributable to certain domestic R&amp;D credit carryforwards. In addition, during fiscal 2021, we provided a valuation allowance for deferred tax assets attributable to foreign tax credit carryforwards which would expire unused. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;">We account for uncertain tax positions in accordance with the guidance provided in ASC 740, “Accounting for Income Taxes.” This guidance describes a recognition threshold and measurement attribute for the financial statement disclosure of tax positions taken or expected to be taken in a tax return and requires recognition of tax benefits that satisfy a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold. ASC 740 also provides guidance on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">de-recognition,</div> classification, interest and penalties, accounting in interim periods and disclosure. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;">On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-time</div> mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded. </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and, subsequent to year end, have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return. </div></div> 4400000 4400000 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Income Per Common Share: </div></div>Basic net income per share is based on the weighted average number of shares outstanding during the period. Diluted net income per share is based on the basic weighted average number of shares and potential common equivalent shares for stock options, restricted stock awards and restricted stock units outstanding during the period using the treasury stock method. In fiscal years 2021, 2020 and 2019, there were 642,623; 202,187 and 326,275, respectively, of common equivalent shares that were not included in the computation of diluted net income per common share because their inclusion would be anti-dilutive. 642623 202187 326275 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement: </div></div>We measure our financial assets at fair value on a recurring basis in accordance with the guidance provided in ASC 820, “Fair Value Measurement and Disclosures,” which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">market participants at the measurement date. In addition, ASC 820 establishes a three-tiered hierarchy for inputs used in management’s determination of fair value of financial instruments that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect management’s belief about the assumptions market participants would use in pricing a financial instrument based on the best information available in the circumstances. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value hierarchy is summarized as follows: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Quoted prices in active markets for identical assets or liabilities; </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities </div></div></div></td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents, accounts receivable, accounts payable, accrued compensation, other accrued expenses and income tax payable are reflected in the consolidated balance sheet at carrying value, which approximates fair value due to the short-term nature of these instruments. </div></div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Self-Insurance:</div></div> We are self-insured for U.S. medical and dental benefits for qualifying employees and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Assumptions are closely monitored and adjusted when warranted by changing circumstances. Our liability for self-insured claims is included within accrued compensation in our consolidated balance sheets and was $0.2 million and $0.6 million, as of January 31, 2021 and 2020. 200000 600000 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation:</div></div> Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grant and has assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (RSA) and restricted stock units (RSU) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the grant date. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience. <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flow from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified with other income tax cash flows as an operating activity. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation becomes deductible for determining income taxes when the related award vests, is exercised, or is forfeited depending on the type of share-based award and subject to relevant tax law. </div></div></div> 0 <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Derivative Financial Instruments:</div></div> We occasionally uses derivative instruments as part of its overall strategy to manage its exposure to market risks primarily associated with fluctuations in foreign currency exchange rates and interest rates. Derivative instruments are recognized as either assets or liabilities in the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the statement of income during the current period. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) (OCI) and reclassified into earnings in the same line item associated with the forecasted transaction, and in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest Expense” when the hedged transactions are interest cash flows associated with floating-rate debt, or “Other, Net” for portions reclassified relating to the remeasurement of the debt). The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any, are recognized in the statement of income during the current period. <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recently Adopted: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13,</div> “Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> modifies the disclosure requirements for fair value measurements by removing, modifying or adding certain disclosures. The provisions of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-13</div> relating to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. The remaining provisions should be applied retrospectively to all periods presented upon their effective date. We adopted the provisions of this guidance effective February 1, 2020. The adoption of this guidance did not have a material impact on our consolidated financial statements and accompanying disclosures. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards Not Yet Adopted: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the FASB issued an ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12,</div> “Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2019-12</div> is effective for fiscal years beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are not electing to early adopt and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and accompanying disclosures. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No other new accounting pronouncements, issued or effective during fiscal 2021, have had or are expected to have a material impact on our consolidated financial statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2—Revenue Recognition</div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We derive revenue from the sale of (i) hardware including, digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers used in the flight deck and in the cabin of military, commercial and business aircraft, (ii) related consumable supplies including paper, labels, tags, inks, toners and ribbons, (iii) repairs and maintenance of equipment and (iv) service agreements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues disaggregated by primary geographic markets and major product types are as follows: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Primary geographical markets: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">70,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">31,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3,950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,145</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,464</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,978</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,369</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major product types: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hardware</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">34,111</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">48,959</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">53,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,838</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service and Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10,150</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">12,649</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">12,272</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Assets and Liabilities </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $285,000 and $466,000 at January 31, 2021 and January 31, 2020, respectively, and are recorded as deferred revenue in the consolidated balance sheet. The decrease in the deferred revenue balance during the period ended January 31, 2021 is primarily due to $466,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2020 offset by cash payments received in advance of satisfying performance obligations.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contract Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized based on the forecasted number of units sold over the estimated benefit term. The balance of these contract assets at January 31, 2020 was $944,000, of which $59,000 was reported in other current assets and $885,000 was reported in other assets in the consolidated balance sheet. Amortization of incremental direct costs was $26,940 for the period ended </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">January 31, 2021. The balance of the deferred incremental direct contract costs net of accumulated amortization at January 31, 202<div style="letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div></div><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">is $</div>917,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">, of which $</div>36,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was reported in other current assets and $</div>881,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> was reported in other assets in the consolidated balance sheet. The contract costs are expected to be amortized over the estimated remaining period of benefit, which we currently estimate to be approximately </div>5<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> years.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenues disaggregated by primary geographic markets and major product types are as follows: </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Primary geographical markets: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">70,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">31,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3,950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,145</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,464</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,978</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,369</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Major product types: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Hardware</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">34,111</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">48,959</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">53,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplies</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,838</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">71,178</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Service and Other</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10,150</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">12,649</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">12,272</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Revenue</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 70911000 83671000 83668000 29029000 29617000 31574000 5574000 5719000 6692000 5105000 8316000 8207000 3950000 4145000 4147000 1464000 1978000 2369000 116033000 133446000 136657000 34111000 48959000 53207000 71772000 71838000 71178000 10150000 12649000 12272000 116033000 133446000 136657000 285000 466000 466000 944000 59000 885000 26940 917000 36000 881000 P5Y <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3—Goodwill </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill by reporting unit is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product<br/> Identification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">T&amp;M</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2019</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,807</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,329</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(295</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(295</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,512</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,034</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,806</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; line-height: 8pt;"> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">After consideration of the impact of the decline in the global economy due to the COVID-19 pandemic, coupled with the grounding of the 737 MAX in March, 2019 and the production halt in January, 2020 which negatively impacted revenues and margins in fiscal 2020 and 2021, we elected to forgo the qualitative assessment and instead performed a quantitative goodwill impairment test to determine if the carrying values of the reporting units are greater than the fair values. We utilized a blended income and market approach. The income approach was based upon a discounted cash flow model which we believe provides a fair value estimate of the reporting unit’s expected long-term operating performance. The market approach compares the reporting units to similar publicly traded companies. Based on our quantitative impairment assessment as of January 31, 2021, we determined that the fair value of the reporting units were in excess of their carrying values and therefore, no goodwill impairment had occurred. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Goodwill by reporting unit is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Product<br/> Identification</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">T&amp;M</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 75%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2019</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,807</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,329</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(295</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(295</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,512</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,034</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign currency translation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">772</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,522</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,806</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 7807000 4522000 12329000 -295000 -295000 7512000 4522000 12034000 772 772 8284000 4522000 12806000 0 <div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4—Intangible Assets </div></div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are as follows: </div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 34%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miltope:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,284</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">816</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,021</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,079</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RITEC:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,423</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,407</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,076</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</div> Agreement</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(950</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(871</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TrojanLabel:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing Technology</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,405</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,118</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,053</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,352</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributor Relations</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(396</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">630</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(297</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,712</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,531</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,791</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets, net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,170</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">      285</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,502</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,109</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">      105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,383</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> There were no impairments to intangible assets during the periods ended January 31, 2021 and 2020. Amortization expense of $4.1 million; $4.2 million and $4.1 million with regard to acquired intangibles has been included in the consolidated statements of income for years ended January 31, 2021, 2020 and 2019, respectively.<div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the next five fiscal years is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,055</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are as follows: </div></div></div> </div> </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 34%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Gross<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Currency<br/> Translation<br/> Adjustment</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Carrying<br/> Amount</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Miltope:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,284</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">816</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,100</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,021</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,079</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RITEC:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,423</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,407</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,830</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,076</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,754</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Competition</div> Agreement</div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(950</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(871</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TrojanLabel:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Existing Technology</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,405</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,118</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,327</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,053</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,352</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Distributor Relations</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(396</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">89</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">630</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(297</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell:</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer Contract Relationships</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(9,712</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,531</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,243</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6,791</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,452</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets, net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,170</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">      285</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,502</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,387</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,109</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">      105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,383</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 3100000 2284000 816000 3100000 2021000 1079000 2830000 1423000 1407000 2830000 1076000 1754000 950000 950000 0 950000 871000 79000 2327000 1405000 196000 1118000 2327000 1053000 78000 1352000 937000 396000 89000 630000 937000 297000 27000 667000 27243000 9712000 17531000 27243000 6791000 20452000 37387000 16170000 285000 21502000 37387000 12109000 105000 25383000 0 0 0 4100000 4200000 4100000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the next five fiscal years is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2025</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2026</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,938</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,956</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,055</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,021</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 3938000 3956000 4055000 3416000 3021000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5—Inventories </div></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of inventories are as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials and Supplies</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,151</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Work-in-Progress</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,076</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,408</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished Goods</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,371</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,712</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,551</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory Reserve</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,652</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,626</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,925</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> </div> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods inventory includes $4.0 million and $3.4 million of demonstration equipment at January 31, 2021 and 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of inventories are as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Materials and Supplies</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,265</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,151</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Work-in-Progress</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,076</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,408</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished Goods</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,371</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,992</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38,712</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39,551</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory Reserve</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,652</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,626</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,060</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33,925</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 20265000 20151000 2076000 1408000 16371000 17992000 38712000 39551000 8652000 5626000 30060000 33925000 4000000.0 3400000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6—Property, Plant and Equipment </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment consist of the following: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land and Land Improvements</div></div></td> <td style="vertical-align: bottom; text-align: right;">  <div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,004</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">967</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings and Leasehold Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,524</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,167</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer Equipment and Software</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,847</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,839</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,046</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,828</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,778</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Property Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,011</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,268</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense on property, plant and equipment was $1.9 million for the year ended January 31, 2021 and $2.0 million for both of the years ended January 31, 2020 and 2019.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property, plant and equipment consist of the following: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Land and Land Improvements</div></div></td> <td style="vertical-align: bottom; text-align: right;">  <div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,004</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">967</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Buildings and Leasehold Improvements</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,642</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,524</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Machinery and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">23,167</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer Equipment and Software</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,847</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,388</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross Property, Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,839</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48,046</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Depreciation</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(38,828</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(36,778</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Property Plant and Equipment</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,011</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap; padding: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$ </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,268</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 1004000 967000 12642000 12524000 23346000 23167000 13847000 11388000 50839000 48046000 38828000 36778000 12011000 11268000 1900000 2000000.0 2000000.0 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7—Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warranty</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional Fees</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">697</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden20399202"><span style="-sec-ix-hidden:hidden20399203">Lease</span> Liabilit</span>y</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Payroll &amp; Sales Tax</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder Relation Fees</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">194</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dealer Commissions</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Accrued Expenses</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,851</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,939</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,711</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses consisted of the following: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warranty</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Professional Fees</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">546</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">697</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><span style="-sec-ix-hidden:hidden20399202"><span style="-sec-ix-hidden:hidden20399203">Lease</span> Liabilit</span>y</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Payroll &amp; Sales Tax</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stockholder Relation Fees</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">194</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dealer Commissions</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">236</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Accrued Expenses</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,851</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,939</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,711</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 730000 850000 546000 697000 372000 416000 292000 193000 91000 194000 57000 236000 1851000 2125000 3939000 4711000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8—Credit Agreement and Long-<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Term Debt </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Credit Agreement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 30, 2020, we entered into an Amended and Restated Credit Agreement (the “A&amp;R Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), our wholly owned subsidiary, ANI ApS, a Danish private limited liability company and TrojanLabel ApS, a Danish private limited liability company and wholly-owned subsidiary of ANI ApS (“TrojanLabel”). The A&amp;R Credit Agreement amended and restated the Credit Agreement dated as of February 28, 2017 (the “Prior Credit Agreement”) by and among us, ANI ApS, TrojanLabel and the Lender. In connection with the A&amp;R Credit Agreement, we entered into an Amended and Restated Security and Pledge Agreement and a mortgage in favor of the Lender with respect to our owned real property in West Warwick, Rhode Island. Under the A&amp;R Credit Agreement, AstroNova, Inc. is the sole borrower, and at January 31, 2021, its obligations are guaranteed by ANI ApS and TrojanLabel. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Immediately prior to the closing of the A&amp;R Credit Agreement, we repaid $1.5 million in principal amount of term loans outstanding under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div>Credit Agreement. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The A&amp;R Credit Agreement provides for (i) a term loan in the principal amount of $15.2 million, which we used to refinance the outstanding term loans borrowed by us and ANI ApS under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior</div> Credit Agreement<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>and a portion of the outstanding revolving loans borrowed by us under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Pr<div style="letter-spacing: 0px; top: 0px;;display:inline;">i<div style="letter-spacing: 0px; top: 0px;;display:inline;">or</div></div></div> Credit Agreement, and (ii) a $10.0 million revolving credit facility available to us for general corporate purposes. Revolving credit loans may be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the third quarter of fiscal year 2021, we repaid the entire outstanding balance under the revolving line of credit. Balances outstanding under the revolving line of credit during the year ended January 31, 2021 bore interest at a weighted average annual rate of 3.41%, and $188,000 of interest was incurred and is included in other income (expense) in the accompanying condensed consolidated income statement for the year ended January 31, 2021. At January 31, 2021, there was no balance outstanding under the revolving line of credit and $10.0 million was available for borrowing under the revolving credit facility. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 10pt; line-height: 12pt;">The A&amp;R Credit Agreement was accounted for as a debt modification in a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">troubled</div> debt restructuring. We incurred $0.2 million of new debt issuance costs related to the term loan, of which $0.1 million of new lender fees were recorded against the debt as debt issuance costs and will be amortized over the term of the loan and $0.1 million of third party fees that were expensed as incurred. Additionally, $0.1 million of unamortized debt issuance costs related to the prior term debt will be amortized over the remaining life of the new term loan. We also incurred $0.1 million of new debt issuance fees in connection with the revolving line of credit which are included as a component of prepaid expenses and other current assets and will be amortized over the remaining life of the A&amp;R Credit Agreement.</div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the A&amp;R Credit Agreement, the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about July 31, 2020 and October 31, 2020 was $0.8 million; the principal amount of the quarterly installment required to be paid on the last day of our fiscal quarter ending January 31, 2021 was $1.1 million; the principal amount of the quarterly installment required to be paid on the last day of the our fiscal quarter ending on or about April 30, 2021 will be $1.1 million; the principal amount of each quarterly installment required to be paid on the last day of each of the our fiscal quarters ending on or about July 31, 2021, October 31, 2021, January 31, 2022 and April 30, 2022 is $1.4 million, and the entire remaining principal balance of the term loan is required to be paid on June 15, 2022. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than June 15, 2022, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the A&amp;R Credit Agreement the term loan and revolving credit loans bear interest at a rate per annum equal to, at the our option, either (a) the LIBOR Rate (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 2.15% to 3.65% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 1.00%, plus a margin that varies within a range of 1.15% to 2.65% based on our consolidated leverage ratio. We are also required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.25% and 0.675% based on our consolidated leverage ratio. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The loans under the A&amp;R Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the A&amp;R Credit Agreement. No amount of the term loan that is repaid may be reborrowed. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Under the A&amp;R Credit Agreement, we must comply with various customary financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants including a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio, a minimum level of EBITDA, a consolidated asset coverage ratio and a minimum level of liquidity. The primary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on capital stock, to repurchase or acquire capital stock, to conduct mergers or acquisitions, to sell assets, to alter the capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the A&amp;R Credit Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the A&amp;R Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or our undergoing a change of control. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the guarantees by ANI ApS and TrojanLabel, our obligations under the A&amp;R Credit Agreement are also secured by substantially all of AstroNova, Inc.’s personal property assets (including a pledge of the equity interests it holds in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island. </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Long-Term Debt</div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt in the accompanying condensed consolidated balance sheets under the A&amp;R Credit Agreement is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (4.65% as of January 31, 2021); maturity date of June 15, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (3.03% as of January 31, 2021); maturity date November 30, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (3.03% as of January 31, 2021); maturity date of January 31, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,784</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,034</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt Issuance Costs, net of accumulated amortization</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(111</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Portion of Term Loan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,326</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,208</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,109</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,715</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended January 31, 2021, 2020 and 2019, we recognized $0.5 million, $0.4 million and $0.6 million of interest expense, respectively, which was included in other income (expense) in the accompanying consolidated income statement.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The schedule of required principal payments remaining under the A&amp;R Credit Agreement on long-term debt outstanding as of January 31, 2021 is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,326</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Refer to Note 23, “Subsequent Event” for details regarding the First Amendment to Credit Agreement to our A&amp;R Credit Agreement, which was entered into subsequent to year end on March 24, 2021. </div></div></div> 1500000 15200000 10000000.0 0.0341 188000 10000000.0 200000 100000 100000 100000 100000 quarterly installment 800000 800000 the principal amount of the quarterly installment required to be paid on the last day of our fiscal quarter ending January 31, 2021 was $1.1 million; the principal amount of the quarterly installment required to be paid on the last day of the our fiscal quarter ending on or about April 30, 2021 will be $1.1 million; the principal amount of each quarterly installment required to be paid on the last day of each of the our fiscal quarters ending on or about July 31, 2021, October 31, 2021, January 31, 2022 and April 30, 2022 is $1.4 million, and the entire remaining principal balance of the term loan is required to be paid on June 15, 2022 1100000 1100000 1400000 1400000 1400000 1400000 2022-06-15 0.0215 0.0365 0.0050 0.0100 1.00 0.0115 0.0265 0.0025 0.00675 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term debt in the accompanying condensed consolidated balance sheets under the A&amp;R Credit Agreement is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 80%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (4.65% as of January 31, 2021); maturity date of June 15, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (3.03% as of January 31, 2021); maturity date November 30, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USD Term Loan (3.03% as of January 31, 2021); maturity date of January 31, 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,784</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,034</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Debt Issuance Costs, net of accumulated amortization</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(141</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(111</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Portion of Term Loan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,326</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,208</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,109</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,715</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 4.65% as of January 31, 2021); maturity date of June 15, 2022 0.0465 2022-06-15 12576000 0 0.0303 0 8250000 0.0303 0 4784000 12576000 13034000 141000 111000 5326000 5208000 7109000 7715000 500000 400000 600000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The schedule of required principal payments remaining under the A&amp;R Credit Agreement on long-term debt outstanding as of January 31, 2021 is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 90%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,326</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fiscal 2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 5326000 7250000 12576000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9—Paycheck Protection Program Loan </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”) from Greenwood pursuant to the Paycheck Protection Program (“PPP”) administered by the United States Small Business Administration (the “SBA”) and authorized by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), enacted on March 27, 2020. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020 (the “PPP Flexibility Act”) which was enacted on June 5, 2020. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date, and is payable monthly. No payments are due on the PPP Loan until the date on which the SBA determines the amount of the PPP Loan that is eligible for forgiveness, so long as we apply for forgiveness within the ten months from the end of the twenty-four week period following the date of loan disbursement, but interest will continue to accrue during the deferral period. We accrued interest for the PPP Loan in the amount of $33,000, which is included in other income (expense) in the accompanying consolidated statements of income for the year ended January 31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PPP Loan may be prepaid at any time without penalty. The loan agreement and promissory note include customary provisions for a loan of this type, including prohibitions on our payment of dividends or repurchase of </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">shares of our stock while the PPP Loan remains outstanding. The loan agreement and promissory note also include events of default relating to, among other things, payment defaults, breaches of the provisions of the loan agreement or the promissory note, and cross-defaults on other loans. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to the limitations and conditions set forth in the CARES Act, the PPP Flexibility Act, and the regulations and guidance provided by the SBA with respect to the PPP, a portion of the PPP Loan may be forgiven in an amount up to the amount of the PPP Loan proceeds that we spent on payroll, rent, utilities and interest on certain debt during the twenty-four-week period following incurrence of the PPP Loan. Interest accrued on the forgiven portion of the principal amount of the PPP Loan is also forgiven. The amount of the PPP Loan to be forgiven in respect of rent, utilities and interest on certain debt will be capped at 40% of the forgiven amount, with the remaining forgiven amount allocated to payroll costs. We have fully utilized the PPP Loan proceeds for qualifying expenses during fiscal year 2021 and subsequent to year end we applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Whether our application for forgiveness will be granted and in what amount is subject to approval by the SBA and may also be subject to further requirements in any regulations and guidelines the SBA may adopt. The PPP Loan is classified as long-term debt in the condensed consolidated balance sheet until the forgiveness determination has been made by the SBA. </div></div></div> 4400000 The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date, and is payable monthly. 2022-05-06 0.010 0 33000 0.40 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 10—Derivative Financial Instruments and Risk Management </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February 28, 2017, as part of the Prior Credit Agreement, we entered into a cross-currency interest rate swap to manage the interest rate risk and foreign currency exchange risk associated with the floating-rate foreign currency-denominated term loan borrowing by ANI ApS and an interest rate swap to manage the interest rate risk associated with our variable rate term loan borrowing (the “Swaps”). Both Swaps were designated as cash flow hedges of floating-rate borrowings. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cross-currency interest rate swap agreement effectively modified our exposure to interest rate risk and foreign currency exchange rate risk by converting our floating-rate debt denominated in U.S. Dollars on ANI ApS’s books to a fixed-rate debt denominated in Danish Kroner for the term of the loan, thus reducing the impact of interest-rate and foreign currency exchange rate changes on future interest expense and principal repayments. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed-rate interest payments in Danish Kroner, as well as exchanges of principal at the inception spot rate, over the life of the term loan. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequently, concurrent with our borrowings to fund the payments for the Asset Purchase and License Agreement with Honeywell International, we entered into an interest rate swap agreement to modify our exposure to interest rate risk by effectively converting our floating-rate borrowings to fixed-rate debt over the term of the loan, thus reducing the impact of interest-rate changes on future interest expense. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed interest rate payments in U.S. dollars over the life of the term loan. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a direct result of the terms of the Lender’s conditions for entry into the A&amp;R Credit Agreement, on July 30, 2020, we terminated the two Swaps that we used to manage the interest rate and foreign currency exchange risks associated with our prior borrowings under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior</div> Credit Agreement. The terms of the A&amp;R Credit Agreement caused those swaps to cease to be effective hedges of the underlying exposures. The termination of the Swaps was contracted immediately prior to the end of the second quarter of fiscal 2021 at a cash cost of approximately $0.7 million, which was settled in the third quarter. Upon termination, the remaining balance of $58,000 in accumulated other comprehensive loss related to the cross-currency interest rate swap was reclassified into earnings as the forecasted foreign currency interest payments will not occur and such balance is included in other expense in the accompanying consolidated statements of income for the period ended January 31, 2021. The remaining balance in accumulated other comprehensive loss related to the interest rate swap of $ 0.1 million is being amortized into earnings through the original term of the hedge relationship as the underlying floating interest rate debt still exists.</div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the notional amount and fair value of our derivative instruments: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt; font-size: 8pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow Hedges</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional Amount</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Derivatives</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional Amount</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Derivatives</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 42%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-currency Interest Rate Swap</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Swap</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the impact of the derivative instruments in our consolidated financial statements for the years ended January 31, 2021 and 2020: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt; font-size: 8pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow Hedge</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Gain(Loss)<br/> Recognized in OCI<br/> on<br/> Derivative</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Location of Gain (Loss)<br/> Reclassified from<br/> Accumulated OCI into<br/> Income</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Gain (Loss)<br/> Reclassified from<br/> Accumulated OCI into<br/> Income</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Swap contracts</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(301</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Other Income</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(248</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At January 31, 2021, we expect to reclassify approximately $0.1 million of net gains on the swap contracts from accumulated other comprehensive loss to earnings during the next 12 months due to changes in foreign exchange rates and the payment of variable interest associated with the floating-rate debt. </div></div></div> 700000 58000 100000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the notional amount and fair value of our derivative instruments: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 42%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt; font-size: 8pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow Hedges</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31, 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional Amount</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Derivatives</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Notional Amount</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Derivatives</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Asset</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Liability</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 42%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-currency Interest Rate Swap</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,489</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Swap</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 4489000 250000 8250000 96000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables present the impact of the derivative instruments in our consolidated financial statements for the years ended January 31, 2021 and 2020: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td rowspan="2" style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt; font-size: 8pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flow Hedge</div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Gain(Loss)<br/> Recognized in OCI<br/> on<br/> Derivative</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Location of Gain (Loss)<br/> Reclassified from<br/> Accumulated OCI into<br/> Income</div></div></div></td> <td rowspan="2" style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount of Gain (Loss)<br/> Reclassified from<br/> Accumulated OCI into<br/> Income</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 44%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Swap contracts</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(301</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">Other Income</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(248</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">338</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> -301000 159000 Other Income -248000 338000 100000 <div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 11—Royalty Obligation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In fiscal 2018, AstroNova, Inc. entered into an Asset Purchase and License Agreement with Honeywell International, Inc. to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid in quarterly installments over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period. Royalty payments are based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments using a present value factor of 2.8%, which is based on the estimated <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">after-tax</div> cost of debt for similar companies. As of January 31, 2021, we had paid an aggregate of $5.5 million of the guaranteed minimum royalty obligation. At January 31, 2021, the current portion of the outstanding guaranteed minimum royalty obligation of $2.0 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $6.1 million is reported as a long-term liability on our consolidated balance sheet. In addition to the guaranteed minimum royalty payments, for the periods ended January 31, 2021 and January 31, 2020, we also incurred excess royalty expense of $31 thousand and $1.2 million, respectively, which is included in cost of revenue in our consolidated statements of income. A total of $0.2 million of excess royalty is payable and reported as a current liability on our consolidated balance sheet at January 31, 2021. </div></div> 15000000.0 P10Y 0.028 5500000 2000000.0 6100000 31000 1200000 200000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 12—Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We enter into lease contracts for certain of its facilities at various locations worldwide. Our leases have remaining lease terms of <span style="-sec-ix-hidden:hidden20381479">one</span> to eight years, some of which include options to extend the lease term for periods of up to five years when it is reasonably certain the Company will exercise such options. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We lease office space from an affiliate. This lease is classified as an operating lease with annual rental payments of $63,000 for both January 31, 2021 and January 31, 2020. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet and other information related to our leases is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 51%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Leases</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Right of Use Assets</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">1,389</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,661</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">—</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Other Accrued Expenses</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"> </div></td> <td style="padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">372</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">—</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long Term</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Lease Liabilities</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">1,065</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,279</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost information is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 35%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of Income Classification</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Lease Costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">  General and Administrative Expense  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt; font-size: 8pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Payments</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,599</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Imputed Interest</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(162</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,437</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of January 31, 2021, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 5.2 years and 4.00%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to leases is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">406</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="clear: both; max-height: 0px; background: none;"/> P8Y options to extend the lease term for periods of up to five years 63000 63000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance sheet and other information related to our leases is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 51%;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 0%; vertical-align: bottom;"/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating Leases</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance Sheet Classification</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/>2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Assets</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Right of Use Assets</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">1,389</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,661</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">—</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Other Accrued Expenses</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"> </div></td> <td style="padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">372</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">416</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 51%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease Liabilities</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">—</div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long Term</div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;;text-align:center;">Lease Liabilities</td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; line-height:normal; font-family:Calibri,sans-serif"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td> <td style="background: rgb(204, 238, 255); padding: 0cm; width: 0%;;vertical-align:bottom;"><div style="margin:0cm 0cm 0.0001pt; text-align:right; line-height:normal; font-family:Calibri,sans-serif;text-align:right;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">1,065</div></div></td> <td style="vertical-align: bottom; width: 0%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom; width: 5%;"><div style="line-height: normal;"> </div></td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,279</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> 1389000 1661000 372000 416000 1065000 1279000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease cost information is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 35%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Leases</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Statement of Income Classification</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Lease Costs</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">  General and Administrative Expense  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">485</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> 485000 449000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of operating lease liabilities are as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt; font-size: 8pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31,<br/> 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 88%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">318</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">292</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">184</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">163</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Payments</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,599</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Imputed Interest</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(162</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease Liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,437</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 372000 318000 292000 184000 163000 270000 1599000 162000 1437000 P5Y2M12D 0.0400 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supplemental cash flow information related to leases is as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 9%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/> January 31,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash paid for operating lease liabilities</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">429</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">406</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr></table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="clear: both; max-height: 0px; background: none;"/> 429000 406000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 13—Accumulated Other Comprehensive Income (Loss) </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the balance of accumulated other comprehensive income (loss) by component are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Holding<br/> Gain (Loss)<br/> on Available<br/> for Sale<br/> Securities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Unrealized<br/> Gain (Losses)<br/> on Cash Flow<br/> Hedges</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2018</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(181</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified from AOCI to Earnings</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(597</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(646</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2019</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(852</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(818</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(133</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified from AOCI to Earnings</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(264</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(264</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(133</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(142</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(275</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2020</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(985</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,093</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(239</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">471</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts Reclassified from AOCI to Earnings</div> </div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency Interest Rate Swap Termination</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">709</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2021</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(275</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(109</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amounts presented above in other comprehensive income (loss) are net of taxes except for translation adjustments associated with our German and Danish subsidiaries. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The changes in the balance of accumulated other comprehensive income (loss) by component are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Foreign Currency<br/> Translation<br/> Adjustments</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Holding<br/> Gain (Loss)<br/> on Available<br/> for Sale<br/> Securities</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/> Unrealized<br/> Gain (Losses)<br/> on Cash Flow<br/> Hedges</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2018</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(181</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(172</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(49</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified from AOCI to Earnings</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(597</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(671</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(646</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2019</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(852</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(818</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(133</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts reclassified from AOCI to Earnings</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(264</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(264</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(133</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(142</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(275</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2020</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(985</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(108</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,093</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss) before reclassification</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(239</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">471</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">Amounts Reclassified from AOCI to Earnings</div> </div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">193</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency Interest Rate Swap Termination</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">45</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Comprehensive Income (Loss)</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">709</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31, 2021</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(275</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(109</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(384</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> -181000 -3000 12000 -172000 -671000 622000 -49000 -3000 600000 597000 -671000 3000 22000 -646000 -852000 34000 -818000 -133000 122000 -11000 264000 264000 -133000 -142000 -275000 -985000 -108000 -1093000 710000 -239000 471000 -193000 -193000 -45000 -45000 710000 -1000 709000 -275000 -109000 -384000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 14—Shareholders’ Equity </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2021, 2020 and 2019, certain of our employees delivered a total of 15,357, 20,329 and 33,430 shares, respectively, of our common stock to satisfy the exercise price and related taxes for stock options exercised and restricted stock vesting. The shares delivered were valued at a total of $0.1 million; $0.5 million and $0.6 million, respectively, and are included in treasury stock in the accompanying consolidated balance sheets at January 31, 2021, 2020 and 2019. These transactions did not impact the number of shares authorized for repurchase under our current repurchase program. </div></div> 15357 20329 33430 100000 500000 600000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 15—Share-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company maintains the following share-based compensation plans: </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Plans: </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (RSAs). The 2018 Plan authorizes the issuance of up to 950,000 shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under the previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or, for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, 186,500 unvested shares of restricted stock and options to purchase an aggregate of 135,500 shares were outstanding as of January 31, 2021. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 or 2015 Plans, but outstanding awards will continue to be governed by those plans. As of January 31, 2021, options to purchase an aggregate of 337,958 shares were outstanding under the 2007 Plan and 10,833 unvested shares of restricted stock and options to purchase an aggregate of 148,625 shares were outstanding under the 2015 Plan. </div></div><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;">We also have a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Director Annual Compensation Program (the “Program”), under which each of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors automatically receives a grant of restricted stock on the date of their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2021 was $60,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Compensation: </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense has been recognized as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">517</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">616</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">783</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,285</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,136</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,088</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,819</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,775</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,886</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%; line-height: 12pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Stock Options: </div></div></div><div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding stock options granted under the plans is summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price Per<br/> Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Outstanding, January 31, 2018</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745,270</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.52</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,125</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.62</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,300</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.10</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,700</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.95</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2019</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">771,145</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">14.30</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(57,175</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">11.60</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(34,526</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">15.73</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(400</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">6.22</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2020</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">679,044</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14.46</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,200</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7.60</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(54,361</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">12.89</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,400</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7.36</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2021</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">622,083</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">14.63</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set forth below is a summary of options outstanding at January 31, 2021: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 20%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td colspan="12" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise prices</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 20%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.00-10.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">41,044</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">41,044</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$10.01-15.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">359,314</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.63</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">326,741</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.65</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$15.01-20.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">221,725</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.48</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">    6.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">167,367</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">622,083</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14.63</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">    5.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">535,152</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14.33</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No options were granted during fiscal 2021 or <div style="letter-spacing: 0px; top: 0px;;display:inline;">fis<div style="letter-spacing: 0px; top: 0px;;display:inline;">cal </div></div>2020. The weighted-average estimated fair value of options granted during fiscal 2019 was $7.43. As of January 31, 2021, there was $0.2 million of unrecognized compensation expense related to the unvested stock options granted under the plans. This expense is expected to be recognized over a weighted-average period of 0.8 years. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of January 31, 2021, the aggregate intrinsic value (the aggregate difference between the closing stock price of our common stock on January 31, 2021, and the exercise price of the outstanding options) that would have been received by the option holders if all options had been exercised was $0.1 million for all exercisable options and $0.1 million for all options outstanding. The total aggregate intrinsic value of options exercised during 2021, 2020 and 2019 was $4,000, $0.5 million and $1.1 million, respectively.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs): </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding RSUs and RSAs granted under the Plan is summarized below: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSAs &amp; RSUs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2018</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">177,347</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.99</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">108,790</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17.85</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(67,447</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(85,023</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.17</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2019</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">133,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">119,522</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19.86</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(59,930</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(58,625</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19.00</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">134,634</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">245,131</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">7.61</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(64,997</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(117,355</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">197,413</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9.96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of January 31, 2021, there was $1.1 million of unrecognized compensation expense related to unvested RSUs and RSAs. This expense is expected to be recognized over a weighted average period of 0.8 years. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employee Stock Purchase Plan (ESPP): </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Our</div> ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair market value on the date of purchase. A total of 247,500 shares were initially reserved for issuance under this plan. Summarized plan activity is as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Reserved, Beginning</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">24,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">33,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">39,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Purchased</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(14,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(8,879</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(5,354</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Reserved, Ending</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10,374</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">24,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">33,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 950000 186500 135500 337958 10833 148625 60000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-based compensation expense has been recognized as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 71%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 73%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Options</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">517</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">616</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">783</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Stock Awards and Restricted Stock Units</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,285</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,136</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,088</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Employee Stock Purchase Plan</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">23</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">15</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,819</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,775</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,886</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 517000 616000 783000 1285000 1136000 1088000 17000 23000 15000 1819000 1775000 1886000 <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding stock options granted under the plans is summarized below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price Per<br/> Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Outstanding, January 31, 2018</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">745,270</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12.52</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">196,000</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18.21</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150,125</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10.62</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(16,300</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15.10</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,700</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8.95</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-size: 0px;"> <td style="width: 83%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2019</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">771,145</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">14.30</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(57,175</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">11.60</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(34,526</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">15.73</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(400</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">6.22</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2020</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">679,044</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">14.46</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Granted</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Exercised</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,200</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7.60</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Forfeited</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">(54,361</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">12.89</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Cancelled</div></div></td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(1,400</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">7.36</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255);"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options Outstanding, January 31, 2021</div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">622,083</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">14.63</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="background-color: rgb(255, 255, 255);"> </td></tr></table> 745270 12.52 196000 18.21 150125 10.62 16300 15.10 3700 8.95 771145 14.30 0 0 57175 11.60 34526 15.73 400 6.22 679044 14.46 0 1200 7.60 54361 12.89 1400 7.36 622083 14.63 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Set forth below is a summary of options outstanding at January 31, 2021: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 20%;"/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 7%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td colspan="12" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Exercisable</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 1pt;;text-align:center;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Range of</div></div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercise prices</div></div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Remaining<br/> Contractual Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise Price</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td></tr> <tr style="font-size: 0px;"> <td style="width: 20%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$5.00-10.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">41,044</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">41,044</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7.97</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$10.01-15.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">359,314</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.63</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4.9</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">326,741</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.65</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: bottom;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">$15.01-20.00</div></td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">221,725</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.48</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">    6.8</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">167,367</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.22</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6.7</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">622,083</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14.63</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">    5.3</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">535,152</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14.33</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5.1</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div></td> <td> </td></tr></table> 5.00 10.00 41044 7.97 P1Y3M18D 41044 7.97 P1Y3M18D 10.01 15.00 359314 13.63 P4Y10M24D 326741 13.65 P4Y8M12D 15.01 20.00 221725 17.48 P6Y9M18D 167367 17.22 P6Y8M12D 622083 14.63 P5Y3M18D 535152 14.33 P5Y1M6D 0 0 7.43 200000 P0Y9M18D 100000 100000 4000 500000 1100000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Aggregated information regarding RSUs and RSAs granted under the Plan is summarized below: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RSAs &amp; RSUs</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date Fair Value</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2018</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">177,347</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">13.99</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">108,790</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">17.85</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(67,447</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(85,023</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">14.17</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 11%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2019</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">133,667</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.90</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">119,522</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19.86</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(59,930</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.50</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(58,625</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19.00</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">134,634</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.79</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">245,131</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">7.61</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(64,997</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">17.28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(117,355</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8.83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at January 31, 2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">197,413</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">9.96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 177347 13.99 108790 17.85 67447 14.26 85023 14.17 133667 16.90 119522 19.86 59930 14.50 58625 19.00 134634 16.79 245131 7.61 64997 17.28 117355 8.83 197413 9.96 1100000 P0Y9M18D 0.15 247500 Summarized plan activity is as follows: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Reserved, Beginning</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">24,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">33,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">39,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Purchased</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(14,600</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(8,879</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(5,354</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shares Reserved, Ending</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10,374</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">24,974</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">33,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 24974 33853 39207 14600 8879 5354 10374 24974 33853 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 16—Income Taxes </div></div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of income (loss) before income taxes are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td colspan="10" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">  </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;">(In thousands)</td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Domestic</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,193</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,859</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the provision/(benefit) for income taxes are as follows:</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,272</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">660</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,807</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">224</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">221</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">457</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">368</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">952</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 78%;"/> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,916</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,249</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">3,216</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(910</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(1,364</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(843</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(189</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(282</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(170</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">78</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(625</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,021</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,638</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,638</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax provision/(benefit)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>differs from the expected tax provision/(benefit) as a result of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax Provision at Statutory Rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">458</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,534</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denmark Statutory Audit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Rate Deferential</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">558</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Based Compensation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(145</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada Withholding Taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State Taxes, Net of Federal Tax Effect</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Global Intangible Low Taxed Incom<div style="display:inline;">e</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Meals and Entertainment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Corporate Rate Change</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition Tax on Repatriated Earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to Provision Adjustment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(207</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Reserves Related to ASC 740 Liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(352</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Valuation Allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(81</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(157</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(209</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(218</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Derived Intangible Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(107</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Tax Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(477</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our effective tax rate for 2021 was 41.1% compared to negative 28.4% in 2020 and 21.6% in 2019. The increase in the effective tax rate in 2021 from 2020 is primarily related to the change in mix of income between relevant jurisdictions in which<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">we <div style="letter-spacing: 0px; top: 0px;;display:inline;">are </div></div>subject to income taxes. Specific items increasing the effective tax rate include foreign rate differential, Denmark statutory audit adjustments, stock-based compensation, and Canada withholding taxes. This increase was offset by the foreign derived intangible income (“FDII”) deduction, the release of a valuation allowance in China, and R&amp;D tax credits expected to be utilized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The decrease in the effective tax rate in 2020 from 2019 is primarily related to lower <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-tax</div> income in 2020 compared to 2019.. Specific items decreasing the effective tax rate include FDII, the release of ASC 740 liabilities, R&amp;D credit utilization, and return to provision adjustments. This decrease was offset by valuation </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">allowances recorded on unbenefited losses in China and on carryforward foreign tax credits expected to expire unused. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of deferred income tax expense arise from various temporary differences and relate to items included in the statement of income. The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities are as follows: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Assets:</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,094</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell Royalty Liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,590</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,583</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State R&amp;D Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,546</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,496</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warranty Reserve</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Accrual</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Operating Loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">ASU 842 Adjustment—Lease Liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized State Tax Benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Tax Credit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Service Contract Revenue</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,855</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,362</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Tax Depreciation in Excess of Book Depreciation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">752</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,002</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">399</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">ASU 842 Adjustment – Lease Liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,966</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,278</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,396</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,721</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,752</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Deferred Tax Assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,557</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,644</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation allowance of $1.7 million at January 31, 2021 relate<div style="letter-spacing: 0px; top: 0px;;display:inline;">s </div>to domestic research and development tax credit carryforwards and foreign tax credit carryforwards which are expected to expire unused. The valuation allowance of $1.8 million at January 31, 2020 included a valuation allowance on China net operating losses, which was released during 2021.     </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At January 31, 2021, we had net operating loss carryforwards of $0.4 million in China, which expire in 2022 through 2026. We have net operating loss carryforwards of $0.2 million in Germany, which can be carried forward indefinitely. We expect to utilize the net operating loss carryforwards in China and Germany before expiration. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At January 31, 2021, we had state research credit carryforwards of approximately $1.5 million which expire in 2021 through 2028. We maintain a full valuation allowance against these credits as we expect these credits to expire unused. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that it is reasonably possible that some unrecognized tax benefits, accrued interest and penalties could decrease income tax expense in the next year due to either the review of previously filed tax returns or the expiration of certain statutes of limitation. The changes in the balances of unrecognized tax benefits, excluding interest and penalties are as </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">follows: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at February 1</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">362</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">618</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">665</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases in prior period tax position<div style="display:inline;">s</div></div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases in current period tax positions</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions related to lapse of statutes of limitations</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(42</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(54</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions related to settlement with tax authorities</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(232</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">384</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">362</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">618</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During fiscal 2021 and 2020, we released $50,000 and $114,000, respectively, of accrued interest and penalties relating to a change in various unrecognized tax positions. During fiscal 2019, we recognized $8,000 of expense related to a change in interest and penalties, which are included as a component of income tax expense in the accompanying statements of income for the period ended January 31, 2019. The Company has accrued potential interest and penalties of $0.3 million included in Income Taxes Payable in the consolidated balance sheet at the end of both January 31, 2021 and 2020. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company and its subsidiaries file income tax returns in U.S. federal jurisdictions, various state jurisdictions, and various foreign jurisdictions. The Company was previously under audit by the IRS for the tax years ended January 31, 2015, 2016, and 2017, but on June 6, 2019, we received formal communication regarding the close of the audit with no additional changes made by the IRS. Therefore, the reserves for federal uncertain tax positions relating to the years in question have been released. In fiscal 2020, we released $232,000 relating to the federal tax exposure for the years previously under audit and $74,000 of related interest (net of federal benefit) and penalties. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company was also notified of an income tax audit from the state of Rhode Island, but no significant items have been raised at this time other than information requests. No assessments have been made as of January 31, 2021. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. income taxes have not been provided on $5.7 million of undistributed earnings of our foreign subsidiaries since it is our intention to permanently reinvest such earnings offshore. If the earnings were distributed in the form of dividends, the Company would not be subject to U.S. tax as a result of the Tax Act but could be subject to foreign income and withholding taxes. Determination of the amount of this unrecognized deferred income tax liability is not practical. </div></div> <div style="text-align: justify; text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of income (loss) before income taxes are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td colspan="10" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;">  </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap;">(In thousands)</td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Domestic</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,193</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,930</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,859</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,372</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(560</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">449</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> -1193000 1930000 6859000 3372000 -560000 449000 2179000 1370000 7308000 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The components of the provision/(benefit) for income taxes are as follows:</div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 78%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,272</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">660</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,807</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">224</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">221</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">457</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">420</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">368</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">952</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 78%;"/> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,916</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">1,249</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%;;text-align:right;">3,216</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 78%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> <div style="margin-top: 0px; margin-bottom: 0px; line-height: normal;"> </div> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(910</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(1,364</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(843</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(189</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(282</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(170</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 78%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign</div></div> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">78</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">8</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(625</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,021</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,638</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;;text-align:right;">(1,638</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;">) </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 0%;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 78%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 2%;"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="background-color: rgb(255, 255, 255); width: 0%;"> </td> </tr> </table> 1272000 660000 1807000 224000 221000 457000 420000 368000 952000 1916000 1249000 3216000 -910000 -1364000 -843000 -189000 -282000 -170000 78000 8000 -625000 -1021000 -1638000 -1638000 895000 -389000 1578000 <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total income tax provision/(benefit)<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>differs from the expected tax provision/(benefit) as a result of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax Provision at Statutory Rate</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">458</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">288</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,534</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denmark Statutory Audit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Rate Deferential</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">197</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">558</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share Based Compensation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">171</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(145</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(127</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada Withholding Taxes</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State Taxes, Net of Federal Tax Effect</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(48</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">226</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Global Intangible Low Taxed Incom<div style="display:inline;">e</div></div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Meals and Entertainment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">56</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Corporate Rate Change</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transition Tax on Repatriated Earnings</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Return to Provision Adjustment</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(207</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Reserves Related to ASC 740 Liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(352</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in Valuation Allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(81</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">256</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">R&amp;D Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(157</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(209</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(218</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Derived Intangible Income</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(150</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(107</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Tax Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(477</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 458000 288000 1534000 -341000 197000 315000 558000 171000 -145000 -127000 -62000 28000 -48000 226000 -14000 -107000 11000 31000 56000 52000 14000 -2000 -207000 58000 -10000 -352000 -34000 -81000 256000 157000 209000 218000 150000 107000 53000 344000 477000 13000 26000 -11000 895000 -389000 1578000 0.411 0.284 0.216 The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities are as follows: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Assets:</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-size: 0px;"> <td style="width: 84%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,700</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,094</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Honeywell Royalty Liability</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,590</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,583</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State R&amp;D Credits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,546</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,496</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">582</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Bad Debt</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Warranty Reserve</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">176</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation Accrual</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">159</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Operating Loss</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">154</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">443</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">ASU 842 Adjustment—Lease Liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized State Tax Benefits</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">101</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">116</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Foreign Tax Credit</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">83</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">113</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Service Contract Revenue</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">68</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">111</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,855</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,362</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred Tax Liabilities:</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated Tax Depreciation in Excess of Book Depreciation</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">752</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,002</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangibles</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">399</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">776</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">ASU 842 Adjustment – Lease Liability</div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">119</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">307</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,577</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,966</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subtotal</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,278</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,396</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation Allowance</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,721</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,752</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Deferred Tax Assets</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,557</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,644</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 2700000 2094000 2590000 2583000 1546000 1496000 600000 582000 245000 165000 176000 205000 159000 159000 154000 443000 125000 101000 116000 83000 113000 68000 111000 308000 295000 8855000 8362000 752000 1002000 399000 776000 119000 0 307000 188000 1577000 1966000 7278000 6396000 1721000 1752000 5557000 4644000 1700000 1800000 400000 2022 through 2026 200000 1500000 2021 through 2028 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 85%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at February 1</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">362</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">618</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">665</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases in prior period tax position<div style="display:inline;">s</div></div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">59</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increases in current period tax positions</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">5</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">2</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">7</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions related to lapse of statutes of limitations</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(42</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(26</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(54</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reductions related to settlement with tax authorities</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(232</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">) </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">—  </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; white-space: nowrap;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance at January 31</div></div></div> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">384</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">362</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">618</div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> </table> 362000 618000 665000 59000 5000 2000 7000 42000 26000 54000 232000 384000 362000 618000 50000 114000 8000 300000 232000 74000 5700000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 17—Nature of Operations, Segment Reporting and Geographical Information </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our operations consist of the design, development, manufacture and sale of specialty printers and data acquisition and analysis systems, including both hardware and software and related consumable supplies. We organize and manage our business as a portfolio of products and services designed around a common theme of data acquisition and information output. We have two reporting segments consistent with our revenue product groups: Product Identification (“PI”) and Test &amp; Measurement (“T&amp;M”). </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our PI segment produces an array of high-technology digital color and monochrome label printers and mini presses, labeling software and supplies for a variety of commercial industries worldwide. AstroNova’s T&amp;M segment produces data acquisition systems used worldwide for a variety of recording, monitoring and troubleshooting applications for many industries including aerospace, automotive, defense, rail, energy, industrial and general manufacturing. The T&amp;M segment also includes our line of aerospace flight deck and cabin printers. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business is conducted in the United States and through foreign branch offices and subsidiaries in Canada, Europe, China, Southeast Asia and Mexico. Manufacturing activities are primarily conducted in the United States. Revenue and service activities outside the United States are conducted through wholly-owned entities and, to a lesser extent, through authorized distributors and agents. Transfer prices are intended to produce gross profit margins as would be associated with an arms-length transaction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accounting policies of the reporting segments are the same as those described in the summary of significant accounting policies herein. We evaluate segment performance based on the segment profit before corporate and financial administration expenses. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized below are the revenue and segment operating profit (loss) (both in dollars and as a percentage of revenue) for each reporting segment: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 36%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">($ in thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit (Loss)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit (Loss)<br/> as a % of Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2021  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2019  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2018  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 36%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-size: 0px;"> <td style="width: 27%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">90,268</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">88,116</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">86,786</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,885</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,509</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">25,765</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">45,330</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">49,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,032</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,281</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,933</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(4.0</td> <td style="vertical-align: bottom; white-space: nowrap;">)% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">23.9</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13,790</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19,843</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(10.3</td> <td style="vertical-align: bottom; white-space: nowrap;">)% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Expenses</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9,420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,123</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,433</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,433</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,720</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expense, Net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(254</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,063</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,412</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Before Income Taxes</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">7,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax Provision (Benefit)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,759</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> </table> <div style="text-align: justify; text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No customer accounted for greater than 10% of net revenue in fiscal 2021, 2020 or 2019. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other information by segment is presented below: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">50,047</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">51,439</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">51,262</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">57,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate*</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14,164</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">115,473</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,664</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">*</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate assets consist principally of cash, cash equivalents, deferred tax assets and refunds, and certain prepaid corporate assets. </div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 58%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Depreciation and<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital Expenditures</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,835</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,928</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,888</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,563</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,935</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,148</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,356</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,264</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,024</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">905</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,983</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,152</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,587</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,906</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,645</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Geographical Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented below is selected financial information by geographic area: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-Lived Assets*</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">70,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">31,226</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">34,072</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">31,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,274</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3,950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,145</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,464</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,978</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,369</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">33,513</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">36,651</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 2%; vertical-align: top;;text-align:left;">*</td> <td style="vertical-align: top;;text-align:left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets exclude goodwill assigned to the T&amp;M segment of $4.5 million at both January 31, 2021 and 2020 and $8.3 million and $7.5 million assigned to the PI segment at January 31, 2021 and 2020, respectively. </div></div> </td> </tr> </table> 2 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summarized below are the revenue and segment operating profit (loss) (both in dollars and as a percentage of revenue) for each reporting segment: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 36%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">($ in thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit (Loss)</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Segment Operating Profit (Loss)<br/> as a % of Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2021    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2020    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">    2019    </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2021  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2019  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">  2018  </div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 36%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-size: 0px;"> <td style="width: 27%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">90,268</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">88,116</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">86,786</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,885</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,509</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">7,910</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9.1</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">25,765</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">45,330</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">49,871</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,032</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,281</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,933</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(4.0</td> <td style="vertical-align: bottom; white-space: nowrap;">)% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13.9</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">23.9</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,853</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13,790</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">19,843</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(10.3</td> <td style="vertical-align: bottom; white-space: nowrap;">)% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">10.3</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14.5</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Expenses</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">9,420</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,357</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">11,123</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating Income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,433</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,433</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,720</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Expense, Net</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(254</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,063</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(1,412</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Before Income Taxes</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,179</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,370</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">7,308</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Tax Provision (Benefit)</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">895</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">(389</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,578</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Income</div></div> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,759</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,730</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> </table> 90268000 88116000 86786000 12885000 7509000 7910000 0.143 0.085 0.091 25765000 45330000 49871000 -1032000 6281000 11933000 -0.040 0.139 0.239 116033000 133446000 136657000 11853000 13790000 19843000 -0.103 0.103 0.145 9420000 11357000 11123000 2433000 2433000 8720000 -254000 -1063000 -1412000 2179000 1370000 7308000 895000 -389000 1578000 1284000 1759000 5730000 0 0 0 <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other information by segment is presented below: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Assets</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 82%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">50,047</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">51,439</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">51,262</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">57,050</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate*</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">14,164</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,175</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">115,473</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,664</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">*</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate assets consist principally of cash, cash equivalents, deferred tax assets and refunds, and certain prepaid corporate assets. </div></div> </td> </tr> </table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 58%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Depreciation and<br/> Amortization</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Capital Expenditures</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Product Identification</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,835</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,928</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,888</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,563</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,001</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,935</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">T&amp;M</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,148</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,356</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,264</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,024</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">905</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">710</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">5,983</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,284</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,152</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,587</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,906</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,645</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 50047000 51439000 51262000 57050000 14164000 8175000 115473000 116664000 1835000 1928000 1888000 1563000 2001000 1935000 4148000 4356000 4264000 1024000 905000 710000 5983000 6284000 6152000 2587000 2906000 2645000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Geographical Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Presented below is selected financial information by geographic area: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Revenue</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Long-Lived Assets*</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 57%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">United States</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">70,911</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,671</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">83,668</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">31,226</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">34,072</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Europe</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,029</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">29,617</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">31,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,274</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,544</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Canada</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,574</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,719</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">6,692</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">13</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Asia</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">5,105</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,316</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">8,207</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Central and South America</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">3,950</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,145</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">4,147</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,464</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">1,978</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">2,369</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,033</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">133,446</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136,657</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">33,513</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">36,651</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 2%; vertical-align: top;;text-align:left;">*</td> <td style="vertical-align: top;;text-align:left;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal; text-align: left;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets exclude goodwill assigned to the T&amp;M segment of $4.5 million at both January 31, 2021 and 2020 and $8.3 million and $7.5 million assigned to the PI segment at January 31, 2021 and 2020, respectively. </div></div> </td> </tr> </table> 70911000 83671000 83668000 31226000 34072000 29029000 29617000 31574000 2274000 2544000 5574000 5719000 6692000 13000 35000 5105000 8316000 8207000 3950000 4145000 4147000 1464000 1978000 2369000 116033000 133446000 136657000 33513000 36651000 4500000 4500000 8300000 7500000 <div><div style="font-size: 10pt;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">Note 18—Employee Benefit Plans</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We sponsor a Profit-Sharing Plan (the “Plan”) which provides retirement benefits to all eligible domestic employees. The Plan allows participants to defer a portion of their cash compensation and contribute such deferral to the Plan through payroll deductions. The Company makes matching contributions up to specified levels. The deferrals are made within the limits prescribed by Section 401(k) of the Internal Revenue Code. </div></div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All contributions are deposited into trust funds. It<div style="letter-spacing: 0px; top: 0px;;display:inline;"> is </div><div style="letter-spacing: 0px; top: 0px;;display:inline;">our</div> policy <div style="letter-spacing: 0px; top: 0px;;display:inline;">to fund any </div>contributions accrued. Our annual contribution amounts are determined by the Board of Directors. Contributions paid or accrued amounted to $0.4 million in fiscal 2021 and $0.5 million in both fiscal 2020 and 2019.</div></div> 400000 500000 500000 Note 19—Product Warranty Liability <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">We offer a manufacturer’s warranty for the majority of our hardware products. The specific terms and conditions of warranty vary depending upon the products sold and country in which we do business. We estimate the warranty costs based on historical claims experience and record a liability in the amount of such estimates at the time product revenue is recognized. We regularly assess the adequacy of our recorded warranty liabilities and adjusts the amounts as necessary. Activity in the product warranty liability, which is included in other accrued expenses in the accompanying consolidated balance sheet, is as follows: </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of the year</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">832</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">575</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for Warranty Expense</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">855</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">1,733</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">1,680</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Warranty Repair<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(975</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(1,715</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(1,423</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, end of the year</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">730</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">832</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> </tr> </table> Activity in the product warranty liability, which is included in other accrued expenses in the accompanying consolidated balance sheet, is as follows: <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="10" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">January 31</div></div></div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(In thousands)</div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 79%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> <td style="width: 0%;"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, beginning of the year</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">832</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">575</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision for Warranty Expense</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">855</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">1,733</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">1,680</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Warranty Repair<div style="letter-spacing: 0px; top: 0px;;display:inline;">s</div></div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(975</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(1,715</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">(1,423</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal; white-space: nowrap;"> </div> </td> <td style="width: 0%;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 79%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance, end of the year</div></div> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">730</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">850</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;">$</td> <td style="vertical-align: bottom; width: 0%; white-space: nowrap;;text-align:right;">832</td> <td style="vertical-align: bottom; white-space: nowrap; width: 0%;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 79%;"> </td> <td style="vertical-align: bottom; width: 4%;">  </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> <td style="vertical-align: bottom; width: 4%;"> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom; width: 0%;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="width: 0%;"> </td> </tr> </table> 850000 832000 575000 855000 1733000 1680000 975000 1715000 1423000 730000 850000 832000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 20—Concentration of Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Credit is generally extended on an uncollateralized basis to almost all customers after review of credit worthiness. Concentration of credit and geographic risk with respect to accounts receivable is limited due to the large number and general dispersion of accounts which constitute our customer base. We periodically perform <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> credit evaluations of our customers. We have not historically experienced significant credit losses on collection of our accounts receivable. </div></div>During the years ended January 31, 2021, 2020 and 2019, one vendor accounted for 23.2%, 21.2% and 21.6% of purchases, and 23.8%, 28.0% and 28.7% of accounts payable, respectively, as of January 31, 2021, 2020 and 2019. 0.232 0.212 0.216 0.238 0.280 0.287 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 21—Commitments and Contingencies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are subject to contingencies, including legal proceedings and claims arising in the normal course of business that cover a wide range of matters including, among others, contract and employment claims; workers compensation claims; product liability; warranty and modification; and adjustment or replacement of component parts of units sold. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Direct costs associated with the estimated resolution of contingencies are accrued at the earliest date at which it is deemed probable that a liability has been incurred and the amount of such liability can be reasonably estimated. While it is impossible to ascertain the ultimate legal and financial liability with respect to contingent liabilities, including lawsuits, we believe that the aggregate amount of such liabilities, if any, in excess of amounts provided or covered by insurance, will not have a material adverse effect on the consolidated financial position or results of operations. It is possible, however, that future results of operations for any particular future period could be materially affected by changes in our assumptions or strategies related to these contingencies or changes out of our control. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 22—Fair Value Measurements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Recorded at Fair Value on a Recurring Basis </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide a summary of the financial liabilities that are measured at fair value: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 48%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities measured at fair value:</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurement at<br/> January 31, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurement at<br/> January 31, 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 48%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Swap Contract (included in Other Long-Term Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnout Liability (included in Other Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 48%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"><div style="display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 48%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We used the market approach to measure fair value of our derivative instruments. These derivative instruments were measured at fair value using readily observable market inputs, such as quotations on interest rates and foreign exchange rates and are classified as Level 2 because they are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> contracts with a bank counterparty that are not traded in an active market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets and Liabilities Not Recorded at Fair Value on the Consolidated Balance Sheet </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement at<br/> January 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt and Related Current Maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  —  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  —  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,586 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,586</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement at<br/> January 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt and Related Current Maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,034</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The above table does not include the PPP loan, as the fair value of the PPP loan approximates its carrying value. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar borrowings with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following tables provide a summary of the financial liabilities that are measured at fair value: </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 48%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.7pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liabilities measured at fair value:</div></div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurement at<br/> January 31, 2021</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair value measurement at<br/> January 31, 2020</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">  </div></td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></td> </tr> <tr style="font-size: 0px;"> <td style="width: 48%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest Rate Swap Contract (included in Other Long-Term Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-size: 10pt; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnout Liability (included in Other Liabilities)</div></div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 48%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 48%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities</div></div> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, serif; letter-spacing: 0px; top: 0px;;display:inline;">    </div> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"><div style="display:inline;"> </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">346</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$<div style="display:inline;"> </div><div style="display:inline;"> </div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">360</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 48%;"> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> <td style="vertical-align: bottom; width: 2%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0px; margin-bottom: 0px; border-top: 3px double rgb(0, 0, 0); line-height: normal;"> </div> </td> <td> </td> </tr> </table> 250000 250000 96000 96000 14000 14000 346000 14000 360000 <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 64%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement at<br/> January 31, 2021</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt and Related Current Maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  —  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">  —  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,586 </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,586</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12,576</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="16" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> <td colspan="4" style="height: 12pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurement at<br/> January 31, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">(In thousands)</td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 1</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 2</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level 3</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Carrying<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.7pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-Term Debt and Related Current Maturities</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,258</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13,034</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> 12586000 12586000 12576000 13258000 13258000 13034000 <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2<div style="letter-spacing: 0px; top: 0px;;display:inline;">3</div>—Subsequent Event </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March 24, 2021, we entered into a First Amendment to Credit Agreement (the “Amendment”) to the A&amp;R Credit Agreement<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>(the “A&amp;R Credit Agreement,”<div style="letter-spacing: 0px; top: 0px;;display:inline;"> as</div> amended by the Amendment; the “Amended Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), ANI ApS and TrojanLabel. Immediately prior to the closing of the Amendment, we repaid $2.6 million in principal amount of the term loan outstanding under the A&amp;R Credit Agreement, resulting in an outstanding balance of the term loan of $10.0 million and no amount drawn and outstanding under the revolving credit facility under the A&amp;R Credit Agreement.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-style: normal; background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div></div> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended Credit Agreement provides for (i) a term loan in the principal amount of $10.0 million, and (ii) a $22.5 million revolving credit facility available for general corporate purposes. At the closing of the Amend<div style="letter-spacing: 0px; top: 0px;;display:inline;">ment<div style="letter-spacing: 0px; top: 0px;;display:inline;">, <div style="letter-spacing: 0px; top: 0px;;display:inline;">w</div><div style="letter-spacing: 0px; top: 0px;;display:inline;">e </div></div></div>borrowed the entire $10.0 million term loan which was used to refinance, in full, the outstanding term loan under the A&amp;R Credit Agreement. Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended Credit Agreement requires that the term loan be paid as follows: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2021 through January 31, 2022 is $187,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2022 through January 31, 2023 is $250,000; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2023 through January 31, 2025 is $312,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2025 and July 31, 2025 is $500,000; and the entire remaining principal balance of the term loan is required to be paid on September 30, 2025. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than September 30, 2025, at which time any outstanding revolving loans will be due and payable in full, and the revolving credit facility will terminate. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended Credit Agreement includes an uncommitted accordion provision under which the term loan and/or revolving credit facility commitments may be increased in an aggregate principal amount not exceeding $10.0 million, subject to obtaining the agreement of the Lender and the satisfaction of certain other conditions. </div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt; line-height: 12pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The interest rates under the <div style="letter-spacing: 0px; top: 0px;;display:inline;">Prior</div> Credit Agreement were modified in the Amended Credit Agreement as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the LIBOR Rate as de<div style="letter-spacing: 0px; top: 0px;;display:inline;">fin<div style="letter-spacing: 0px; top: 0px;;display:inline;">ed</div></div> in the Amended Credit Agreement (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.30% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.30% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.30% based on our consolidated leverage ratio. The commitment fee paid on the undrawn portion of the revolving credit facility was $28,000 for fiscal year 2021 and is included in the interest expense line in the consolidated income statement for the period ended January 31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As under the Prior Credit Agreement, the loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We must comply with various customary financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. The minimum EBITDA, minimum consolidated asset coverage ratio, minimum liquidity and maximum capital expenditures covenants with which we were required to comply under the Prior Credit Agreement were eliminated by the Amendment. The primary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Amendment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control. </div></div></div> <div id="tx56468_106a" style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 8pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests held in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island. Pursuant to the Amendment, the guarantees of our obligations under the Prior Credit Agreement that were previously provided by ANI ApS and TrojanLabel were released. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> 2.6 10.0 10.0 22.5 10.0 187500 187500 187500 187500 250000 250000 250000 312500 312500 312500 312500 312500 312500 312500 312500 quarterly installment 500000 500000 10000000.0 0.0160 0.0230 0.0050 0.0100 0.50 0.0060 0.0130 0.0015 0.0030 28,000 <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="tx56468_107" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES </div></div></div></div> </div> </div> <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 8pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 65%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance at<br/> Beginning<br/> of Year</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Provision/<br/> (Benefit)<br/> Charged to<br/> Operations</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Deductions(2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Balance<br/> at End<br/> of Year</div></div></td> <td style="vertical-align: bottom; padding-bottom: 1pt;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allowance for Doubtful Accounts(1):</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;">(In thousands)</td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">  </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> <td colspan="2" style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year Ended January 31,</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">194</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">4</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">1,054</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2020</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">521</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">546</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(211</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">856</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2019</div></div> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">377</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">310</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(166</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">521</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The allowance for doubtful accounts has been netted against accounts receivable in the balance sheets as of the respective balance sheet dates. </div></div> </td> </tr> </table> <div style="clear: both; max-height: 0px; background: none;"/> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td> <td style="vertical-align: top;;text-align:left;"> <div style="text-align: justify; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uncollectible accounts written off, net of recoveries. </div></div> </td> </tr> </table> 856000 194000 -4000 1054000 521000 546000 211000 856000 377000 310000 166000 521000 XML 16 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover Page - USD ($)
12 Months Ended
Jan. 31, 2021
Apr. 09, 2021
Jul. 31, 2020
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Period End Date Jan. 31, 2021    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Entity Registrant Name AstroNova, Inc.    
Entity Central Index Key 0000008146    
Current Fiscal Year End Date --01-31    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Well-known Seasoned Issuer No    
Entity Filer Category Non-accelerated Filer    
Trading Symbol ALOT    
Entity Shell Company false    
Entity Small Business true    
Entity Emerging Growth Company false    
Title of 12(b) Security Common Stock    
Security Exchange Name NASDAQ    
Entity Incorporation, State or Country Code RI    
Entity File Number 0-13200    
Document Annual Report true    
Document Transition Report false    
Entity Tax Identification Number 05-0318215    
Entity Address, Address Line One 600 East Greenwich Avenue    
Entity Address, City or Town West Warwick    
Entity Address, Postal Zip Code 02893    
Entity Address, State or Province RI    
City Area Code 401    
Local Phone Number 828-4000    
Entity Public Float     $ 47,045,000
Entity Common Stock, Shares Outstanding   7,212,977  
ICFR Auditor Attestation Flag false    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
CURRENT ASSETS    
Cash and Cash Equivalents $ 11,439 $ 4,249
Accounts Receivable, net of reserves of $1,054 in 2021 and $856 in 2020 17,415 19,784
Inventories 30,060 33,925
Prepaid Expenses and Other Current Assets 1,807 2,193
Total Current Assets 60,721 60,151
Property, Plant and Equipment, net 12,011 11,268
Identifiable Intangibles, net 21,502 25,383
Goodwill 12,806 12,034
Deferred Tax Assets, net 5,941 5,079
Right of Use Asset 1,389 1,661
Other 1,103 1,088
TOTAL ASSETS 115,473 116,664
CURRENT LIABILITIES    
Accounts Payable 5,734 4,409
Accrued Compensation 2,852 2,700
Other Accrued Expenses 3,939 4,711
Revolving Credit Facility   6,500
Current Portion of Long-Term Debt 5,326 5,208
Current Liability—Royalty Obligation 2,000 2,000
Current Liability—Excess Royalty Payment Due 177 773
Income Taxes Payable 655  
Deferred Revenue 285 466
Total Current Liabilities 20,968 26,767
NON CURRENT LIABILITIES    
Long-Term Debt, net of current portion 7,109 7,715
Royalty Obligation, net of current portion 6,161 8,012
Long-Term Debt—PPP Loan 4,422  
Lease Liabilities, net of current portion 1,065 1,279
Income Taxes Payable 681 1,081
Deferred Tax Liabilities 384 435
TOTAL LIABILITIES 40,790 45,289
Commitments and Contingencies (See Note 21)
SHAREHOLDERS' EQUITY    
Preferred Stock, $10 Par Value, Authorized 100,000 shares, None Issued
Common Stock, $0.05 Par Value, Authorized 13,000,000 shares; Issued 10,425,094 shares in 2021 and 10,343,610 shares in 2020 521 517
Additional Paid-in Capital 58,049 56,130
Retained Earnings 50,085 49,298
Treasury Stock, at Cost, 3,297,058 shares in 2021 and 3,281,701 shares in 2020 (33,588) (33,477)
Accumulated Other Comprehensive Loss, net of tax (384) (1,093)
TOTAL SHAREHOLDERS' EQUITY 74,683 71,375
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 115,473 $ 116,664
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Statement of Financial Position [Abstract]    
Accounts Receivable, Reserves $ 1,054 $ 856
Preferred Stock, Par Value $ 10 $ 10
Preferred Stock, Shares Authorized 100,000 100,000
Preferred Stock, Shares Issued 0 0
Common Stock, Par Value $ 0.05 $ 0.05
Common Stock, Shares Authorized 13,000,000 13,000,000
Common Stock, Shares Issued 10,425,094 10,343,610
Treasury Stock, Shares 3,297,058 3,281,701
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Income Statement [Abstract]      
Revenue $ 116,033 $ 133,446 $ 136,657
Cost of Revenue 74,673 84,688 82,658
Gross Profit 41,360 48,758 53,999
Costs and Expenses:      
Selling and Marketing 23,301 26,884 26,343
Research and Development 6,206 8,084 7,813
General and Administrative 9,420 11,357 11,123
Operating Expenses 38,927 46,325 45,279
Operating Income 2,433 2,433 8,720
Other Expense:      
Interest Income (Expense), net (955) (682) (731)
Gain (Loss) on Foreign Currency Transactions (590) 448 745
Other, Net 111 67 64
Other Expense, net (254) (1,063) (1,412)
Income before Income Taxes 2,179 1,370 7,308
Income Tax Provision (Benefit) 895 (389) 1,578
Net Income $ 1,284 $ 1,759 $ 5,730
Net Income Per Common Share—Basic $ 0.18 $ 0.25 $ 0.83
Net Income Per Common Share—Diluted $ 0.18 $ 0.24 $ 0.81
Weighted Average Number of Common Shares Outstanding—Basic 7,104 7,024 6,881
Dilutive Effect of Common Stock Equivalents 62 214 203
Weighted Average Number of Common Shares Outstanding—Diluted 7,166 7,238 7,084
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Statement of Comprehensive Income [Abstract]      
Net Income $ 1,284 $ 1,759 $ 5,730
Other Comprehensive Income (Loss), net of taxes and reclassification adjustments:      
Foreign Currency Translation Adjustments 710 (133) (671)
Change in Value of Derivatives Designated as Cash Flow Hedge (239) 122 622
(Gains) Losses from Cash Flow Hedges Reclassified to Income Statement 193 (264) (600)
Cross-Currency Interest Rate Swap Terminations 45    
Realized Gain on Securities Available for Sale Reclassified to Income Statement     3
Other Comprehensive Income (Loss) 709 (275) (646)
Comprehensive Income $ 1,993 $ 1,484 $ 5,084
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Changes in Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Jan. 31, 2018 $ 63,647 $ 500 $ 50,016 $ 45,700 $ (32,397) $ (172)
Beginning Balance, Shares at Jan. 31, 2018   9,996,120        
Share-Based Compensation 1,886   1,886      
Employee Option Exercises $ 1,310 $ 7 1,669   (366)  
Employee Option Exercises, Shares 150,125 154,992        
Restricted Stock Awards Vested, net $ (233) $ 4 (3)   (234)  
Restricted Stock Awards Vested, net, Shares   67,447        
Reclassification due to adoption of ASU 2018-02 14     14    
Common Stock—cash dividend (1,933)     (1,933)    
Net Income 5,730     5,730    
Other Comprehensive Income (Loss) (646)         (646)
Ending Balance at Jan. 31, 2019 69,775 $ 511 53,568 49,511 (32,997) (818)
Ending Balance, Shares at Jan. 31, 2019   10,218,559        
Share-Based Compensation 1,775   1,775      
Employee Option Exercises $ 782 $ 3 790   (11)  
Employee Option Exercises, Shares 57,175 65,121        
Restricted Stock Awards Vested, net $ (469) $ 3 (3)   (469)  
Restricted Stock Awards Vested, net, Shares   59,930        
Common Stock—cash dividend (1,972)     (1,972)    
Net Income 1,759     1,759    
Other Comprehensive Income (Loss) (275)         (275)
Ending Balance at Jan. 31, 2020 71,375 $ 517 56,130 49,298 (33,477) (1,093)
Ending Balance, Shares at Jan. 31, 2020   10,343,610        
Share-Based Compensation 1,819   1,819      
Employee Option Exercises $ 104 $ 1 103      
Employee Option Exercises, Shares 1,200 16,487        
Restricted Stock Awards Vested, net $ (111) $ 3 (3)   (111)  
Restricted Stock Awards Vested, net, Shares   64,997        
Common Stock—cash dividend (497)     (497)    
Net Income 1,284     1,284    
Other Comprehensive Income (Loss) 709         709
Ending Balance at Jan. 31, 2021 $ 74,683 $ 521 $ 58,049 $ 50,085 $ (33,588) $ (384)
Ending Balance, Shares at Jan. 31, 2021   10,425,094        
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) - $ / shares
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Statement of Stockholders' Equity [Abstract]      
Cash dividend per share $ 0.28 $ 0.28 $ 0.07
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Cash Flows from Operating Activities:      
Net Income $ 1,284 $ 1,759 $ 5,730
Adjustments to Reconcile Net Income to Net Cash Provided By Operating Activities:      
Depreciation and Amortization 5,983 6,284 6,152
Amortization of Debt Issuance Costs 75 49 51
Share-Based Compensation 1,819 1,775 1,886
Deferred Income Tax Provision (Benefit) (1,021) (1,638) (1,638)
Changes in Assets and Liabilities:      
Accounts Receivable 2,702 3,594 (1,493)
Inventories 4,247 (3,938) (2,872)
Accounts Payable and Accrued Expenses (57) (2,732) (2,342)
Income Taxes Payable 1,482 (1,773) (151)
Other (970) (156) (318)
Net Cash Provided by Operating Activities 15,544 3,224 5,005
Cash Flows from Investing Activities:      
Proceeds from Sales/Maturities of Securities Available for Sale     1,511
Cash Paid for Honeywell Asset Purchase and License Agreement     (400)
Additions to Property, Plant and Equipment (2,587) (2,906) (2,645)
Net Cash Used by Investing Activities (2,587) (2,906) (1,534)
Cash Flows from Financing Activities:      
Net Proceeds Employee Stock Option Plans 9 654 1,228
Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan 95 128 82
Net Cash Used for Payment of Taxes Related to Vested Restricted Stock (111) (469) (233)
Net (Repayments)/Borrowings under Revolving Credit Facility (6,500) 5,000 1,500
Payment of Minimum Guarantee Royalty Obligation (2,000) (1,875) (1,625)
Proceeds from Long-Term Debt – PPP Loan 4,422    
Proceeds from Long-Term Debt Borrowings 15,232    
Payoff of Long-Term Debt (11,732)    
Principal Payments on Long-Term Debt (3,958) (5,208) (5,130)
Payments of Debt Issuance Costs (100)    
Dividends Paid (497) (1,972) (1,933)
Net Cash Used by Financing Activities (5,140) (3,742) (6,111)
Effect of Foreign Exchange Rate Changes on Cash and Cash Equivalents (627) 139 (3)
Net Increase (Decrease) in Cash and Cash Equivalents 7,190 (3,285) (2,643)
Cash and Cash Equivalents, Beginning of Year 4,249 7,534 10,177
Cash and Cash Equivalents, End of Year 11,439 4,249 7,534
Supplemental Information:      
Interest 677 531 636
Income Taxes, Net of Refunds $ 446 2,913 3,472
Schedule of non-cash financing activities:      
Value of Shares Received in Satisfaction of Option Exercise Price   $ 11 $ 366
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
12 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 1—Summary of Significant Accounting Policies
Basis of Presentation:
The accompanying financial statements and accompanying notes have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Our fiscal year end is January 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation:
The consolidated financial statements include the accounts of AstroNova, Inc. and its subsidiaries. All material intercompany accounts and transactions are eliminated in consolidation.
Reclassification:
Certain amounts in prior year’s financial statements have been reclassified to conform to the current year’s presentation.
Use of Estimates:
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect these financial statements and accompanying notes. Some of the more significant estimates relate to the allowances for doubtful accounts, inventory valuation, valuation and estimated lives of intangible assets, impairment of long-lived assets, goodwill, income taxes, share-based compensation and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters. Consequently, actual results could differ from those estimates.
Cash and Cash Equivalents:
Highly liquid investments with an original maturity of 90 days or less are considered to be cash equivalents. Similar investments with original maturities beyond three months are classified as securities available for sale. At January 31, 2021 and 2020, $4.6 million and $3.4 million, respectively, was held in foreign bank accounts.
Inventories:
Inventories are stated at the lower of cost
(first-in,
first-out)
or net realizable value and include material, labor and manufacturing overhead.
Property, Plant and Equipment:
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets (land improvements—10 to 20 years; buildings and leasehold improvements—10 to 45 years; machinery and equipment—3 to 10 years and computer equipment and software—3 to 10 years).
Revenue Recognition:
We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Topic 606 defines a five step process to recognize revenue and requires more judgment and estimates within the revenue recognition process than required under previous U.S. GAAP, including identifying contracts with customers, identifying performance obligations in the contract, determining and estimating the amount of any variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and recognizing revenue when the entity satisfies each performance obligation. 
The vast majority of our revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration we expect to receive in exchange for such products, which is generally at the contractually stated prices, and is recognized when we satisfy a performance obligation by transferring control of a product to a customer. The transfer of control generally occurs at one point in time, upon shipment, when title and risk of loss pass to the customer. Returns and customer credits are infrequent and are recorded as a reduction to revenue. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.
 
Many of the contracts entered into with customers are commonly comprised of a combination of equipment, supplies, installation and/or training services. We determine performance obligations by assessing whether the products or services are distinct from other elements of the contract. In order to be distinct, the product must perform either on its own or with readily available resources and must be separate within the context of the contract.
Most of our hardware products contain embedded operating systems and data management software which is included in the purchase price of the equipment. The software is deemed incidental to the systems as a whole, as it is not sold or marketed separately, and its production costs are minor compared to those of the hardware system. Hardware and software elements are typically delivered at the same time and are accounted for as a single performance obligation for which revenue is recognized at the point in time when ownership is transferred to the customer.
Installation and training services vary based on certain factors such as the complexity of the equipment, staffing availability in a geographic location and customer preferences, and can range from a few days to a few months. The delivery of installation and training services are not assessed to determine whether they are separate performance obligations, as the amounts are not material to the contract.
Shipping and handling activities that occur after control over a product has transferred to a customer are accounted for as fulfillment activities rather than performance obligations, as allowed under a practical expedient provided by Topic 606. The shipping and handling fees charged to customers are recognized as revenue and the related costs are included in cost of revenue at the point in time when ownership of the product is transferred to the customer.
We may perform service at the request of the customer, generally for the repair and maintenance of products previously sold. These services are short in duration and total less than 10% of revenue for the years ended January 31, 2021 and 2020. Revenue is recognized as services are rendered and accepted by the customer. We also provide service agreements on certain of our Product Identification equipment. Service agreements are purchased separately from the equipment and provide for the right to obtain service and maintenance on the equipment for a period of typically one to two years. Accordingly, revenue on these agreements is recognized over the term of the agreements. The portion of service agreement contracts that are uncompleted at the end of any reporting period are included in deferred revenue.
We generally provide warranties for our products. The standard warranty period is typically 12 months for most hardware products except for airborne printers, which typically have warranties that extend for
3-5
years, consistent with industry practice. Such assurance-type warranties are not deemed to be separate performance obligations from the hardware product and costs associated with providing the warranties are accrued in accordance with ASC 450, “Contingencies,” as we have the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. Our estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that our experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue. On occasion, customers request a warranty period longer than our standard warranty. In those instances, in which extended warranty services are separately quoted to the customer, an additional performance obligation is created, and the associated revenue is deferred and recognized as service revenue ratably over the term of the extended warranty period. The portion of service contracts and extended warranty services agreements that are uncompleted at the end of any reporting period are included in deferred revenue.
We recognize an asset for the incremental direct costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. Costs related to obtaining sales contracts for our aerospace printer products have been capitalized and are being amortized based on the forecasted number of units sold over the estimated benefit term. We apply the practical expedient to expense costs incurred for costs to obtain a contract when the amortization period would have been less than a year. These costs include sales commissions paid to the internal direct sales team as well as to third-party representatives and distributors. Contractual
agreements with each of these parties outline commission structures and rates to be paid. Generally speaking, the contracts are all individual procurement decisions by the customers and do not include renewal provisions and as such the majority of the contracts have an economic life of significantly less than a year.
Accounts Receivables and Allowance for Doubtful Accounts:
Standard payment terms are typically 30 days after shipment but vary by type and geographic location of our customer. Credit is extended based upon an evaluation of the customer’s financial condition. In circumstances where we are aware of a customer’s inability to meet its financial obligations, an allowance is established. The remainder of the allowance established is based on a variety of factors, including the age of amounts outstanding relative to their contractual due date, historical
write-off
experience and current market assessments. Accounts receivable are stated at their estimated net realizable value.
Research and Development Costs:
We charge costs to expense in the period incurred, and these expenses are presented in the consolidated statement of income. The following costs are included in research and development expense: salaries and benefits, external engineering service costs, engineering related information costs and supplies.
Foreign Currency Translation:
The financial statements of foreign subsidiaries and branches are measured using the local currency as the functional currency. Foreign currency-denominated assets and liabilities are translated into U.S. dollars at
year-end
exchange rates with the translation adjustment recorded as a component of accumulated comprehensive income (loss) in shareholders’ equity. Revenues and expenses are translated at the average monthly exchange rates in effect during the related period. We do not provide for U.S. income taxes on foreign currency translation adjustments associated with our subsidiaries in Germany, Denmark and China since their undistributed earnings are considered to be permanently invested. Included in our consolidated statements of income was a net transactional foreign exchange gain of $0.6 million in fiscal 2021, and a net transaction foreign exchange loss of $0.4 million in fiscal 2020 and $0.7 million for fiscal 2019.
Advertising:
We
expense advertising costs as incurred. Advertising costs including advertising production, trade shows and other activities are designed to enhance demand for our products and amounted to approximately $0.9 million; $1.8 million and $1.9 million in fiscal 2021, 2020 and 2019, respectively.
Long-Lived Assets:
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, as determined by the discounting of future cash flows. There were no impairment charges for our long-lived assets in fiscal years 2021, 2020 or 2019.
Intangible Assets:
Intangible assets include the value of customer and distributor relationships, existing technology and
non-competition
agreements acquired in connection with business and asset acquisitions and are stated at cost (fair value at acquisition) less accumulated amortization. These intangible assets have a definite life and are amortized over the assets’ useful lives using a systematic and rational basis which is representative of the assets’ use. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. If necessary, an impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the asset. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. There were no impairment charges for our intangible assets in fiscal years 2021, 2020 or 2019.
Goodwill:
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate indicate that the carrying value of an asset might be
impaired. Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment, or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment are aggregated as a single reporting unit if they have similar economic characteristics. We determined that each of our operating segments (Product Identification and T&M) represents a reporting unit for purposes of goodwill impairment testing.
The accounting guidance related to goodwill impairment testing allows for the performance of an optional qualitative assessment of whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this qualitative assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. Additionally, we can elect to forgo the qualitative assessment and perform the quantitative test. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using a blended income and market approach. The income approach is based on a discounted cash flow model and provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. The market approach, compares the reporting unit to publicly traded companies and transactions involving similar business, and requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference. We performed a quantitative analysis of the reporting units as of January 31, 2021 and determined that the fair value was in excess of our carrying value and therefore, no goodwill impairment has occurred. See Note 3, “Goodwill,” for further details.
Leases:
On February 1, 2019 we adopted ASC 842, Leases. This guidance requires a lessee to recognize assets and liabilities on the balance sheet for all leases, with the result being the recognition of a right of use (ROU) asset and a lease liability. The lease liability is equal to the present value of the minimum lease payments for the term of the lease, including any optional renewal periods determined to be reasonably certain to be exercised, using a discount rate determined at lease commencement. This discount rate is the rate implicit in the lease, if known; otherwise, the incremental borrowing rate for the expected lease term is used. Our incremental borrowing rate approximates the rate we would have to pay to borrow on a collateralized basis over a similar term at lease inception. The value of the ROU asset is equal to the initial measurement of the lease liability plus any lease payments made to the lessor at or before the commencement date and any unamortized initial direct costs incurred by the lessee, less any unamortized lease incentives received. Several of our lease contracts include options to extend the lease term and we include the renewal options for these leases in the determination of the ROU asset and lease liability when the likelihood of renewal is determined to be reasonably certain.
We enter into lease contracts for certain of our facilities at various locations worldwide. At inception of a contract, we determine whether the contract is or contains a lease. If we have a right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the asset, then the contract contains a lease.
There are two types of leases, operating leases and finance leases. Lease classification is determined at lease commencement. We have made an accounting policy election to apply the short-term exception, which does not require the capitalization of leases with terms of 12 months or less. All of our leases are classified as operating leases. Operating lease expense is recognized on a straight-line basis over the lease term and included in general and administrative expense on the consolidated statement of income. ROU assets are classified in other long-term assets, short-term lease liabilities are classified in other current liabilities, and long-term lease liabilities are classified in other long-term liabilities in the consolidated balance sheet. In the statement of cash flow, payments for operating leases are classified as operating activities.
 
In addition, several of our lease agreements include
non-lease
components for items such as common area maintenance and utilities which are accounted for separately from the lease component.
 
Income Taxes:
We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and tax basis of the assets and liabilities and are measured using statutory tax rates that will be in effect when the differences are expected to reverse. Our deferred taxes are presented as
non-current
in the accompanying consolidated balance sheet. An allowance against deferred tax assets is recognized when it is
more-likely-than-not
that some portion or all of the deferred tax assets will not be realized. At January 31, 2021 and 2020, a valuation allowance was provided for deferred tax assets attributable to certain domestic R&D credit carryforwards. In addition, during fiscal 2021, we provided a valuation allowance for deferred tax assets attributable to foreign tax credit carryforwards which would expire unused.
We account for uncertain tax positions in accordance with the guidance provided in ASC 740, “Accounting for Income Taxes.” This guidance describes a recognition threshold and measurement attribute for the financial statement disclosure of tax positions taken or expected to be taken in a tax return and requires recognition of tax benefits that satisfy a
more-likely-than-not
threshold. ASC 740 also provides guidance on
de-recognition,
classification, interest and penalties, accounting in interim periods and disclosure.
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a
one-time
mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and, subsequent to year end, have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return.
Net Income Per Common Share:
Basic net income per share is based on the weighted average number of shares outstanding during the period. Diluted net income per share is based on the basic weighted average number of shares and potential common equivalent shares for stock options, restricted stock awards and restricted stock units outstanding during the period using the treasury stock method. In fiscal years 2021, 2020 and 2019, there were 642,623; 202,187 and 326,275, respectively, of common equivalent shares that were not included in the computation of diluted net income per common share because their inclusion would be anti-dilutive.
Fair Value Measurement:
We measure our financial assets at fair value on a recurring basis in accordance with the guidance provided in ASC 820, “Fair Value Measurement and Disclosures,” which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In addition, ASC 820 establishes a three-tiered hierarchy for inputs used in management’s determination of fair value of financial instruments that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect management’s belief about the assumptions market participants would use in pricing a financial instrument based on the best information available in the circumstances.
The fair value hierarchy is summarized as follows:
 
 
 
Level 1—Quoted prices in active markets for identical assets or liabilities;
 
 
 
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
 
 
 
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities
Cash and cash equivalents, accounts receivable, accounts payable, accrued compensation, other accrued expenses and income tax payable are reflected in the consolidated balance sheet at carrying value, which approximates fair value due to the short-term nature of these instruments.
Self-Insurance:
We are self-insured for U.S. medical and dental benefits for qualifying employees and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Assumptions are closely monitored and adjusted when warranted by changing circumstances. Our liability for self-insured claims is included within accrued compensation in our consolidated balance sheets and was $0.2 million and $0.6 million, as of January 31, 2021 and 2020.
Share-Based Compensation:
Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grant and has assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (RSA) and restricted stock units (RSU) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the grant date. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience.
Cash flow from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified with other income tax cash flows as an operating activity.
Share-based compensation becomes deductible for determining income taxes when the related award vests, is exercised, or is forfeited depending on the type of share-based award and subject to relevant tax law.
Derivative Financial Instruments:
We occasionally uses derivative instruments as part of its overall strategy to manage its exposure to market risks primarily associated with fluctuations in foreign currency exchange rates and interest rates. Derivative instruments are recognized as either assets or liabilities in the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the statement of income during the current period. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.
For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) (OCI) and reclassified into earnings in the same line item associated with the forecasted transaction, and in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest Expense” when the hedged transactions are interest cash flows associated with floating-rate debt, or “Other, Net” for portions reclassified relating to the remeasurement of the debt). The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any, are recognized in the statement of income during the current period.
Recent Accounting Pronouncements
Recently Adopted:
Fair Value Measurement
In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”)
2018-13,
“Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” ASU
2018-13
modifies the disclosure requirements for fair value measurements by removing, modifying or adding certain disclosures. The provisions of ASU
2018-13
relating to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. The remaining provisions should be applied retrospectively to all periods presented upon their effective date. We adopted the provisions of this guidance effective February 1, 2020. The adoption of this guidance did not have a material impact on our consolidated financial statements and accompanying disclosures.
Recent Accounting Standards Not Yet Adopted:
Income Taxes
In December 2019, the FASB issued an ASU
2019-12,
“Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU
2019-12
is effective for fiscal years beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are not electing to early adopt and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and accompanying disclosures.
No other new accounting pronouncements, issued or effective during fiscal 2021, have had or are expected to have a material impact on our consolidated financial statements.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition
12 Months Ended
Jan. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Note 2—Revenue Recognition
We derive revenue from the sale of (i) hardware including, digital color label printers and specialty OEM printing systems, portable data acquisition systems and airborne printers used in the flight deck and in the cabin of military, commercial and business aircraft, (ii) related consumable supplies including paper, labels, tags, inks, toners and ribbons, (iii) repairs and maintenance of equipment and (iv) service agreements.
Revenues disaggregated by primary geographic markets and major product types are as follows:
Primary geographical markets:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
United States
   $ 70,911      $ 83,671      $ 83,668  
Europe
     29,029        29,617        31,574  
Canada
     5,574        5,719        6,692  
Asia
     5,105        8,316        8,207  
Central and South America
     3,950        4,145        4,147  
Other
     1,464        1,978        2,369  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
Major product types:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
Hardware
   $ 34,111      $ 48,959      $ 53,207  
Supplies
     71,772        71,838        71,178  
Service and Other
     10,150        12,649        12,272  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
Contract Assets and Liabilities
We normally do not have contract assets, which are primarily unbilled accounts receivable that are conditional on something other than the passage of time.
Our contract liabilities, which represent billings in excess of revenue recognized, are related to advanced billings for purchased service agreements and extended warranties. Contract liabilities were $285,000 and $466,000 at January 31, 2021 and January 31, 2020, respectively, and are recorded as deferred revenue in the consolidated balance sheet. The decrease in the deferred revenue balance during the period ended January 31, 2021 is primarily due to $466,000 of revenue recognized during the period that was included in the deferred revenue balance at January 31, 2020 offset by cash payments received in advance of satisfying performance obligations.
Contract Costs
We have determined that certain costs related to obtaining sales contracts for our aerospace printer products meet the requirement to be capitalized. These costs are deferred and amortized based on the forecasted number of units sold over the estimated benefit term. The balance of these contract assets at January 31, 2020 was $944,000, of which $59,000 was reported in other current assets and $885,000 was reported in other assets in the consolidated balance sheet. Amortization of incremental direct costs was $26,940 for the period ended
January 31, 2021. The balance of the deferred incremental direct contract costs net of accumulated amortization at January 31, 202
1
is $
917,000
, of which $
36,000
was reported in other current assets and $
881,000
was reported in other assets in the consolidated balance sheet. The contract costs are expected to be amortized over the estimated remaining period of benefit, which we currently estimate to be approximately
5
 years.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill
12 Months Ended
Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill
Note 3—Goodwill
Goodwill by reporting unit is as follows:
 
(In thousands)
  
Product
Identification
 
 
T&M
 
  
Total
 
Balance at January 31, 2019
   $ 7,807     $ 4,522      $ 12,329  
Foreign currency translation
     (295     —          (295
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2020
   $ 7,512     $ 4,522      $ 12,034
Foreign currency translation
     772       —          772  
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2021
   $ 8,284     $ 4,522      $ 12,806  
  
 
 
   
 
 
    
 
 
 
 
After consideration of the impact of the decline in the global economy due to the COVID-19 pandemic, coupled with the grounding of the 737 MAX in March, 2019 and the production halt in January, 2020 which negatively impacted revenues and margins in fiscal 2020 and 2021, we elected to forgo the qualitative assessment and instead performed a quantitative goodwill impairment test to determine if the carrying values of the reporting units are greater than the fair values. We utilized a blended income and market approach. The income approach was based upon a discounted cash flow model which we believe provides a fair value estimate of the reporting unit’s expected long-term operating performance. The market approach compares the reporting units to similar publicly traded companies. Based on our quantitative impairment assessment as of January 31, 2021, we determined that the fair value of the reporting units were in excess of their carrying values and therefore, no goodwill impairment had occurred.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets
12 Months Ended
Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets
Note 4—Intangible Assets
Intangible assets are as follows:
 
   
January 31, 2021
   
January 31, 2020
 
(In thousands)
 
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
   
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
 
Miltope:
                                                               
Customer Contract Relationships
  $ 3,100     $ (2,284   $ —       $ 816     $ 3,100     $ (2,021   $ —       $ 1,079  
RITEC:
                                                               
Customer Contract Relationships
    2,830       (1,423     —         1,407       2,830       (1,076     —         1,754  
Non-Competition
Agreement
    950       (950     —         —         950       (871     —         79  
TrojanLabel:
                                                               
Existing Technology
    2,327       (1,405     196       1,118       2,327       (1,053     78       1,352  
Distributor Relations
    937       (396     89       630       937       (297     27       667  
Honeywell:
                                                               
Customer Contract Relationships
    27,243       (9,712     —         17,531       27,243       (6,791     —         20,452  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Intangible Assets, net
  $ 37,387     $ (16,170   $       285     $ 21,502     $ 37,387     $ (12,109   $       105     $ 25,383  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
There were no impairments to intangible assets during the periods ended January 31, 2021 and 2020. Amortization expense of $4.1 million; $4.2 million and $4.1 million with regard to acquired intangibles has been included in the consolidated statements of income for years ended January 31, 2021, 2020 and 2019, respectively.
Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
2022
 
  
2023
 
  
2024
 
  
2025
 
  
2026
 
Estimated amortization expense
   $ 3,938      $ 3,956      $ 4,055      $ 3,416      $ 3,021  
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories
12 Months Ended
Jan. 31, 2021
Inventory Disclosure [Abstract]  
Inventories
Note 5—Inventories
The components of inventories are as follows:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)              
Materials and Supplies
   $ 20,265      $ 20,151  
Work-in-Progress
     2,076        1,408  
Finished Goods
     16,371        17,992  
    
 
 
    
 
 
 
       38,712        39,551  
Inventory Reserve
     (8,652      (5,626
    
 
 
    
 
 
 
     $ 30,060      $ 33,925  
    
 
 
    
 
 
 
Finished goods inventory includes $4.0 million and $3.4 million of demonstration equipment at January 31, 2021 and 2020, respectively.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment
12 Months Ended
Jan. 31, 2021
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment
Note 6—Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
  
  
1,004     
967  
Buildings and Leasehold Improvements
     12,642        12,524  
Machinery and Equipment
     23,346        23,167  
Computer Equipment and Software
     13,847        11,388  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     50,839        48,046  
Accumulated Depreciation
     (38,828      (36,778
    
 
 
    
 
 
 
Net Property Plant and Equipment
  
12,011     
11,268  
    
 
 
    
 
 
 
Depreciation expense on property, plant and equipment was $1.9 million for the year ended January 31, 2021 and $2.0 million for both of the years ended January 31, 2020 and 2019.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses
12 Months Ended
Jan. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses
Note 7—Accrued Expenses
Accrued expenses consisted of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Warranty
   $ 730      $ 850  
Professional Fees
     546        697  
Lease Liability
     372        416  
Accrued Payroll & Sales Tax
     292        193  
Stockholder Relation Fees
     91        194  
Dealer Commissions
     57        236  
Other Accrued Expenses
     1,851        2,125  
    
 
 
    
 
 
 
     $ 3,939      $ 4,711  
    
 
 
    
 
 
 
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt
12 Months Ended
Jan. 31, 2021
Debt Disclosure [Abstract]  
Credit Agreement and Long- Term Debt
Note 8—Credit Agreement and Long-
 
Term Debt
Credit Agreement
On July 30, 2020, we entered into an Amended and Restated Credit Agreement (the “A&R Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), our wholly owned subsidiary, ANI ApS, a Danish private limited liability company and TrojanLabel ApS, a Danish private limited liability company and wholly-owned subsidiary of ANI ApS (“TrojanLabel”). The A&R Credit Agreement amended and restated the Credit Agreement dated as of February 28, 2017 (the “Prior Credit Agreement”) by and among us, ANI ApS, TrojanLabel and the Lender. In connection with the A&R Credit Agreement, we entered into an Amended and Restated Security and Pledge Agreement and a mortgage in favor of the Lender with respect to our owned real property in West Warwick, Rhode Island. Under the A&R Credit Agreement, AstroNova, Inc. is the sole borrower, and at January 31, 2021, its obligations are guaranteed by ANI ApS and TrojanLabel.
Immediately prior to the closing of the A&R Credit Agreement, we repaid $1.5 million in principal amount of term loans outstanding under the 
Prior
 
Credit Agreement.
The A&R Credit Agreement provides for (i) a term loan in the principal amount of $15.2 million, which we used to refinance the outstanding term loans borrowed by us and ANI ApS under the 
Prior
Credit Agreement
 
and a portion of the outstanding revolving loans borrowed by us under the
Pr
i
or
 Credit Agreement, and (ii) a $10.0 million revolving credit facility available to us for general corporate purposes. Revolving credit loans may be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
During the third quarter of fiscal year 2021, we repaid the entire outstanding balance under the revolving line of credit. Balances outstanding under the revolving line of credit during the year ended January 31, 2021 bore interest at a weighted average annual rate of 3.41%, and $188,000 of interest was incurred and is included in other income (expense) in the accompanying condensed consolidated income statement for the year ended January 31, 2021. At January 31, 2021, there was no balance outstanding under the revolving line of credit and $10.0 million was available for borrowing under the revolving credit facility.
The A&R Credit Agreement was accounted for as a debt modification in a
non-
troubled
debt restructuring. We incurred $0.2 million of new debt issuance costs related to the term loan, of which $0.1 million of new lender fees were recorded against the debt as debt issuance costs and will be amortized over the term of the loan and $0.1 million of third party fees that were expensed as incurred. Additionally, $0.1 million of unamortized debt issuance costs related to the prior term debt will be amortized over the remaining life of the new term loan. We also incurred $0.1 million of new debt issuance fees in connection with the revolving line of credit which are included as a component of prepaid expenses and other current assets and will be amortized over the remaining life of the A&R Credit Agreement.
Under the A&R Credit Agreement, the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about July 31, 2020 and October 31, 2020 was $0.8 million; the principal amount of the quarterly installment required to be paid on the last day of our fiscal quarter ending January 31, 2021 was $1.1 million; the principal amount of the quarterly installment required to be paid on the last day of the our fiscal quarter ending on or about April 30, 2021 will be $1.1 million; the principal amount of each quarterly installment required to be paid on the last day of each of the our fiscal quarters ending on or about July 31, 2021, October 31, 2021, January 31, 2022 and April 30, 2022 is $1.4 million, and the entire remaining principal balance of the term loan is required to be paid on June 15, 2022. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than June 15, 2022, and any outstanding revolving loans thereunder will be due and payable in full, and the revolving credit facility will terminate, on such date. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
Under the A&R Credit Agreement the term loan and revolving credit loans bear interest at a rate per annum equal to, at the our option, either (a) the LIBOR Rate (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 2.15% to 3.65% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 1.00%, plus a margin that varies within a range of 1.15% to 2.65% based on our consolidated leverage ratio. We are also required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.25% and 0.675% based on our consolidated leverage ratio.
The loans under the A&R Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the A&R Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
Under the A&R Credit Agreement, we must comply with various customary financial and
non-financial
covenants including a maximum consolidated leverage ratio, a minimum consolidated fixed charge coverage ratio, a minimum level of EBITDA, a consolidated asset coverage ratio and a minimum level of liquidity. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on capital stock, to repurchase or acquire capital stock, to conduct mergers or acquisitions, to sell assets, to alter the capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the A&R Credit Agreement.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the A&R Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or our undergoing a change of control.
In addition to the guarantees by ANI ApS and TrojanLabel, our obligations under the A&R Credit Agreement are also secured by substantially all of AstroNova, Inc.’s personal property assets (including a pledge of the equity interests it holds in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island.
Long-Term Debt
Long-term debt in the accompanying condensed consolidated balance sheets under the A&R Credit Agreement is as follows:
 
 
  
January 31
 
(In thousands)
  
2021
 
  
2020
 
USD Term Loan (4.65% as of January 31, 2021); maturity date of June 15, 2022
   $ 12,576      $ —    
USD Term Loan (3.03% as of January 31, 2021); maturity date November 30, 2022
     —          8,250  
USD Term Loan (3.03% as of January 31, 2021); maturity date of January 31, 2022
     —          4,784  
    
 
 
    
 
 
 
       12,576        13,034  
Debt Issuance Costs, net of accumulated amortization
     (141      (111
Current Portion of Term Loan
     (5,326      (5,208
    
 
 
    
 
 
 
Long-Term Debt
   $ 7,109      $ 7,715  
    
 
 
    
 
 
 
During the years ended January 31, 2021, 2020 and 2019, we recognized $0.5 million, $0.4 million and $0.6 million of interest expense, respectively, which was included in other income (expense) in the accompanying consolidated income statement.
The schedule of required principal payments remaining under the A&R Credit Agreement on long-term debt outstanding as of January 31, 2021 is as follows:
 
(In thousands)
  
 
 
Fiscal 2022
   $ 5,326  
Fiscal 2023
     7,250  
    
 
 
 
     $ 12,576  
    
 
 
 
Refer to Note 23, “Subsequent Event” for details regarding the First Amendment to Credit Agreement to our A&R Credit Agreement, which was entered into subsequent to year end on March 24, 2021.
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Paycheck Protection Program Loan
12 Months Ended
Jan. 31, 2021
Debt Disclosure [Abstract]  
Paycheck Protection Program Loan
Note 9—Paycheck Protection Program Loan
On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”) from Greenwood pursuant to the Paycheck Protection Program (“PPP”) administered by the United States Small Business Administration (the “SBA”) and authorized by the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), enacted on March 27, 2020. The terms of the PPP Loan were subsequently revised in accordance with the provisions of the Paycheck Protection Flexibility Act of 2020 (the “PPP Flexibility Act”) which was enacted on June 5, 2020.
The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date, and is payable monthly. No payments are due on the PPP Loan until the date on which the SBA determines the amount of the PPP Loan that is eligible for forgiveness, so long as we apply for forgiveness within the ten months from the end of the twenty-four week period following the date of loan disbursement, but interest will continue to accrue during the deferral period. We accrued interest for the PPP Loan in the amount of $33,000, which is included in other income (expense) in the accompanying consolidated statements of income for the year ended January 31, 2021.
The PPP Loan may be prepaid at any time without penalty. The loan agreement and promissory note include customary provisions for a loan of this type, including prohibitions on our payment of dividends or repurchase of
 
shares of our stock while the PPP Loan remains outstanding. The loan agreement and promissory note also include events of default relating to, among other things, payment defaults, breaches of the provisions of the loan agreement or the promissory note, and cross-defaults on other loans.
Subject to the limitations and conditions set forth in the CARES Act, the PPP Flexibility Act, and the regulations and guidance provided by the SBA with respect to the PPP, a portion of the PPP Loan may be forgiven in an amount up to the amount of the PPP Loan proceeds that we spent on payroll, rent, utilities and interest on certain debt during the twenty-four-week period following incurrence of the PPP Loan. Interest accrued on the forgiven portion of the principal amount of the PPP Loan is also forgiven. The amount of the PPP Loan to be forgiven in respect of rent, utilities and interest on certain debt will be capped at 40% of the forgiven amount, with the remaining forgiven amount allocated to payroll costs. We have fully utilized the PPP Loan proceeds for qualifying expenses during fiscal year 2021 and subsequent to year end we applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Whether our application for forgiveness will be granted and in what amount is subject to approval by the SBA and may also be subject to further requirements in any regulations and guidelines the SBA may adopt. The PPP Loan is classified as long-term debt in the condensed consolidated balance sheet until the forgiveness determination has been made by the SBA.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Derivative Financial Instruments and Risk Management
12 Months Ended
Jan. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivative Financial Instruments and Risk Management
Note 10—Derivative Financial Instruments and Risk Management
On February 28, 2017, as part of the Prior Credit Agreement, we entered into a cross-currency interest rate swap to manage the interest rate risk and foreign currency exchange risk associated with the floating-rate foreign currency-denominated term loan borrowing by ANI ApS and an interest rate swap to manage the interest rate risk associated with our variable rate term loan borrowing (the “Swaps”). Both Swaps were designated as cash flow hedges of floating-rate borrowings.
Our cross-currency interest rate swap agreement effectively modified our exposure to interest rate risk and foreign currency exchange rate risk by converting our floating-rate debt denominated in U.S. Dollars on ANI ApS’s books to a fixed-rate debt denominated in Danish Kroner for the term of the loan, thus reducing the impact of interest-rate and foreign currency exchange rate changes on future interest expense and principal repayments. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed-rate interest payments in Danish Kroner, as well as exchanges of principal at the inception spot rate, over the life of the term loan.
Subsequently, concurrent with our borrowings to fund the payments for the Asset Purchase and License Agreement with Honeywell International, we entered into an interest rate swap agreement to modify our exposure to interest rate risk by effectively converting our floating-rate borrowings to fixed-rate debt over the term of the loan, thus reducing the impact of interest-rate changes on future interest expense. This swap involved the receipt of floating interest rate amounts in U.S. Dollars in exchange for fixed interest rate payments in U.S. dollars over the life of the term loan.
As a direct result of the terms of the Lender’s conditions for entry into the A&R Credit Agreement, on July 30, 2020, we terminated the two Swaps that we used to manage the interest rate and foreign currency exchange risks associated with our prior borrowings under the
Prior
Credit Agreement. The terms of the A&R Credit Agreement caused those swaps to cease to be effective hedges of the underlying exposures. The termination of the Swaps was contracted immediately prior to the end of the second quarter of fiscal 2021 at a cash cost of approximately $0.7 million, which was settled in the third quarter. Upon termination, the remaining balance of $58,000 in accumulated other comprehensive loss related to the cross-currency interest rate swap was reclassified into earnings as the forecasted foreign currency interest payments will not occur and such balance is included in other expense in the accompanying consolidated statements of income for the period ended January 31, 2021. The remaining balance in accumulated other comprehensive loss related to the interest rate swap of $ 0.1 million is being amortized into earnings through the original term of the hedge relationship as the underlying floating interest rate debt still exists.
The following table summarizes the notional amount and fair value of our derivative instruments:
 
Cash Flow Hedges
(In thousands)
  
January 31, 2021
 
  
January 31, 2020
 
  
Notional Amount
 
  
Fair Value Derivatives
 
  
Notional Amount
 
  
Fair Value Derivatives
 
 
  
Asset
 
  
Liability
 
  
Asset
 
  
Liability
 
Cross-currency Interest Rate Swap
   $      $      $      $ 4,489      $      $ 250  
Interest Rate Swap
   $      $      $      $ 8,250      $      $ 96  
The following tables present the impact of the derivative instruments in our consolidated financial statements for the years ended January 31, 2021 and 2020:
 
 
  
Years Ended
 
Cash Flow Hedge
(In thousands)
  
Amount of Gain(Loss)
Recognized in OCI
on
Derivative
 
  
Location of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
January 31,
2021
 
 
January 31,
2020
 
  
January 31,
2021
 
 
January 31,
2020
 
Swap contracts
   $ (301   $ 159        Other Income      $ (248   $ 338  
    
 
 
   
 
 
             
 
 
   
 
 
 
At January 31, 2021, we expect to reclassify approximately $0.1 million of net gains on the swap contracts from accumulated other comprehensive loss to earnings during the next 12 months due to changes in foreign exchange rates and the payment of variable interest associated with the floating-rate debt.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Royalty Obligation
12 Months Ended
Jan. 31, 2021
Royalty Obligation Disclosure [Abstract]  
Royalty Obligation
Note 11—Royalty Obligation
In fiscal 2018, AstroNova, Inc. entered into an Asset Purchase and License Agreement with Honeywell International, Inc. to acquire an exclusive, perpetual, world-wide license to manufacture Honeywell’s narrow-format flight deck printers for two aircraft families along with certain inventory used in the manufacturing of the licensed printers. The purchase price included a guaranteed minimum royalty payment of $15.0 million, to be paid in quarterly installments over a
ten-year
period. Royalty payments are based on gross revenues from the sales of the printers, paper and repair services of the licensed products. The royalty rates vary based on the year in which they are paid or earned and product sold or service provided, and range from single-digit to mid double-digit percentages of gross revenue.
The guaranteed minimum royalty payment obligation was recorded at the present value of the minimum annual royalty payments using a present value factor of 2.8%, which is based on the estimated
after-tax
cost of debt for similar companies. As of January 31, 2021, we had paid an aggregate of $5.5 million of the guaranteed minimum royalty obligation. At January 31, 2021, the current portion of the outstanding guaranteed minimum royalty obligation of $2.0 million is to be paid over the next twelve months and is reported as a current liability and the remainder of $6.1 million is reported as a long-term liability on our consolidated balance sheet. In addition to the guaranteed minimum royalty payments, for the periods ended January 31, 2021 and January 31, 2020, we also incurred excess royalty expense of $31 thousand and $1.2 million, respectively, which is included in cost of revenue in our consolidated statements of income. A total of $0.2 million of excess royalty is payable and reported as a current liability on our consolidated balance sheet at January 31, 2021.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
12 Months Ended
Jan. 31, 2021
Leases [Abstract]  
Leases
Note 12—Leases
We enter into lease contracts for certain of its facilities at various locations worldwide. Our leases have remaining lease terms of one to eight years, some of which include options to extend the lease term for periods of up to five years when it is reasonably certain the Company will exercise such options.
We lease office space from an affiliate. This lease is classified as an operating lease with annual rental payments of $63,000 for both January 31, 2021 and January 31, 2020.
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
  
January 31,
2021
    
January 31,
2020
 
Lease Assets
   Right of Use Assets   
$
1,389
 
 
$ 1,661  
Lease Liabilities
Current
   Other Accrued Expenses   
 
372
 
 
  416  
Lease Liabilities
Long Term
   Lease Liabilities   
$
1,065
 
 
$ 1,279  
Lease cost information is as follows:
 
Operating Leases
(In thousands)
  
Statement of Income Classification
    
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Operating Lease Costs
       General and Administrative Expense        $ 485      $ 449  
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
January 31,
2021
 
2022
   $ 372  
2023
     318  
2024
     292  
2025
     184  
2026
     163  
Thereafter
     270  
    
 
 
 
Total Lease Payments
     1,599  
Less: Imputed Interest
     (162
    
 
 
 
Total Lease Liabilities
   $ 1,437  
    
 
 
 
As of January 31, 2021, the weighted-average remaining lease term and weighted-average discount rate for our operating leases are 5.2 years and 4.00%, respectively. We calculated the weighted-average discount rate using incremental borrowing rates, which equal the rates of interest that we would pay to borrow funds on a fully collateralized basis over a similar term.
Supplemental cash flow information related to leases is as follows:
 
(In thousands)
  
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Cash paid for operating lease liabilities
   $ 429      $ 406  
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive Loss
12 Months Ended
Jan. 31, 2021
Equity [Abstract]  
Accumulated Other Comprehensive Loss
Note 13—Accumulated Other Comprehensive Income (Loss)
The changes in the balance of accumulated other comprehensive income (loss) by component are as follows:
 
(In thousands)   
Foreign Currency
Translation
Adjustments
   
Unrealized
Holding
Gain (Loss)
on Available
for Sale
Securities
   
Net
Unrealized
Gain (Losses)
on Cash Flow
Hedges
   
Total
 
Balance at January 31, 2018
   $ (181   $ (3   $ 12     $ (172
Other Comprehensive Income (Loss) before reclassification
     (671     —         622       (49
Amounts reclassified from AOCI to Earnings
     —         3       (600     (597
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (671     3       22       (646
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2019
   $ (852   $ —       $ 34     $ (818
Other Comprehensive Income (Loss) before reclassification
     (133     —         122       (11
Amounts reclassified from AOCI to Earnings
     —         —         (264     (264
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (133     —         (142     (275
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2020
   $ (985   $ —       $ (108   $ (1,093
Other Comprehensive Income (Loss) before reclassification
     710       —         (239     471  
Amounts Reclassified from AOCI to Earnings
     —         —         193       193  
Cross-Currency Interest Rate Swap Termination
     —         —         45       45  
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     710       —         (1     709  
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2021
   $ (275   $ —       $ (109   $ (384
    
 
 
   
 
 
   
 
 
   
 
 
 
The amounts presented above in other comprehensive income (loss) are net of taxes except for translation adjustments associated with our German and Danish subsidiaries.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity
12 Months Ended
Jan. 31, 2021
Federal Home Loan Banks [Abstract]  
Shareholders' Equity
Note 14—Shareholders’ Equity
During fiscal 2021, 2020 and 2019, certain of our employees delivered a total of 15,357, 20,329 and 33,430 shares, respectively, of our common stock to satisfy the exercise price and related taxes for stock options exercised and restricted stock vesting. The shares delivered were valued at a total of $0.1 million; $0.5 million and $0.6 million, respectively, and are included in treasury stock in the accompanying consolidated balance sheets at January 31, 2021, 2020 and 2019. These transactions did not impact the number of shares authorized for repurchase under our current repurchase program.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation
12 Months Ended
Jan. 31, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
Note 15—Share-Based Compensation
The Company maintains the following share-based compensation plans:
Stock Plans:
We have one equity incentive plan from which we are authorized to grant equity awards, the AstroNova, Inc. 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provides for, among other things, the issuance of awards, including incentive stock options,
non-qualified
stock options, stock appreciation rights, time-based restricted stock units (“RSUs”), or performance-based restricted stock units (“PSUs”) and restricted stock awards (RSAs). The 2018 Plan authorizes the issuance of up to 950,000 shares of common stock, plus an additional number of shares equal to the number of shares subject to awards granted under the previous equity incentive plans that are forfeited, cancelled, satisfied without the issuance of stock, otherwise terminated (other than by exercise), or, for shares of stock issued pursuant to any unvested award, that are reacquired by us at not more
than the grantee’s purchase price (other than by exercise). Under the 2018 Plan, all awards to employees generally have a minimum vesting period of one year. Options granted under the 2018 Plan must be issued at an exercise price of not less than the fair market value of our common stock on the date of grant and expire after ten years. Under the 2018 Plan, 186,500 unvested shares of restricted stock and options to purchase an aggregate of 135,500 shares were outstanding as of January 31, 2021.
In addition to the 2018 Plan, we previously granted equity awards under our 2015 Equity Incentive Plan (the “2015 Plan”) and our 2007 Equity Incentive Plan (the “2007 Plan”). No new awards may be issued under either the 2007 or 2015 Plans, but outstanding awards will continue to be governed by those plans. As of January 31, 2021, options to purchase an aggregate of 337,958 shares were outstanding under the 2007 Plan and 10,833 unvested shares of restricted stock and options to purchase an aggregate of 148,625 shares were outstanding under the 2015 Plan.
We also have a
Non-Employee
Director Annual Compensation Program (the “Program”), under which each of our
non-employee
directors automatically receives a grant of restricted stock on the date of their
re-election
to our board of directors. The number of whole shares granted is equal to the number calculated by dividing the stock component of the director compensation amount determined by the compensation committee for that year by the fair market value of our stock on that day. The value of the restricted stock award for fiscal 2021 was $60,000. Shares of restricted stock granted under the Program become vested on the first anniversary of the date of grant, conditioned upon the recipient’s continued service on our board of directors through that date.
Share-Based Compensation:
Share-based compensation expense has been recognized as follows:
 
 
 
Years Ended January 31
 
 
 
    2021    
 
  
    2020    
 
  
    2019    
 
(In thousands)
 
 
 
  
 
 
  
 
 
Stock Options
   $ 517      $ 616      $ 783  
Restricted Stock Awards and Restricted Stock Units
     1,285        1,136        1,088  
Employee Stock Purchase Plan
     17        23        15  
    
 
 
    
 
 
    
 
 
 
Total
   $ 1,819      $ 1,775      $ 1,886  
    
 
 
    
 
 
    
 
 
 
Stock Options:
Aggregated information regarding stock options granted under the plans is summarized below:
 
    
Number
of Shares
   
Weighted-
Average
Exercise
Price Per
Share
 
Options Outstanding, January 31, 2018
     745,270     $ 12.52  
Options Granted
     196,000       18.21  
Options Exercised
     (150,125     10.62  
Options Forfeited
     (16,300     15.10  
Options Cancelled
     (3,700     8.95  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2019
     771,145     $ 14.30  
Options Granted
     —         —    
Options Exercised
     (57,175     11.60  
Options Forfeited
     (34,526     15.73  
Options Cancelled
     (400     6.22  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2020
     679,044     $ 14.46  
Options Granted
     —         —    
Options Exercised
     (1,200     7.60  
Options Forfeited
     (54,361     12.89  
Options Cancelled
     (1,400     7.36  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2021
     622,083     $ 14.63  
    
 
 
   
 
 
 
Set forth below is a summary of options outstanding at January 31, 2021:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
     41,044      $ 7.97        1.3        41,044      $ 7.97        1.3  
$10.01-15.00
     359,314        13.63        4.9        326,741        13.65        4.7  
$15.01-20.00
     221,725        17.48            6.8        167,367        17.22        6.7  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       622,083      $ 14.63            5.3        535,152      $ 14.33        5.1  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
No options were granted during fiscal 2021 or
fis
cal
2020. The weighted-average estimated fair value of options granted during fiscal 2019 was $7.43. As of January 31, 2021, there was $0.2 million of unrecognized compensation expense related to the unvested stock options granted under the plans. This expense is expected to be recognized over a weighted-average period of 0.8 years.
As of January 31, 2021, the aggregate intrinsic value (the aggregate difference between the closing stock price of our common stock on January 31, 2021, and the exercise price of the outstanding options) that would have been received by the option holders if all options had been exercised was $0.1 million for all exercisable options and $0.1 million for all options outstanding. The total aggregate intrinsic value of options exercised during 2021, 2020 and 2019 was $4,000, $0.5 million and $1.1 million, respectively.
Restricted Stock Units (RSUs) and Restricted Stock Awards (RSAs):
Aggregated information regarding RSUs and RSAs granted under the Plan is summarized below:
 
 
  
RSAs & RSUs
 
  
Weighted-Average
Grant Date Fair Value
 
Outstanding at January 31, 2018
  
 
177,347
 
  
$
13.99
 
Granted
  
 
108,790
 
  
 
17.85
 
Vested
  
 
(67,447
  
 
14.26
 
Forfeited
  
 
(85,023
  
 
14.17
 
 
  
 
 
 
  
 
 
 
Outstanding at January 31, 2019
     133,667      $ 16.90  
Granted
     119,522        19.86  
Vested
     (59,930      14.50  
Forfeited
     (58,625      19.00  
    
 
 
    
 
 
 
Outstanding at January 31, 2020
     134,634      $ 16.79  
    
 
 
    
 
 
 
Granted
     245,131        7.61  
Vested
     (64,997      17.28  
Forfeited
     (117,355      8.83  
    
 
 
    
 
 
 
Outstanding at January 31, 2021
     197,413      $ 9.96  
    
 
 
    
 
 
 
As of January 31, 2021, there was $1.1 million of unrecognized compensation expense related to unvested RSUs and RSAs. This expense is expected to be recognized over a weighted average period of 0.8 years.
Employee Stock Purchase Plan (ESPP):
Our
 ESPP allows eligible employees to purchase shares of common stock at a 15% discount from fair market value on the date of purchase. A total of 247,500 shares were initially reserved for issuance under this plan. Summarized plan activity is as follows:
 
    
Years Ended January 31
 
    
    2021    
    
    2020    
    
    2019    
 
Shares Reserved, Beginning
     24,974        33,853        39,207  
Shares Purchased
     (14,600      (8,879      (5,354
    
 
 
    
 
 
    
 
 
 
Shares Reserved, Ending
     10,374        24,974        33,853  
    
 
 
    
 
 
    
 
 
 
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
12 Months Ended
Jan. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes
Note 16—Income Taxes
The components of income (loss) before income taxes are as follows:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Domestic
   $ (1,193   $ 1,930     $ 6,859  
Foreign
     3,372       (560     449  
    
 
 
   
 
 
   
 
 
 
     $ 2,179     $ 1,370     $ 7,308  
    
 
 
   
 
 
   
 
 
 
The components of the provision/(benefit) for income taxes are as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Current:
  
     
 
     
 
     
Federal
   $ 1,272      $ 660      $ 1,807  
State
     224        221        457  
Foreign
     420        368        952  
    
 
 
    
 
 
    
 
 
 
     1,916        1,249        3,216
 
    
 
 
    
 
 
    
 
 
 
 
Deferred:
                        
Federal
   $ (910   $ (1,364   $ (843
State
     (189     (282     (170
Foreign
     78       8       (625
    
 
 
   
 
 
   
 
 
 
       (1,021     (1,638     (1,638
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Total income tax provision/(benefit)
 
differs from the expected tax provision/(benefit) as a result of the following:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Income Tax Provision at Statutory Rate
   $ 458     $ 288     $ 1,534  
Denmark Statutory Audit
     341       —         —    
Foreign Rate Deferential
     197       315       558  
Share Based Compensation
     171       (145     (127
Canada Withholding Taxes
     62       —         —    
State Taxes, Net of Federal Tax Effect
     28       (48     226  
Global Intangible Low Taxed Incom
e
     14       107       —    
Meals and Entertainment
     11       31       56  
U.S. Corporate Rate Change
     —         —         52  
Transition Tax on Repatriated Earnings
     —         —         14  
Return to Provision Adjustment
     (2     (207     58  
Change in Reserves Related to ASC 740 Liability
     (10     (352     (34
Change in Valuation Allowance
     (81     256       —    
R&D Credits
     (157     (209     (218
Foreign Derived Intangible Income
     (150     (107     (53
Foreign Tax Credits
     —         (344     (477
Other
     13       26       (11
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Our effective tax rate for 2021 was 41.1% compared to negative 28.4% in 2020 and 21.6% in 2019. The increase in the effective tax rate in 2021 from 2020 is primarily related to the change in mix of income between relevant jurisdictions in which
 
we
are
subject to income taxes. Specific items increasing the effective tax rate include foreign rate differential, Denmark statutory audit adjustments, stock-based compensation, and Canada withholding taxes. This increase was offset by the foreign derived intangible income (“FDII”) deduction, the release of a valuation allowance in China, and R&D tax credits expected to be utilized.
The decrease in the effective tax rate in 2020 from 2019 is primarily related to lower
pre-tax
income in 2020 compared to 2019.. Specific items decreasing the effective tax rate include FDII, the release of ASC 740 liabilities, R&D credit utilization, and return to provision adjustments. This decrease was offset by valuation
allowances recorded on unbenefited losses in China and on carryforward foreign tax credits expected to expire unused.
The components of deferred income tax expense arise from various temporary differences and relate to items included in the statement of income. The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities are as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
(In thousands)
  
 
 
 
 
 
Deferred Tax Assets:
  
     
 
     
Inventory
   $ 2,700     $ 2,094  
Honeywell Royalty Liability
     2,590       2,583  
State R&D Credits
     1,546       1,496  
Share-Based Compensation
     600       582  
Bad Debt
     245       165  
Warranty Reserve
     176       205  
Compensation Accrual
     159       159  
Net Operating Loss
     154       443  
ASU 842 Adjustment—Lease Liability
     125       —    
Unrecognized State Tax Benefits
     101       116  
Foreign Tax Credit
     83       113  
Deferred Service Contract Revenue
     68       111  
Other
     308       295  
    
 
 
   
 
 
 
       8,855       8,362  
Deferred Tax Liabilities:
                
Accumulated Tax Depreciation in Excess of Book Depreciation
     752       1,002  
Intangibles
     399       776  
ASU 842 Adjustment – Lease Liability
     119       —    
Other
     307       188  
    
 
 
   
 
 
 
       1,577       1,966  
    
 
 
   
 
 
 
Subtotal
     7,278       6,396  
Valuation Allowance
     (1,721     (1,752
    
 
 
   
 
 
 
Net Deferred Tax Assets
   $ 5,557     $ 4,644  
    
 
 
   
 
 
 
The valuation allowance of $1.7 million at January 31, 2021 relate
s
to domestic research and development tax credit carryforwards and foreign tax credit carryforwards which are expected to expire unused. The valuation allowance of $1.8 million at January 31, 2020 included a valuation allowance on China net operating losses, which was released during 2021.    
At January 31, 2021, we had net operating loss carryforwards of $0.4 million in China, which expire in 2022 through 2026. We have net operating loss carryforwards of $0.2 million in Germany, which can be carried forward indefinitely. We expect to utilize the net operating loss carryforwards in China and Germany before expiration.
At January 31, 2021, we had state research credit carryforwards of approximately $1.5 million which expire in 2021 through 2028. We maintain a full valuation allowance against these credits as we expect these credits to expire unused.
We believe that it is reasonably possible that some unrecognized tax benefits, accrued interest and penalties could decrease income tax expense in the next year due to either the review of previously filed tax returns or the expiration of certain statutes of limitation. The changes in the balances of unrecognized tax benefits, excluding interest and penalties are as
follows:
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance at February 1
  
$
362
 
 
$
618
 
 
$
665
 
Increases in prior period tax position
s
  
 
59
 
 
 
—  
 
 
 
—  
 
Increases in current period tax positions
  
 
5
 
 
 
2
 
 
 
7
 
Reductions related to lapse of statutes of limitations
  
 
(42
 
 
(26
 
 
(54
Reductions related to settlement with tax authorities
  
 
—  
 
 
 
(232
 
 
—  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Balance at January 31
  
$
384
 
 
$
362
 
 
$
618
 
 
  
 
 
 
 
 
 
 
 
 
 
 
During fiscal 2021 and 2020, we released $50,000 and $114,000, respectively, of accrued interest and penalties relating to a change in various unrecognized tax positions. During fiscal 2019, we recognized $8,000 of expense related to a change in interest and penalties, which are included as a component of income tax expense in the accompanying statements of income for the period ended January 31, 2019. The Company has accrued potential interest and penalties of $0.3 million included in Income Taxes Payable in the consolidated balance sheet at the end of both January 31, 2021 and 2020.
The Company and its subsidiaries file income tax returns in U.S. federal jurisdictions, various state jurisdictions, and various foreign jurisdictions. The Company was previously under audit by the IRS for the tax years ended January 31, 2015, 2016, and 2017, but on June 6, 2019, we received formal communication regarding the close of the audit with no additional changes made by the IRS. Therefore, the reserves for federal uncertain tax positions relating to the years in question have been released. In fiscal 2020, we released $232,000 relating to the federal tax exposure for the years previously under audit and $74,000 of related interest (net of federal benefit) and penalties.
The Company was also notified of an income tax audit from the state of Rhode Island, but no significant items have been raised at this time other than information requests. No assessments have been made as of January 31, 2021.
U.S. income taxes have not been provided on $5.7 million of undistributed earnings of our foreign subsidiaries since it is our intention to permanently reinvest such earnings offshore. If the earnings were distributed in the form of dividends, the Company would not be subject to U.S. tax as a result of the Tax Act but could be subject to foreign income and withholding taxes. Determination of the amount of this unrecognized deferred income tax liability is not practical.
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information
12 Months Ended
Jan. 31, 2021
Segment Reporting [Abstract]  
Nature of Operations, Segment Reporting and Geographical Information
Note 17—Nature of Operations, Segment Reporting and Geographical Information
Our operations consist of the design, development, manufacture and sale of specialty printers and data acquisition and analysis systems, including both hardware and software and related consumable supplies. We organize and manage our business as a portfolio of products and services designed around a common theme of data acquisition and information output. We have two reporting segments consistent with our revenue product groups: Product Identification (“PI”) and Test & Measurement (“T&M”).
Our PI segment produces an array of high-technology digital color and monochrome label printers and mini presses, labeling software and supplies for a variety of commercial industries worldwide. AstroNova’s T&M segment produces data acquisition systems used worldwide for a variety of recording, monitoring and troubleshooting applications for many industries including aerospace, automotive, defense, rail, energy, industrial and general manufacturing. The T&M segment also includes our line of aerospace flight deck and cabin printers.
Business is conducted in the United States and through foreign branch offices and subsidiaries in Canada, Europe, China, Southeast Asia and Mexico. Manufacturing activities are primarily conducted in the United States. Revenue and service activities outside the United States are conducted through wholly-owned entities and, to a lesser extent, through authorized distributors and agents. Transfer prices are intended to produce gross profit margins as would be associated with an arms-length transaction.
The accounting policies of the reporting segments are the same as those described in the summary of significant accounting policies herein. We evaluate segment performance based on the segment profit before corporate and financial administration expenses.
Summarized below are the revenue and segment operating profit (loss) (both in dollars and as a percentage of revenue) for each reporting segment:
 
($ in thousands)
 
Revenue
 
 
Segment Operating Profit (Loss)
 
 
Segment Operating Profit (Loss)
as a % of Revenue
 
 
 
2021
 
 
2020
 
 
2019
 
 
    2021    
 
 
    2020    
 
 
    2019    
 
 
  2021  
 
 
  2019  
 
 
  2018  
 
Product Identification
  $ 90,268     $ 88,116     $ 86,786     $ 12,885     $ 7,509     $ 7,910       14.3     8.5     9.1
T&M
    25,765       45,330       49,871       (1,032     6,281       11,933       (4.0 )%      13.9     23.9
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total
  $ 116,033     $ 133,446     $ 136,657       11,853       13,790       19,843       (10.3 )%      10.3     14.5
   
 
 
   
 
 
   
 
 
                           
 
 
   
 
 
   
 
 
 
Corporate Expenses
                            9,420       11,357       11,123                          
                           
 
 
   
 
 
   
 
 
                         
Operating Income
                            2,433       2,433       8,720                          
Other Expense, Net
                            (254     (1,063     (1,412                        
                           
 
 
   
 
 
   
 
 
                         
Income Before Income Taxes
                            2,179       1,370       7,308                          
Income Tax Provision (Benefit)
                            895       (389     1,578                          
                           
 
 
   
 
 
   
 
 
                         
Net Income
                          $ 1,284     $ 1,759     $ 5,730                          
                           
 
 
   
 
 
   
 
 
                         
No customer accounted for greater than 10% of net revenue in fiscal 2021, 2020 or 2019.
Other information by segment is presented below:
 
(In thousands)
  
Assets
 
 
  
2021
 
  
2020
 
Product Identification
   $ 50,047      $ 51,439  
T&M
     51,262        57,050  
Corporate*
     14,164        8,175  
    
 
 
    
 
 
 
Total
   $ 115,473      $ 116,664  
    
 
 
    
 
 
 
 
*
Corporate assets consist principally of cash, cash equivalents, deferred tax assets and refunds, and certain prepaid corporate assets.
 
(In thousands)   
Depreciation and
Amortization
    
Capital Expenditures
 
    
2021
    
2020
    
2019
    
2021
    
2020
    
2019
 
Product Identification
   $ 1,835      $ 1,928      $ 1,888      $ 1,563      $ 2,001      $ 1,935  
T&M
     4,148        4,356        4,264        1,024        905        710  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 5,983      $ 6,284      $ 6,152      $ 2,587      $ 2,906      $ 2,645  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Geographical Data
Presented below is selected financial information by geographic area:
 
(In thousands)
  
Revenue
 
  
Long-Lived Assets*
 
 
  
2021
 
  
2020
 
  
2019
 
  
2021
 
  
2020
 
United States
   $ 70,911      $ 83,671      $ 83,668      $ 31,226      $ 34,072  
Europe
     29,029        29,617        31,574        2,274        2,544  
Canada
     5,574        5,719        6,692        13        35  
Asia
     5,105        8,316        8,207        —          —    
Central and South America
     3,950        4,145        4,147        —          —    
Other
     1,464        1,978        2,369        —          —    
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 116,033      $ 133,446      $ 136,657      $ 33,513      $ 36,651  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
*
Long-lived assets exclude goodwill assigned to the T&M segment of $4.5 million at both January 31, 2021 and 2020 and $8.3 million and $7.5 million assigned to the PI segment at January 31, 2021 and 2020, respectively.
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefit Plans
12 Months Ended
Jan. 31, 2021
Postemployment Benefits [Abstract]  
Employee Benefit Plans
Note 18—Employee Benefit Plans
We sponsor a Profit-Sharing Plan (the “Plan”) which provides retirement benefits to all eligible domestic employees. The Plan allows participants to defer a portion of their cash compensation and contribute such deferral to the Plan through payroll deductions. The Company makes matching contributions up to specified levels. The deferrals are made within the limits prescribed by Section 401(k) of the Internal Revenue Code.
All contributions are deposited into trust funds. It
 is
our
 policy
to fund any
contributions accrued. Our annual contribution amounts are determined by the Board of Directors. Contributions paid or accrued amounted to $0.4 million in fiscal 2021 and $0.5 million in both fiscal 2020 and 2019.
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Product Warranty Liability
12 Months Ended
Jan. 31, 2021
Guarantees and Product Warranties [Abstract]  
Product Warranty Liability Note 19—Product Warranty Liability
We offer a manufacturer’s warranty for the majority of our hardware products. The specific terms and conditions of warranty vary depending upon the products sold and country in which we do business. We estimate the warranty costs based on historical claims experience and record a liability in the amount of such estimates at the time product revenue is recognized. We regularly assess the adequacy of our recorded warranty liabilities and adjusts the amounts as necessary. Activity in the product warranty liability, which is included in other accrued expenses in the accompanying consolidated balance sheet, is as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance, beginning of the year
   $ 850     $ 832     $ 575  
Provision for Warranty Expense
     855       1,733       1,680  
Cost of Warranty Repair
s
     (975     (1,715     (1,423
    
 
 
   
 
 
   
 
 
 
Balance, end of the year
   $ 730     $ 850     $ 832  
    
 
 
   
 
 
   
 
 
 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Concentration of Risk
12 Months Ended
Jan. 31, 2021
Risks and Uncertainties [Abstract]  
Concentration of Risk
Note 20—Concentration of Risk
Credit is generally extended on an uncollateralized basis to almost all customers after review of credit worthiness. Concentration of credit and geographic risk with respect to accounts receivable is limited due to the large number and general dispersion of accounts which constitute our customer base. We periodically perform
on-going
credit evaluations of our customers. We have not historically experienced significant credit losses on collection of our accounts receivable.
During the years ended January 31, 2021, 2020 and 2019, one vendor accounted for 23.2%, 21.2% and 21.6% of purchases, and 23.8%, 28.0% and 28.7% of accounts payable, respectively, as of January 31, 2021, 2020 and 2019.
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
12 Months Ended
Jan. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies
Note 21—Commitments and Contingencies
We are subject to contingencies, including legal proceedings and claims arising in the normal course of business that cover a wide range of matters including, among others, contract and employment claims; workers compensation claims; product liability; warranty and modification; and adjustment or replacement of component parts of units sold.
Direct costs associated with the estimated resolution of contingencies are accrued at the earliest date at which it is deemed probable that a liability has been incurred and the amount of such liability can be reasonably estimated. While it is impossible to ascertain the ultimate legal and financial liability with respect to contingent liabilities, including lawsuits, we believe that the aggregate amount of such liabilities, if any, in excess of amounts provided or covered by insurance, will not have a material adverse effect on the consolidated financial position or results of operations. It is possible, however, that future results of operations for any particular future period could be materially affected by changes in our assumptions or strategies related to these contingencies or changes out of our control.
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
12 Months Ended
Jan. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Note 22—Fair Value Measurements
Assets and Liabilities Recorded at Fair Value on a Recurring Basis
The following tables provide a summary of the financial liabilities that are measured at fair value:
 
Liabilities measured at fair value:
  
Fair value measurement at
January 31, 2021
 
  
Fair value measurement at
January 31, 2020
 
(in thousands)
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)
   $ —        $ —        $ —        $ —        $ —        $ 250      $ —        $ 250  
Interest Rate Swap Contract (included in Other Long-Term Liabilities)
     —          —          —          —          —          96        —          96  
Earnout Liability (included in Other Liabilities)
     —          —          —          —          —          —          14        14  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $
    
—        $
    
—        $
    
—        $
    
—        $
 
 
—        $
 
 
346      $
 
 
14      $
 
 
360  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
We used the market approach to measure fair value of our derivative instruments. These derivative instruments were measured at fair value using readily observable market inputs, such as quotations on interest rates and foreign exchange rates and are classified as Level 2 because they are
over-the-counter
contracts with a bank counterparty that are not traded in an active market.
Assets and Liabilities Not Recorded at Fair Value on the Consolidated Balance Sheet
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
Fair Value Measurement at
January 31, 2021
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $   —        $   —        $ 12,586      $ 12,586      $ 12,576  
     
    
Fair Value Measurement at
January 31, 2020
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $ —        $ —        $ 13,258      $ 13,258      $ 13,034  
The above table does not include the PPP loan, as the fair value of the PPP loan approximates its carrying value.
The fair value of our long-term debt, including the current portion, is estimated by discounting the future cash flows using current interest rates at which similar borrowings with the same maturities would be made to borrowers with similar credit ratings and is classified as Level 3.
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Event
12 Months Ended
Jan. 31, 2021
Subsequent Events [Abstract]  
Subsequent Event
Note 2
3
—Subsequent Event
On March 24, 2021, we entered into a First Amendment to Credit Agreement (the “Amendment”) to the A&R Credit Agreement
 
(the “A&R Credit Agreement,”
 as
amended by the Amendment; the “Amended Credit Agreement”) with Bank of America, N.A., as lender (the “Lender”), ANI ApS and TrojanLabel. Immediately prior to the closing of the Amendment, we repaid $2.6 million in principal amount of the term loan outstanding under the A&R Credit Agreement, resulting in an outstanding balance of the term loan of $10.0 million and no amount drawn and outstanding under the revolving credit facility under the A&R Credit Agreement.
The Amended Credit Agreement provides for (i) a term loan in the principal amount of $10.0 million, and (ii) a $22.5 million revolving credit facility available for general corporate purposes. At the closing of the Amend
ment
,
w
e
borrowed the entire $10.0 million term loan which was used to refinance, in full, the outstanding term loan under the A&R Credit Agreement. Under the Amended Credit Agreement, revolving credit loans may continue to be borrowed, at our option, in U.S. Dollars or, subject to certain conditions, Euros, British Pounds, Canadian Dollars or Danish Kroner.
The Amended Credit Agreement requires that the term loan be paid as follows: the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2021 through January 31, 2022 is $187,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2022 through January 31, 2023 is $250,000; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2023 through January 31, 2025 is $312,500; the principal amount of each quarterly installment required to be paid on the last day of each of our fiscal quarters ending on or about April 30, 2025 and July 31, 2025 is $500,000; and the entire remaining principal balance of the term loan is required to be paid on September 30, 2025. We may voluntarily prepay the term loan, in whole or in part, from time to time without premium or penalty (other than customary breakage costs, if applicable). We may repay borrowings under the revolving credit facility at any time without premium or penalty (other than customary breakage costs, if applicable), but in any event no later than September 30, 2025, at which time any outstanding revolving loans will be due and payable in full, and the revolving credit facility will terminate. We may reduce or terminate the revolving line of credit at any time, subject to certain thresholds and conditions, without premium or penalty.
The Amended Credit Agreement includes an uncommitted accordion provision under which the term loan and/or revolving credit facility commitments may be increased in an aggregate principal amount not exceeding $10.0 million, subject to obtaining the agreement of the Lender and the satisfaction of certain other conditions.
The interest rates under the
Prior
Credit Agreement were modified in the Amended Credit Agreement as follows: the term loan and revolving credit loans bear interest at a rate per annum equal to, at our option, either (a) the LIBOR Rate as de
fin
ed
 in the Amended Credit Agreement (or in the case of revolving credit loans denominated in a currency other than U.S. Dollars, the applicable quoted rate), plus a margin that varies within a range of 1.60% to 2.30% based on our consolidated leverage ratio, or (b) a fluctuating reference rate equal to the highest of (i) the federal fund rate plus 0.50%, (ii) Bank of America’s publicly announced prime rate, (iii) the LIBOR Rate plus 1.00% or (iv) 0.50%, plus a margin that varies within a range of 0.60% to 1.30% based on our consolidated leverage ratio. In addition to certain other fees and expenses that we are required to pay to the Lender, we are required to pay a commitment fee on the undrawn portion of the revolving credit facility that varies within a range of 0.15% and 0.30% based on our consolidated leverage ratio. The commitment fee paid on the undrawn portion of the revolving credit facility was $28,000 for fiscal year 2021 and is included in the interest expense line in the consolidated income statement for the period ended January 31, 2021.
As under the Prior Credit Agreement, the loans under the Amended Credit Agreement are subject to certain mandatory prepayments, subject to various exceptions, from (a) net cash proceeds from certain dispositions of property, (b) net cash proceeds from certain issuances of equity, (c) net cash proceeds from certain issuances of additional debt and (d) net cash proceeds from certain extraordinary receipts.
Amounts repaid under the revolving credit facility may be reborrowed, subject to continued compliance with the Amended Credit Agreement. No amount of the term loan that is repaid may be reborrowed.
We must comply with various customary financial and
non-financial
covenants under the Amended Credit Agreement. The financial covenants under the Amended Credit Agreement consist of a maximum consolidated leverage ratio and a minimum consolidated fixed charge coverage ratio. The minimum EBITDA, minimum consolidated asset coverage ratio, minimum liquidity and maximum capital expenditures covenants with which we were required to comply under the Prior Credit Agreement were eliminated by the Amendment. The primary
non-financial
covenants limit our and our subsidiaries’ ability to incur future indebtedness, to place liens on assets, to pay dividends or distributions on their capital stock, to repurchase or acquire their capital stock, to conduct mergers or acquisitions, to sell assets, to alter their capital structure, to make investments and loans, to change the nature of their business, and to prepay subordinated indebtedness, in each case subject to certain exceptions and thresholds as set forth in the Amended Credit Agreement, certain of which provisions were modified by the Amendment.
The Lender is entitled to accelerate repayment of the loans and to terminate its revolving credit commitment under the Amended Credit Agreement upon the occurrence of any of various customary events of default, which include, among other events, the following (which are subject, in some cases, to certain grace periods): failure to pay when due any principal, interest or other amounts in respect of the loans, breach of any of our covenants or representations under the loan documents, default under any other of our or our subsidiaries’ significant indebtedness agreements, a bankruptcy, insolvency or similar event with respect to us or any of our subsidiaries, a significant unsatisfied judgment against us or any of our subsidiaries, or a change of control.
Our obligations under the Amended Credit Agreement continue to be secured by substantially all of our personal property assets (including a pledge of the equity interests held in ANI ApS, in our wholly-owned German subsidiary AstroNova GmbH, and in our wholly-owned French subsidiary AstroNova SAS), subject to certain exceptions, and by a mortgage on our owned real property in West Warwick, Rhode Island. Pursuant to the Amendment, the guarantees of our obligations under the Prior Credit Agreement that were previously provided by ANI ApS and TrojanLabel were released.
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Schedule II - Valuation and Qualifying Accounts and Reserves
12 Months Ended
Jan. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]  
Schedule II - Valuation and Qualifying Accounts and Reserves
SCHEDULE II—VALUATION AND QUALIFYING ACCOUNTS AND RESERVES
 
Description
  
Balance at
Beginning
of Year
    
Provision/
(Benefit)
Charged to
Operations
    
Deductions(2)
   
Balance
at End
of Year
 
Allowance for Doubtful Accounts(1):
                                  
(In thousands)                           
Year Ended January 31,
                                  
2021
   $ 856      $ 194      $ 4     $ 1,054  
2020
   $ 521      $ 546      $ (211   $ 856  
2019
   $ 377      $ 310      $ (166   $ 521  
 
(1)
The allowance for doubtful accounts has been netted against accounts receivable in the balance sheets as of the respective balance sheet dates.
(2)
Uncollectible accounts written off, net of recoveries.
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Jan. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation:
The accompanying financial statements and accompanying notes have been prepared by us pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) and are presented in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”). Our fiscal year end is January 31. Unless otherwise stated, all years and dates refer to our fiscal year.
Principles of Consolidation
Principles of Consolidation:
The consolidated financial statements include the accounts of AstroNova, Inc. and its subsidiaries. All material intercompany accounts and transactions are eliminated in consolidation.
Reclassification
Reclassification:
Certain amounts in prior year’s financial statements have been reclassified to conform to the current year’s presentation.
Use of Estimates
Use of Estimates:
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect these financial statements and accompanying notes. Some of the more significant estimates relate to the allowances for doubtful accounts, inventory valuation, valuation and estimated lives of intangible assets, impairment of long-lived assets, goodwill, income taxes, share-based compensation and warranty reserves. Management’s estimates are based on the facts and circumstances available at the time estimates are made, past historical experience, risk of loss, general economic conditions and trends, and management’s assessments of the probable future outcome of these matters. Consequently, actual results could differ from those estimates.
Cash and Cash Equivalents
Cash and Cash Equivalents:
Highly liquid investments with an original maturity of 90 days or less are considered to be cash equivalents. Similar investments with original maturities beyond three months are classified as securities available for sale. At January 31, 2021 and 2020, $4.6 million and $3.4 million, respectively, was held in foreign bank accounts.
Inventories
Inventories:
Inventories are stated at the lower of cost
(first-in,
first-out)
or net realizable value and include material, labor and manufacturing overhead.
Property, Plant and Equipment
Property, Plant and Equipment:
Property, plant and equipment are stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets (land improvements—10 to 20 years; buildings and leasehold improvements—10 to 45 years; machinery and equipment—3 to 10 years and computer equipment and software—3 to 10 years).
Revenue Recognition
Revenue Recognition:
We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “Revenue from Contracts with Customers (“Topic 606”).” The core principle of Topic 606 is to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Topic 606 defines a five step process to recognize revenue and requires more judgment and estimates within the revenue recognition process than required under previous U.S. GAAP, including identifying contracts with customers, identifying performance obligations in the contract, determining and estimating the amount of any variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation and recognizing revenue when the entity satisfies each performance obligation. 
The vast majority of our revenue is generated from the sale of distinct products. Revenue is measured as the amount of consideration we expect to receive in exchange for such products, which is generally at the contractually stated prices, and is recognized when we satisfy a performance obligation by transferring control of a product to a customer. The transfer of control generally occurs at one point in time, upon shipment, when title and risk of loss pass to the customer. Returns and customer credits are infrequent and are recorded as a reduction to revenue. Sales taxes and value added taxes collected concurrently with revenue generating activities are excluded from revenue.
Many of the contracts entered into with customers are commonly comprised of a combination of equipment, supplies, installation and/or training services. We determine performance obligations by assessing whether the products or services are distinct from other elements of the contract. In order to be distinct, the product must perform either on its own or with readily available resources and must be separate within the context of the contract.
Most of our hardware products contain embedded operating systems and data management software which is included in the purchase price of the equipment. The software is deemed incidental to the systems as a whole, as it is not sold or marketed separately, and its production costs are minor compared to those of the hardware system. Hardware and software elements are typically delivered at the same time and are accounted for as a single performance obligation for which revenue is recognized at the point in time when ownership is transferred to the customer.
Installation and training services vary based on certain factors such as the complexity of the equipment, staffing availability in a geographic location and customer preferences, and can range from a few days to a few months. The delivery of installation and training services are not assessed to determine whether they are separate performance obligations, as the amounts are not material to the contract.
Shipping and handling activities that occur after control over a product has transferred to a customer are accounted for as fulfillment activities rather than performance obligations, as allowed under a practical expedient provided by Topic 606. The shipping and handling fees charged to customers are recognized as revenue and the related costs are included in cost of revenue at the point in time when ownership of the product is transferred to the customer.
We may perform service at the request of the customer, generally for the repair and maintenance of products previously sold. These services are short in duration and total less than 10% of revenue for the years ended January 31, 2021 and 2020. Revenue is recognized as services are rendered and accepted by the customer. We also provide service agreements on certain of our Product Identification equipment. Service agreements are purchased separately from the equipment and provide for the right to obtain service and maintenance on the equipment for a period of typically one to two years. Accordingly, revenue on these agreements is recognized over the term of the agreements. The portion of service agreement contracts that are uncompleted at the end of any reporting period are included in deferred revenue.
We generally provide warranties for our products. The standard warranty period is typically 12 months for most hardware products except for airborne printers, which typically have warranties that extend for
3-5
years, consistent with industry practice. Such assurance-type warranties are not deemed to be separate performance obligations from the hardware product and costs associated with providing the warranties are accrued in accordance with ASC 450, “Contingencies,” as we have the ability to ascertain the likelihood of the liability and can reasonably estimate the amount of the liability. Our estimate of costs to service the warranty obligations is based on historical experience and expectations of future conditions. To the extent that our experience in warranty claims or costs associated with servicing those claims differ from the original estimates, revisions to the estimated warranty liability are recorded at that time, with an offsetting adjustment to cost of revenue. On occasion, customers request a warranty period longer than our standard warranty. In those instances, in which extended warranty services are separately quoted to the customer, an additional performance obligation is created, and the associated revenue is deferred and recognized as service revenue ratably over the term of the extended warranty period. The portion of service contracts and extended warranty services agreements that are uncompleted at the end of any reporting period are included in deferred revenue.
We recognize an asset for the incremental direct costs of obtaining a contract with a customer if we expect the benefit of those costs to be longer than one year. Costs related to obtaining sales contracts for our aerospace printer products have been capitalized and are being amortized based on the forecasted number of units sold over the estimated benefit term. We apply the practical expedient to expense costs incurred for costs to obtain a contract when the amortization period would have been less than a year. These costs include sales commissions paid to the internal direct sales team as well as to third-party representatives and distributors. Contractual
agreements with each of these parties outline commission structures and rates to be paid. Generally speaking, the contracts are all individual procurement decisions by the customers and do not include renewal provisions and as such the majority of the contracts have an economic life of significantly less than a year.
Accounts Receivables and Allowance for Doubtful Accounts
Accounts Receivables and Allowance for Doubtful Accounts:
Standard payment terms are typically 30 days after shipment but vary by type and geographic location of our customer. Credit is extended based upon an evaluation of the customer’s financial condition. In circumstances where we are aware of a customer’s inability to meet its financial obligations, an allowance is established. The remainder of the allowance established is based on a variety of factors, including the age of amounts outstanding relative to their contractual due date, historical
write-off
experience and current market assessments. Accounts receivable are stated at their estimated net realizable value.
Research and Development Costs
Research and Development Costs:
We charge costs to expense in the period incurred, and these expenses are presented in the consolidated statement of income. The following costs are included in research and development expense: salaries and benefits, external engineering service costs, engineering related information costs and supplies.
Foreign Currency Translation
Foreign Currency Translation:
The financial statements of foreign subsidiaries and branches are measured using the local currency as the functional currency. Foreign currency-denominated assets and liabilities are translated into U.S. dollars at
year-end
exchange rates with the translation adjustment recorded as a component of accumulated comprehensive income (loss) in shareholders’ equity. Revenues and expenses are translated at the average monthly exchange rates in effect during the related period. We do not provide for U.S. income taxes on foreign currency translation adjustments associated with our subsidiaries in Germany, Denmark and China since their undistributed earnings are considered to be permanently invested. Included in our consolidated statements of income was a net transactional foreign exchange gain of $0.6 million in fiscal 2021, and a net transaction foreign exchange loss of $0.4 million in fiscal 2020 and $0.7 million for fiscal 2019.
Advertising
Advertising:
We
expense advertising costs as incurred. Advertising costs including advertising production, trade shows and other activities are designed to enhance demand for our products and amounted to approximately $0.9 million; $1.8 million and $1.9 million in fiscal 2021, 2020 and 2019, respectively.
Long-Lived Assets
Long-Lived Assets:
Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. If the projected undiscounted cash flows are less than the carrying value, then an impairment charge would be recorded for the excess of the carrying value over the fair value, as determined by the discounting of future cash flows. There were no impairment charges for our long-lived assets in fiscal years 2021, 2020 or 2019.
Intangible Assets
Intangible Assets:
Intangible assets include the value of customer and distributor relationships, existing technology and
non-competition
agreements acquired in connection with business and asset acquisitions and are stated at cost (fair value at acquisition) less accumulated amortization. These intangible assets have a definite life and are amortized over the assets’ useful lives using a systematic and rational basis which is representative of the assets’ use. Intangible assets with a definite life are tested for impairment whenever events or circumstances indicate that the carrying amount of an asset (asset group) may not be recoverable. If necessary, an impairment loss is recognized when the carrying amount of an asset exceeds the estimated undiscounted cash flows used in determining the fair value of the asset. The amount of the impairment loss recorded is calculated by the excess of the asset’s carrying value over its fair value. Fair value is generally determined using a discounted cash flow analysis. There were no impairment charges for our intangible assets in fiscal years 2021, 2020 or 2019.
Goodwill
Goodwill:
Goodwill represents the excess of the aggregate purchase price over the fair value of the net assets acquired in a purchase business combination. Management evaluates the recoverability of goodwill annually or more frequently if events or changes in circumstances, such as declines in revenue, earnings or cash flows, or material adverse changes in the business climate indicate that the carrying value of an asset might be
impaired. Goodwill is tested for impairment at the reporting unit level. A reporting unit is an operating segment, or a business unit one level below an operating segment if discrete financial information for that business is prepared and regularly reviewed by segment management. However, components within an operating segment are aggregated as a single reporting unit if they have similar economic characteristics. We determined that each of our operating segments (Product Identification and T&M) represents a reporting unit for purposes of goodwill impairment testing.
The accounting guidance related to goodwill impairment testing allows for the performance of an optional qualitative assessment of whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. Factors that management considers in this qualitative assessment include macroeconomic conditions, industry and market considerations, overall financial performance (both current and projected), changes in management and strategy and changes in the composition or carrying amount of net assets. If this qualitative assessment indicates that it is more likely than not that the fair value of a reporting unit is less than its carrying value, then a quantitative assessment is required for the reporting unit. Additionally, we can elect to forgo the qualitative assessment and perform the quantitative test. The quantitative assessment compares the fair value of the reporting unit with its carrying value. We estimate the fair value of our reporting units using a blended income and market approach. The income approach is based on a discounted cash flow model and provides a fair value estimate based upon the reporting unit’s expected long-term operating cash flow performance. The market approach, compares the reporting unit to publicly traded companies and transactions involving similar business, and requires the use of many assumptions and estimates including future revenue, expenses, capital expenditures, and working capital, as well as discount factors and income tax rates. If the fair value of the reporting unit exceeds the carrying value of the net assets including goodwill assigned to that unit, goodwill is not impaired. If the carrying value of the reporting unit’s net assets including goodwill exceeds the fair value of the reporting unit, then we record an impairment charge based on that difference. We performed a quantitative analysis of the reporting units as of January 31, 2021 and determined that the fair value was in excess of our carrying value and therefore, no goodwill impairment has occurred. See Note 3, “Goodwill,” for further details.
Leases
Leases:
On February 1, 2019 we adopted ASC 842, Leases. This guidance requires a lessee to recognize assets and liabilities on the balance sheet for all leases, with the result being the recognition of a right of use (ROU) asset and a lease liability. The lease liability is equal to the present value of the minimum lease payments for the term of the lease, including any optional renewal periods determined to be reasonably certain to be exercised, using a discount rate determined at lease commencement. This discount rate is the rate implicit in the lease, if known; otherwise, the incremental borrowing rate for the expected lease term is used. Our incremental borrowing rate approximates the rate we would have to pay to borrow on a collateralized basis over a similar term at lease inception. The value of the ROU asset is equal to the initial measurement of the lease liability plus any lease payments made to the lessor at or before the commencement date and any unamortized initial direct costs incurred by the lessee, less any unamortized lease incentives received. Several of our lease contracts include options to extend the lease term and we include the renewal options for these leases in the determination of the ROU asset and lease liability when the likelihood of renewal is determined to be reasonably certain.
We enter into lease contracts for certain of our facilities at various locations worldwide. At inception of a contract, we determine whether the contract is or contains a lease. If we have a right to obtain substantially all of the economic benefits from the use of the identified asset and the right to direct the use of the asset, then the contract contains a lease.
There are two types of leases, operating leases and finance leases. Lease classification is determined at lease commencement. We have made an accounting policy election to apply the short-term exception, which does not require the capitalization of leases with terms of 12 months or less. All of our leases are classified as operating leases. Operating lease expense is recognized on a straight-line basis over the lease term and included in general and administrative expense on the consolidated statement of income. ROU assets are classified in other long-term assets, short-term lease liabilities are classified in other current liabilities, and long-term lease liabilities are classified in other long-term liabilities in the consolidated balance sheet. In the statement of cash flow, payments for operating leases are classified as operating activities.
Income Taxes
Income Taxes:
We use the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting basis and tax basis of the assets and liabilities and are measured using statutory tax rates that will be in effect when the differences are expected to reverse. Our deferred taxes are presented as
non-current
in the accompanying consolidated balance sheet. An allowance against deferred tax assets is recognized when it is
more-likely-than-not
that some portion or all of the deferred tax assets will not be realized. At January 31, 2021 and 2020, a valuation allowance was provided for deferred tax assets attributable to certain domestic R&D credit carryforwards. In addition, during fiscal 2021, we provided a valuation allowance for deferred tax assets attributable to foreign tax credit carryforwards which would expire unused.
We account for uncertain tax positions in accordance with the guidance provided in ASC 740, “Accounting for Income Taxes.” This guidance describes a recognition threshold and measurement attribute for the financial statement disclosure of tax positions taken or expected to be taken in a tax return and requires recognition of tax benefits that satisfy a
more-likely-than-not
threshold. ASC 740 also provides guidance on
de-recognition,
classification, interest and penalties, accounting in interim periods and disclosure.
On December 22, 2017, the 2017 Tax Cuts and Jobs Act (“Tax Act”) was enacted into law and the new legislation contains several key tax provisions that affected us, including a
one-time
mandatory transition tax on accumulated foreign earnings and a reduction of the corporate income tax rate to 21% effective January 1, 2018, among others. We are required to recognize the effect of the tax law changes in the period of enactment, such as determining the transition tax, remeasuring our U.S. deferred tax assets and liabilities as well as reassessing the net realizability of our deferred tax assets and liabilities. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”), which allows us to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. All accounting under SAB 118 was finalized during the quarter ending January 31, 2019 with no material changes from the provisional amounts previously recorded.
On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was signed into law. The legislation had sweeping effects including various types of economic relief for impacted businesses and industries. One such relief provision was the Paycheck Protection Program, which provided short-term cash flow assistance to finance employee payroll and qualified expenses. On May 6, 2020, we entered into a loan agreement with, and executed a promissory note in favor of Greenwood Credit Union (“Greenwood”) pursuant to which we borrowed $4.4 million (the “PPP Loan”). On December 27, 2020 the Consolidated Appropriations Act, 2021, H.R. 133 was signed into law. The legislation permits the deductibility of expenses to the extent that the payment of such expenses results (or is expected to result) in the forgiveness of a loan (covered loan) guaranteed under the Paycheck Protection Program. We have fully utilized the PPP Loan proceeds for qualifying expenses and, subsequent to year end, have applied for forgiveness of the PPP Loan (including all associated accrued interest) in accordance with the terms of the CARES Act, as amended by the PPP Flexibility Act. Consistent with the legislation, we expect to deduct the full $4.4 million of qualified expenses on our 2020 federal tax return.
Net Income Per Common Share
Net Income Per Common Share:
Basic net income per share is based on the weighted average number of shares outstanding during the period. Diluted net income per share is based on the basic weighted average number of shares and potential common equivalent shares for stock options, restricted stock awards and restricted stock units outstanding during the period using the treasury stock method. In fiscal years 2021, 2020 and 2019, there were 642,623; 202,187 and 326,275, respectively, of common equivalent shares that were not included in the computation of diluted net income per common share because their inclusion would be anti-dilutive.
Fair Value Measurement
Fair Value Measurement:
We measure our financial assets at fair value on a recurring basis in accordance with the guidance provided in ASC 820, “Fair Value Measurement and Disclosures,” which defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants at the measurement date. In addition, ASC 820 establishes a three-tiered hierarchy for inputs used in management’s determination of fair value of financial instruments that emphasizes the use of observable inputs over the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that reflect management’s belief about the assumptions market participants would use in pricing a financial instrument based on the best information available in the circumstances.
The fair value hierarchy is summarized as follows:
 
 
 
Level 1—Quoted prices in active markets for identical assets or liabilities;
 
 
 
Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and
 
 
 
Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities
Cash and cash equivalents, accounts receivable, accounts payable, accrued compensation, other accrued expenses and income tax payable are reflected in the consolidated balance sheet at carrying value, which approximates fair value due to the short-term nature of these instruments.
Self-Insurance
Self-Insurance:
We are self-insured for U.S. medical and dental benefits for qualifying employees and maintain stop-loss coverage from a third party which limits our exposure to large claims. We record a liability associated with these benefits that includes an estimate of both claims filed and losses incurred but not yet reported based on historical claims experience. In estimating this accrual, we utilize an independent third-party broker to estimate a range of expected losses, which are based on analyses of historical data. Assumptions are closely monitored and adjusted when warranted by changing circumstances. Our liability for self-insured claims is included within accrued compensation in our consolidated balance sheets and was $0.2 million and $0.6 million, as of January 31, 2021 and 2020.
Share-Based Compensation
Share-Based Compensation:
Share-based compensation expense is measured based on the estimated fair value of the share-based award when granted and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant). We have estimated the fair value of each option on the date of grant using the Black-Scholes option-pricing model. Our estimate of share-based compensation requires several complex and subjective assumptions including our stock price volatility, employee exercise patterns (expected life of the options), the risk-free interest rate and our dividend yield. The stock price volatility assumption is based on the historical weekly price data of our common stock over a period equivalent to the weighted average expected life of our options. Management evaluated whether there were factors during that period which were unusual and would distort the volatility figure if used to estimate future volatility and concluded that there were no such factors. In determining the expected life of the option grants, we have observed the actual terms of prior grants with similar characteristics and the actual vesting schedule of the grant and has assessed the expected risk tolerance of different option groups. The risk-free interest rate is based on the actual U.S. Treasury zero coupon rates for bonds matching the expected term of the option as of the option grant date. The dividend assumption is based upon the prior year’s average dividend yield. No compensation expense is recognized for options that are forfeited for which the employee does not render the requisite service. Our accounting for share-based compensation for restricted stock awards (RSA) and restricted stock units (RSU) is also based on the fair value method. The fair value of the RSUs and RSAs is based on the closing market price of our common stock on the grant date. Reductions in compensation expense associated with forfeited awards are estimated at the date of grant, and this estimated forfeiture rate is adjusted periodically based on actual forfeiture experience.
Cash flow from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) is classified with other income tax cash flows as an operating activity.
Share-based compensation becomes deductible for determining income taxes when the related award vests, is exercised, or is forfeited depending on the type of share-based award and subject to relevant tax law.
Derivative Financial Instruments
Derivative Financial Instruments:
We occasionally uses derivative instruments as part of its overall strategy to manage its exposure to market risks primarily associated with fluctuations in foreign currency exchange rates and interest rates. Derivative instruments are recognized as either assets or liabilities in the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging relationship. For derivative instruments not designated as hedging instruments, the gain or loss is recognized in the statement of income during the current period. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) (OCI) and reclassified into earnings in the same line item associated with the forecasted transaction, and in the same period or periods during which the hedged transaction affects earnings (e.g., in “Interest Expense” when the hedged transactions are interest cash flows associated with floating-rate debt, or “Other, Net” for portions reclassified relating to the remeasurement of the debt). The remaining gain or loss on the derivative instrument in excess of the cumulative change in the present value of future cash flows of the hedged item, if any, are recognized in the statement of income during the current period.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted:
Fair Value Measurement
In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”)
2018-13,
“Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.” ASU
2018-13
modifies the disclosure requirements for fair value measurements by removing, modifying or adding certain disclosures. The provisions of ASU
2018-13
relating to changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. The remaining provisions should be applied retrospectively to all periods presented upon their effective date. We adopted the provisions of this guidance effective February 1, 2020. The adoption of this guidance did not have a material impact on our consolidated financial statements and accompanying disclosures.
Recent Accounting Standards Not Yet Adopted:
Income Taxes
In December 2019, the FASB issued an ASU
2019-12,
“Simplifying the Accounting for Income Taxes,” which simplifies the accounting for income taxes, eliminates certain exceptions within ASC 740, Income Taxes, and clarifies certain aspects of the current guidance to promote consistency among reporting entities. ASU
2019-12
is effective for fiscal years beginning after December 15, 2020. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. Most amendments within the standard are required to be applied on a prospective basis, while certain amendments must be applied on a retrospective or modified retrospective basis. We are not electing to early adopt and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and accompanying disclosures.
No other new accounting pronouncements, issued or effective during fiscal 2021, have had or are expected to have a material impact on our consolidated financial statements.
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition (Tables)
12 Months Ended
Jan. 31, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Revenues Disaggregated by Primary Geographic Markets and Major Product Type
Revenues disaggregated by primary geographic markets and major product types are as follows:
Primary geographical markets:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
United States
   $ 70,911      $ 83,671      $ 83,668  
Europe
     29,029        29,617        31,574  
Canada
     5,574        5,719        6,692  
Asia
     5,105        8,316        8,207  
Central and South America
     3,950        4,145        4,147  
Other
     1,464        1,978        2,369  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
Major product types:
 
    
Year Ended
 
(In thousands)
  
January 31,
2021
    
January 31,
2020
    
January 31,
2019
 
Hardware
   $ 34,111      $ 48,959      $ 53,207  
Supplies
     71,772        71,838        71,178  
Service and Other
     10,150        12,649        12,272  
    
 
 
    
 
 
    
 
 
 
Total Revenue
   $ 116,033      $ 133,446      $ 136,657  
    
 
 
    
 
 
    
 
 
 
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill (Tables)
12 Months Ended
Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Summary of Goodwill by reporting unit
Goodwill by reporting unit is as follows:
 
(In thousands)
  
Product
Identification
 
 
T&M
 
  
Total
 
Balance at January 31, 2019
   $ 7,807     $ 4,522      $ 12,329  
Foreign currency translation
     (295     —          (295
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2020
   $ 7,512     $ 4,522      $ 12,034
Foreign currency translation
     772       —          772  
    
 
 
   
 
 
    
 
 
 
Balance at January 31, 2021
   $ 8,284     $ 4,522      $ 12,806  
  
 
 
   
 
 
    
 
 
 
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets (Tables)
12 Months Ended
Jan. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives
Intangible assets are as follows:
 
   
January 31, 2021
   
January 31, 2020
 
(In thousands)
 
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
   
Gross
Carrying
Amount
   
Accumulated
Amortization
   
Currency
Translation
Adjustment
   
Net
Carrying
Amount
 
Miltope:
                                                               
Customer Contract Relationships
  $ 3,100     $ (2,284   $ —       $ 816     $ 3,100     $ (2,021   $ —       $ 1,079  
RITEC:
                                                               
Customer Contract Relationships
    2,830       (1,423     —         1,407       2,830       (1,076     —         1,754  
Non-Competition
Agreement
    950       (950     —         —         950       (871     —         79  
TrojanLabel:
                                                               
Existing Technology
    2,327       (1,405     196       1,118       2,327       (1,053     78       1,352  
Distributor Relations
    937       (396     89       630       937       (297     27       667  
Honeywell:
                                                               
Customer Contract Relationships
    27,243       (9,712     —         17,531       27,243       (6,791     —         20,452  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Intangible Assets, net
  $ 37,387     $ (16,170   $       285     $ 21,502     $ 37,387     $ (12,109   $       105     $ 25,383  
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Summary of Estimated Amortization Expense
Estimated amortization expense for the next five fiscal years is as follows:
 
(In thousands)
  
2022
 
  
2023
 
  
2024
 
  
2025
 
  
2026
 
Estimated amortization expense
   $ 3,938      $ 3,956      $ 4,055      $ 3,416      $ 3,021  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories (Tables)
12 Months Ended
Jan. 31, 2021
Inventory Disclosure [Abstract]  
Components of Inventories
The components of inventories are as follows:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)              
Materials and Supplies
   $ 20,265      $ 20,151  
Work-in-Progress
     2,076        1,408  
Finished Goods
     16,371        17,992  
    
 
 
    
 
 
 
       38,712        39,551  
Inventory Reserve
     (8,652      (5,626
    
 
 
    
 
 
 
     $ 30,060      $ 33,925  
    
 
 
    
 
 
 
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment (Tables)
12 Months Ended
Jan. 31, 2021
Property, Plant and Equipment [Abstract]  
Summary of Property, Plant and Equipment
Property, plant and equipment consist of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Land and Land Improvements
  
  
1,004     
967  
Buildings and Leasehold Improvements
     12,642        12,524  
Machinery and Equipment
     23,346        23,167  
Computer Equipment and Software
     13,847        11,388  
    
 
 
    
 
 
 
Gross Property, Plant and Equipment
     50,839        48,046  
Accumulated Depreciation
     (38,828      (36,778
    
 
 
    
 
 
 
Net Property Plant and Equipment
  
12,011     
11,268  
    
 
 
    
 
 
 
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Tables)
12 Months Ended
Jan. 31, 2021
Payables and Accruals [Abstract]  
Summary of Accrued Expenses
Accrued expenses consisted of the following:
 
 
  
January 31
 
 
  
2021
 
  
2020
 
(In thousands)
  
 
 
  
 
 
Warranty
   $ 730      $ 850  
Professional Fees
     546        697  
Lease Liability
     372        416  
Accrued Payroll & Sales Tax
     292        193  
Stockholder Relation Fees
     91        194  
Dealer Commissions
     57        236  
Other Accrued Expenses
     1,851        2,125  
    
 
 
    
 
 
 
     $ 3,939      $ 4,711  
    
 
 
    
 
 
 
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt (Tables)
12 Months Ended
Jan. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets
Long-term debt in the accompanying condensed consolidated balance sheets under the A&R Credit Agreement is as follows:
 
 
  
January 31
 
(In thousands)
  
2021
 
  
2020
 
USD Term Loan (4.65% as of January 31, 2021); maturity date of June 15, 2022
   $ 12,576      $ —    
USD Term Loan (3.03% as of January 31, 2021); maturity date November 30, 2022
     —          8,250  
USD Term Loan (3.03% as of January 31, 2021); maturity date of January 31, 2022
     —          4,784  
    
 
 
    
 
 
 
       12,576        13,034  
Debt Issuance Costs, net of accumulated amortization
     (141      (111
Current Portion of Term Loan
     (5,326      (5,208
    
 
 
    
 
 
 
Long-Term Debt
   $ 7,109      $ 7,715  
    
 
 
    
 
 
 
Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding
The schedule of required principal payments remaining under the A&R Credit Agreement on long-term debt outstanding as of January 31, 2021 is as follows:
 
(In thousands)
  
 
 
Fiscal 2022
   $ 5,326  
Fiscal 2023
     7,250  
    
 
 
 
     $ 12,576  
    
 
 
 
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Derivative Financial Instruments and Risk Management (Tables)
12 Months Ended
Jan. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Summarizes the Notional Amount and Fair Value of the Derivative Instrument
The following table summarizes the notional amount and fair value of our derivative instruments:
 
Cash Flow Hedges
(In thousands)
  
January 31, 2021
 
  
January 31, 2020
 
  
Notional Amount
 
  
Fair Value Derivatives
 
  
Notional Amount
 
  
Fair Value Derivatives
 
 
  
Asset
 
  
Liability
 
  
Asset
 
  
Liability
 
Cross-currency Interest Rate Swap
   $      $      $      $ 4,489      $      $ 250  
Interest Rate Swap
   $      $      $      $ 8,250      $      $ 96  
Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements
The following tables present the impact of the derivative instruments in our consolidated financial statements for the years ended January 31, 2021 and 2020:
 
 
  
Years Ended
 
Cash Flow Hedge
(In thousands)
  
Amount of Gain(Loss)
Recognized in OCI
on
Derivative
 
  
Location of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
Amount of Gain (Loss)
Reclassified from
Accumulated OCI into
Income
 
  
January 31,
2021
 
 
January 31,
2020
 
  
January 31,
2021
 
 
January 31,
2020
 
Swap contracts
   $ (301   $ 159        Other Income      $ (248   $ 338  
    
 
 
   
 
 
             
 
 
   
 
 
 
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
12 Months Ended
Jan. 31, 2021
Leases [Abstract]  
Schedule Of Balance Sheet And Other Information Related To Operating Leases
Balance sheet and other information related to our leases is as follows:
 
Operating Leases
(In thousands)
  
Balance Sheet Classification
  
January 31,
2021
    
January 31,
2020
 
Lease Assets
   Right of Use Assets   
$
1,389
 
 
$ 1,661  
Lease Liabilities
Current
   Other Accrued Expenses   
 
372
 
 
  416  
Lease Liabilities
Long Term
   Lease Liabilities   
$
1,065
 
 
$ 1,279  
Schedule Lease Cost Information
Lease cost information is as follows:
 
Operating Leases
(In thousands)
  
Statement of Income Classification
    
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Operating Lease Costs
       General and Administrative Expense        $ 485      $ 449  
Schedule of Maturities Of Lease Liabilities
Maturities of operating lease liabilities are as follows:
 
(In thousands)
  
January 31,
2021
 
2022
   $ 372  
2023
     318  
2024
     292  
2025
     184  
2026
     163  
Thereafter
     270  
    
 
 
 
Total Lease Payments
     1,599  
Less: Imputed Interest
     (162
    
 
 
 
Total Lease Liabilities
   $ 1,437  
    
 
 
 
Supplemental Cash Flow Information Related To Leases
Supplemental cash flow information related to leases is as follows:
 
(In thousands)
  
Year Ended
January 31,
2021
    
Year Ended
January 31,
2020
 
Cash paid for operating lease liabilities
   $ 429      $ 406  
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive Loss (Tables)
12 Months Ended
Jan. 31, 2021
Equity [Abstract]  
Changes in Balance of Accumulated Other Comprehensive Loss
The changes in the balance of accumulated other comprehensive income (loss) by component are as follows:
 
(In thousands)   
Foreign Currency
Translation
Adjustments
   
Unrealized
Holding
Gain (Loss)
on Available
for Sale
Securities
   
Net
Unrealized
Gain (Losses)
on Cash Flow
Hedges
   
Total
 
Balance at January 31, 2018
   $ (181   $ (3   $ 12     $ (172
Other Comprehensive Income (Loss) before reclassification
     (671     —         622       (49
Amounts reclassified from AOCI to Earnings
     —         3       (600     (597
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (671     3       22       (646
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2019
   $ (852   $ —       $ 34     $ (818
Other Comprehensive Income (Loss) before reclassification
     (133     —         122       (11
Amounts reclassified from AOCI to Earnings
     —         —         (264     (264
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     (133     —         (142     (275
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2020
   $ (985   $ —       $ (108   $ (1,093
Other Comprehensive Income (Loss) before reclassification
     710       —         (239     471  
Amounts Reclassified from AOCI to Earnings
     —         —         193       193  
Cross-Currency Interest Rate Swap Termination
     —         —         45       45  
    
 
 
   
 
 
   
 
 
   
 
 
 
Other Comprehensive Income (Loss)
     710       —         (1     709  
    
 
 
   
 
 
   
 
 
   
 
 
 
Balance at January 31, 2021
   $ (275   $ —       $ (109   $ (384
    
 
 
   
 
 
   
 
 
   
 
 
 
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation (Tables)
12 Months Ended
Jan. 31, 2021
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation Expense
Share-based compensation expense has been recognized as follows:
 
 
 
Years Ended January 31
 
 
 
    2021    
 
  
    2020    
 
  
    2019    
 
(In thousands)
 
 
 
  
 
 
  
 
 
Stock Options
   $ 517      $ 616      $ 783  
Restricted Stock Awards and Restricted Stock Units
     1,285        1,136        1,088  
Employee Stock Purchase Plan
     17        23        15  
    
 
 
    
 
 
    
 
 
 
Total
   $ 1,819      $ 1,775      $ 1,886  
    
 
 
    
 
 
    
 
 
 
Aggregated Information Regarding Stock Options Granted
Aggregated information regarding stock options granted under the plans is summarized below:
 
    
Number
of Shares
   
Weighted-
Average
Exercise
Price Per
Share
 
Options Outstanding, January 31, 2018
     745,270     $ 12.52  
Options Granted
     196,000       18.21  
Options Exercised
     (150,125     10.62  
Options Forfeited
     (16,300     15.10  
Options Cancelled
     (3,700     8.95  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2019
     771,145     $ 14.30  
Options Granted
     —         —    
Options Exercised
     (57,175     11.60  
Options Forfeited
     (34,526     15.73  
Options Cancelled
     (400     6.22  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2020
     679,044     $ 14.46  
Options Granted
     —         —    
Options Exercised
     (1,200     7.60  
Options Forfeited
     (54,361     12.89  
Options Cancelled
     (1,400     7.36  
    
 
 
   
 
 
 
Options Outstanding, January 31, 2021
     622,083     $ 14.63  
    
 
 
   
 
 
 
Summary of Options Outstanding
Set forth below is a summary of options outstanding at January 31, 2021:
 
Outstanding
 
  
Exercisable
 
Range of
Exercise prices
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted-
Average
Remaining
Contractual Life
 
  
Number of
Shares
 
  
Weighted-
Average
Exercise Price
 
  
Weighted
Average
Remaining
Contractual
Life
 
$5.00-10.00
     41,044      $ 7.97        1.3        41,044      $ 7.97        1.3  
$10.01-15.00
     359,314        13.63        4.9        326,741        13.65        4.7  
$15.01-20.00
     221,725        17.48            6.8        167,367        17.22        6.7  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
       622,083      $ 14.63            5.3        535,152      $ 14.33        5.1  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Aggregated Information Regarding RSUs and RSAs Granted
Aggregated information regarding RSUs and RSAs granted under the Plan is summarized below:
 
 
  
RSAs & RSUs
 
  
Weighted-Average
Grant Date Fair Value
 
Outstanding at January 31, 2018
  
 
177,347
 
  
$
13.99
 
Granted
  
 
108,790
 
  
 
17.85
 
Vested
  
 
(67,447
  
 
14.26
 
Forfeited
  
 
(85,023
  
 
14.17
 
 
  
 
 
 
  
 
 
 
Outstanding at January 31, 2019
     133,667      $ 16.90  
Granted
     119,522        19.86  
Vested
     (59,930      14.50  
Forfeited
     (58,625      19.00  
    
 
 
    
 
 
 
Outstanding at January 31, 2020
     134,634      $ 16.79  
    
 
 
    
 
 
 
Granted
     245,131        7.61  
Vested
     (64,997      17.28  
Forfeited
     (117,355      8.83  
    
 
 
    
 
 
 
Outstanding at January 31, 2021
     197,413      $ 9.96  
    
 
 
    
 
 
 
Summarized Plan Activity Summarized plan activity is as follows:
    
Years Ended January 31
 
    
    2021    
    
    2020    
    
    2019    
 
Shares Reserved, Beginning
     24,974        33,853        39,207  
Shares Purchased
     (14,600      (8,879      (5,354
    
 
 
    
 
 
    
 
 
 
Shares Reserved, Ending
     10,374        24,974        33,853  
    
 
 
    
 
 
    
 
 
 
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes (Tables)
12 Months Ended
Jan. 31, 2021
Income Tax Disclosure [Abstract]  
Components of Income before Income Taxes
The components of income (loss) before income taxes are as follows:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Domestic
   $ (1,193   $ 1,930     $ 6,859  
Foreign
     3,372       (560     449  
    
 
 
   
 
 
   
 
 
 
     $ 2,179     $ 1,370     $ 7,308  
    
 
 
   
 
 
   
 
 
 
Components of Provision for Income Taxes
The components of the provision/(benefit) for income taxes are as follows:
 
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Current:
  
     
 
     
 
     
Federal
   $ 1,272      $ 660      $ 1,807  
State
     224        221        457  
Foreign
     420        368        952  
    
 
 
    
 
 
    
 
 
 
     1,916        1,249        3,216
 
    
 
 
    
 
 
    
 
 
 
 
Deferred:
                        
Federal
   $ (910   $ (1,364   $ (843
State
     (189     (282     (170
Foreign
     78       8       (625
    
 
 
   
 
 
   
 
 
 
       (1,021     (1,638     (1,638
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit)
Total income tax provision/(benefit)
 
differs from the expected tax provision/(benefit) as a result of the following:
 
    
January 31
 
    
2021
   
2020
   
2019
 
(In thousands)                   
Income Tax Provision at Statutory Rate
   $ 458     $ 288     $ 1,534  
Denmark Statutory Audit
     341       —         —    
Foreign Rate Deferential
     197       315       558  
Share Based Compensation
     171       (145     (127
Canada Withholding Taxes
     62       —         —    
State Taxes, Net of Federal Tax Effect
     28       (48     226  
Global Intangible Low Taxed Incom
e
     14       107       —    
Meals and Entertainment
     11       31       56  
U.S. Corporate Rate Change
     —         —         52  
Transition Tax on Repatriated Earnings
     —         —         14  
Return to Provision Adjustment
     (2     (207     58  
Change in Reserves Related to ASC 740 Liability
     (10     (352     (34
Change in Valuation Allowance
     (81     256       —    
R&D Credits
     (157     (209     (218
Foreign Derived Intangible Income
     (150     (107     (53
Foreign Tax Credits
     —         (344     (477
Other
     13       26       (11
    
 
 
   
 
 
   
 
 
 
     $ 895     $ (389   $ 1,578  
    
 
 
   
 
 
   
 
 
 
Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities are as follows:
 
  
January 31
 
 
  
2021
 
 
2020
 
(In thousands)
  
 
 
 
 
 
Deferred Tax Assets:
  
     
 
     
Inventory
   $ 2,700     $ 2,094  
Honeywell Royalty Liability
     2,590       2,583  
State R&D Credits
     1,546       1,496  
Share-Based Compensation
     600       582  
Bad Debt
     245       165  
Warranty Reserve
     176       205  
Compensation Accrual
     159       159  
Net Operating Loss
     154       443  
ASU 842 Adjustment—Lease Liability
     125       —    
Unrecognized State Tax Benefits
     101       116  
Foreign Tax Credit
     83       113  
Deferred Service Contract Revenue
     68       111  
Other
     308       295  
    
 
 
   
 
 
 
       8,855       8,362  
Deferred Tax Liabilities:
                
Accumulated Tax Depreciation in Excess of Book Depreciation
     752       1,002  
Intangibles
     399       776  
ASU 842 Adjustment – Lease Liability
     119       —    
Other
     307       188  
    
 
 
   
 
 
 
       1,577       1,966  
    
 
 
   
 
 
 
Subtotal
     7,278       6,396  
Valuation Allowance
     (1,721     (1,752
    
 
 
   
 
 
 
Net Deferred Tax Assets
   $ 5,557     $ 4,644  
    
 
 
   
 
 
 
Changes in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance at February 1
  
$
362
 
 
$
618
 
 
$
665
 
Increases in prior period tax position
s
  
 
59
 
 
 
—  
 
 
 
—  
 
Increases in current period tax positions
  
 
5
 
 
 
2
 
 
 
7
 
Reductions related to lapse of statutes of limitations
  
 
(42
 
 
(26
 
 
(54
Reductions related to settlement with tax authorities
  
 
—  
 
 
 
(232
 
 
—  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Balance at January 31
  
$
384
 
 
$
362
 
 
$
618
 
 
  
 
 
 
 
 
 
 
 
 
 
 
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information (Tables)
12 Months Ended
Jan. 31, 2021
Segment Reporting [Abstract]  
Net Sales and Segment Operating Profit (loss) for Each Reporting Segment
Summarized below are the revenue and segment operating profit (loss) (both in dollars and as a percentage of revenue) for each reporting segment:
 
($ in thousands)
 
Revenue
 
 
Segment Operating Profit (Loss)
 
 
Segment Operating Profit (Loss)
as a % of Revenue
 
 
 
2021
 
 
2020
 
 
2019
 
 
    2021    
 
 
    2020    
 
 
    2019    
 
 
  2021  
 
 
  2019  
 
 
  2018  
 
Product Identification
  $ 90,268     $ 88,116     $ 86,786     $ 12,885     $ 7,509     $ 7,910       14.3     8.5     9.1
T&M
    25,765       45,330       49,871       (1,032     6,281       11,933       (4.0 )%      13.9     23.9
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total
  $ 116,033     $ 133,446     $ 136,657       11,853       13,790       19,843       (10.3 )%      10.3     14.5
   
 
 
   
 
 
   
 
 
                           
 
 
   
 
 
   
 
 
 
Corporate Expenses
                            9,420       11,357       11,123                          
                           
 
 
   
 
 
   
 
 
                         
Operating Income
                            2,433       2,433       8,720                          
Other Expense, Net
                            (254     (1,063     (1,412                        
                           
 
 
   
 
 
   
 
 
                         
Income Before Income Taxes
                            2,179       1,370       7,308                          
Income Tax Provision (Benefit)
                            895       (389     1,578                          
                           
 
 
   
 
 
   
 
 
                         
Net Income
                          $ 1,284     $ 1,759     $ 5,730                          
                           
 
 
   
 
 
   
 
 
                         
Summary of Other Information by Segment
Other information by segment is presented below:
 
(In thousands)
  
Assets
 
 
  
2021
 
  
2020
 
Product Identification
   $ 50,047      $ 51,439  
T&M
     51,262        57,050  
Corporate*
     14,164        8,175  
    
 
 
    
 
 
 
Total
   $ 115,473      $ 116,664  
    
 
 
    
 
 
 
 
*
Corporate assets consist principally of cash, cash equivalents, deferred tax assets and refunds, and certain prepaid corporate assets.
 
(In thousands)   
Depreciation and
Amortization
    
Capital Expenditures
 
    
2021
    
2020
    
2019
    
2021
    
2020
    
2019
 
Product Identification
   $ 1,835      $ 1,928      $ 1,888      $ 1,563      $ 2,001      $ 1,935  
T&M
     4,148        4,356        4,264        1,024        905        710  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 5,983      $ 6,284      $ 6,152      $ 2,587      $ 2,906      $ 2,645  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Summary of Selected Financial Information by Geographic Area
Geographical Data
Presented below is selected financial information by geographic area:
 
(In thousands)
  
Revenue
 
  
Long-Lived Assets*
 
 
  
2021
 
  
2020
 
  
2019
 
  
2021
 
  
2020
 
United States
   $ 70,911      $ 83,671      $ 83,668      $ 31,226      $ 34,072  
Europe
     29,029        29,617        31,574        2,274        2,544  
Canada
     5,574        5,719        6,692        13        35  
Asia
     5,105        8,316        8,207        —          —    
Central and South America
     3,950        4,145        4,147        —          —    
Other
     1,464        1,978        2,369        —          —    
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 116,033      $ 133,446      $ 136,657      $ 33,513      $ 36,651  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
*
Long-lived assets exclude goodwill assigned to the T&M segment of $4.5 million at both January 31, 2021 and 2020 and $8.3 million and $7.5 million assigned to the PI segment at January 31, 2021 and 2020, respectively.
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Product Warranty Liability (Tables)
12 Months Ended
Jan. 31, 2021
Guarantees and Product Warranties [Abstract]  
Activity in Product Warranty Liability Activity in the product warranty liability, which is included in other accrued expenses in the accompanying consolidated balance sheet, is as follows:
 
  
January 31
 
 
  
2021
 
 
2020
 
 
2019
 
(In thousands)
  
 
 
 
 
 
 
 
 
Balance, beginning of the year
   $ 850     $ 832     $ 575  
Provision for Warranty Expense
     855       1,733       1,680  
Cost of Warranty Repair
s
     (975     (1,715     (1,423
    
 
 
   
 
 
   
 
 
 
Balance, end of the year
   $ 730     $ 850     $ 832  
    
 
 
   
 
 
   
 
 
 
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
12 Months Ended
Jan. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Financial Assets and Liabilities Measured at Fair Value
The following tables provide a summary of the financial liabilities that are measured at fair value:
 
Liabilities measured at fair value:
  
Fair value measurement at
January 31, 2021
 
  
Fair value measurement at
January 31, 2020
 
(in thousands)
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)
   $ —        $ —        $ —        $ —        $ —        $ 250      $ —        $ 250  
Interest Rate Swap Contract (included in Other Long-Term Liabilities)
     —          —          —          —          —          96        —          96  
Earnout Liability (included in Other Liabilities)
     —          —          —          —          —          —          14        14  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total liabilities
   $
    
—        $
    
—        $
    
—        $
    
—        $
 
 
—        $
 
 
346      $
 
 
14      $
 
 
360  
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value
Our long-term debt, including the current portion of long-term debt not reflected in the financial statements at fair value, is reflected in the table below:
 
    
Fair Value Measurement at
January 31, 2021
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $   —        $   —        $ 12,586      $ 12,586      $ 12,576  
     
    
Fair Value Measurement at
January 31, 2020
        
(In thousands)   
Level 1
    
Level 2
    
Level 3
    
Total
    
Carrying
Value
 
Long-Term Debt and Related Current Maturities
   $ —        $ —        $ 13,258      $ 13,258      $ 13,034  
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
May 06, 2020
Summary Of Significant Accounting Policies [Line Items]        
Highly liquid investments with an original maturity 90 days or less      
Cash of held in foreign bank accounts $ 4,600,000 $ 3,400,000    
Net transactional foreign exchange losses 600,000 400,000 $ 700,000  
Advertising expense 900,000 1,800,000 1,900,000  
Impairment of Long lived assets held for use 0 0 0  
Impairment of intangible assets $ 0 $ 0 $ 0  
Number of common equivalent shares 642,623 202,187 326,275  
No compensation expense is recognized on forfeited options $ 0      
Liability for self-insured claims 200,000 $ 600,000    
Green wood Credit Union [Member] | Paycheck Protection Program Loan [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Debt instrument face amount       $ 4,400,000
Promissory Note [Member] | Paycheck Protection Program Loan [Member] | Greenwood Credit Union [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Debt related commitment fees and debt issuance costs $ 4,400,000      
Maximum [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Percentage of revenue satisfied for services 10.00% 10.00%    
Maximum [Member] | Airborne Product [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Products warranty period 5 years      
Minimum [Member] | Airborne Product [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Products warranty period 3 years      
Land Improvements [Member] | Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 20 years      
Land Improvements [Member] | Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 10 years      
Building And Leasehold Improvements [Member] | Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 45 years      
Building And Leasehold Improvements [Member] | Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 10 years      
Machinery and Equipment [Member] | Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 10 years      
Machinery and Equipment [Member] | Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 3 years      
Computer Equipment And Software [Member] | Maximum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 10 years      
Computer Equipment And Software [Member] | Minimum [Member]        
Summary Of Significant Accounting Policies [Line Items]        
Estimated useful lives of the assets 3 years      
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Disaggregation of Revenue [Line Items]      
Total Revenue $ 116,033 $ 133,446 $ 136,657
United States [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 70,911 83,671 83,668
Europe [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 29,029 29,617 31,574
Canada [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 5,574 5,719 6,692
Asia [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 5,105 8,316 8,207
Central and South America [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 3,950 4,145 4,147
Other [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue $ 1,464 $ 1,978 $ 2,369
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Disaggregation of Revenue [Line Items]      
Total Revenue $ 116,033 $ 133,446 $ 136,657
Hardware [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 34,111 48,959 53,207
Supplies [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue 71,772 71,838 71,178
Service and Other [Member]      
Disaggregation of Revenue [Line Items]      
Total Revenue $ 10,150 $ 12,649 $ 12,272
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Recognition - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Disaggregation of Revenue [Abstract]    
Contract liabilities and extended warranties $ 285,000 $ 466,000
Revenue recognized 466,000  
Contract assets balance 881,000 885,000
Amortization of incremental direct costs 26,940  
Deferred incremental direct contract costs reported in other current assets $ 36,000 59,000
Amortization period of contract costs 5 years  
Deferred incremental direct costs net of accumulated amortization $ 917,000 $ 944,000
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill - Summary of Goodwill by reporting unit (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Goodwill [Line Items]    
Balance at beginning $ 12,034,000 $ 12,329,000
Foreign currency translation 772 (295,000)
Balance at end 12,806,000 12,034,000
Product Idenification [Member]    
Goodwill [Line Items]    
Balance at beginning 7,512,000 7,807,000
Foreign currency translation 772 (295,000)
Balance at end 8,284,000 7,512,000
T M [Member]    
Goodwill [Line Items]    
Balance at beginning 4,522,000 4,522,000
Balance at end $ 4,522,000 $ 4,522,000
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Goodwill - Additional Information (Detail)
12 Months Ended
Jan. 31, 2021
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill impaired $ 0
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount $ 37,387 $ 37,387
Accumulated Amortization (16,170) (12,109)
Currency Translation Adjustment 285 105
Net Carrying Amount 21,502 25,383
Customer Contract Relationships [Member] | Honeywell Asset Purchase and License Agreement [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 27,243 27,243
Accumulated Amortization (9,712) (6,791)
Net Carrying Amount 17,531 20,452
Customer Contract Relationships [Member] | Miltope [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 3,100 3,100
Accumulated Amortization (2,284) (2,021)
Net Carrying Amount 816 1,079
Customer Contract Relationships [Member] | RITEC [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,830 2,830
Accumulated Amortization (1,423) (1,076)
Net Carrying Amount 1,407 1,754
Non-Competition Agreement [Member] | RITEC [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 950 950
Accumulated Amortization (950) (871)
Net Carrying Amount 0 79
Existing Technology [Member] | TrojanLabel ApS [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 2,327 2,327
Accumulated Amortization (1,405) (1,053)
Currency Translation Adjustment 196 78
Net Carrying Amount 1,118 1,352
Distributor Relations [Member] | TrojanLabel ApS [Member]    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Amount 937 937
Accumulated Amortization (396) (297)
Currency Translation Adjustment 89 27
Net Carrying Amount $ 630 $ 667
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Impairment of Intangible Assets (Excluding Goodwill) [Abstract]      
Impairments of intangible assets $ 0 $ 0 $ 0
Amortization expense $ 4,100,000 $ 4,200,000 $ 4,100,000
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Assets - Summary of Estimated Amortization Expense (Detail)
$ in Thousands
Jan. 31, 2021
USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]  
2022 $ 3,938
2023 3,956
2024 4,055
2025 3,416
2026 $ 3,021
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories - Additional Information (Detail) - USD ($)
$ in Millions
Jan. 31, 2021
Jan. 31, 2020
Inventory Disclosure [Abstract]    
Inventory demonstration equipment $ 4.0 $ 3.4
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Inventories - Components of Inventories (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Inventory Disclosure [Abstract]    
Materials and Supplies $ 20,265 $ 20,151
Work-in-Progress 2,076 1,408
Finished Goods 16,371 17,992
Inventory, Gross 38,712 39,551
Inventory Reserve (8,652) (5,626)
Inventories $ 30,060 $ 33,925
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Property, Plant and Equipment [Abstract]    
Land and Land Improvements $ 1,004 $ 967
Buildings and Leasehold Improvements 12,642 12,524
Machinery and Equipment 23,346 23,167
Computer Equipment and Software 13,847 11,388
Gross Property, Plant and Equipment 50,839 48,046
Accumulated Depreciation (38,828) (36,778)
Net Property Plant and Equipment $ 12,011 $ 11,268
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Property, Plant and Equipment - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Property, Plant and Equipment [Abstract]      
Depreciation expense on property, plant and equipment $ 1.9 $ 2.0 $ 2.0
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Jan. 31, 2018
Payables and Accruals [Abstract]        
Warranty $ 730 $ 850 $ 832 $ 575
Professional Fees 546 697    
Lease Liability 372 416    
Accrued Payroll & Sales Tax 292 193    
Stockholder Relation Fees 91 194    
Dealer Commissions 57 236    
Other Accrued Expenses 1,851 2,125    
Total $ 3,939 $ 4,711    
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List] Lease Liability Lease Liability    
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Debt Instrument [Line Items]    
USD Term Loan $ 12,576 $ 13,034
Debt Issuance Costs, net of accumulated amortization (141) (111)
Current Portion of Term Loan (5,326) (5,208)
Long-Term Debt 7,109 7,715
Term Loan Due June 15, 2022 [Member]    
Debt Instrument [Line Items]    
USD Term Loan 12,576 0
Term Loan Due November 30, 2022 [Member]    
Debt Instrument [Line Items]    
USD Term Loan 0 8,250
Term Loan Due January 31, 2022 [Member]    
Debt Instrument [Line Items]    
USD Term Loan $ 0 $ 4,784
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail)
12 Months Ended
Jan. 31, 2021
Term Loan Due June 15, 2022 [Member]  
Debt Instrument [Line Items]  
Debt instrument, description of variable rate basis 4.65% as of January 31, 2021); maturity date of June 15, 2022
Interest rate 4.65%
Debt instrument, maturity date Jun. 15, 2022
Term Loan Due November 30, 2022 [Member]  
Debt Instrument [Line Items]  
Interest rate 3.03%
Term Loan Due January 31, 2022 [Member]  
Debt Instrument [Line Items]  
Interest rate 3.03%
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) - Term Loan [Member]
$ in Thousands
Jan. 31, 2021
USD ($)
Debt Instrument [Line Items]  
Fiscal 2022 $ 5,326
Fiscal 2023 7,250
Long-term Debt $ 12,576
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Credit Agreement and Long- Term Debt - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Mar. 24, 2021
Apr. 30, 2022
Apr. 30, 2021
Jan. 31, 2021
Oct. 31, 2020
Aug. 01, 2020
Jul. 31, 2020
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Debt Instrument [Line Items]                    
Interest Expense               $ 500,000 $ 400,000 $ 600,000
Term Loan [Member]                    
Debt Instrument [Line Items]                    
Payments for debt issuance costs       $ 200,000       200,000    
Capilaized finance costs       100,000       100,000    
Debt related expenses       $ 100,000       $ 100,000    
Principal payment terms               the principal amount of the quarterly installment required to be paid on the last day of our fiscal quarter ending January 31, 2021 was $1.1 million; the principal amount of the quarterly installment required to be paid on the last day of the our fiscal quarter ending on or about April 30, 2021 will be $1.1 million; the principal amount of each quarterly installment required to be paid on the last day of each of the our fiscal quarters ending on or about July 31, 2021, October 31, 2021, January 31, 2022 and April 30, 2022 is $1.4 million, and the entire remaining principal balance of the term loan is required to be paid on June 15, 2022    
Longterm Debt instrument, maturity date       Jun. 15, 2022       Jun. 15, 2022    
Debt Instrument, Frequency of Periodic Payment               quarterly installment    
Debt Instrument, principal Periodic payment         $ 800,000 $ 1,400,000        
Term Loan [Member] | Forecast [Member]                    
Debt Instrument [Line Items]                    
Debt Instrument, principal Periodic payment   $ 1,400,000 $ 1,100,000              
Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Fees related to the revolving line of credit               $ 100,000    
Unamortized debt issuance cost       $ 100,000       $ 100,000    
Variable interest rate               1.00    
LIBOR [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Interest rate 1.00%             1.00%    
Federal Funds Effective Swap Rate [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Interest rate               0.50%    
Minimum [Member] | Term Loan [Member]                    
Debt Instrument [Line Items]                    
Debt Instrument, principal Periodic payment       1,100,000     $ 800,000      
Minimum [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Percentage added to variable rate               1.15%    
Commitment fee rate               0.25%    
Minimum [Member] | LIBOR [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Interest rate               2.15%    
Maximum [Member] | Term Loan [Member]                    
Debt Instrument [Line Items]                    
Debt Instrument, principal Periodic payment       1,400,000     $ 1,400,000      
Maximum [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Percentage added to variable rate               2.65%    
Commitment fee rate               0.675%    
Maximum [Member] | LIBOR [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Interest rate               3.65%    
Bank of America, N.A. [Member]                    
Debt Instrument [Line Items]                    
Term loans repaid               $ 1,500,000    
Bank of America, N.A. [Member] | Term Loan [Member]                    
Debt Instrument [Line Items]                    
Term loan, principal amount       15,200,000       15,200,000    
Bank of America, N.A. [Member] | Revolving Credit Facility [Member]                    
Debt Instrument [Line Items]                    
Maximum borrowing capacity       $ 10,000,000.0       $ 10,000,000.0    
Revolving line of credit, Outstanding loan amount weighted average interest rate       3.41%       3.41%    
Credit facility, remaining borrowing capacity       $ 10,000,000.0       $ 10,000,000.0    
Bank of America, N.A. [Member] | Revolving Credit Facility [Member] | Other Expense [Member]                    
Debt Instrument [Line Items]                    
Revolving line of credit, Interest expenses incurred               $ 188,000    
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Paycheck Protection Program Loan - Additional information (Detail) - Paycheck Protection Program Loan [Member] - USD ($)
12 Months Ended
Jan. 31, 2021
May 06, 2020
Percent of loan to be forgiven 40.00%  
Green wood Credit Union [Member]    
Debt instrument face amount   $ 4,400,000
Loan, payment terms The PPP Loan, which will mature on May 6, 2022, is unsecured and bears interest at a rate of 1.0% per annum, accruing from the loan date, and is payable monthly.  
Loan, maturity date May 06, 2022  
Loan, interest rate 1.00%  
Loan, payments due $ 0  
Green wood Credit Union [Member] | Other Expense [Member]    
Loan, interest accrued $ 33,000  
XML 83 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Derivative Financial Instruments and Risk Management - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Aug. 01, 2020
Jan. 31, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest Rate Swap Termination   $ 45,000
Cash Flow Hedging [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Cash paid termination of swaps $ 700,000  
Cross Currency Interest Rate Contract [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Amount of gain reclassify from Accumulated OCI into loss during next 12 months   100,000
Interest Rate Swap Termination   100,000
Cross Currency Interest Rate Contract [Member] | Cash Flow Hedging [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Amount of Gain Reclassified from Accumulated OCI into Income (Expense)   $ 58,000
XML 84 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail) - Cash Flow Hedge [Member] - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Cross Currency Interest Rate Contract [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Amount of Gain (Loss) Recognized in OCI on Derivative $ (301) $ 159
Location of Gain Reclassified from Accumulated OCI into Income (Expense) Other Income  
Amount of Gain (Loss) Reclassified from Accumulated OCI into Income $ (248) 338
Cross Currency Interest Rate Swap [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional Amount   4,489
Fair Value Derivatives, Liability   250
Interest Rate Swap [Member]    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Notional Amount   8,250
Fair Value Derivatives, Liability   $ 96
XML 85 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Royalty Obligation - Additional Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2018
Guaranteed Minimum Royalty Payment $ 5,500    
Royalty Obligation, Current 2,000 $ 2,000  
Royalty Obligation Non Current 6,161 8,012  
Accrued Royalties, Current, Excess Royalty Payment Due $ 177 773  
Honeywell Asset Purchase and License Agreement [Member]      
Payment Term Period 10 years    
Minimum Royalty Payment Obligations     $ 15,000
Fair Value Assumption Percentage Of Present Value Factor 2.80%    
Royalty Obligation, Current $ 2,000    
Royalty Obligation Non Current 6,100    
Excess Royalty Payments $ 31 $ 1,200  
XML 86 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Lessee, Operating Lease, Option to Extend options to extend the lease term for periods of up to five years  
Lease expense, related party $ 63,000 $ 63,000
Operating Lease, Weighted Average Remaining Lease Term 5 years 2 months 12 days  
Operating Lease, Weighted Average Discount Rate, Percent 4.00%  
Maximum [Member]    
Operating Lease Remaining Lease Term 8 years  
Minimum [Member]    
Operating Lease Remaining Lease Term 1 year  
XML 87 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Operating Leases [Abstract]    
Right of Use Assets $ 1,389 $ 1,661
Other Accrued Expenses 372 416
Lease Liabilities $ 1,065 $ 1,279
XML 88 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Lease Cost Information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
General and Administrative Expense [Member]    
Operating Lease Costs $ 485 $ 449
XML 89 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Maturities of lease liabilities (Detail)
$ in Thousands
Jan. 31, 2021
USD ($)
Leases [Abstract]  
2022 $ 372
2023 318
2024 292
2025 184
2026 163
Thereafter 270
Total Lease Payments 1,599
Less: Imputed Interest (162)
Total Lease Liabilities $ 1,437
XML 90 R75.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Supplemental cash flow information (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Cash paid for amounts included in the measurement of lease liabilities [Abstract]    
Cash paid for operating lease liabilities $ 429 $ 406
XML 91 R76.htm IDEA: XBRL DOCUMENT v3.21.1
Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Schedule of Capitalization, Equity [Line Items]      
Beginning Balance $ 71,375 $ 69,775 $ 63,647
Other Comprehensive Income (Loss) 709 (275) (646)
Ending Balance 74,683 71,375 69,775
Foreign Currency Translation Adjustments [Member]      
Schedule of Capitalization, Equity [Line Items]      
Beginning Balance (985) (852) (181)
Other Comprehensive Loss Income (Loss) before reclassification 710 (133) (671)
Other Comprehensive Income (Loss) 710 (133) (671)
Ending Balance (275) (985) (852)
Unrealized Holding Gain/(Loss) on Available for Sale Securities [Member]      
Schedule of Capitalization, Equity [Line Items]      
Beginning Balance     (3)
Amounts reclassified from AOCL to Earnings     3
Other Comprehensive Income (Loss)     3
Net Unrealized Gain/(Loss) on Cash Flow Hedges [Member]      
Schedule of Capitalization, Equity [Line Items]      
Beginning Balance (108) 34 12
Other Comprehensive Loss Income (Loss) before reclassification (239) 122 622
Amounts reclassified from AOCL to Earnings 193 (264) (600)
Cross-Currency Interest Rate Swap Termination 45    
Other Comprehensive Income (Loss) (1) (142) 22
Ending Balance (109) (108) 34
Accumulated Other Comprehensive Income (Loss) [Member]      
Schedule of Capitalization, Equity [Line Items]      
Beginning Balance (1,093) (818) (172)
Other Comprehensive Loss Income (Loss) before reclassification 471 (11) (49)
Amounts reclassified from AOCL to Earnings 193 (264) (597)
Cross-Currency Interest Rate Swap Termination 45    
Other Comprehensive Income (Loss) 709 (275) (646)
Ending Balance $ (384) $ (1,093) $ (818)
XML 92 R77.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Additional information (Detail) - USD ($)
$ in Millions
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Class of Stock [Line Items]      
Company shares given to employees, shares 15,357 20,329 33,430
Company shares given to employees, value $ 0.1 $ 0.5 $ 0.6
XML 93 R78.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares outstanding 622,083 679,044 771,145 745,270
Number of options granted 0 0 196,000  
Options granted weighted-average fair value per share     $ 7.43  
Aggregate intrinsic value of options exercised $ 4,000 $ 500,000 $ 1,100,000  
Reservation of shares under Stock Purchase Plan 247,500      
Restricted Stock or Unit Expense $ 1,285,000 $ 1,136,000 $ 1,088,000  
2015 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares outstanding 10,833      
Employee Stock Purchase Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Employee Stock Purchase Plan discount rate 15.00%      
2007 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares outstanding 337,958      
2018 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Shares authorized for grant under the Plan 950,000      
Number of shares outstanding 135,500      
Stock Options [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation expense related to options $ 200,000      
Unrecognized compensation expense to be recognized, Weighted average period 9 months 18 days      
Aggregate intrinsic value of option exercised $ 100,000      
Aggregate intrinsic value of the options outstanding $ 100,000      
2014 Restricted Stock Units (RSUs) [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Unrecognized compensation expense to be recognized, Weighted average period 9 months 18 days      
Unrecognized compensation expense related to RSUs and RSAs $ 1,100,000      
RSA [Member] | 2015 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares outstanding 148,625      
RSA [Member] | 2018 Equity Incentive Plan [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of unvested shares 186,500      
Restricted Stock Award [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Restricted Stock or Unit Expense $ 60,000      
XML 94 R79.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Share-Based Compensation Expense (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Share-based Compensation [Abstract]      
Stock Options $ 517 $ 616 $ 783
Restricted Stock Awards and Restricted Stock Units 1,285 1,136 1,088
Employee Stock Purchase Plan 17 23 15
Total $ 1,819 $ 1,775 $ 1,886
XML 95 R80.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail) - $ / shares
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Share-based Compensation [Abstract]      
Beginning balance, Number of Options 679,044 771,145 745,270
Granted, Number of Options 0 0 196,000
Exercised, Number of Options (1,200) (57,175) (150,125)
Forfeited, Number of Options (54,361) (34,526) (16,300)
Canceled, Number of Options (1,400) (400) (3,700)
Ending balance, Number of Options 622,083 679,044 771,145
Beginning balance, Weighted-Average Exercise Price Per Share $ 14.46 $ 14.30 $ 12.52
Granted, Weighted-Average Exercise Price Per Share   0 18.21
Exercised, Weighted-Average Exercise Price Per Share 7.60 11.60 10.62
Forfeited, Weighted-Average Exercise Price Per Share 12.89 15.73 15.10
Cancelled, Weighted-Average Exercise Price Per Share 7.36 6.22 8.95
Ending balance, Weighted-Average Exercise Price Per Share $ 14.63 $ 14.46 $ 14.30
XML 96 R81.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Summary of Options Outstanding (Detail) - $ / shares
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Number of shares outstanding, total 622,083 679,044 771,145 745,270
Outstanding, Weighted Average Exercise Price $ 14.63      
Exercisable, Weighted Average Exercise Price $ 14.33      
Outstanding Remaining Contractual Life 5 years 3 months 18 days      
Number of shares exercisable, total 535,152      
Exercisable Remaining Contractual Life 5 years 1 month 6 days      
$5.00 - $10.00 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Outstanding Range of Exercise prices, Lower Limit $ 5.00      
Outstanding Range of Exercise prices, Upper Limit $ 10.00      
Outstanding, Number of shares 41,044      
Outstanding, Weighted Average Exercise Price $ 7.97      
Exercisable, Weighted Average Exercise Price $ 7.97      
Outstanding Remaining Contractual Life 1 year 3 months 18 days      
Exercisable, Number of shares 41,044      
Exercisable Remaining Contractual Life 1 year 3 months 18 days      
$10.01 - $15.00 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Outstanding Range of Exercise prices, Lower Limit $ 10.01      
Outstanding Range of Exercise prices, Upper Limit $ 15.00      
Outstanding, Number of shares 359,314      
Outstanding, Weighted Average Exercise Price $ 13.63      
Exercisable, Weighted Average Exercise Price $ 13.65      
Outstanding Remaining Contractual Life 4 years 10 months 24 days      
Exercisable, Number of shares 326,741      
Exercisable Remaining Contractual Life 4 years 8 months 12 days      
$15.01 - $20.00 [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Outstanding Range of Exercise prices, Lower Limit $ 15.01      
Outstanding Range of Exercise prices, Upper Limit $ 20.00      
Outstanding, Number of shares 221,725      
Outstanding, Weighted Average Exercise Price $ 17.48      
Exercisable, Weighted Average Exercise Price $ 17.22      
Outstanding Remaining Contractual Life 6 years 9 months 18 days      
Exercisable, Number of shares 167,367      
Exercisable Remaining Contractual Life 6 years 8 months 12 days      
XML 97 R82.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail) - Restricted Stock Award And Restricted Stock Unit [Member] - $ / shares
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Beginning balance, Outstanding Restricted Stock Units and Restricted Stock Awards 134,634 133,667 177,347
Granted, Restricted Stock Units and Restricted Stock Awards 245,131 119,522 108,790
Vested, Restricted Stock Units and Restricted Stock Awards (64,997) (59,930) (67,447)
Forfeited, Restricted Stock Units and Restricted Stock Awards (117,355) (58,625) (85,023)
Ending balance, Outstanding Restricted Stock Units and Restricted Stock Awards 197,413 134,634 133,667
Beginning balance, Weighted Average Grant Date Fair Value $ 16.79 $ 16.90 $ 13.99
Granted, Weighted Average Grant Date Fair Value 7.61 19.86 17.85
Vested, Weighted Average Grant Date Fair Value 17.28 14.50 14.26
Forfeited, Weighted Average Grant Date Fair Value 8.83 19.00 14.17
Ending balance, Weighted Average Grant Date Fair Value $ 9.96 $ 16.79 $ 16.90
XML 98 R83.htm IDEA: XBRL DOCUMENT v3.21.1
Share-Based Compensation - Summarized Plan Activity (Detail) - Employee Stock Purchase Plan [Member] - shares
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares Reserved, Beginning Balance 24,974 33,853 39,207
Shares Purchased (14,600) (8,879) (5,354)
Shares Reserved, Ending Balance 10,374 24,974 33,853
XML 99 R84.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Deferred Tax Assets:    
Inventory $ 2,700 $ 2,094
Honeywell Royalty Liability 2,590 2,583
State R&D Credits 1,546 1,496
Share-Based Compensation 600 582
Bad Debt 245 165
Warranty Reserve 176 205
Compensation Accrual 159 159
Net Operating Loss 154 443
ASU 842 Adjustment—Lease Liability 125  
Unrecognized State Tax Benefits 101 116
Foreign Tax Credit 83 113
Deferred Service Contract Revenue 68 111
Other 308 295
Deferred Tax Assets, Total 8,855 8,362
Deferred Tax Liabilities:    
Accumulated Tax Depreciation in Excess of Book Depreciation 752 1,002
Intangibles 399 776
ASU 842 Adjustment – Lease Liability 119 0
Other 307 188
Deferred Tax Liabilities, Total 1,577 1,966
Subtotal 7,278 6,396
Valuation Allowance (1,721) (1,752)
Net Deferred Tax Assets $ 5,557 $ 4,644
XML 100 R85.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Income Tax Disclosure [Abstract]      
Income Tax Provision at Statutory Rate $ 458 $ 288 $ 1,534
Denmark Statutory Audit 341    
Foreign Rate Deferential 197 315 558
Share Based Compensation 171 (145) (127)
Canada Withholding Taxes 62    
State Taxes, Net of Federal Tax Effect 28 (48) 226
Global Intangible Low Taxed Income 14 107  
Meals and Entertainment 11 31 56
U.S Corporate Rate Change     52
Transition Tax on Repatriated Earnings     14
Return to Provision Adjustment (2) (207) 58
Change in Reserves Related to ASC 740 Liability (10) (352) (34)
Change in Valuation Allowance (81) 256  
R&D Credits (157) (209) (218)
Foreign Deferred Intangible Income (150) (107) (53)
Foreign Tax Credits   (344) (477)
Other 13 26 (11)
Total $ 895 $ (389) $ 1,578
XML 101 R86.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Components of Income before Income Taxes (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Income Tax Disclosure [Abstract]      
Domestic $ (1,193) $ 1,930 $ 6,859
Foreign 3,372 (560) 449
Income before Income Taxes $ 2,179 $ 1,370 $ 7,308
XML 102 R87.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Components of Provision for Income Taxes (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Current:      
Federal $ 1,272 $ 660 $ 1,807
State 224 221 457
Foreign 420 368 952
Current Income Tax Expense 1,916 1,249 3,216
Deferred:      
Federal (910) (1,364) (843)
State (189) (282) (170)
Foreign 78 8 (625)
Deferred Income Tax Expense Total (1,021) (1,638) (1,638)
Total $ 895 $ (389) $ 1,578
XML 103 R88.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Income Tax Disclosure [Abstract]      
Balance at February 1 $ 362 $ 618 $ 665
Increases in prior period tax positions 59    
Increases in current period tax positions 5 2 7
Reductions related to lapse of statutes of limitations (42) (26) (54)
Reductions related to settlement with tax authorities   (232)  
Balance at January 31 $ 384 $ 362 $ 618
XML 104 R89.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Additional Information (Detail) - USD ($)
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Jan. 31, 2018
Effective tax rate for income from continuing operation 41.10% 28.40% 21.60%  
Valuation allowance $ 1,721,000 $ 1,752,000    
Recognized (benefit) expense related to interest and penalties 50,000 114,000 $ 8,000  
Accrued potential interest and penalties   300,000    
Deferred Tax Assets Operating loss carryforwards 154,000 443,000    
Deferred tax assets tax credit carryforwards research $ 1,546,000 1,496,000    
Deferred tax assets tax credit carryforwards expiration period 2021 through 2028      
Deemed repatriated earnings $ 5,700,000      
Recognized tax benefits excluding interest and penalties 384,000 362,000 $ 618,000 $ 665,000
CHINA        
Deferred Tax Assets Operating loss carryforwards $ 400,000      
Deferred tax assets operating loss carryforwards expiration period 2022 through 2026      
DELAWARE        
Deferred Tax Assets Operating loss carryforwards $ 200,000      
Federal Tax [Member]        
Recognized (benefit) expense related to interest and penalties   74,000    
Recognized tax benefits excluding interest and penalties   $ 232,000    
XML 105 R90.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail)
$ in Thousands
12 Months Ended
Jan. 31, 2021
USD ($)
Segment
Jan. 31, 2020
USD ($)
Segment
Jan. 31, 2019
USD ($)
Segment
Segment Reporting Information [Line Items]      
Number of reporting segments | Segment 2    
Customer accounted for greater than 10% of net sales | Segment 0 0 0
Goodwill assigned $ 12,806 $ 12,034 $ 12,329
T&M [Member]      
Segment Reporting Information [Line Items]      
Goodwill assigned 4,500 4,500  
Product Identification [Member]      
Segment Reporting Information [Line Items]      
Goodwill assigned $ 8,300 $ 7,500  
XML 106 R91.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Segment Reporting Information [Line Items]      
Revenue $ 116,033 $ 133,446 $ 136,657
Corporate Expenses 9,420 11,357 11,123
Operating Income 2,433 2,433 8,720
Other Expense, Net $ (254) $ (1,063) $ (1,412)
Segment Operating Profit % of Net Sales (10.30%) 10.30% 14.50%
Income before Income Taxes $ 2,179 $ 1,370 $ 7,308
Income Tax Provision (Benefit) 895 (389) 1,578
Net Income 1,284 1,759 5,730
Operating Segments [Member]      
Segment Reporting Information [Line Items]      
Operating Income 11,853 13,790 19,843
Operating Segments [Member] | Product Identification [Member]      
Segment Reporting Information [Line Items]      
Revenue 90,268 88,116 86,786
Operating Income $ 12,885 $ 7,509 $ 7,910
Segment Operating Profit % of Net Sales 14.30% 8.50% 9.10%
Operating Segments [Member] | T&M [Member]      
Segment Reporting Information [Line Items]      
Revenue $ 25,765 $ 45,330 $ 49,871
Operating Income $ (1,032) $ 6,281 $ 11,933
Segment Operating Profit % of Net Sales (4.00%) 13.90% 23.90%
Corporate Expenses [Member]      
Segment Reporting Information [Line Items]      
Corporate Expenses $ 9,420 $ 11,357 $ 11,123
XML 107 R92.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Segment Reporting Information [Line Items]      
Assets $ 115,473 $ 116,664  
Depreciation and Amortization 5,983 6,284 $ 6,152
Capital Expenditures 2,587 2,906 2,645
Operating Segments [Member] | Product Identification [Member]      
Segment Reporting Information [Line Items]      
Assets 50,047 51,439  
Depreciation and Amortization 1,835 1,928 1,888
Capital Expenditures 1,563 2,001 1,935
Operating Segments [Member] | T&M [Member]      
Segment Reporting Information [Line Items]      
Assets 51,262 57,050  
Depreciation and Amortization 4,148 4,356 4,264
Capital Expenditures 1,024 905 $ 710
Corporate Expenses [Member]      
Segment Reporting Information [Line Items]      
Assets $ 14,164 $ 8,175  
XML 108 R93.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue $ 116,033 $ 133,446 $ 136,657
Long-Lived Assets 33,513 36,651  
United States [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue 70,911 83,671 83,668
Long-Lived Assets 31,226 34,072  
Europe [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue 29,029 29,617 31,574
Long-Lived Assets 2,274 2,544  
Asia [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue 5,105 8,316 8,207
Canada [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue 5,574 5,719 6,692
Long-Lived Assets 13 35  
Central and South America [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue 3,950 4,145 4,147
Other [Member]      
Revenues from External Customers and Long-Lived Assets [Line Items]      
Revenue $ 1,464 $ 1,978 $ 2,369
XML 109 R94.htm IDEA: XBRL DOCUMENT v3.21.1
Employee Benefit Plans - Additional Information (Detail) - USD ($)
$ in Millions
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Postemployment Benefits [Abstract]      
Contributions paid or accrued amounted $ 0.4 $ 0.5 $ 0.5
XML 110 R95.htm IDEA: XBRL DOCUMENT v3.21.1
Product Warranty Liability - Activity in Product Warranty Liability (Detail) - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Product Warranties Disclosures [Abstract]      
Balance, beginning of the year $ 850 $ 832 $ 575
Provision for Warranty Expense 855 1,733 1,680
Cost of Warranty Repairs (975) (1,715) (1,423)
Balance, end of the year $ 730 $ 850 $ 832
XML 111 R96.htm IDEA: XBRL DOCUMENT v3.21.1
Concentration of Risk - Additional Information (Detail) - Vendor [Member]
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
Purchases [Member]      
Concentration Risk [Line Items]      
Concentration Risk, Percentage 23.20% 21.20% 21.60%
Trade Accounts Payables [Member]      
Concentration Risk [Line Items]      
Concentration Risk, Percentage 23.80% 28.00% 28.70%
XML 112 R97.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)   $ 250
Interest Rate Swap Contract (included in Other Long-Term Liabilities)   96
Earnout Liability (included in Other Liabilities)   14
Total Liabilities   360
Level 2 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities) 250
Interest Rate Swap Contract (included in Other Long-Term Liabilities) 96
Total Liabilities 346
Level 3 [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Earnout Liability (included in Other Liabilities)   14
Total Liabilities   $ 14
XML 113 R98.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) - USD ($)
$ in Thousands
Jan. 31, 2021
Jan. 31, 2020
Fair Value [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term Debt and Related Current Maturities $ 12,586 $ 13,258
Fair Value [Member] | Level 3 [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term Debt and Related Current Maturities 12,586 13,258
Carrying Value [Member]    
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]    
Long-Term Debt and Related Current Maturities $ 12,576 $ 13,034
XML 114 R99.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Event - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Jul. 31, 2025
Apr. 30, 2025
Jan. 01, 2025
Oct. 31, 2024
Jul. 31, 2024
Apr. 30, 2024
Jan. 01, 2024
Oct. 31, 2023
Jul. 31, 2023
Apr. 30, 2023
Jan. 01, 2023
Jul. 31, 2022
Apr. 30, 2022
Jan. 31, 2022
Oct. 31, 2021
Jul. 31, 2021
Apr. 30, 2021
Apr. 24, 2021
Mar. 24, 2021
Apr. 30, 2022
Apr. 30, 2021
Jan. 31, 2021
Oct. 31, 2020
Aug. 01, 2020
Jul. 31, 2020
Jan. 31, 2021
Bank Of America [Member]                                                    
Subsequent Event [Line Items]                                                    
Term loans repaid                                                   $ 1,500,000
Term Loan [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, principal Periodic payment                                             $ 800,000 $ 1,400,000    
Debt Instrument, Frequency of Periodic Payment                                                   quarterly installment
Term Loan [Member] | Scenario, Forecast [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, principal Periodic payment                                       $ 1,400,000 $ 1,100,000          
Term Loan [Member] | Maximum [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, principal Periodic payment                                           $ 1,400,000     $ 1,400,000  
Term Loan [Member] | Minimum [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, principal Periodic payment                                           1,100,000     $ 800,000  
Term Loan [Member] | First Amendment to Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, Frequency of Periodic Payment                                   quarterly installment                
Term Loan [Member] | First Amendment to Credit Agreement [Member] | Scenario, Forecast [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt Instrument, principal Periodic payment $ 500,000 $ 500,000 $ 312,500 $ 312,500 $ 312,500 $ 312,500 $ 312,500 $ 312,500 $ 312,500 $ 312,500 $ 250,000 $ 250,000 $ 250,000 $ 187,500 $ 187,500 $ 187,500 $ 187,500                  
Term Loan [Member] | Bank Of America [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt instrument face amount                                           15,200,000       $ 15,200,000
Term Loan [Member] | Bank Of America [Member] | First Amendment to Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt borrowed                                     $ 10.0              
Revolving Credit Facility [Member]                                                    
Subsequent Event [Line Items]                                                    
Variable interest rate                                                   1.00
Revolving Credit Facility [Member] | Interest Expense [Member]                                                    
Subsequent Event [Line Items]                                                    
Commitment Fee Paid                                                   28,000
Revolving Credit Facility [Member] | Maximum [Member]                                                    
Subsequent Event [Line Items]                                                    
Percentage added to variable rate                                                   2.65%
Commitment fee rate                                                   0.675%
Revolving Credit Facility [Member] | Minimum [Member]                                                    
Subsequent Event [Line Items]                                                    
Percentage added to variable rate                                                   1.15%
Commitment fee rate                                                   0.25%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                     1.00%             1.00%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                                   3.65%
Revolving Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                                   2.15%
Revolving Credit Facility [Member] | Bank Of America [Member]                                                    
Subsequent Event [Line Items]                                                    
Maximum borrowing capacity                                           $ 10,000,000.0       $ 10,000,000.0
Subsequent Event [Member] | Term Loan [Member] | Bank Of America [Member] | First Amendment to Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt instrument face amount                                     $ 10.0              
Subsequent Event [Member] | Term Loan [Member] | Bank Of America [Member] | Existing Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Term loans repaid                                     2.6              
Debt instrument face amount                                     $ 10.0              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Variable interest rate                                     0.50              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member] | Maximum [Member]                                                    
Subsequent Event [Line Items]                                                    
Percentage added to variable rate                                     1.30%              
Commitment fee rate                                     0.30%              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member] | Minimum [Member]                                                    
Subsequent Event [Line Items]                                                    
Percentage added to variable rate                                     0.60%              
Commitment fee rate                                     0.15%              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                     0.50%              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                     2.30%              
Subsequent Event [Member] | Revolving Credit Facility [Member] | First Amendment to Credit Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]                                                    
Subsequent Event [Line Items]                                                    
Interest rate basis spread                                     1.60%              
Subsequent Event [Member] | Revolving Credit Facility [Member] | Bank Of America [Member] | First Amendment to Credit Agreement [Member]                                                    
Subsequent Event [Line Items]                                                    
Debt instrument face amount                                     $ 22.5              
Maximum borrowing capacity                                     $ 10,000,000.0              
XML 115 R100.htm IDEA: XBRL DOCUMENT v3.21.1
Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) - Allowance for Doubtful Accounts [Member] - USD ($)
$ in Thousands
12 Months Ended
Jan. 31, 2021
Jan. 31, 2020
Jan. 31, 2019
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]      
Balance at Beginning of Year $ 856 $ 521 $ 377
Provision/(Benefit) Charged to Operations 194 546 310
Deductions 4 (211) (166)
Balance at End of Year $ 1,054 $ 856 $ 521
EXCEL 116 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 117 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 118 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 119 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 292 527 1 false 90 0 false 6 false false R1.htm 1001 - Document - Cover Page Sheet http://astro-med.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Consolidated Balance Sheets Sheet http://astro-med.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Consolidated Statements of Income Sheet http://astro-med.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 4 false false R5.htm 1005 - Statement - Consolidated Statements of Comprehensive Income Sheet http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity Sheet http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity Consolidated Statements of Changes in Shareholders' Equity Statements 6 false false R7.htm 1007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) Sheet http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical Consolidated Statements of Changes in Shareholders' Equity (Parenthetical) Statements 7 false false R8.htm 1008 - Statement - Consolidated Statements of Cash Flows Sheet http://astro-med.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 1009 - Disclosure - Summary of Significant Accounting Policies Sheet http://astro-med.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 1010 - Disclosure - Revenue Recognition Sheet http://astro-med.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 1011 - Disclosure - Goodwill Sheet http://astro-med.com/role/Goodwill Goodwill Notes 11 false false R12.htm 1012 - Disclosure - Intangible Assets Sheet http://astro-med.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 1013 - Disclosure - Inventories Sheet http://astro-med.com/role/Inventories Inventories Notes 13 false false R14.htm 1014 - Disclosure - Property, Plant and Equipment Sheet http://astro-med.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 14 false false R15.htm 1015 - Disclosure - Accrued Expenses Sheet http://astro-med.com/role/AccruedExpenses Accrued Expenses Notes 15 false false R16.htm 1016 - Disclosure - Credit Agreement and Long- Term Debt Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebt Credit Agreement and Long- Term Debt Notes 16 false false R17.htm 1017 - Disclosure - Paycheck Protection Program Loan Sheet http://astro-med.com/role/PaycheckProtectionProgramLoan Paycheck Protection Program Loan Notes 17 false false R18.htm 1018 - Disclosure - Derivative Financial Instruments and Risk Management Sheet http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagement Derivative Financial Instruments and Risk Management Notes 18 false false R19.htm 1019 - Disclosure - Royalty Obligation Sheet http://astro-med.com/role/RoyaltyObligation Royalty Obligation Notes 19 false false R20.htm 1020 - Disclosure - Leases Sheet http://astro-med.com/role/Leases Leases Notes 20 false false R21.htm 1021 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 21 false false R22.htm 1022 - Disclosure - Shareholders' Equity Sheet http://astro-med.com/role/ShareholdersEquity Shareholders' Equity Notes 22 false false R23.htm 1023 - Disclosure - Share-Based Compensation Sheet http://astro-med.com/role/ShareBasedCompensation Share-Based Compensation Notes 23 false false R24.htm 1024 - Disclosure - Income Taxes Sheet http://astro-med.com/role/IncomeTaxes Income Taxes Notes 24 false false R25.htm 1025 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformation Nature of Operations, Segment Reporting and Geographical Information Notes 25 false false R26.htm 1026 - Disclosure - Employee Benefit Plans Sheet http://astro-med.com/role/EmployeeBenefitPlans Employee Benefit Plans Notes 26 false false R27.htm 1027 - Disclosure - Product Warranty Liability Sheet http://astro-med.com/role/ProductWarrantyLiability Product Warranty Liability Notes 27 false false R28.htm 1028 - Disclosure - Concentration of Risk Sheet http://astro-med.com/role/ConcentrationOfRisk Concentration of Risk Notes 28 false false R29.htm 1029 - Disclosure - Commitments and Contingencies Sheet http://astro-med.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 29 false false R30.htm 1030 - Disclosure - Fair Value Measurements Sheet http://astro-med.com/role/FairValueMeasurements Fair Value Measurements Notes 30 false false R31.htm 1031 - Disclosure - Subsequent Event Sheet http://astro-med.com/role/SubsequentEvent Subsequent Event Notes 31 false false R32.htm 1032 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves Sheet http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReserves Schedule II - Valuation and Qualifying Accounts and Reserves Notes 32 false false R33.htm 1033 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://astro-med.com/role/SummaryOfSignificantAccountingPolicies 33 false false R34.htm 1034 - Disclosure - Revenue Recognition (Tables) Sheet http://astro-med.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://astro-med.com/role/RevenueRecognition 34 false false R35.htm 1035 - Disclosure - Goodwill (Tables) Sheet http://astro-med.com/role/GoodwillTables Goodwill (Tables) Tables http://astro-med.com/role/Goodwill 35 false false R36.htm 1036 - Disclosure - Intangible Assets (Tables) Sheet http://astro-med.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://astro-med.com/role/IntangibleAssets 36 false false R37.htm 1037 - Disclosure - Inventories (Tables) Sheet http://astro-med.com/role/InventoriesTables Inventories (Tables) Tables http://astro-med.com/role/Inventories 37 false false R38.htm 1038 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://astro-med.com/role/PropertyPlantAndEquipment 38 false false R39.htm 1039 - Disclosure - Accrued Expenses (Tables) Sheet http://astro-med.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://astro-med.com/role/AccruedExpenses 39 false false R40.htm 1040 - Disclosure - Credit Agreement and Long- Term Debt (Tables) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtTables Credit Agreement and Long- Term Debt (Tables) Tables http://astro-med.com/role/CreditAgreementAndLongTermDebt 40 false false R41.htm 1041 - Disclosure - Derivative Financial Instruments and Risk Management (Tables) Sheet http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementTables Derivative Financial Instruments and Risk Management (Tables) Tables http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagement 41 false false R42.htm 1042 - Disclosure - Leases (Tables) Sheet http://astro-med.com/role/LeasesTables Leases (Tables) Tables http://astro-med.com/role/Leases 42 false false R43.htm 1043 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://astro-med.com/role/AccumulatedOtherComprehensiveLoss 43 false false R44.htm 1044 - Disclosure - Share-Based Compensation (Tables) Sheet http://astro-med.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://astro-med.com/role/ShareBasedCompensation 44 false false R45.htm 1045 - Disclosure - Income Taxes (Tables) Sheet http://astro-med.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://astro-med.com/role/IncomeTaxes 45 false false R46.htm 1046 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information (Tables) Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationTables Nature of Operations, Segment Reporting and Geographical Information (Tables) Tables http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformation 46 false false R47.htm 1047 - Disclosure - Product Warranty Liability (Tables) Sheet http://astro-med.com/role/ProductWarrantyLiabilityTables Product Warranty Liability (Tables) Tables http://astro-med.com/role/ProductWarrantyLiability 47 false false R48.htm 1048 - Disclosure - Fair Value Measurements (Tables) Sheet http://astro-med.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://astro-med.com/role/FairValueMeasurements 48 false false R49.htm 1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 49 false false R50.htm 1050 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) Sheet http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail) Details 50 false false R51.htm 1051 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) Sheet http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail) Details 51 false false R52.htm 1052 - Disclosure - Revenue Recognition - Additional Information (Detail) Sheet http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail Revenue Recognition - Additional Information (Detail) Details 52 false false R53.htm 1053 - Disclosure - Goodwill - Summary of Goodwill by reporting unit (Detail) Sheet http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail Goodwill - Summary of Goodwill by reporting unit (Detail) Details 53 false false R54.htm 1054 - Disclosure - Goodwill - Additional Information (Detail) Sheet http://astro-med.com/role/GoodwillAdditionalInformationDetail Goodwill - Additional Information (Detail) Details 54 false false R55.htm 1055 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Sheet http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail) Details 55 false false R56.htm 1056 - Disclosure - Intangible Assets - Additional Information (Detail) Sheet http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail Intangible Assets - Additional Information (Detail) Details 56 false false R57.htm 1057 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail) Sheet http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail Intangible Assets - Summary of Estimated Amortization Expense (Detail) Details 57 false false R58.htm 1058 - Disclosure - Inventories - Additional Information (Detail) Sheet http://astro-med.com/role/InventoriesAdditionalInformationDetail Inventories - Additional Information (Detail) Details 58 false false R59.htm 1059 - Disclosure - Inventories - Components of Inventories (Detail) Sheet http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail Inventories - Components of Inventories (Detail) Details 59 false false R60.htm 1060 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail) Details 60 false false R61.htm 1061 - Disclosure - Property, Plant and Equipment - Additional Information (Detail) Sheet http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail Property, Plant and Equipment - Additional Information (Detail) Details 61 false false R62.htm 1062 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail) Sheet http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail Accrued Expenses - Summary of Accrued Expenses (Detail) Details 62 false false R63.htm 1063 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail) Details 63 false false R64.htm 1064 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail) Details 64 false false R65.htm 1065 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail) Details 65 false false R66.htm 1066 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail) Sheet http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail Credit Agreement and Long- Term Debt - Additional Information (Detail) Details 66 false false R67.htm 1067 - Disclosure - Paycheck Protection Program Loan - Additional information (Detail) Sheet http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail Paycheck Protection Program Loan - Additional information (Detail) Details 67 false false R68.htm 1068 - Disclosure - Derivative Financial Instruments and Risk Management - Additional Information (Detail) Sheet http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail Derivative Financial Instruments and Risk Management - Additional Information (Detail) Details 68 false false R69.htm 1069 - Disclosure - Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail) Sheet http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail) Details 69 false false R70.htm 1070 - Disclosure - Royalty Obligation - Additional Information (Detail) Sheet http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail Royalty Obligation - Additional Information (Detail) Details 70 false false R71.htm 1071 - Disclosure - Leases - Additional Information (Detail) Sheet http://astro-med.com/role/LeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 71 false false R72.htm 1072 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) Sheet http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail) Details 72 false false R73.htm 1073 - Disclosure - Leases - Lease Cost Information (Detail) Sheet http://astro-med.com/role/LeasesLeaseCostInformationDetail Leases - Lease Cost Information (Detail) Details 73 false false R74.htm 1074 - Disclosure - Leases - Maturities of lease liabilities (Detail) Sheet http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail Leases - Maturities of lease liabilities (Detail) Details 74 false false R75.htm 1075 - Disclosure - Leases - Supplemental cash flow information (Detail) Sheet http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail Leases - Supplemental cash flow information (Detail) Details 75 false false R76.htm 1076 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) Sheet http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail) Details 76 false false R77.htm 1077 - Disclosure - Shareholders' Equity - Additional information (Detail) Sheet http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail Shareholders' Equity - Additional information (Detail) Details 77 false false R78.htm 1078 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 78 false false R79.htm 1079 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail Share-Based Compensation - Share-Based Compensation Expense (Detail) Details 79 false false R80.htm 1080 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail) Details 80 false false R81.htm 1081 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail Share-Based Compensation - Summary of Options Outstanding (Detail) Details 81 false false R82.htm 1082 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail) Details 82 false false R83.htm 1083 - Disclosure - Share-Based Compensation - Summarized Plan Activity (Detail) Sheet http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail Share-Based Compensation - Summarized Plan Activity (Detail) Details 83 false false R84.htm 1084 - Disclosure - Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail) Sheet http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail) Details 84 false false R85.htm 1085 - Disclosure - Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail) Sheet http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail) Details 85 false false R86.htm 1086 - Disclosure - Income Taxes - Components of Income before Income Taxes (Detail) Sheet http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail Income Taxes - Components of Income before Income Taxes (Detail) Details 86 false false R87.htm 1087 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Detail) Sheet http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail Income Taxes - Components of Provision for Income Taxes (Detail) Details 87 false false R88.htm 1088 - Disclosure - Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) Sheet http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail) Details 88 false false R89.htm 1089 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 89 false false R90.htm 1090 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail) Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail) Details 90 false false R91.htm 1091 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail) Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail) Details 91 false false R92.htm 1092 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail) Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail) Details 92 false false R93.htm 1093 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail) Sheet http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail) Details 93 false false R94.htm 1094 - Disclosure - Employee Benefit Plans - Additional Information (Detail) Sheet http://astro-med.com/role/EmployeeBenefitPlansAdditionalInformationDetail Employee Benefit Plans - Additional Information (Detail) Details 94 false false R95.htm 1095 - Disclosure - Product Warranty Liability - Activity in Product Warranty Liability (Detail) Sheet http://astro-med.com/role/ProductWarrantyLiabilityActivityInProductWarrantyLiabilityDetail Product Warranty Liability - Activity in Product Warranty Liability (Detail) Details 95 false false R96.htm 1096 - Disclosure - Concentration of Risk - Additional Information (Detail) Sheet http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail Concentration of Risk - Additional Information (Detail) Details 96 false false R97.htm 1097 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) Sheet http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail) Details 97 false false R98.htm 1098 - Disclosure - Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) Sheet http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail) Details 98 false false R99.htm 1099 - Disclosure - Subsequent Event - Additional Information (Detail) Sheet http://astro-med.com/role/SubsequentEventAdditionalInformationDetail Subsequent Event - Additional Information (Detail) Details 99 false false R100.htm 1100 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) Sheet http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail Schedule II - Valuation and Qualifying Accounts and Reserves (Detail) Details http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReserves 100 false false All Reports Book All Reports d56468d10k.htm alot-20210131.xsd alot-20210131_cal.xml alot-20210131_def.xml alot-20210131_lab.xml alot-20210131_pre.xml d56468dex1034.htm d56468dex1035.htm d56468dex21.htm d56468dex231.htm d56468dex311.htm d56468dex312.htm d56468dex321.htm d56468dex322.htm http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/us-gaap/2020-01-31 true true JSON 122 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d56468d10k.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 292, "dts": { "calculationLink": { "local": [ "alot-20210131_cal.xml" ] }, "definitionLink": { "local": [ "alot-20210131_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d56468d10k.htm" ] }, "labelLink": { "local": [ "alot-20210131_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "alot-20210131_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "alot-20210131.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 720, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 3, "http://xbrl.sec.gov/dei/2020-01-31": 4, "total": 7 }, "keyCustom": 49, "keyStandard": 478, "memberCustom": 42, "memberStandard": 48, "nsprefix": "alot", "nsuri": "http://astro-med.com/20210131", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://astro-med.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Revenue Recognition", "role": "http://astro-med.com/role/RevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1100 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves (Detail)", "role": "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail", "shortName": "Schedule II - Valuation and Qualifying Accounts and Reserves (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018_AllowanceForCreditLossMemberusgaapValuationAllowancesAndReservesTypeAxis", "decimals": "-3", "lang": null, "name": "us-gaap:ValuationAllowancesAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Goodwill", "role": "http://astro-med.com/role/Goodwill", "shortName": "Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Intangible Assets", "role": "http://astro-med.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Inventories", "role": "http://astro-med.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Property, Plant and Equipment", "role": "http://astro-med.com/role/PropertyPlantAndEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Accrued Expenses", "role": "http://astro-med.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Credit Agreement and Long- Term Debt", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebt", "shortName": "Credit Agreement and Long- Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:PaycheckProtectionProgramLoan", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Paycheck Protection Program Loan", "role": "http://astro-med.com/role/PaycheckProtectionProgramLoan", "shortName": "Paycheck Protection Program Loan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:PaycheckProtectionProgramLoan", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Derivative Financial Instruments and Risk Management", "role": "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagement", "shortName": "Derivative Financial Instruments and Risk Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:RoyaltyObligationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Royalty Obligation", "role": "http://astro-med.com/role/RoyaltyObligation", "shortName": "Royalty Obligation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:RoyaltyObligationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Consolidated Balance Sheets", "role": "http://astro-med.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Leases", "role": "http://astro-med.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Shareholders' Equity", "role": "http://astro-med.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Share-Based Compensation", "role": "http://astro-med.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Income Taxes", "role": "http://astro-med.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformation", "shortName": "Nature of Operations, Segment Reporting and Geographical Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Employee Benefit Plans", "role": "http://astro-med.com/role/EmployeeBenefitPlans", "shortName": "Employee Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Product Warranty Liability", "role": "http://astro-med.com/role/ProductWarrantyLiability", "shortName": "Product Warranty Liability", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Concentration of Risk", "role": "http://astro-med.com/role/ConcentrationOfRisk", "shortName": "Concentration of Risk", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Commitments and Contingencies", "role": "http://astro-med.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Fair Value Measurements", "role": "http://astro-med.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Subsequent Event", "role": "http://astro-med.com/role/SubsequentEvent", "shortName": "Subsequent Event", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Schedule II - Valuation and Qualifying Accounts and Reserves", "role": "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReserves", "shortName": "Schedule II - Valuation and Qualifying Accounts and Reserves", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Revenue Recognition (Tables)", "role": "http://astro-med.com/role/RevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Goodwill (Tables)", "role": "http://astro-med.com/role/GoodwillTables", "shortName": "Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Intangible Assets (Tables)", "role": "http://astro-med.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Inventories (Tables)", "role": "http://astro-med.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Property, Plant and Equipment (Tables)", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Accrued Expenses (Tables)", "role": "http://astro-med.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Consolidated Statements of Income", "role": "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Credit Agreement and Long- Term Debt (Tables)", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables", "shortName": "Credit Agreement and Long- Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Derivative Financial Instruments and Risk Management (Tables)", "role": "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementTables", "shortName": "Derivative Financial Instruments and Risk Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Leases (Tables)", "role": "http://astro-med.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1043 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1044 - Disclosure - Share-Based Compensation (Tables)", "role": "http://astro-med.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1045 - Disclosure - Income Taxes (Tables)", "role": "http://astro-med.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1046 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information (Tables)", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationTables", "shortName": "Nature of Operations, Segment Reporting and Geographical Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1047 - Disclosure - Product Warranty Liability (Tables)", "role": "http://astro-med.com/role/ProductWarrantyLiabilityTables", "shortName": "Product Warranty Liability (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1048 - Disclosure - Fair Value Measurements (Tables)", "role": "http://astro-med.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:CashEquivalentsMaturityPeriodDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1049 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "div", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "alot:CashEquivalentsMaturityPeriodDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Consolidated Statements of Comprehensive Income", "role": "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome", "shortName": "Consolidated Statements of Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1050 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail)", "role": "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "shortName": "Revenue Recognition - Summary of Revenues Disaggregated by Primary Geographic Markets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_OthersCountriesMembersrtStatementGeographicalAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1051 - Disclosure - Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail)", "role": "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail", "shortName": "Revenue Recognition - Summary of Revenues Disaggregated by Primary Product Type (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_HardwareProductsMembersrtProductOrServiceAxis", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1052 - Disclosure - Revenue Recognition - Additional Information (Detail)", "role": "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail", "shortName": "Revenue Recognition - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1053 - Disclosure - Goodwill - Summary of Goodwill by reporting unit (Detail)", "role": "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail", "shortName": "Goodwill - Summary of Goodwill by reporting unit (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfGoodwillTextBlock", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1054 - Disclosure - Goodwill - Additional Information (Detail)", "role": "http://astro-med.com/role/GoodwillAdditionalInformationDetail", "shortName": "Goodwill - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:GoodwillDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1055 - Disclosure - Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "role": "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "shortName": "Intangible Assets - Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1056 - Disclosure - Intangible Assets - Additional Information (Detail)", "role": "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail", "shortName": "Intangible Assets - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1057 - Disclosure - Intangible Assets - Summary of Estimated Amortization Expense (Detail)", "role": "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail", "shortName": "Intangible Assets - Summary of Estimated Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "alot:InventoryDemonstrationEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1058 - Disclosure - Inventories - Additional Information (Detail)", "role": "http://astro-med.com/role/InventoriesAdditionalInformationDetail", "shortName": "Inventories - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "alot:InventoryDemonstrationEquipment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1059 - Disclosure - Inventories - Components of Inventories (Detail)", "role": "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail", "shortName": "Inventories - Components of Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsAndSupplies", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Consolidated Statements of Changes in Shareholders' Equity", "role": "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "shortName": "Consolidated Statements of Changes in Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018_CommonStockMemberusgaapStatementEquityComponentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LandAndLandImprovements", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1060 - Disclosure - Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail", "shortName": "Property, Plant and Equipment - Summary of Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LandAndLandImprovements", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1061 - Disclosure - Property, Plant and Equipment - Additional Information (Detail)", "role": "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail", "shortName": "Property, Plant and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1062 - Disclosure - Accrued Expenses - Summary of Accrued Expenses (Detail)", "role": "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "shortName": "Accrued Expenses - Summary of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:AccruedProfessionalFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1063 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail)", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "shortName": "Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMemberusgaapCreditFacilityAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1064 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail)", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "shortName": "Credit Agreement and Long- Term Debt - Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets (Parenthetical) (Detail)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMemberusgaapCreditFacilityAxis", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentDescriptionOfVariableRateBasis", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_TermLoanMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1065 - Disclosure - Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail)", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail", "shortName": "Credit Agreement and Long- Term Debt - Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_TermLoanMemberusgaapCreditFacilityAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1066 - Disclosure - Credit Agreement and Long- Term Debt - Additional Information (Detail)", "role": "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "shortName": "Credit Agreement and Long- Term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_PaycheckProtectionProgramLoanMemberusgaapCreditFacilityAxis", "decimals": "2", "first": true, "lang": null, "name": "alot:PercentOfLoanToBeForgiven", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1067 - Disclosure - Paycheck Protection Program Loan - Additional information (Detail)", "role": "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "shortName": "Paycheck Protection Program Loan - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_PaycheckProtectionProgramLoanMemberusgaapCreditFacilityAxis", "decimals": "2", "first": true, "lang": null, "name": "alot:PercentOfLoanToBeForgiven", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1068 - Disclosure - Derivative Financial Instruments and Risk Management - Additional Information (Detail)", "role": "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "shortName": "Derivative Financial Instruments and Risk Management - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P05_03_2020To08_01_2020_CashFlowHedgingMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis", "decimals": "-5", "lang": null, "name": "alot:CashPaidTerminationOfSwaps", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_CashFlowHedgeMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1069 - Disclosure - Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail)", "role": "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail", "shortName": "Derivative Financial Instruments and Risk Management - Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_CashFlowHedgeMemberusgaapDerivativeInstrumentsGainLossByHedgingRelationshipAxis_CrossCurrencyInterestRateContractMemberusgaapDerivativeInstrumentRiskAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "role": "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical", "shortName": "Consolidated Statements of Changes in Shareholders' Equity (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:CommonStockDividendsPerShareCashPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "div", "div", "alot:RoyaltyObligationDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "alot:GuaranteedMinimumRoyaltyPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1070 - Disclosure - Royalty Obligation - Additional Information (Detail)", "role": "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail", "shortName": "Royalty Obligation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "alot:RoyaltyObligationDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "alot:GuaranteedMinimumRoyaltyPayment", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1071 - Disclosure - Leases - Additional Information (Detail)", "role": "http://astro-med.com/role/LeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseOptionToExtend", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1072 - Disclosure - Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail)", "role": "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail", "shortName": "Leases - Schedule Of Balance Sheet And Other Information Related To Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R73": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1073 - Disclosure - Leases - Lease Cost Information (Detail)", "role": "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "shortName": "Leases - Lease Cost Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasesRentExpenseNet", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1074 - Disclosure - Leases - Maturities of lease liabilities (Detail)", "role": "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail", "shortName": "Leases - Maturities of lease liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1075 - Disclosure - Leases - Supplemental cash flow information (Detail)", "role": "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "shortName": "Leases - Supplemental cash flow information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1076 - Disclosure - Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail)", "role": "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "shortName": "Accumulated Other Comprehensive Loss - Changes in Balance of Accumulated Other Comprehensive Loss (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018_AccumulatedTranslationAdjustmentMemberusgaapStatementEquityComponentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "alot:StockDeliveredDuringPeriodSharesStockOptionsExercise", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1077 - Disclosure - Shareholders' Equity - Additional information (Detail)", "role": "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail", "shortName": "Shareholders' Equity - Additional information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "alot:StockDeliveredDuringPeriodSharesStockOptionsExercise", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1078 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2018To01_31_2019", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1079 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Share-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockOptionPlanExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Consolidated Statements of Cash Flows", "role": "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1080 - Disclosure - Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail", "shortName": "Share-Based Compensation - Aggregated Information Regarding Stock Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1081 - Disclosure - Share-Based Compensation - Summary of Options Outstanding (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail", "shortName": "Share-Based Compensation - Summary of Options Outstanding (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "ix:continuation", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "2", "lang": null, "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020_RestrictedStockAwardAndRestrictedStockUnitMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1082 - Disclosure - Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail", "shortName": "Share-Based Compensation - Aggregated Information Regarding RSUs and RSAs Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018_RestrictedStockAwardAndRestrictedStockUnitMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1083 - Disclosure - Share-Based Compensation - Summarized Plan Activity (Detail)", "role": "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail", "shortName": "Share-Based Compensation - Summarized Plan Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2018_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1084 - Disclosure - Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail)", "role": "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail", "shortName": "Income Taxes - Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsInventory", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1085 - Disclosure - Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail)", "role": "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail", "shortName": "Income Taxes - Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit) (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1086 - Disclosure - Income Taxes - Components of Income before Income Taxes (Detail)", "role": "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail", "shortName": "Income Taxes - Components of Income before Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1087 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Detail)", "role": "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail", "shortName": "Income Taxes - Components of Provision for Income Taxes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1088 - Disclosure - Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail)", "role": "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail", "shortName": "Income Taxes - Change in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1089 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Summary of Significant Accounting Policies", "role": "http://astro-med.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1090 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail)", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "shortName": "Nature of Operations, Segment Reporting and Geographical Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1091 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail)", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "shortName": "Nature of Operations, Segment Reporting and Geographical Information - Net Sales and Segment Operating Profit (loss) for Each Reporting Segment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "3", "lang": null, "name": "alot:PercentageOfOperatingProfitToNetSales", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1092 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail)", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail", "shortName": "Nature of Operations, Segment Reporting and Geographical Information - Summary of Other Information by Segment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_OperatingSegmentsMembersrtConsolidationItemsAxis_ProductIdentificationMemberusgaapStatementBusinessSegmentsAxis", "decimals": "-3", "lang": null, "name": "us-gaap:Assets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1093 - Disclosure - Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail)", "role": "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "shortName": "Nature of Operations, Segment Reporting and Geographical Information - Summary of Selected Financial Information by Geographic Area (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:NoncurrentAssets", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1094 - Disclosure - Employee Benefit Plans - Additional Information (Detail)", "role": "http://astro-med.com/role/EmployeeBenefitPlansAdditionalInformationDetail", "shortName": "Employee Benefit Plans - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrualClassifiedCurrent", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1095 - Disclosure - Product Warranty Liability - Activity in Product Warranty Liability (Detail)", "role": "http://astro-med.com/role/ProductWarrantyLiabilityActivityInProductWarrantyLiabilityDetail", "shortName": "Product Warranty Liability - Activity in Product Warranty Liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021", "decimals": "-3", "lang": null, "name": "us-gaap:ProductWarrantyAccrualWarrantiesIssued", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_CostOfGoodsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1096 - Disclosure - Concentration of Risk - Additional Information (Detail)", "role": "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "shortName": "Concentration of Risk - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_CostOfGoodsTotalMemberusgaapConcentrationRiskByBenchmarkAxis_SupplierConcentrationRiskMemberusgaapConcentrationRiskByTypeAxis", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyFairValueHedgeLiabilityAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1097 - Disclosure - Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail)", "role": "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail", "shortName": "Fair Value Measurements - Summary of Financial Assets and Liabilities Measured at Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ForeignCurrencyFairValueHedgeLiabilityAtFairValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1098 - Disclosure - Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail)", "role": "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail", "shortName": "Fair Value Measurements - Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "PAsOn01_31_2021_EstimateOfFairValueFairValueDisclosureMemberusgaapFairValueByMeasurementBasisAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DebtLongtermAndShorttermCombinedAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:DebtDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P02_01_2020To01_31_2021_BankOfAmericaMemberusgaapLineOfCreditFacilityAxis", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RepaymentsOfDebt", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1099 - Disclosure - Subsequent Event - Additional Information (Detail)", "role": "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "shortName": "Subsequent Event - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d56468d10k.htm", "contextRef": "P04_24_2021To04_24_2021_FirstAmendmentToCreditAgreementMemberALOTCreditAgreementAxis_TermLoanMemberusgaapCreditFacilityAxis", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 90, "tag": { "alot_AccruedPayrollAndSalesTaxesCurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued payroll and sales taxes current.", "label": "Accrued Payroll and Sales Taxes Current", "terseLabel": "Accrued Payroll & Sales Tax" } } }, "localname": "AccruedPayrollAndSalesTaxesCurrent", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "alot_AccruedRoyaltiesCurrentExcessRoyaltyPaymentDue": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 27.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued royalties in excess of guaranteed minimum royalty obligation- amount due within one year.", "label": "Accrued Royalties, Current, Excess Royalty Payment Due", "verboseLabel": "Current Liability\u2014Excess Royalty Payment Due" } } }, "localname": "AccruedRoyaltiesCurrentExcessRoyaltyPaymentDue", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_AccruedStockHolderRelationFees": { "auth_ref": [], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued stock holder relation fees.", "label": "Accrued Stock Holder Relation Fees", "terseLabel": "Stockholder Relation Fees" } } }, "localname": "AccruedStockHolderRelationFees", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "alot_AirborneProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Airborne product.", "label": "Airborne Product [Member]", "terseLabel": "Airborne Product [Member]" } } }, "localname": "AirborneProductMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_BankOfAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank of america.", "label": "Bank Of America [Member]", "terseLabel": "Bank of America, N.A. [Member]", "verboseLabel": "Bank Of America [Member]" } } }, "localname": "BankOfAmericaMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_BuildingAndLeaseholdImprovementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building And Leasehold Improvements [Member]", "label": "Building And Leasehold Improvements [Member]", "terseLabel": "Building And Leasehold Improvements [Member]" } } }, "localname": "BuildingAndLeaseholdImprovementsMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_CashEquivalentsMaturityPeriodDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash equivalents maturity period description.", "label": "Cash Equivalents Maturity Period Description", "terseLabel": "Highly liquid investments with an original maturity" } } }, "localname": "CashEquivalentsMaturityPeriodDescription", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_CashFlowHedgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash flow hedge.", "label": "Cash Flow Hedge [Member]", "terseLabel": "Cash Flow Hedge [Member]" } } }, "localname": "CashFlowHedgeMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "alot_CashHeldInForeignBankAccounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash held in foreign bank accounts.", "label": "Cash Held In Foreign Bank Accounts", "terseLabel": "Cash of held in foreign bank accounts" } } }, "localname": "CashHeldInForeignBankAccounts", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]" } } }, "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail" ], "xbrltype": "stringItemType" }, "alot_CashPaidTerminationOfSwaps": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid termination of swaps.", "label": "Cash Paid Termination Of Swaps", "terseLabel": "Cash paid termination of swaps" } } }, "localname": "CashPaidTerminationOfSwaps", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_CentralAndSouthAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Central and South America.", "label": "Central And South America [Member]", "terseLabel": "Central and South America [Member]" } } }, "localname": "CentralAndSouthAmericaMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "alot_CompensationExpensesOfOptionForfeitedForNotRenderingInRequestedService": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Compensation expenses of option forfeited for not rendering in requested service.", "label": "Compensation Expenses Of Option Forfeited For Not Rendering In Requested Service", "terseLabel": "No compensation expense is recognized on forfeited options" } } }, "localname": "CompensationExpensesOfOptionForfeitedForNotRenderingInRequestedService", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_ComputerEquipmentAndSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Equipment And Software [Member]", "label": "Computer Equipment And Software [Member]", "terseLabel": "Computer Equipment And Software [Member]" } } }, "localname": "ComputerEquipmentAndSoftwareMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability revenue recognized including additions.", "label": "Contract With Customer Liability Revenue Recognized Including Additions", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognizedIncludingAdditions", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_CreditAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Axis]" } } }, "localname": "CreditAgreementAxis", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_CreditAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit Agreement", "label": "Credit Agreement [Domain]" } } }, "localname": "CreditAgreementDomain", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_CrossCurrencyInterestRateSwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cross Currency Interest Rate Swap [Member]", "label": "Cross Currency Interest Rate Swap [Member]", "terseLabel": "Cross Currency Interest Rate Swap [Member]" } } }, "localname": "CrossCurrencyInterestRateSwapMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "alot_DebtInstrumentAdditionalBasisSpread": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt instrument additional basis spread.", "label": "Debt Instrument Additional Basis Spread", "terseLabel": "Percentage added to variable rate", "verboseLabel": "Percentage added to variable rate" } } }, "localname": "DebtInstrumentAdditionalBasisSpread", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alot_DeferredTaxAssetsAccountingStandardAdjustmentLeaseLiability": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 15.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Assets Accounting Standard Adjustment Lease Liability", "label": "Deferred Tax Assets Accounting Standard Adjustment Lease Liability", "terseLabel": "ASU 842 Adjustment\u2014Lease Liability" } } }, "localname": "DeferredTaxAssetsAccountingStandardAdjustmentLeaseLiability", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxAssetsCompensationAccruals": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets compensation accruals.", "label": "Deferred Tax Assets Compensation Accruals", "terseLabel": "Compensation Accrual" } } }, "localname": "DeferredTaxAssetsCompensationAccruals", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxAssetsDeferredServiceContractRevenue": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 10.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets deferred service contract revenue.", "label": "Deferred Tax Assets Deferred Service Contract Revenue", "terseLabel": "Deferred Service Contract Revenue" } } }, "localname": "DeferredTaxAssetsDeferredServiceContractRevenue", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxAssetsLiabilitiesGross": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets liabilities gross.", "label": "Deferred Tax Assets Liabilities Gross", "totalLabel": "Subtotal" } } }, "localname": "DeferredTaxAssetsLiabilitiesGross", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating loss carryforwards expiration period.", "label": "Deferred Tax Assets Operating Loss Carryforwards Expiration Period", "terseLabel": "Deferred tax assets operating loss carryforwards expiration period" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsExpirationPeriod", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_DeferredTaxAssetsRoyaltyLiability": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets, royalty liability.", "label": "Deferred Tax Assets, Royalty Liability", "terseLabel": "Honeywell Royalty Liability" } } }, "localname": "DeferredTaxAssetsRoyaltyLiability", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxAssetsTaxCreditCarryforwardsExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax credit carryforwards expiration period.", "label": "Deferred Tax Assets Tax credit Carryforwards Expiration Period", "terseLabel": "Deferred tax assets tax credit carryforwards expiration period" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsExpirationPeriod", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_DeferredTaxAssetsUnrecognizedTaxBenefits": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 9.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets unrecognized tax benefits.", "label": "Deferred Tax Assets Unrecognized Tax Benefits", "terseLabel": "Unrecognized State Tax Benefits" } } }, "localname": "DeferredTaxAssetsUnrecognizedTaxBenefits", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DeferredTaxLiabilityAccountingStandardAdjustmentLeaseLiability": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 20.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred Tax Liability Accounting Standard Adjustment Lease Liability", "label": "Deferred Tax Liability Accounting Standard Adjustment Lease Liability", "terseLabel": "ASU 842 Adjustment \u2013 Lease Liability" } } }, "localname": "DeferredTaxLiabilityAccountingStandardAdjustmentLeaseLiability", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "alot_DistributorRelationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributor relations.", "label": "Distributor Relations [Member]", "terseLabel": "Distributor Relations [Member]" } } }, "localname": "DistributorRelationsMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_EmployeeStockPurchasePlanExpense": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 3.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan expense.", "label": "Employee Stock Purchase Plan Expense", "verboseLabel": "Employee Stock Purchase Plan" } } }, "localname": "EmployeeStockPurchasePlanExpense", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "alot_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee stock purchase plan.", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ExcessRoyaltyPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of royalty expense paid in excess of guaranteed minimum payments.", "label": "Excess Royalty Payments" } } }, "localname": "ExcessRoyaltyPayments", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_ExistingCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing credit agreement", "label": "Existing Credit Agreement [Member]", "terseLabel": "Existing Credit Agreement [Member]" } } }, "localname": "ExistingCreditAgreementMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_ExistingTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing technology.", "label": "Existing Technology [Member]", "terseLabel": "Existing Technology [Member]" } } }, "localname": "ExistingTechnologyMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_FairValueAssumptionPercentageOfPresentValueFactor": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair Value Assumption Percentage Of Present Value Factor", "label": "Fair Value Assumption Percentage Of Present Value Factor" } } }, "localname": "FairValueAssumptionPercentageOfPresentValueFactor", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alot_FinitelivedIntangibleassetsAccumulatedForeignCurrencyTranslationAdjustment": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finite-lived\u200b intangible assets accumulated foreign currency translation adjustment.", "label": "Finite Lived Intangible Assets Accumulated Foreign Currency Translation Adjustment", "terseLabel": "Currency Translation Adjustment" } } }, "localname": "FinitelivedIntangibleassetsAccumulatedForeignCurrencyTranslationAdjustment", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "alot_FirstAmendmentToCreditAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First amendment to credit agreement.", "label": "First Amendment to Credit Agreement [Member]", "terseLabel": "First Amendment to Credit Agreement [Member]" } } }, "localname": "FirstAmendmentToCreditAgreementMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_GreenWoodCreditUnionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Green wood credit union.", "label": "Green wood Credit Union [Member]", "terseLabel": "Green wood Credit Union [Member]" } } }, "localname": "GreenWoodCreditUnionMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_GreenwoodCreditUnionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Greenwood Credit Union [Member]" } } }, "localname": "GreenwoodCreditUnionMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_GuaranteedMinimumRoyaltyPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Guaranteed minimum royalty payment.", "label": "Guaranteed Minimum Royalty Payment" } } }, "localname": "GuaranteedMinimumRoyaltyPayment", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_HardwareProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hardware products.", "label": "Hardware Products [Member]", "terseLabel": "Hardware [Member]" } } }, "localname": "HardwareProductsMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_HoneywellAssetPurchaseAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Honeywell Asset Purchase and License Agreement [Member]", "label": "Honeywell Asset Purchase and License Agreement [Member]", "terseLabel": "Honeywell Asset Purchase and License Agreement [Member]" } } }, "localname": "HoneywellAssetPurchaseAndLicenseAgreementMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_IncomeTaxReconciliationForeignTaxCredit": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 15.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation foreign tax credit.", "label": "Income Tax Reconciliation Foreign Tax Credit", "negatedLabel": "Foreign Tax Credits" } } }, "localname": "IncomeTaxReconciliationForeignTaxCredit", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "alot_IncomeTaxReconciliationGlobalIntangibleLowTaxedIncome": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 14.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation global intangible low taxed income.", "label": "Income Tax Reconciliation Global Intangible Low Taxed Income", "negatedLabel": "Global Intangible Low Taxed Income" } } }, "localname": "IncomeTaxReconciliationGlobalIntangibleLowTaxedIncome", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "alot_IncomeTaxReconciliationOtherAdjustmentsStatuoryAudit": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 16.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation Other Adjustments Statuory Audit", "label": "Income Tax Reconciliation Other Adjustments Statuory Audit", "negatedLabel": "Denmark Statutory Audit" } } }, "localname": "IncomeTaxReconciliationOtherAdjustmentsStatuoryAudit", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "alot_IncomeTaxReconciliationOtherAdjustmentsWithholdingTaxes": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 17.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income Tax Reconciliation Other Adjustments Withholding Taxes", "label": "Income Tax Reconciliation Other Adjustments Withholding Taxes", "negatedLabel": "Canada Withholding Taxes" } } }, "localname": "IncomeTaxReconciliationOtherAdjustmentsWithholdingTaxes", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "alot_Incometaxreconciliationchangeinreserves": { "auth_ref": [], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 13.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Income tax reconciliation change in reserves.", "label": "IncomeTaxReconciliationChangeInReserves", "terseLabel": "Change in Reserves Related to ASC 740 Liability" } } }, "localname": "Incometaxreconciliationchangeinreserves", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "alot_InventoryDemonstrationEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventory demonstration equipment.", "label": "Inventory Demonstration Equipment", "terseLabel": "Inventory demonstration equipment" } } }, "localname": "InventoryDemonstrationEquipment", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/InventoriesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_LeaseExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease expense incurred on related party lease agreement.", "label": "Lease expense, related party" } } }, "localname": "LeaseExpenseRelatedParty", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_MiltopeCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Miltope Corporation [Member]", "label": "Miltope Corporation [Member]", "terseLabel": "Miltope [Member]" } } }, "localname": "MiltopeCorporationMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_MinimumRoyaltyPaymentObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum royalty payment obligations.", "label": "Minimum Royalty Payment Obligations" } } }, "localname": "MinimumRoyaltyPaymentObligations", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_NumberOfCustomersAccountingForCreditRisk": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers accounting for credit risk.", "label": "Number Of Customers Accounting For Credit Risk", "terseLabel": "Customer accounted for greater than 10% of net sales" } } }, "localname": "NumberOfCustomersAccountingForCreditRisk", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "alot_OperatingLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases [Abstract]" } } }, "localname": "OperatingLeasesAbstract", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "alot_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other countries.", "label": "Other Countries [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherCountriesMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail" ], "xbrltype": "domainItemType" }, "alot_OthersCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Others Countries [Member]", "label": "Others Countries [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OthersCountriesMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "alot_PaycheckProtectionProgramLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck protection program loan.", "label": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoan", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoan" ], "xbrltype": "textBlockItemType" }, "alot_PaycheckProtectionProgramLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Paycheck Protection Program Loan [Member]", "terseLabel": "Paycheck Protection Program Loan [Member]" } } }, "localname": "PaycheckProtectionProgramLoanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_PaycheckProtectionProgramLoanNoncurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 35.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Paycheck protection program loan noncurrent.", "label": "Paycheck Protection Program Loan Noncurrent", "terseLabel": "Long-Term Debt\u2014PPP Loan" } } }, "localname": "PaycheckProtectionProgramLoanNoncurrent", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "alot_PaymentTermPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Payment term period.", "label": "Payment Term Period" } } }, "localname": "PaymentTermPeriod", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alot_PaymentsOfMinimumGuaranteeRoyaltyObligation": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 23.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Outflow of Minimum Guarantee Royalty Obligation", "label": "Payments Of Minimum Guarantee Royalty Obligation", "negatedLabel": "Payment of Minimum Guarantee Royalty Obligation" } } }, "localname": "PaymentsOfMinimumGuaranteeRoyaltyObligation", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alot_Payoffoflongtermdebt": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 28.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "PayoffOfLongtermDebt", "label": "PayoffOfLongtermDebt", "negatedLabel": "Payoff of Long-Term Debt" } } }, "localname": "Payoffoflongtermdebt", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alot_PercentOfLoanToBeForgiven": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent capped for forgiveness of rent, utilities and interest on debt related to PPP Loan.", "label": "Percent Of Loan To Be Forgiven", "verboseLabel": "Percent of loan to be forgiven" } } }, "localname": "PercentOfLoanToBeForgiven", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "alot_PercentageOfOperatingProfitToNetSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of operating profit to net sales.", "label": "Percentage Of Operating Profit To Net Sales", "terseLabel": "Segment Operating Profit % of Net Sales" } } }, "localname": "PercentageOfOperatingProfitToNetSales", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "percentItemType" }, "alot_Proceedsfromissuanceofpaycheckprotectionprogramloan": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 27.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "ProceedsFromIssuanceOfPaycheckProtectionProgramLoan", "label": "ProceedsFromIssuanceOfPaycheckProtectionProgramLoan", "terseLabel": "Proceeds from Long-Term Debt \u2013 PPP Loan" } } }, "localname": "Proceedsfromissuanceofpaycheckprotectionprogramloan", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "alot_ProductIdenificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Idenification [Member]", "terseLabel": "Product Idenification [Member]" } } }, "localname": "ProductIdenificationMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "domainItemType" }, "alot_ProductIdentificationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Product identification.", "label": "Product Identification [Member]", "terseLabel": "Product Identification [Member]" } } }, "localname": "ProductIdentificationMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "alot_ProductsWarrantyPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Products warranty period.", "label": "Products Warranty Period", "terseLabel": "Products warranty period" } } }, "localname": "ProductsWarrantyPeriod", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "alot_PromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]" } } }, "localname": "PromissoryNoteMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RangeFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range five.", "label": "Range Five [Member]", "terseLabel": "$15.01 - $20.00 [Member]" } } }, "localname": "RangeFiveMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range four.", "label": "Range Four [Member]", "terseLabel": "$10.01 - $15.00 [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Range three.", "label": "Range Three [Member]", "terseLabel": "$5.00 - $10.00 [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "alot_ReservationOfSharesUnderEmployeeStockPurchasePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reservation of shares under employee stock purchase plan.", "label": "Reservation Of Shares Under Employee Stock Purchase Plan", "terseLabel": "Reservation of shares under Stock Purchase Plan" } } }, "localname": "ReservationOfSharesUnderEmployeeStockPurchasePlan", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alot_RestrictedStockAwardAndRestrictedStockUnitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Award And Restricted Stock Unit [Member]", "label": "Restricted Stock Award And Restricted Stock Unit [Member]", "terseLabel": "Restricted Stock Award And Restricted Stock Unit [Member]" } } }, "localname": "RestrictedStockAwardAndRestrictedStockUnitMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "domainItemType" }, "alot_RestrictedStockAwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock award.", "label": "Restricted Stock Award [Member]" } } }, "localname": "RestrictedStockAwardMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_RoyaltyObligationCurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 25.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the short term portion of the guaranteed minimum royalty obligation related to Honeywell Agreement.", "label": "Royalty Obligation, Current", "terseLabel": "Current Liability\u2014Royalty Obligation" } } }, "localname": "RoyaltyObligationCurrent", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RoyaltyObligationDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty Obligation Disclosure [Abstract]" } } }, "localname": "RoyaltyObligationDisclosureAbstract", "nsuri": "http://astro-med.com/20210131", "xbrltype": "stringItemType" }, "alot_RoyaltyObligationDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Obligation Disclosure", "label": "Royalty Obligation Disclosure [Text Block]", "verboseLabel": "Royalty Obligation" } } }, "localname": "RoyaltyObligationDisclosureTextBlock", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RoyaltyObligation" ], "xbrltype": "textBlockItemType" }, "alot_RoyaltyObligationNonCurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 32.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of the long term portion of the guaranteed minimum royalty obligation related to Honeywell Agreement.", "label": "Royalty Obligation Non Current", "verboseLabel": "Royalty Obligation, net of current portion" } } }, "localname": "RoyaltyObligationNonCurrent", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_RuggedInformationTechnologyEquipmentCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rugged Information Technology Equipment Corporation [Member]", "label": "Rugged Information Technology Equipment Corporation [Member]", "terseLabel": "RITEC [Member]" } } }, "localname": "RuggedInformationTechnologyEquipmentCorporationMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_ServiceAndOtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service and other.", "label": "Service And Other [Member]", "terseLabel": "Service and Other [Member]" } } }, "localname": "ServiceAndOtherMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_StockDeliveredDuringPeriodSharesStockOptionsExercise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock delivered by employers to satisfy the exercise price for stock options exercised and restricted stock vested.", "label": "Stock Delivered During Period Shares Stock Options Exercise", "terseLabel": "Company shares given to employees, shares" } } }, "localname": "StockDeliveredDuringPeriodSharesStockOptionsExercise", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "alot_StockDeliveredDuringPeriodSharesStockOptionsExerciseAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Dollar value of stock delivered by employers to satisfy the exercise price for stock options exercised and restricted stock vested.", "label": "Stock Delivered During Period Shares Stock Options Exercise, Amount", "terseLabel": "Company shares given to employees, value" } } }, "localname": "StockDeliveredDuringPeriodSharesStockOptionsExerciseAmount", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "alot_SummaryOfSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Line Items]", "terseLabel": "Summary Of Significant Accounting Policies [Line Items]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_SummaryOfSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "terseLabel": "Summary Of Significant Accounting Policies [Table]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesTable", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "alot_SuppliesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplies.", "label": "Supplies [Member]", "terseLabel": "Supplies [Member]" } } }, "localname": "SuppliesMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "domainItemType" }, "alot_TMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "T M [Member]", "terseLabel": "T M [Member]" } } }, "localname": "TMMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "domainItemType" }, "alot_TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan due January thirty one two thousand and twenty two.", "label": "Term Loan Due January Thirty One Two Thousand And Twenty Two [Member]", "terseLabel": "Term Loan Due January 31, 2022 [Member]" } } }, "localname": "TermLoanDueJanuaryThirtyOneTwoThousandAndTwentyTwoMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "alot_TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan due June fifteen two thousand and twenty two.", "label": "Term Loan Due June Fifteen Two Thousand And Twenty Two [Member]", "verboseLabel": "Term Loan Due June 15, 2022 [Member]" } } }, "localname": "TermLoanDueJuneFifteenTwoThousandAndTwentyTwoMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "alot_TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Term Loan Due November 30, 2022 [Member]", "documentation": "Term loan due November thirty two thousand and twenty two.", "label": "Term Loan Due November Thirty Two Thousand And Twenty Two [Member]" } } }, "localname": "TermLoanDueNovemberThirtyTwoThousandAndTwentyTwoMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail" ], "xbrltype": "domainItemType" }, "alot_TermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term loan.", "label": "Term Loan [Member]", "terseLabel": "Term Loan [Member]" } } }, "localname": "TermLoanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TestAndMeasurementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Test and measurement.", "label": "Test And Measurement [Member]", "terseLabel": "T&M [Member]" } } }, "localname": "TestAndMeasurementMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "alot_TradeAccountsPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade Accounts Payables [Member]", "label": "Trade Accounts Payables [Member]", "terseLabel": "Trade Accounts Payables [Member]" } } }, "localname": "TradeAccountsPayablesMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TrojanlabelApSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "TrojanLabel ApS.", "label": "Trojanlabel ApS [Member]", "terseLabel": "TrojanLabel ApS [Member]" } } }, "localname": "TrojanlabelApSMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Equity Incentive Plan.", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandFifteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Fifteen Equity Incentive Plan [Member]", "label": "Two Thousand Fifteen Equity Incentive Plan [Member]", "terseLabel": "2015 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandFifteenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_TwoThousandSevenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Seven Equity Incentive Plan [Member]", "label": "Two Thousand Seven Equity Incentive Plan [Member]", "terseLabel": "2007 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSevenEquityIncentivePlanMember", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "alot_UnrealizedGainLossOnTerminationOfInterestRateCashFlowHedgesPreTaxAccumulatedOtherComprehensiveIncomeLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unrealized gain loss on termination of interest rate cash flow hedges pre tax accumulated other comprehensive income loss.", "label": "Unrealized gain loss on termination of interest rate cash flow hedges pre tax accumulated other comprehensive income loss", "negatedLabel": "Cross-Currency Interest Rate Swap Termination" } } }, "localname": "UnrealizedGainLossOnTerminationOfInterestRateCashFlowHedgesPreTaxAccumulatedOtherComprehensiveIncomeLoss", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "alot_ValueOfSharesReceivedInSatisfactionOfOptionExercisePrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares received in satisfaction of option exercise price.", "label": "Value of Shares Received in Satisfaction of Option Exercise Price", "terseLabel": "Value of Shares Received in Satisfaction of Option Exercise Price" } } }, "localname": "ValueOfSharesReceivedInSatisfactionOfOptionExercisePrice", "nsuri": "http://astro-med.com/20210131", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "terseLabel": "Canada [Member]" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r717" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r719" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r718" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r714", "r715", "r716" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r712" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r713" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://astro-med.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Asia.", "label": "Asia [Member]", "terseLabel": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r203", "r216", "r217", "r218", "r219", "r221", "r223", "r227" ], "lang": { "en-us": { "role": { "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r203", "r216", "r217", "r218", "r219", "r221", "r223", "r227" ], "lang": { "en-us": { "role": { "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.", "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe.", "label": "Europe [Member]", "terseLabel": "Europe [Member]" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r416", "r419", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r680", "r683" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r416", "r419", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r680", "r683" ], "lang": { "en-us": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r230", "r340", "r343", "r635", "r679", "r681" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r230", "r340", "r343", "r635", "r679", "r681" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r374", "r416", "r419", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r680", "r683" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r374", "r416", "r419", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r680", "r683" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r417", "r720" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period.", "label": "Forecast [Member]", "terseLabel": "Scenario, Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": { "auth_ref": [ "r150", "r723" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]", "terseLabel": "Schedule II - Valuation and Qualifying Accounts and Reserves" } } }, "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReserves" ], "xbrltype": "textBlockItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r231", "r232", "r340", "r344", "r682", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r231", "r232", "r340", "r344", "r682", "r697", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r721", "r722" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r300", "r417", "r622" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r236", "r619" ], "lang": { "en-us": { "role": { "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Title of individual, or nature of relationship to individual or group of individuals.", "label": "Title of Individual [Domain]", "terseLabel": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]" } } }, "localname": "ValuationAndQualifyingAccountsAbstract", "nsuri": "http://fasb.org/srt/2020-01-31", "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r150", "r723" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "stringItemType" }, "stpr_DE": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DELAWARE" } } }, "localname": "DE", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r45" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r5", "r26", "r237", "r238" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, Net, Current", "verboseLabel": "Accounts Receivable, net of reserves of $1,054 in 2021 and $856 in 2020" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r19", "r645", "r663" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 29.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income Taxes Payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 30.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Total", "verboseLabel": "Other Accrued Expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r11", "r12", "r50" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional Fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r11", "r12", "r50" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission, Current", "terseLabel": "Dealer Commissions" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements": { "auth_ref": [ "r597" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated amortization of debt issuance costs related to line of credit arrangements.", "label": "Accumulated Amortization of Debt Issuance Costs, Line of Credit Arrangements", "verboseLabel": "Debt related expenses" } } }, "localname": "AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r287" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r72", "r80", "r83", "r525" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Net Unrealized Gain/(Loss) on Cash Flow Hedges [Member]" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r74", "r75", "r76", "r80", "r83" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Investment Gain (Loss) Attributable to Parent [Member]", "terseLabel": "Unrealized Holding Gain/(Loss) on Available for Sale Securities [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r29", "r78", "r79", "r80", "r666", "r691", "r695" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated Other Comprehensive Loss, net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r77", "r80", "r83", "r152", "r153", "r154", "r526", "r686", "r687" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r71", "r80", "r83", "r526", "r584", "r585", "r586", "r587", "r589" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustments [Member]" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r27" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional\u00a0Paid-in\u00a0Capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r152", "r153", "r154", "r453", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r155", "r156", "r157", "r158", "r248", "r249", "r250", "r251", "r252", "r253", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r495", "r496", "r497", "r498", "r637", "r638", "r639", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition", "terseLabel": "Share-Based Compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to Reconcile Net Income to Net Cash Provided By Operating Activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Costs, Policy [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForCreditLossMember": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Allowance for credit loss from right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "SEC Schedule, 12-09, Allowance, Credit Loss [Member]", "terseLabel": "Allowance for Doubtful Accounts [Member]" } } }, "localname": "AllowanceForCreditLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r33", "r240", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Accounts Receivable, Reserves" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r100", "r123", "r595" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of Debt Issuance Costs" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r123", "r272", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of common equivalent shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements and Non-arrangement Transactions [Domain]", "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r134", "r211", "r218", "r225", "r247", "r520", "r527", "r577", "r643", "r662" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r67", "r134", "r247", "r520", "r527", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": { "auth_ref": [ "r677", "r678" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability as of the balance sheet date for the estimated ultimate cost of settling claims and claim adjustment expense relating to insured events that have occurred on or before the balance sheet date for those liabilities owed to another party as a result of assuming another insurer's primary obligation.", "label": "Assumed Liability for Unpaid Claims and Claims Adjustment Expense", "verboseLabel": "Liability for self-insured claims" } } }, "localname": "AssumedLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r422", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r538", "r543" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r9", "r286" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and Leasehold Improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r415", "r418" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r415", "r418", "r511", "r512" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r515", "r516", "r517" ], "calculation": { "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Earnout Liability (included in Other Liabilities)" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedComputerSoftwareGross": { "auth_ref": [ "r711" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated amortization of capitalized costs for computer software, including but not limited to, acquired and internally developed computer software.", "label": "Capitalized Computer Software, Gross", "terseLabel": "Computer Equipment and Software" } } }, "localname": "CapitalizedComputerSoftwareGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "terseLabel": "Amortization of incremental direct costs" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortizationPeriod": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "Amortization period of cost capitalized in obtaining or fulfilling contract with customer, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Capitalized Contract Cost, Amortization Period", "verboseLabel": "Amortization period of contract costs" } } }, "localname": "CapitalizedContractCostAmortizationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_CapitalizedContractCostNet": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Net", "terseLabel": "Deferred incremental direct costs net of accumulated amortization" } } }, "localname": "CapitalizedContractCostNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostNetCurrent": { "auth_ref": [ "r260" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as current.", "label": "Capitalized Contract Cost, Net, Current", "terseLabel": "Deferred incremental direct contract costs reported in other current assets" } } }, "localname": "CapitalizedContractCostNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "verboseLabel": "Carrying Value [Member]" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r40", "r125" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r15", "r126", "r129" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r119", "r125", "r128" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents, End of Year", "periodStartLabel": "Cash and Cash Equivalents, Beginning of Year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r119", "r582" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash and Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r132", "r134", "r169", "r170", "r171", "r173", "r175", "r182", "r183", "r184", "r247", "r577" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r299", "r649", "r670" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies (See Note 21)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r296", "r297", "r298", "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r59" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "periodEndLabel": "Shares Reserved, Ending Balance", "periodStartLabel": "Shares Reserved, Beginning Balance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Cash dividend per share" } } }, "localname": "CommonStockDividendsPerShareCashPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquityParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r152", "r153" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common Stock, $0.05 Par Value, Authorized 13,000,000 shares; Issued 10,425,094 shares in 2021 and 10,343,610 shares in 2020" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r351", "r352", "r420", "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/EmployeeBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Assets [Abstract]", "terseLabel": "Deferred Tax Assets:" } } }, "localname": "ComponentsOfDeferredTaxAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred Tax Liabilities:" } } }, "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r86", "r88", "r89", "r97", "r653", "r673" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r96", "r108", "r652", "r672" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r191", "r192", "r234", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r191", "r192", "r234", "r574", "r575", "r696" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r191", "r192", "r234", "r574", "r575", "r696" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "Concentration Risk Disclosure [Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r191", "r192", "r234", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage", "verboseLabel": "Percentage of revenue satisfied for services" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r189", "r191", "r192", "r193", "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r191", "r192", "r234", "r574", "r575" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r129", "r522" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r328", "r330", "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract with Customer, Asset, Net", "terseLabel": "Contract assets balance" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r328", "r329", "r341" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities and extended warranties" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r221", "r227", "r229" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate Expenses [Member]" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Cost of Goods, Total [Member]", "terseLabel": "Purchases [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r103", "r134", "r247", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 6.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of Revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CrossCurrencyInterestRateContractMember": { "auth_ref": [ "r375", "r550" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.", "label": "Cross Currency Interest Rate Contract [Member]", "terseLabel": "Cross Currency Interest Rate Contract [Member]" } } }, "localname": "CrossCurrencyInterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r135", "r491", "r501" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r139", "r491" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 4.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r491", "r501", "r503" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense (Benefit)", "totalLabel": "Current Income Tax Expense" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r135", "r491", "r501" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 3.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r190", "r234" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerContractsMember": { "auth_ref": [ "r514" ], "lang": { "en-us": { "role": { "documentation": "Entity's established relationships with its customers through contracts.", "label": "Customer Contracts [Member]", "terseLabel": "Customer Contract Relationships [Member]" } } }, "localname": "CustomerContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "Credit Agreement and Long- Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r18", "r19", "r20", "r644", "r647", "r661" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "definitionGuidance": "Interest rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Interest rate basis spread" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r310", "r647", "r661" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "terseLabel": "USD Term Loan" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.", "label": "Debt Instrument, Description of Variable Rate Basis", "terseLabel": "Debt instrument, description of variable rate basis" } } }, "localname": "DebtInstrumentDescriptionOfVariableRateBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r594", "r596" ], "crdr": "credit", "lang": { "en-us": { "role": { "disclosureGuidance": "Term loan, principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "verboseLabel": "Debt instrument face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFee": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Description of a fee associated with the debt instrument, including a commitment fee on unborrowed portions of a lender's total contractual commitment.", "label": "Debt Instrument, Fee", "terseLabel": "Commitment Fee Paid" } } }, "localname": "DebtInstrumentFee", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": { "auth_ref": [ "r56", "r658" ], "lang": { "en-us": { "role": { "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).", "label": "Debt Instrument, Frequency of Periodic Payment", "terseLabel": "Debt Instrument, Frequency of Periodic Payment" } } }, "localname": "DebtInstrumentFrequencyOfPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r137" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "verboseLabel": "Loan, interest accrued" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": { "auth_ref": [ "r52", "r594" ], "lang": { "en-us": { "role": { "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.", "label": "Debt Instrument, Interest Rate, Basis for Effective Rate", "verboseLabel": "Variable interest rate" } } }, "localname": "DebtInstrumentInterestRateBasisForEffectiveRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Loan, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r53", "r563" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Debt instrument, maturity date", "verboseLabel": "Loan, maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r56" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPaymentTerms": { "auth_ref": [ "r54", "r658" ], "lang": { "en-us": { "role": { "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment.", "label": "Debt Instrument, Payment Terms", "verboseLabel": "Loan, payment terms" } } }, "localname": "DebtInstrumentPaymentTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r56", "r658" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Debt Instrument, Periodic Payment", "verboseLabel": "Loan, payments due" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r56" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Debt Instrument, Periodic Payment, Principal", "verboseLabel": "Debt Instrument, principal Periodic payment" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r56", "r136", "r318", "r321", "r322", "r323", "r593", "r594", "r596", "r659" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsGross": { "auth_ref": [ "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Gross", "verboseLabel": "Capilaized finance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r597" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "verboseLabel": "Payments for debt issuance costs" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "terseLabel": "Long-Term Debt and Related Current Maturities" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r106" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "terseLabel": "Debt related commitment fees and debt issuance costs" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtWeightedAverageInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average interest rate of debt outstanding.", "label": "Debt, Weighted Average Interest Rate", "verboseLabel": "Revolving line of credit, Outstanding loan amount weighted average interest rate" } } }, "localname": "DebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r492", "r501" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense (Benefit)", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r44", "r595" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedLabel": "Debt Issuance Costs, net of accumulated amortization" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r492", "r501" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 8.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Foreign Income Tax Expense (Benefit)", "terseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r123", "r135", "r492", "r501", "r502", "r503" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "totalLabel": "Deferred Income Tax Expense Total" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r21", "r22", "r482", "r646", "r660" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 16.0, "parentTag": "alot_DeferredTaxAssetsLiabilitiesGross", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Tax Liabilities, Gross", "totalLabel": "Deferred Tax Liabilities, Total" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "auth_ref": [ "r124" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.", "label": "Deferred Income Taxes and Tax Credits", "verboseLabel": "Deferred Income Tax Provision (Benefit)" } } }, "localname": "DeferredIncomeTaxesAndTaxCredits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 28.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r492", "r501" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": 7.0, "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State and Local Income Tax Expense (Benefit)", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r483" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 2.0, "parentTag": "alot_DeferredTaxAssetsLiabilitiesGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Deferred Tax Assets, Total" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInventory": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.", "label": "Deferred Tax Assets, Inventory", "terseLabel": "Inventory" } } }, "localname": "DeferredTaxAssetsInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r485" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net Deferred Tax Assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetNoncurrent": { "auth_ref": [ "r465", "r466", "r467", "r468", "r483" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as noncurrent.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Noncurrent", "terseLabel": "Deferred Tax Assets, net" } } }, "localname": "DeferredTaxAssetsNetNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 12.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net Operating Loss", "verboseLabel": "Deferred Tax Assets Operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 13.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": { "auth_ref": [ "r488", "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 14.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign", "terseLabel": "Foreign Tax Credit" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r488", "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "State R&D Credits", "verboseLabel": "Deferred tax assets tax credit carryforwards research" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Share-Based Compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 11.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the provision for loan losses.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Provision for Loan Losses", "terseLabel": "Bad Debt" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsProvisionForLoanLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 8.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from warranty reserves.", "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Warranty Reserves", "terseLabel": "Warranty Reserve" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r484" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 21.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 17.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.", "label": "Deferred Tax Liabilities, Intangible Assets", "terseLabel": "Intangibles" } } }, "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r465", "r467", "r468" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 33.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "terseLabel": "Deferred Tax Liabilities" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesOther": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 19.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.", "label": "Deferred Tax Liabilities, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxLiabilitiesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "auth_ref": [ "r489", "r490" ], "calculation": { "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail": { "order": 18.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "terseLabel": "Accumulated Tax Depreciation in Excess of Book Depreciation" } } }, "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTaxEffectsOfTemporaryDifferencesThatGaveRiseToSignificantPortionsOfDeferredTaxAssetsAndLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Contributions paid or accrued amounted" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/EmployeeBenefitPlansAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r123", "r285" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense on property, plant and equipment" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r123", "r206" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and Amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r68", "r69", "r541", "r633" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Fair\u00a0Value\u00a0Derivatives, Liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r539", "r542", "r548", "r552" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivative Financial Instruments and Risk Management" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagement" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r536", "r539", "r548" ], "lang": { "en-us": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r557" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Amount of gain reclassify from Accumulated OCI into loss during next 12 months" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet": { "auth_ref": [ "r547", "r551" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net", "terseLabel": "Amount of Gain Reclassified from Accumulated OCI into Income (Expense)", "verboseLabel": "Amount of Gain (Loss) Reclassified from Accumulated OCI into Income" } } }, "localname": "DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsIncomeStatementLocationOfGainOrLossReclassifiedFromAccumulatedOCI": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The income statement location of the effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.", "label": "Derivative Instruments, Income Statement Location of Gain (Loss) Reclassified from Accumulated OCI", "terseLabel": "Location of Gain Reclassified from Accumulated OCI into Income (Expense)" } } }, "localname": "DerivativeInstrumentsIncomeStatementLocationOfGainOrLossReclassifiedFromAccumulatedOCI", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r532", "r534" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "verboseLabel": "Notional\u00a0Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r129", "r140", "r531", "r533", "r536", "r537", "r554" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivative Financial Instruments" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r340", "r343", "r344", "r345", "r346", "r347", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Summary of Revenues Disaggregated by Primary Geographic Markets and Major Product Type" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r457" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r324" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Common Stock\u2014cash dividend" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Federal Tax [Member]" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r98", "r159", "r160", "r161", "r162", "r163", "r167", "r169", "r173", "r174", "r175", "r178", "r179", "r654", "r674" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net Income Per Common Share\u2014Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r98", "r159", "r160", "r161", "r162", "r163", "r169", "r173", "r174", "r175", "r178", "r179", "r654", "r674" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Income Per Common Share\u2014Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r129", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Income Per Common Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r582" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of Foreign Exchange Rate Changes on Cash and Cash Equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate for income from continuing operation" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued Compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation expense to be recognized, Weighted average period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation expense related to RSUs and RSAs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r446" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expense related to options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r152", "r153", "r154", "r156", "r164", "r166", "r181", "r251", "r317", "r324", "r453", "r454", "r455", "r497", "r498", "r583", "r584", "r585", "r586", "r587", "r589", "r686", "r687", "r688" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r571" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "verboseLabel": "Fair Value [Member]" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r559", "r560", "r561", "r565" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r559", "r572", "r573" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r414", "r560", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail", "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r559", "r566" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r559", "r560", "r562", "r563", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r375", "r376", "r381", "r414", "r560", "r625" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r414", "r560", "r626" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail", "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r414", "r624", "r625", "r626" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail", "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r564", "r567" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r129", "r568", "r570" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FederalFundsEffectiveSwapRateMember": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.", "label": "Federal Funds Effective Swap Rate [Member]", "verboseLabel": "Federal Funds Effective Swap Rate [Member]" } } }, "localname": "FederalFundsEffectiveSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FederalHomeLoanBanksAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Federal Home Loan Banks [Abstract]" } } }, "localname": "FederalHomeLoanBanksAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r277" ], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsSummaryOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r273", "r274", "r277", "r280", "r636", "r640" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]" } } }, "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r277", "r640" ], "calculation": { "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Amount" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r273", "r276" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r277", "r636" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Net Carrying Amount", "verboseLabel": "Identifiable Intangibles, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyFairValueHedgeLiabilityAtFairValue": { "auth_ref": [ "r542" ], "calculation": { "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as foreign currency fair value hedging instruments.", "label": "Foreign Currency Fair Value Hedge Liability at Fair Value", "terseLabel": "Cross-Currency Interest Rate Swap Contract (included in Other Long-Term Liabilities)" } } }, "localname": "ForeignCurrencyFairValueHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r578", "r579", "r580", "r581" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Net transactional foreign exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "auth_ref": [ "r124", "r580", "r581" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 14.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Gain (Loss) on Foreign Currency Transactions" } } }, "localname": "ForeignCurrencyTransactionGainLossUnrealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r129", "r591" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ForeignEarningsRepatriated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign earnings repatriated from subsidiaries outside the country of domicile.", "label": "Foreign Earnings Repatriated", "terseLabel": "Deemed repatriated earnings" } } }, "localname": "ForeignEarningsRepatriated", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 10.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "Corporate Expenses", "verboseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r262", "r264", "r642" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at beginning", "terseLabel": "Goodwill", "verboseLabel": "Goodwill assigned" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r129", "r267" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r129", "r275" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillDisclosureTextBlock": { "auth_ref": [ "r271" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill.", "label": "Goodwill Disclosure [Text Block]", "terseLabel": "Goodwill" } } }, "localname": "GoodwillDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/Goodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r266" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign currency translation" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r123", "r263", "r265", "r269" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill impaired" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r102", "r134", "r211", "r217", "r221", "r224", "r227", "r247", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesAndProductWarrantiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guarantees and Product Warranties [Abstract]" } } }, "localname": "GuaranteesAndProductWarrantiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets (Excluding Goodwill) [Abstract]" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwillAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r123", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Impairments of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r123", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r123", "r284", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "verboseLabel": "Impairment of Long lived assets held for use" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r129", "r283", "r292" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "terseLabel": "Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r138", "r504" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r94", "r211", "r217", "r221", "r224", "r227", "r641", "r650", "r657", "r675" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r138", "r504" ], "calculation": { "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesComponentsOfIncomeBeforeIncomeTaxesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r471", "r480", "r487", "r499", "r505", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple": { "auth_ref": [ "r500", "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative tax effect on beginning retained earnings from change in accounting principle.", "label": "Income Tax Effects Allocated Directly to Equity, Cumulative Effect of Change in Accounting Principle", "verboseLabel": "Reclassification due to adoption of ASU 2018-02" } } }, "localname": "IncomeTaxEffectsAllocatedDirectlyToEquityCumulativeEffectOfChangeInAccountingPrinciple", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r135", "r165", "r166", "r209", "r469", "r500", "r507", "r676" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "positiveLabel": "Income Tax Provision (Benefit)", "terseLabel": "Income Tax Provision (Benefit)", "totalLabel": "Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetail", "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r90", "r129", "r463", "r464", "r480", "r481", "r486", "r493", "r698" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 12.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "terseLabel": "Change in Valuation Allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "auth_ref": [ "r462", "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.", "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount", "terseLabel": "U.S Corporate Rate Change" } } }, "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 9.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount", "terseLabel": "Foreign Rate Deferential" } } }, "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount", "terseLabel": "Income Tax Provision at Statutory Rate" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 10.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount", "terseLabel": "Meals and Entertainment" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 11.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount", "terseLabel": "Share Based Compensation" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 8.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "terseLabel": "Other" } } }, "localname": "IncomeTaxReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 5.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount", "terseLabel": "Return to Provision Adjustment" } } }, "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.", "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount", "terseLabel": "Transition Tax on Repatriated Earnings" } } }, "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount", "terseLabel": "State Taxes, Net of Federal Tax Effect" } } }, "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 7.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount", "negatedLabel": "Foreign Deferred Intangible Income" } } }, "localname": "IncomeTaxReconciliationTaxCreditsForeign", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "auth_ref": [ "r470" ], "calculation": { "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail": { "order": 6.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "negatedLabel": "R&D Credits" } } }, "localname": "IncomeTaxReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesReconciliationOfIncomeTaxProvisionBenefitWithTheAmountComputedByApplyingTheStatutoryFederalIncomeTaxRateToTheIncomeBeforeIncomeTaxProvisionBenefitDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Income Taxes, Net of Refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts Payable and Accrued Expenses" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts Receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "verboseLabel": "Income Taxes Payable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "verboseLabel": "Changes in Assets and Liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.", "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other" } } }, "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r92", "r205", "r592", "r595", "r656" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseDebt": { "auth_ref": [ "r106", "r312" ], "crdr": "debit", "lang": { "en-us": { "role": { "definitionGuidance": "Revolving line of credit, Interest expenses incurred", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.", "label": "Interest Expense, Debt" } } }, "localname": "InterestExpenseDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r655" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 12.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest Income (Expense), net" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r117", "r120", "r127" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFairValueHedgeLiabilityAtFairValue": { "auth_ref": [ "r542" ], "calculation": { "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value as of the balance sheet date of all derivative liabilities designated as interest rate fair value hedging instruments.", "label": "Interest Rate Fair Value Hedge Liability at Fair Value", "verboseLabel": "Interest Rate Swap Contract (included in Other Long-Term Liabilities)" } } }, "localname": "InterestRateFairValueHedgeLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r62" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 4.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r65" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Inventory, Gross" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r4", "r65" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r14", "r66", "r129", "r180", "r255", "r256", "r258" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsAndSupplies": { "auth_ref": [ "r64" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.", "label": "Inventory, Raw Materials and Supplies, Gross", "terseLabel": "Materials and Supplies" } } }, "localname": "InventoryRawMaterialsAndSupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r65", "r150", "r257" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 5.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "negatedLabel": "Inventory Reserve" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcess": { "auth_ref": [ "r63" ], "calculation": { "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory, Work in Process, Gross", "terseLabel": "Work-in-Progress" } } }, "localname": "InventoryWorkInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesComponentsOfInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandAndLandImprovements": { "auth_ref": [ "r10", "r16" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated deprecation and depletion of real estate held for productive use and additions or improvements to real estate held for productive use, examples include, but are not limited to, walkways, driveways, fences, and parking lots. Excludes land held for sale.", "label": "Land and Land Improvements", "terseLabel": "Land and Land Improvements" } } }, "localname": "LandAndLandImprovements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandImprovementsMember": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to real estate held.", "label": "Land Improvements [Member]", "terseLabel": "Land Improvements [Member]" } } }, "localname": "LandImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r611" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "verboseLabel": "Schedule Lease Cost Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "verboseLabel": "Schedule of Maturities Of Lease Liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r612" ], "calculation": { "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r612" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Imputed Interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r607" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Option to Extend" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Operating Lease Remaining Lease Term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r614" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorLeasesPolicyTextBlock": { "auth_ref": [ "r615", "r616", "r617", "r618" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.", "label": "Lessor, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LessorLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49", "r134", "r219", "r247", "r521", "r527", "r528", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r134", "r247", "r577", "r648", "r668" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r51", "r134", "r247", "r521", "r527", "r528", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r559" ], "calculation": { "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsSummaryOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "NON CURRENT LIABILITIES" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r47", "r136" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "verboseLabel": "Fees related to the revolving line of credit" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "verboseLabel": "Commitment fee rate" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r47" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "presentationGuidance": "Maximum borrowing capacity", "verboseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r47" ], "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Credit facility, remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LinesOfCreditCurrent": { "auth_ref": [ "r18", "r644" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 26.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Line of Credit, Current", "terseLabel": "Revolving Credit Facility" } } }, "localname": "LinesOfCreditCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "London Interbank Offered Rate (LIBOR) [Member]", "terseLabel": "LIBOR [Member]", "verboseLabel": "London Interbank Offered Rate (LIBOR) [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r311", "r647", "r665" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 24.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Current Portion of Term Loan", "terseLabel": "Current Portion of Long-Term Debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentTerms": { "auth_ref": [ "r309", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of timing of required repayments, sinking fund requirements, and other redeemable securities at fixed or determinable prices and dates in the five years immediately following the date of the latest balance sheet presented in the financial statements, and the amount thereafter to fully repay the principal of long-term debt. These disclosures may be made either on an individual debt or security basis, by type of debt or security basis, or on a combined basis.", "label": "Long-term Debt, Maturities, Repayment Terms", "verboseLabel": "Principal payment terms" } } }, "localname": "LongTermDebtMaturitiesRepaymentTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r142", "r309" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months", "verboseLabel": "Fiscal 2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r142", "r309" ], "calculation": { "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-term Debt, Maturities, Repayments of Principal in Year Two", "verboseLabel": "Fiscal 2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfRequiredPrincipalPaymentsRemainingOnLongTermDebtOutstandingDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturityDate": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "Maturity date of long-term debt, in CCYY-MM-DD format.", "label": "Long-term Debt, Maturity Date", "verboseLabel": "Longterm Debt instrument, maturity date" } } }, "localname": "LongTermDebtMaturityDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r56" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 31.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt", "verboseLabel": "Long-Term Debt, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.", "label": "Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate", "terseLabel": "Interest rate" } } }, "localname": "LongTermDebtPercentageBearingVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail" ], "xbrltype": "percentItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r9", "r286" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment, Gross", "terseLabel": "Machinery and Equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]", "terseLabel": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r119" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used by Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r119", "r121", "r124" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r84", "r87", "r95", "r124", "r134", "r155", "r159", "r160", "r161", "r162", "r165", "r166", "r172", "r211", "r217", "r221", "r224", "r227", "r247", "r577", "r651", "r671" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income", "totalLabel": "Net Income", "verboseLabel": "Net Income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Schedule of non-cash financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r513" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-Competition Agreement [Member]" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncurrentAssets": { "auth_ref": [ "r232" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.", "label": "Long-Lived Assets", "terseLabel": "Long-Lived Assets" } } }, "localname": "NoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other Expense, Net", "totalLabel": "Other Expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Expense:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reporting segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingCostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Costs and Expenses [Abstract]", "terseLabel": "Costs and Expenses:" } } }, "localname": "OperatingCostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r211", "r217", "r221", "r224", "r227" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income", "totalLabel": "Operating Income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r603" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "verboseLabel": "Total Lease Liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesMaturitiesOfLeaseLiabilitiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r603" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "definitionGuidance": "Other Accrued Expenses", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Lease Liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "extensibleListItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r603" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 34.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Lease Liabilities", "verboseLabel": "Lease Liabilities, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r605", "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "verboseLabel": "Cash paid for operating lease liabilities" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r602" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of Use Assets", "verboseLabel": "Right of Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/LeasesScheduleOfBalanceSheetAndOtherInformationRelatedToOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r610", "r613" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r609", "r613" ], "lang": { "en-us": { "role": { "definitionGuidance": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r303", "r598", "r599", "r600", "r601" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.", "label": "Lessee, Operating Lease, Disclosure [Table Text Block]", "verboseLabel": "Schedule Of Balance Sheet And Other Information Related To Operating Leases" } } }, "localname": "OperatingLeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeasesRentExpenseNet": { "auth_ref": [ "r600" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.", "label": "Operating Leases, Rent Expense, Net", "verboseLabel": "Operating Lease Costs" } } }, "localname": "OperatingLeasesRentExpenseNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r216", "r217", "r218", "r219", "r221", "r227" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments [Member]" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r13", "r50" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "verboseLabel": "Other Accrued Expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Other Assets, Miscellaneous, Noncurrent", "verboseLabel": "Other" } } }, "localname": "OtherAssetsMiscellaneousNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r80", "r91", "r583", "r585", "r589" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "terseLabel": "Other Comprehensive Loss Income (Loss) before reclassification" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r72", "r78" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Change in Value of Derivatives Designated as Cash Flow Hedge" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r72", "r78", "r540", "r545", "r556" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of Gain (Loss) Recognized in OCI on Derivative" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementScheduleOfImpactOfTheDerivativeInstrumentsInTheCondensedConsolidatedFinancialStatementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r78", "r81" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 5.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedLabel": "(Gains) Losses from Cash Flow Hedges Reclassified to Income Statement" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "auth_ref": [ "r73", "r78", "r546", "r556" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 7.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "terseLabel": "Cross-Currency Interest Rate Swap Terminations", "verboseLabel": "Interest Rate Swap Termination" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r70" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign Currency Translation Adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r85", "r88", "r91", "r96", "r317", "r583", "r588", "r589", "r652", "r672" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income (Loss)", "totalLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive Income (Loss), net of taxes and reclassification adjustments:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "auth_ref": [ "r78", "r81", "r82", "r246" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "order": 6.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "negatedLabel": "Realized Gain on Securities Available for Sale Reclassified to Income Statement" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r551" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r107" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 13.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other, Net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r116" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payments of Debt Issuance Costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends Paid" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r114" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 26.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Net Cash Used for Payment of Taxes Related to Vested Restricted Stock" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r111" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedLabel": "Cash Paid for Honeywell Asset Purchase and License Agreement" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r111" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Additions to Property, Plant and Equipment", "terseLabel": "Capital Expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r422", "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsScheduleOfCompanysLongTermDebtIncludingTheCurrentPortionNotReflectedInFinancialStatementsAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par Value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r24" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred Stock, $10 Par Value, Authorized 100,000 shares, None Issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r38", "r39" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.", "label": "Reclassification, Policy [Policy Text Block]", "terseLabel": "Reclassification" } } }, "localname": "PriorPeriodReclassificationAdjustmentDescription", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProceedsFromBankDebt": { "auth_ref": [ "r113" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from bank borrowing during the year.", "label": "Proceeds from Bank Debt", "verboseLabel": "Debt borrowed" } } }, "localname": "ProceedsFromBankDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r113" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from Long-Term Debt Borrowings" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r112", "r448" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options", "terseLabel": "Net Proceeds Employee Stock Option Plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfLinesOfCredit": { "auth_ref": [ "r141" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 24.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "label": "Proceeds from (Repayments of) Lines of Credit", "verboseLabel": "Net (Repayments)/Borrowings under Revolving Credit Facility" } } }, "localname": "ProceedsFromRepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r109", "r110", "r245" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Proceeds from Sales/Maturities of Securities Available for Sale" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r112" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 25.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Net Cash Proceeds from Share Purchases under Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantiesDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product Warranties Disclosures [Abstract]" } } }, "localname": "ProductWarrantiesDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ProductWarrantyAccrualClassifiedCurrent": { "auth_ref": [ "r50", "r302", "r304" ], "calculation": { "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Product Warranty Accrual, Current", "periodEndLabel": "Balance, end of the year", "periodStartLabel": "Balance, beginning of the year", "terseLabel": "Warranty" } } }, "localname": "ProductWarrantyAccrualClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesSummaryOfAccruedExpensesDetail", "http://astro-med.com/role/ProductWarrantyLiabilityActivityInProductWarrantyLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r305" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Cost of Warranty Repairs" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ProductWarrantyLiabilityActivityInProductWarrantyLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r306" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provision for Warranty Expense" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ProductWarrantyLiabilityActivityInProductWarrantyLiabilityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Product Warranty Liability" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ProductWarrantyLiability" ], "xbrltype": "textBlockItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r84", "r87", "r118", "r134", "r155", "r165", "r166", "r211", "r217", "r221", "r224", "r227", "r247", "r519", "r523", "r524", "r529", "r530", "r577", "r657" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r288" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r293", "r699", "r700", "r701" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r286" ], "calculation": { "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Gross Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r16", "r17", "r288", "r669" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, net", "totalLabel": "Net Property Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/PropertyPlantAndEquipmentSummaryOfPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r129", "r288", "r699", "r700" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r16", "r288" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/PropertyPlantAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r16", "r286" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Estimated useful lives of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r129", "r239", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables, Policy [Policy Text Block]", "terseLabel": "Accounts Receivables and Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r80", "r83", "r91", "r583", "r587", "r589" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedLabel": "Amounts reclassified from AOCL to Earnings" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r219", "r221" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of each significant reconciling item, other than profit (loss), revenues, or assets, in the reconciliation of totals of such items in reportable segments to the entity's corresponding consolidated amount.", "label": "Reconciliation of Other Significant Reconciling Items from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Other Information by Segment" } } }, "localname": "ReconciliationOfOtherSignificantReconcilingItemsFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RegulatedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Regulated Operations [Abstract]" } } }, "localname": "RegulatedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "verboseLabel": "Term loans repaid" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r115" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Principal Payments on Long-Term Debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReportingUnitAxis": { "auth_ref": [ "r268", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by reporting unit.", "label": "Reporting Unit [Axis]" } } }, "localname": "ReportingUnitAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ReportingUnitDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Level of reporting at which goodwill is tested for impairment.", "label": "Reporting Unit [Domain]" } } }, "localname": "ReportingUnitDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r460", "r711" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r129", "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedStockExpense": { "auth_ref": [ "r123" ], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 2.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.", "label": "Restricted Stock or Unit Expense", "terseLabel": "Restricted Stock Awards and Restricted Stock Units" } } }, "localname": "RestrictedStockExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "RSA [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "2014 Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r28", "r324", "r456", "r667", "r690", "r695" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r152", "r153", "r154", "r156", "r164", "r166", "r251", "r453", "r454", "r455", "r497", "r498", "r686", "r688" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTaxStatusAxis": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Axis]", "terseLabel": "Retirement Plan Tax Status [Axis]" } } }, "localname": "RetirementPlanTaxStatusAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTaxStatusDomain": { "auth_ref": [ "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Tax Status [Domain]", "terseLabel": "Retirement Plan Tax Status [Domain]" } } }, "localname": "RetirementPlanTaxStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r202", "r203", "r216", "r222", "r223", "r230", "r231", "r234", "r339", "r340", "r635" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryGeographicMarketsDetail", "http://astro-med.com/role/RevenueRecognitionSummaryOfRevenuesDisaggregatedByPrimaryProductTypeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r342", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/RevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r130", "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition, Policy [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r191", "r234" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue, Net [Member]", "terseLabel": "Sales Revenue, Net [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r80", "r588", "r589" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in Balance of Accumulated Other Comprehensive Loss" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Capitalization, Equity [Line Items]", "terseLabel": "Schedule of Capitalization, Equity [Line Items]" } } }, "localname": "ScheduleOfCapitalizationEquityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.", "label": "Schedule of Capitalization, Equity [Table]", "terseLabel": "Schedule of Capitalization, Equity [Table]" } } }, "localname": "ScheduleOfCapitalizationEquityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Company's Long-Term Debt Including the Current Portion Not Reflected in Financial Statements at Fair Value" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "verboseLabel": "Supplemental Cash Flow Information Related To Leases" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]", "terseLabel": "Share-Based Compensation Expense" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Components of Provision for Income Taxes" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Schedule of Long Term Debt in the Accompanying Condensed Consolidated Balance Sheets" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Tax Effects of Temporary Differences that gave Rise to Significant Portions of Deferred Tax Assets and Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r539", "r548", "r553" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Schedule of Impact of the Derivative Instruments in the Condensed Consolidated Financial Statements" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r544" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Schedule of Summarizes the Notional Amount and Fair Value of the Derivative Instrument" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/DerivativeFinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "verboseLabel": "Reconciliation of income tax provision/(benefit) With The Amount Computed By Applying The Statutory Federal Income Tax Rate To The Income Before Income Tax Provision/(benefit)" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r559", "r560" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Financial Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r273", "r276", "r636" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r273", "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Fair Value of Acquired Identifiable Intangible Assets and Related Estimated Useful Lives" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillSummaryOfGoodwillByReportingUnitDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r267", "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Summary of Goodwill by reporting unit" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/GoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Components of Income before Income Taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r14", "r35", "r36", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Components of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Required Principal Payments Remaining on Long Term Debt Outstanding" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Activity in Product Warranty Liability" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ProductWarrantyLiabilityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r101", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "terseLabel": "Summary of Selected Financial Information by Geographic Area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r93", "r233" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfSelectedFinancialInformationByGeographicAreaDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r211", "r214", "r220", "r267" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r211", "r214", "r220", "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Net Sales and Segment Operating Profit (loss) for Each Reporting Segment" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r422", "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail", "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of employee stock purchase plan activity.", "label": "Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "terseLabel": "Summarized Plan Activity" } } }, "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]", "terseLabel": "Summary of Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r426", "r438", "r441" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Aggregated Information Regarding Stock Options Granted" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Aggregated Information Regarding RSUs and RSAs Granted" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r58", "r132", "r182", "r183", "r314", "r315", "r316", "r318", "r319", "r320", "r321", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r479", "r494" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Changes in Balance of Unrecognized Tax Benefits, Excluding Interest and Penalties" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Summary of Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r198", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r227", "r234", "r679" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r198", "r200", "r201", "r211", "r215", "r221", "r225", "r226", "r227", "r228", "r230", "r233", "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Nature of Operations, Segment Reporting and Geographical Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SelfInsuranceReservePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).", "label": "Self Insurance Reserve [Policy Text Block]", "verboseLabel": "Self-Insurance" } } }, "localname": "SelfInsuranceReservePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling and Marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r122" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-Based Compensation", "totalLabel": "Total" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows", "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation [Abstract]" } } }, "localname": "ShareBasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Discount rate from fair value on purchase date that participants pay for shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date", "terseLabel": "Employee Stock Purchase Plan discount rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance, Outstanding Restricted Stock Units and Restricted Stock Awards", "periodStartLabel": "Beginning balance, Outstanding Restricted Stock Units and Restricted Stock Awards", "terseLabel": "Number of unvested shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted Average Grant Date Fair Value", "periodStartLabel": "Beginning balance, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested, Restricted Stock Units and Restricted Stock Awards" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail", "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for grant under the Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of shares exercisable, total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r440" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Canceled, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited, Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted, Number of Options", "verboseLabel": "Number of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Options granted weighted-average fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of the options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r428", "r447" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance, Number of Options", "periodStartLabel": "Beginning balance, Number of Options", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of shares outstanding, total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail", "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance, Weighted-Average Exercise Price Per Share", "periodStartLabel": "Beginning balance, Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r421", "r424" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Equity Award [Domain]", "terseLabel": "Equity Award [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingRsusAndRsasGrantedDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "verboseLabel": "Exercised, Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "verboseLabel": "Cancelled, Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited, Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "verboseLabel": "Granted, Weighted-Average Exercise Price Per Share" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r129", "r422", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]", "terseLabel": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]", "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit", "terseLabel": "Outstanding Range of Exercise prices, Lower Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Exercisable Options", "terseLabel": "Exercisable, Number of shares" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options", "terseLabel": "Outstanding, Number of shares" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit", "terseLabel": "Outstanding Range of Exercise prices, Upper Limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareholdersEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r447" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of option exercised" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable Remaining Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price", "terseLabel": "Exercisable, Weighted Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Exercise Price", "terseLabel": "Outstanding, Weighted Average Exercise Price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Outstanding Options, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding Remaining Contractual Life" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummaryOfOptionsOutstandingDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r1", "r198", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r216", "r217", "r218", "r219", "r221", "r222", "r223", "r224", "r225", "r227", "r234", "r267", "r291", "r294", "r295", "r679" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationAdditionalInformationDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationNetSalesAndSegmentOperatingProfitLossForEachReportingSegmentDetail", "http://astro-med.com/role/NatureOfOperationsSegmentReportingAndGeographicalInformationSummaryOfOtherInformationBySegmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r23", "r24", "r25", "r132", "r134", "r169", "r170", "r171", "r173", "r175", "r182", "r183", "r184", "r247", "r317", "r577" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r61", "r152", "r153", "r154", "r156", "r164", "r166", "r181", "r251", "r317", "r324", "r453", "r454", "r455", "r497", "r498", "r583", "r584", "r585", "r586", "r587", "r589", "r686", "r687", "r688" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r152", "r153", "r154", "r181", "r635" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/LeasesLeaseCostInformationDetail", "http://astro-med.com/role/LeasesSupplementalCashFlowInformationDetail", "http://astro-med.com/role/PaycheckProtectionProgramLoanAdditionalInformationDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r24", "r25", "r317", "r324" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "negatedLabel": "Shares Purchased" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r317", "r324" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Restricted Stock Awards Vested, net, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r24", "r25", "r317", "r324", "r430" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised, Number of Options", "terseLabel": "Employee Option Exercises, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity", "http://astro-med.com/role/ShareBasedCompensationAggregatedInformationRegardingStockOptionsGrantedDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r24", "r25", "r317", "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Restricted Stock Awards Vested, net" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r61", "r317", "r324" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Employee Option Exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionPlanExpense": { "auth_ref": [ "r123" ], "calculation": { "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail": { "order": 1.0, "parentTag": "us-gaap_ShareBasedCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for option under share-based payment arrangement.", "label": "Stock or Unit Option Plan Expense", "terseLabel": "Stock Options" } } }, "localname": "StockOptionPlanExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationShareBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r25", "r30", "r31", "r134", "r241", "r247", "r577" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/AccumulatedOtherComprehensiveLossChangesInBalanceOfAccumulatedOtherComprehensiveLossDetail", "http://astro-med.com/role/ConsolidatedBalanceSheets", "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r133", "r324", "r327" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r590", "r621" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r590", "r621" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r590", "r621" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r590", "r621" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r620", "r623" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SubsequentEvent" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ShareBasedCompensationSummarizedPlanActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]", "terseLabel": "Vendor [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConcentrationOfRiskAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TaxesPayableCurrentAndNoncurrent": { "auth_ref": [ "r19", "r645", "r664" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 36.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.", "label": "Taxes Payable", "terseLabel": "Income Taxes Payable" } } }, "localname": "TaxesPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r60", "r325" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r60", "r325" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r60", "r325", "r326" ], "calculation": { "http://astro-med.com/role/ConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock, at Cost, 3,297,058 shares in 2021 and 3,281,701 shares in 2020" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r155", "r156", "r157", "r158", "r248", "r249", "r250", "r251", "r252", "r253", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r495", "r496", "r497", "r498", "r637", "r638", "r639", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/LeasesAdditionalInformationDetail", "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type of Arrangement and Non-arrangement Transactions [Axis]", "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IntangibleAssetsFairValueOfAcquiredIdentifiableIntangibleAssetsAndRelatedEstimatedUsefulLivesDetail", "http://astro-med.com/role/RoyaltyObligationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_UnamortizedDebtIssuanceExpense": { "auth_ref": [ "r44" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset.", "label": "Unamortized Debt Issuance Expense", "terseLabel": "Unamortized debt issuance cost" } } }, "localname": "UnamortizedDebtIssuanceExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r461", "r474" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at January 31", "periodStartLabel": "Balance at February 1", "verboseLabel": "Recognized tax benefits excluding interest and penalties" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail", "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r477" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "negatedLabel": "Reductions related to settlement with tax authorities" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued potential interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": { "auth_ref": [ "r472" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense", "terseLabel": "Recognized (benefit) expense related to interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r476" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions", "terseLabel": "Increases in current period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r475" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions", "terseLabel": "Increases in prior period tax positions" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": { "auth_ref": [ "r478" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.", "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations", "negatedLabel": "Reductions related to lapse of statutes of limitations" } } }, "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/IncomeTaxesChangeInBalanceOfUnrecognizedTaxBenefitsExcludingInterestAndPenaltiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r185", "r186", "r187", "r188", "r194", "r195", "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r143", "r148" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Balance at End of Year", "periodStartLabel": "Balance at Beginning of Year" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r146" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Provision/(Benefit) Charged to Operations" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r147" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Deductions" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r143", "r144", "r145", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r143", "r144", "r145", "r147", "r148" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ScheduleIiValuationAndQualifyingAccountsAndReservesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/CreditAgreementAndLongTermDebtAdditionalInformationDetail", "http://astro-med.com/role/CreditAgreementAndLongTermDebtScheduleOfLongTermDebtInTheAccompanyingCondensedConsolidatedBalanceSheetsParentheticalDetail", "http://astro-med.com/role/SubsequentEventAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r175" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 16.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Dilutive Effect of Common Stock Equivalents" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r168", "r175" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Common Shares Outstanding\u2014Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r167", "r175" ], "calculation": { "http://astro-med.com/role/ConsolidatedStatementsOfIncome": { "order": 15.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Common Shares Outstanding\u2014Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://astro-med.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r108": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(ColumnA))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131251-203054" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r271": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/subtopic&trid=2144439" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r282": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r293": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r298": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68070138&loc=d3e11281-110244" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12524-110249" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6036836-161870" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r327": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r351": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "http://asc.fasb.org/topic&trid=2127225" }, "r352": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "http://asc.fasb.org/topic&trid=2197446" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r457": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32059-109318" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31928-109318" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31958-109318" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e39076-109324" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5333-128473" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(6)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41675-113959" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121607252&loc=SL5864739-113975" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994" }, "r558": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13467-108611" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13476-108611" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r591": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549808&loc=d3e36991-112694" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 1,3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121580752&loc=d3e38371-112697" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41499-112717" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121573735&loc=d3e41502-112717" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r614": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919352-209981" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL117410129-209981" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL117410129-209981" }, "r618": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "14", "Topic": "842", "URI": "http://asc.fasb.org/section&trid=77888298" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r623": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4),(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(cc)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r712": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r713": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r714": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r715": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r716": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r717": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r718": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r719": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r720": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r721": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r722": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r723": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "09" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 123 0001193125-21-114283-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-114283-xbrl.zip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�BXU02$5 VH^^9/,C^KAOA?O"%ZI0K,J"K/"O+3G,@&S B9$$V 06W7QLC0ZTF108 M[3TYQ)OIA!T>]!)6KE")+5C7VJ% T)HBPYN-QLC -M7Y?AOL?"LHG#K?*JZE MOI.OOJMVZ$7?53ON#D\>HCS8[3*\*Y/\//#7B>MGLD$,-MI 1Q.ERW,(HQ3" M?KY#0Q['@SK::@!Q<+,"P"VQ;(:-= M9]X(BX51C'?]CRM/)PSM7:%8P[$>%""'#HNP[ S))G1TD&R"ABV2\PK*.=Y\ MMTM?OV=!2MF)H[G\1Q_,Y:__>K&6(+?]1P!2QQYJ9D F2I=&)61_98O*SW.",H-91@UM(XR]JGYUR84MZ\+'U+ M"%!) 5IP>9P,@;4,[G+C6>"HF_'.%8CL\MC--!'S/'RV:36TWX#1XY( MAR?Q@6($I6S3>'/E6H@SVO8EQ.E<%E]71YHZ0XNP;A-'&.OQ)>0R87\&Q-DT M_EQA33:[;;3)IG:"FW%7O)!QNV">2X0--> 5C5TY%BI>^S/)VZ&Z(:0C,8AG M>&]!"X>.F[ \%JS\@UDQX6331[A1;_KH'QUN^A@O_:'Z_.GFZ>H2/3ZMGZX> M8?9^8L++2PT?Y4+:<*YZW3&A.]I%L)="KDJ*Q MLYJA"EZ%LHJ\'3LYT?L/#A1I*-.!D6EG"J7%1K=6Y^+ L*O(.6*L4]IR-FTZ M'@ZQ<;O0;^6NYFZ/.[$>*6\ JB^3F72G']+9[A6Q76RJ+6O46HXF5+F)X! 5 M04Q+IURD"8LAH_EDUOLT*Z)_2$5K9^.WH799?,)*&O'NIJ9"%1G+EL0*8M:4 M0)4;1HG4_C-/HK+)V 5Y$*,PRC 1$#Q)T@#H"14=['$'KDJ?<,'SW^MB;2UH MX=6H(\D )2)TJ[*D U!MV3$"7>(MSF@:0*GNE (R)4(9/A#@L:;\2/6Q6I2:$7GHEBQ67;J,QSB;\4]%%96*5/CV!+! U!H8T^J2 ([L2U/4ME MJ881?< [=5+)1NZ0EBKV8%NU;X*$'3'*@M=DW]1U]#STX]3 '+%GZJ(27.D, M7IV&"%ZM%*Z0=I/DV]YH\*:([H42S+*V!IO-<7_D"9L#S2&*!RJD\_F,&)M4 M4ENS );/<1[JPL8W29GZ=1V&$:MJK#K=GMZONS+:DT= Z3G]W'8(6R4.JO=; M3;^H[AC5/8/4S9Y],"I9F_+8@)6PYP%[KP:V1TBWK'Z]'.+9%FA3(3ZN$9\) M**#6NT1\4/4,=/_PN'G!X3'&=]LJI;7IY;B2PN&BK^9:N-XI6](UL6KKPR-K MP[CW%T+#H+O#RP,[:B7(I4%7AC17DK8.,2+C5#3091N:Z,2'K*K*X>T#0CFV M0% P9H.2MH:"@_+A8A\0'F1$T@RS%A2SY3TJ8[-N0IQ$VV@3:/.:&RD1P-N9*4T-:"9@.&GCWK$-G]WA<\61T+6>O01$GLC M.7.&J_Y<=E#4GTAWRV'EF-U:9)F1M'6X%,HX%5[PU[[RK1]Y5I3#VU\$E6/K M'@K7:8:C7<(O4S:GIRQ(\I@9M@]D:;Y-5GJ5Y\ 0)<$GM5Z MTZK-1MO"JH:>'[,B4N9Y^O-WX]1SD[M M#0>@2@J'.J;FNH^UJB5J-05-][\(ZR[UP8"8/O@-<(%%.OTQP^:R61:TP.CO M2V(#IA6JR(#3_CL4"%I3I(BST1DIW*8<'F;IWX*$C\GAT7"0*&WK[%!1SJEP MC-\$6:'=+, MXOY(W=Z5(FDX[H]9V12UVD(JU C.P97)A(^.0CD!AY52+0"2"4KV<-SMZ%YI MFV9[]H$GO'E)TCC=G:[(@GB@XEAKX,C.7*GG6%F%ZW[6#VIUA)J>4-V5+[H] MF]@W3U<7\&H_";$=FP /5RN#X1MLW>TH-:/P=_2["(.B!>O/T\9U(O# M7>8PZ83[(OVYWO,)L2X0ZP/T0 9>3I=[TA&8[>].1P#6"YUL6+,JE3ZX)S]T M4R'E,-RN.JCUH.:Z1P)[HJTZ- _06!V4';[5*Q\85,\.U*FVC!0N7^DIN1:> M4U0/*.JF0![W#*RC!\S#(O*7Z ";K\L2/L(#/#UV)FQ7+Z.\R*+G(VE?CY)^ M3ZJC<+7QU'(M*5Y6-6Z0 +E_7)![9YM&,VXZ.T-'H+':_HT>_JQJ/=>![!5Q M..D[@6;7J%<]=7M7BJ?A6,C77S9M[XD!E6XASITIG DK'75S A0K91LS[$7= M%N@UYB\W^W'"@(*!QP MBB! T N]6C?I8BQ3#X_IS ^=4\LZ]""LU=-"F8K_R*5-:)EH'$Y02'NA;87R M1!<-R!V@F0;8>J&G'S+]HQ8SJ1\Z6,DQ5.,8G7>KG4H:]GMT$639B64WVM,B M0)[J40=9 [2F ZL)1Q+\$W'W$T%?,=4OS];AWXYYL9>G79W]"ZZ./68=%;FR M(94CUEX(M,\UFX\ '*\L.D(#Q75V)C._LG1.<3S5%*MS'P<:<\9Z_^??_N&' M=S_^&46-XI0)MMNY%[>:Q\ HJ+\%=-[T1#YPMUW35,8[MN>A15K?W=#"S)UVM!C( MUTE(1K@UP.WQ-1[1#N[)H48-EU+8,;9ZL, B:'2,+]*ZU+V1..YKY4@03ZES MFB;X](;CF'FD]P00+T%.J]O=1AN7J_)7YKV2'H^CEI MTONKZ*09]P/HK2WV2&AW>O $S%VI!L)WA=I' S"N[1S"Y;Q89>]$PU?EDP!Q MB+I)4.AP<]FZ8A)9T^TE#80NMXXF&4QE404] MH43I(#?SE0'P5TAV<%)F%# M9X4D+^X]KX_%,<-MAJ_XJ%OX6-.Z]>.^U$;^H7>IK"QL!\EEGW0QRS=!C/X3 M!QGZ&)!/TSH6?CACJ3Z MP!2!]NA=Z,$PZ0FB?N^I\EI =T@LCQFW/BOLTULZJ[ZR_KQ65R[QC-I*.OQ: ME%4N.P'3CU^7KK90.UU56Y#U65.O"8CF75I9AU[K:BGSG$LKZ?%KT5:%] 11 MO_NZU+4-W1F6UA9N?5;8)_+Y>9WALD>O5;:2>LX%EG;YM2BM2GX"JW_]NK2V M@]\9EMDV>'W5VT_X2_'TAN-7_#%-BI>1 ?!6'7NKQ9(QF$>9:<>(]XQXUU^# M4EL,!X'>#U^/;JLP/DW%50"?$)1SD[SBA#0^7>)]FM!#,/:]*NF<*@C'2.8J MZ,;,OW ]5E&@#DF3: \@G&:*%&%'"JR2PEF@C"6B.H$Q+N%D%0BSP(0 !877 M?%%3D[_@D$8CZ-9<%8'+BWT5S\I!YS?VM"F+-X%]6V;-?I=GT'MY+4J$:W@M M1 "P;7I(V6\(@675L\(6AA?";%H$L35FQ[()@E;M,T?YI .@\^H;IW9MW;_:]0]07R$_W&BC59X#ALF-H"#!-H MT._,VB*$!\^L*B[K5T8Q?49#E_";_2%+7_FK5=.FWT#GM&ZE7@*QQ&/9GFEB MFP+4J9PFQBT.\ M 2SN&95-NYN64"-_QP"0(+>#)X^[LW( M<0=]Y;[%!'\3H4,5,,K01U%O ^](&6RN%0>+PI.L:@6"5 X[>/45Q Y;[I2D M?0"@48EN,X<*T.-/**:C.;)Q8^,',%@]*$?DQT,-ZT,-:]" +1T@^B"6H6%" MX.%ZL\F..'PLTLVO/Z5QB.LJ2M=8>BUB1>4J[-#(O>3(D1(@1H$X25V("U$B M@+##P5*PEB\6S#N+-K2#42?8T"&&K&(-1V,I9U@JIZ.J*H:VA @HUO".6+> MUEYB9WVW4? Q]<"+"Q#14GJK> M4_!%AW)K2L>'LGHIE#CG5#SJAJT C! &[/.)\\_!_O#G1B#H$4QJ$?B^A,GLG\O,$^Z?1TE9&<:!?%]FD<\,T5! M'&Z:M>(VRL'P8/&9<2Q\0K57Z"G /4W4/41]$OS&42_ U2&Z:L? M)G_.A(?KVK#3X^&*YC(LX;FXH9DSF U^"@@CVN@$26NG00HR;H4;T\T+#H\Q M*_)WFR:[,Z)0>T1I44. M\?\(DF.0G9Y>HJPXW27XZ2U]>DF/.0\5?7HC7SV1W^E+GHWOSY7K/4%BH20F MA17M"Y'.4-D;XMTATA_-!8RJ'A'I$O$^V>\!2Z(M/@0_OE\AF@4-OA;:5'QW M7'POP&WE^,\]PS&=X; UPP4'>4I 7A P%Q7(Z?\*#G+R^\%[!+.5^D1CU0FG M7)ZI-FI0;P 6:IBT>N6L^JH,%(AQL@JK<#(*/[[ST$:-0+?*0D%!>ZA]FF%R M:^M43VYIGMR:IO]Q3/!UM"TP3B;[3M9=0;A-]G(:W 72$2I[@C%'AJO>925_ M_SL/+=!0$"L=) @$#_:-)LYGXQ;1^=R62)[3ZBQQ7'$;)?BFP'O=&R,E!=BQ M19MK\2*YL[5'O]#&B+7VXJ!B+M[ACB8$S.B/)P3 0&'](LBR4Y3LUOOTJ+T MUY.!H5[@7XB#[IQO@3XG'OAKJ!PBG05UW(;F>='V@ZQAJR,)%3"IXF<)YA=_P2MW$Y!*Z$1K"YH MD22J@19&4%:_*AUZ2<;6VN9WB< L?H]W@[NP:LJD4@(?#+^- %%+@'TE0+B$ M );!O(-$H N6@6^X]4N&??WJ)0,^E.9>XGR310=>&?HO01;1>ZX'PMAYD$?V M&Q93-V#:;93/J.^M'N@B4O6!:">(]>*#$1@G9]LLA%TY7RLY,RKGLTQ..)VS M0ZU>"^T@ZS #%=E84/><P%;O.<2O_LRT$S0/UEC4"AFRQD+6G8:VC<3Z MBW9U%)LZU"\)GWW\=%>Q7V@KH(.[F9AUB7D5#OJ05H$ !K&7Z3Z(=#E]9(V! M4%OS:H ";^+B9T^.T"8H;[6[NK6:A;5XMK10_BR29PZ?RJT^(6 M$_J"TGSW"'2=V/:-RL.#".>$F;Z!#$-\F &KH3^P7:,HP9 M =/VH>ESA9I>Z3ZX[I?6L7)00M?R_&SN ;F.\@V1$;J4[BQ(UVTM1L/<4VUG MI;W?TKF4O.[.5]UNY)U)I7F)^[?TJU!DM?2-_O[XU>AO#[N3U+8'7!AMM=1" M,.TR:@U,)N!)+$*AVP:U,VR7SH/DU[OM>H^S:!/H]TS2IJXV3G(^Q>Q5R:_H M;HO*=I![J $,IS7#*_3IN_5WL.&Q\XZTLWV@!LB=S>#2*+;:$0X#1\#;@55Q MYV?B97XKPSHD;>VT9*2,6^7U1MELMKP+5/5!]T%E+ZCN!E7] MP&K79)E+6;>UK%DMZW,MZT8AJU,GV[5YFCKX=$:LW7M;[ZNAEFV8H9&%'E> ;VAMX M6-% F$K#B@9BU$-%-%5!&MJ1C\JH*BTT7!V7>?8QMT+JZF/& 2N/N>61Y%^1 M*FKK*8U#*=ANS7ZG!KE+L]BA>;2'L=R_N)_[]M&U89LN-G4X^Q(^Q6UN^T)E MD"MDV8X4J&E02-2?#B[Q)&+"G&":-^JC[[ECD M19"$[&\T"C%@[[316R5Y4$H>^?*,P1*1LMV&!1R=UB.HGCBO6R^*S=XR"D"E*HO,C!,>%9IDHP,]J#6SGRJ(*FY M,),>P#KSK'Y*01FZQMB8L,6Z!V 77BZ5M??>D-.*((AWX)-_:R#2QL_5@-*=OGU.R@PC.&Q;!?.QGXG0H78991 R##4$O<50 M<4HX602KAUJ3Y! OK"#5Q0Y6?2VQPY0W$>[T3Q.>K93D_D2P5_*,BEAG*;M\ M?6:BDJR)L*^D*&12>!29WL')W0 M\5^S;Y^$"5@OM*F,3!""2F3$LK8\'C(U-,@U478 F,M'(9DQD<_//<2BAGM-!GH$/T29]>R:Q,$U[%=#^U M#D,&NB!N?52B]?:DKE[-V,EARF#1URCB)6GF9@C#D)Q:=!&0 #X0< M2>+L D\R'&M,%8/="8H3N.%T1FJ%*=MA+U(&M^^1V)27:?9U7:+-T7T MBBUN20?U!.;=V$AI='(Z]Z>5ST.#C>N>P&]6ITE<>VU>W9>.P*K>9; &*I1. M7F?X[T><;$YW6V+GHS2,-F5PN[4RZKH TT*M7$;UJZE9;H62'I4=^) ;U:%X M<#IHQJ9>^0(D M!]]5BGB$6NAZ%J ^SK=>YM0=@"UR&IF,:T#?[*^:'$)^>)53A#O4ES6UF ?? M5C<3(/5KFPF-+I^ E"$8O=!<56(72SJGCT/T$JBC1'LK%E#R%W=RN'U58H$K M\8F)!:B&:<(V@<\L_\J6[ 9#NN^[O3F_>S#JB"6]VYM.*XDDUX:$#M6$ MJ*3D282_8<3? NO/:-GH7\$R*,'.C.-[77MMDESRVJN2.PMQC4.H;*%DL*AYJBY[J.J:8E84T3;@M:[6(9WESI@ MP$P?]P; @&+=6!-#0P.+=V7!"05J0"ME+,<_,.[U]3.,X'&9=F23[O%C098: M>@)R2[\4I8G!UFNIG*8CT7$O1E?1UJANCJKV'MA.BWD0TY88)P$<1T8[:J"# MQY+2'FG0Y(%-LIH/2T1!V::[X@5GY5L4XR9.UM@A>J2\]B'#&E5/GKS8MJB' MN(\-]?B.!D2>%2TPD'_U@4!^]=<:C8\;G 19E"J6)DU;!S#0<2HX,N6? 5<= MX\!6LV\'A01FB M<;>E]>*>TG-,OK"+R.Y.@DP3@:M'!CJ>%>'KM'($*Q_XE*)SC"H"D!<%8]A/ MMSSO4)&B9TQ#@:7L.PN]-Z*F$W#O!C)68?9CQGX3' XTKVR:U0./"WC)'.$=!$C81S61#%;93R)"IN[^_9RCT(A[_WNYMNHX(+O1)_UI;#'?R MX>GY(!$H3%;^/#8W0\<0L 3ZL%P=E<_V"*%5].V03KQX?B*1;>C+$]Z%!Z&W MDZ3DNO05/#51H='^E8D*BI[$W=JO,]X\)1GQP&+Q)R-S1-2:UIP/U&34 M$Q#P=Q]]1=UD.,CQ>K/)CCBL]'; FJ.@!UQN5!)9K#2<=(5*XGKM\4-=[$7K M+2\!)_!'=0RP,RTN6LRY5*4L>@UHB%'#7+Y.PI]PN(N2W9I&'[%=V&64;^(T M/Q(VG^@;4ZUZC>[3J^V0="/ M.>R#H!P3[BG(4)65::AID+--H(X6K&PHMUV+MLOP%T=:HU9Q> M6# "@$1!P[FG-8C8(67%?;I%N8Q[9S<49MQTKB@<@<;JCF+&X0>[:) 8C0]! ME-RF>?Z -W&0Y]$VXE%:UV3B6@GH[RYNGE(>T'65%]&>_NX3+GC::WIC\Y0% M2;[%M,[TT$5]$1:@U_]EQM5N>5PA^G7T#?W^MZC/ :(ZB=H%)@@3]!Z,L[%" M-2.T&&R9F;Z\XFQQXY%_X6:LRX$@2KRCHYM5'SO)!S1*R)"1I9>>V&743TGP MEP*]_P'MTZ1X ;XV3R,-JB>;(&]$Z2(N-4'6GHQ)&C,_,-#0.-4W'N1WD0%_K+L:^ M2YTQHJ>O%D;HN$,^/:2ZCM.WDB7CFSA%>X>(5W$L/7ZC#>M+ A]>QVG'NX\3 M[6##>C /4?[K"#^E(0/V1EK\6VT.O7,Z9A( VK?HX\C&@^B#"$(3+M*DR(*- M768//1F()DCYUP"I:@_L+RPH (PFJ'&DU@0UB!SZ#1GQX"^.64;3>+?#G"OF MS)Z$;0\N?0MKJ01O@U*BBK0;K-_"'F@:12CIG/I7PW I>%S#0.E.W\Z#F-8X M>WS!V#:CCIK$H49I^.Z#K&R*6%M3(ATW&K,4]RXUPH2:.OI2," MQKW235%A!]356E(":/SK/2TSA"9&S55[>G4*(G53EW%R(I_Z0Y8%\\':A<;- MQ[#3:#@%'H0PN"7!8!W_9CG&6SK&+[3=X$@WE>:H?#,:@&?0)!M29YIE)<<@ M%YPE+H;4/<\QUM=4QX.RTU^$LN4P3:6D)3 1.$T-:#KXW:KXDYVZ3 M6-KHL!U4@&-(%*DU[[;T@OTN,P?*#(TQF>&#T#$H9H@BA[[;FTU"KN)K9U!/"KET'4?:7(#[BNVWSR]LH>&9EHJPLE:D+ M$-MCE$MC3>IF*T2[0:R?%?K '++ZC]#&8;"$E."??_O^]^_^S,CXCPTIL9Q* MV6 TV@Z;:AVU R:$UGU*>4EZ'IQLI65]$A"M$OA6:]$*58W+5TSPL>9&[JL& M7#7D;,.H@APP:NC+T>(XW_M%NC]D^(7X"&S!I*LD70P[AUEU4"K>IAGNOS]: M)^%3\$6C'S-_QW66^1E'2)Z@OO.!VG%C[N\*]=N M^UBD&U,0I8;&95$H#>?">2%M0I'+&GEP 6X<=J&6DFG,'899M3@P7GW+&KL, MGI+Q:D*'!Q?$ZC$6HH.4 SPES7N3?YD@V.GLV$%ZPFSDI6S4N573QNJ MN5!?G\>L\_RX/]"^F[3,=]M[,BSD9];B.MBT>NVKP8B.7.G%&!EE!W7\T!$U MO;0RCM-$6&5'93/>%9CVC)[8CCK!SJJ5?ODRNQ.4\,,QR(*DP#B4&@N5RAG) M7"F8F?_^@#<42+$$@2F.Y61TU,3E3%@IQ:09V,.=)E'6/ M=B*DJZH!0!D';PEG&-^1C0L9C&1W2U.6W['%YBF]^E+@1) ,C6J&:#-WR[/J[W4W.X.[ MVP#/[K4N(M^0; M%#4?CE%(GU]\#6([O6$9B6GA$F4DH#W17IK,FBZ'-"2SW*R,U5YI5[YHKUS. MX3"N^BG+AI5=>0MDS?0. K)F;B>X\>Q+9;CA R\>>1]DTO@T0WM7SKR&8]%/ MH6:N="U7=7', VT.YM2;1KSCUSL9;BO7?L"P-]Y]W)X XM9OZ)N+D-[Q=^:B M;!?L,HQ'[5&7\^O%Y6.@;R_K -B_E\ID[>,[<9ZL0E9&R]:3R3O':!@0;;8O M:A1.6#NZG\C7SSE+**%:.I3-7:T<:GX- ,G1+U5CN(=[AM'N+!N&H89R?/,' M8MS+-42?_MM !^;2BA*8H$,-)ED,KRHG9(D4VI;QNA-%01=I#G,8.@A->J=: M 25W&O$!)X2?>)V$ZY">9U+-I*&.)4_&MYZ6] XUQ%8BX:Z"T[&PURYEI2U> MO*\<-&%]\ V:+5A/MWZ^49W;7Q[Q?^(@NR;L#O1Y]5T!>[\&.:W]X-9;IJJG M%2)](=H9NI9$+\-YQ0-E)JCYO6_^KPT\;3QA&VSZIXCK+9G[&;6QUY^'*MF7 M>+I>!K3'KT4[3>(_O> ,,XF^!D65PG>LMDJQZY_*?L)?BJ)*Y!ZCN[PR&RU-N.(Z>Y=XKK(6@A-(_? UZ*L*NV-55@5<_[260NWI M+9W)X64]>:BCC92SJ";IRF_55,M+X/+CUZ"1/5Q.\71;H/14_\B'Y]IREGWY MJH.EI/-H(>WL*]!#A',HW/QJEA9!/)>:R9#"FF ,%3QBDSI120$6 M,*)+&ZC6+3\B1'2\M]>PJEV$/8H.,68S-&!E8D$,NB^_3C.N.C21:7P,<7B3 M/+W@C^1[QXP%NMYM.Q^/S$%T\_3MLN3&#",A+,]DWO32QRW'S AZ"^.:$B%->8"R=0%E_SJMA$ &;O-8]>!7.O\OUAK+V& M\ZZ^I;4<@DKY8_Y5KZ7M@.,.\0]X5V:KY@REB6X)L*)RB'T]]WT8U:U1TQS8 M" ^8ACZ"+.; 82+&S0L.CS&^VUX$AXBX9M$_&$M7?S\2G^8I>(YU1TA6U"Z3 M,UI)TX=71447^R[="G%*] NC!2HTXEHJIQDI[?$GY*:T!Y\O^G0;)?BFP'MM MFE/;'KS1J[948U!(Z1'KP$L%6U \?S1-0.8P;1-@Z4=>Z!$U<#+1.3S# 7MJ3L>U7!DO9Y]S3]NJ1!#LHU; M:H/+G5&7E7YU'X4LO*Q?<<^RREI8B'D_XW3O->OXB)NU7G4"L6J5TLJLRN** M19DU>1FC,NQJ:.'A*@_96A:D+O1U=W'+,F(%&7V #7I&LH1.B?OB^15JPF'\ MYR3#U,O!855"X2ZA[]^C)."UQ-H5$3LE%_+[#!,>+'BGO:H.[-U]W]6AOL,1 M[6M9\VFTHU5$8KJ2TX1SS>>IF8FJ2IT9K=2YZ19OSA'Y&"J"+RAH&;.4&;-- MQYA%W$6@'W%MM: 'FI7(/=.5R&TQ G9[XEJW.ST M78**.6F]@ETY6A=%%CT?"WK\2+VW^X#YL["EJA<:'3HB+<6C_7Y?#@Y1-V%H M?$C*,*?>]!W8.94&RI(TTWF3O!)#26U^)[3K==T>ZB!Z M_90%21XS)V@=_NW(^1NBS=H.8'18+Y-.H.DUJ0M$7> MDMH[S;3 JT8?+< *<1_,2N6=GUCA//NX"@D5R+VOC'O=92BO:?A\0KS*H2?Q M$\M( 7.+J\23^N96"2:'^O 2T,NB YGH%QH_EZ6[+-B;*K]JB%QJ@XYW 4:T M,6I:H[*YH@JL(TU84 *G6F!$D: $1@A!ZX"QIJV>#%P/E'5NU3A25+R%U(7Y MI(#7!WT%7QLXP51W%F*1),J@: ]4X_E6$R+6+_-\"QWMM@#C+K&N18JN3+4 MDPF7P[SN-8ZC5YSA\/*81K2=J2D M@OED&*K[0;RC,LP#\:Y*H)6=H:HWMUHRI]#T^BI(3BCGXNU(=ZS&&=X?XO2$ M:8YO_B>PB] I..Y<:H*#V.J",Y=L3>V"(RZ[1(8LV_*R4DZQU+*LV=*BMK]H_8'* #;#:^=RZO:'H?"C2R#&6T >B(^F4VG5Z2R6?]_V_O: MWLAM;,V_0F!G!PE0R>WNS,6=V0 7*+]TQ@NGN]=V$@SR(5!5T;8V9:FNI')W M[:]?ONB=XJLD'JKZ?FFX;?*0Y^AY#LE#\E#8"1WZY)Z#VTY4:CJ>[#Z1C_ A M>L%F0?')F_,=3)_>7GTUADM MWB7EO=XG'>ZQ>#&T7LV7.TJ@$#?N]OTZ"% K@2'>I52@ @S,OR1QD=_=_V(+ MZGX].' +&FA!SFJ@;TB=_-NP$*_5Y=V;MW]#;@H!$F,89!J"#"-LQ*9*3SZ; M54EAKZWA:U-$V6LMU,NI-B D#$W?">1[LKM1H-[5_CPZ'M'B0,'Q.US$/"TH M730\1%_NB:;'7!.>4M;RZN55O1<-7Y5&M#A-3H%X!=!0ULQ*^'7I6C2)#ET+ M)7 V:*-9FGKPC)!&6U1P HTV>5 D &:HHT%&L/+'CBJLI!DK4\.ZG$GZ"@$.M4NU#T4 M+ED@=D*.GZI#^*05]2I16\W74E'??TVYQL,9 "X!Q/-E!^D$A"TDW#1\MV;MW]?@)\PAJ;,5?C%I:VWF/;+ MS3!G>!\_CO4,>A$ CL% +Z5?*.L'[18<="38^O<%> 535,J<@E=(VOH$_] , MZ*BM[(S?KLCN,8$ M CAPB[/7>(N'5?B0)OP>'NMMSA[T;?_],LV+#VGQ+USSW:5;^BI9[ M"^$O)1TY!\'HE><14\8'5AC9^EOE;[!F^-5.H8S\,"-)%Z)/4/R\!PED)-7;9_.P2\; M6-[S)+EV\\\91"OR0[G$D/<<@V.AP$>;P:8ZWCP(V-2@;Z^%CE!6-BD.I,$<#. MQ]3J-KGRCDQ= RU]7AAR@V__'A$@=DVO%\WZ4?&41[" ]TBNXGQ+,Z#1YYM^ MCK(_S_TLS-S?96C[HD6)D;Z7,KXKMH^?*0FXIG-R=#"A_]%.MQQ3F$RMSO. M(RS'^;:&])N$C-I)'F_G=K.*-A?D4%66F]-UMMI=H;KE);M'&TNNGYXR_$0' MA;A6O7[0@3[44+W'D#9"E^P'M?RUC)]V9P1G6$?MLBH MC87AQ#>WY*YI 7$%"\W[\8/&$G.=0?$1G[(PP$ <:GX;D,GI)@T?^BM4T$,@ M9S(XSQ3]T8TN"QB,>8>K7?OUL7A.,WJZ9X[!6-[6$@9CA:5F&(P;;I:G>9H& M%S86V]HM1U%=AAUA9U&5\B0(74- G>F9G6N3^24=T1;@EP8C/#]E:3[+W6)5 M:TOP34IK^8T4LU:7.FLR,V#CF]-NX'=AGME*Z9^XB@93Y$7X8KU_F3=8W7$N M8 ]G7/.3] J7*JL ]U1&TV?MPP%D\D#WO5%9)8C7,2RZ7UX.&=RT9_OY ;V. MT4.2YEF,'HP\STA)O)"0N7S&FCW-VXZ^JV[1S-NI[=C*7[>:M=H9H0KD@9)I]&D7IBD->''0 MITQ&P%!)(C,,@D^=-WF11=O"?M);5X2?KC8Z&$\T?Z\JA9A L_=-#*S9* G/_D!KW<)3!YQA(6U(EL5I: M^I)ZB7^(,SY_JQ;YL\8&!UJ#GUN-M-:\D;^ZQ2;V-YT;^P>W6\)B:;,?9C8S MWR4]P;L_NQ,*"J9-'[>3TFPYGJEU&+=W(; *2[*L*C-Z*^,>+,B#F5O5V\44 MX4IRU1.>E.E,+B]86GO@2D,EX;MA.]&Q@1O_+&Z[6-JK?P?&V5A+&E(L7>2, MUR5,_.-RAI[W:?:(X^*881^3XL'6%C2D#%MKSN&CU>+R)\5FYBM+G=VL6$&U MJ=V5@F/.OOC>\X\U;6-N2U?_7UW+C/ M6=R!M6>=Q1Z*TMRO/9VGM7U#LXSS]?YCK=^:Y;Z=;A?1\

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�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

\X3 (T3I/G\$>T>J;%M\9$[31! :. MP(+#DVX;H/.3M.NE+Z=W?O+Z!+A9MZ0$08)Z/3 NC(!0=@.B0-IYR49@WI\L M4[X)CJ]6+$W(_+I+CBV\$429>F 4#]CT9H,OSEN7F^\0D(UQ[Z2)A\C XQG( MP 4C3]A6W?L# PRK'.1UT13K:O;5GS81_$;[>3_&]UKZEW%XB8RH#UFU^-V>TW&F=,"ZA_- G]OD-]"_[!FSJXY@SM6'%E3:&KW*1=G&@#32GW0NO3 AI=8UJPQ MYN(9SV+/NV& ]A@#U,14D+P&IQOGG$/"],9CWZ-5W H"U$(K5KBBO6FU,O#! M^E5;@TN2DP@DLZF)F$TF!PY$",PX(A+V"20:[WG^ >X%29'$^<8 9S H>UR4 M>BMZS@:*&]:<8@R-5Q\&_H090!MP-YUXM0(?#\F!L*>%*5.+5S'GJ]=:T6TB M27=CMSZQ&Y*[E-_LM/K'X#LQB^W(\)0D+$SJ#CR(*W]$)KS5,AZ&(6=$!);. MD8.Y M"M]+PI-V*(]T;LB$&*(C-2^!2^//*FN-^3,?LKK#"#$2.^XW_Q%@5\ MOO* OYRX?3W$YK2M KV, RM*L<7#)>@D?RY)3I)8?(J3D8>R-4C=5@EEC['2 MOK4D*<)UWTR4 ->KRX=B\/,VA[H^9SQAO:V#EY04, [Y9U1%)P'9;^'XPNL!U?",4\G.SGTX"'?:BUDM6G*V M9\%U*&GZR'T<<4TZ+%U[S#J&\*=?.7!2+ M W_H3<*,H +BOKP((JF08@,:<(*B"7!UW7AK['*<=WK0QZP M6C%F">:..L.!(BL,SG''#= M6@5<'^64'G;VCKL@4<>AUV>3(J>(47AGIL&5P*@I&-^DU'(!N"T*C3T5^<,K M.]6'HGO]=8D9RWH2RKIL7:B%@*='I!,I$Z]$>^?#WG2!"F9CC/=-9:-BI)%: MQ>FQ.HF=X!#@'64D:3]U[X1\3ND#$1T;> M=_S 7&H-M6"EO]/U-FQG_R)"*Q?F.< QP&\@(8D2,1[+7DT@2$<>1W_7]-U5 MW<1_2RZ=LV(P)Q>KY]7 Y]J^H+PXF%_*2$SFLA5V[U(V@X2_2*N'8]]1#$:Z M7'+H1^= 'A@R!'72\_K?I?>:UE!922_9LO/KRO8?@#__)# (YEMEP#BN34^=D(Y+G#C./(I]3OS)P MT0)L$LC=M%+*U0G&(NZ8&ZV.$E.LT'+UG 2HO[ M$_QC[>F([X4);B>)O][2&8LJQ>VZ\KY:N8[ ?PH;T?5#\BWLM>9%>Q YDA3) M6R[02;1QLD/BA_XE!DT\=B]"#!U(^Q-3$S2ZFI0S%$J0N&UT3OKH7[FI"\[Q M=W-$9QZ4G;NJUE_NNM68HD#I<&/JXF;28,GR'_G914S)=[#BL#\!:LAT5GO+ MV0(O#D [I;'R4A^E,3D=V.N2[^8&9N>ZBB:?T7>,I(N]%P^F6@1ILMW+ 1%K M&>M:2K=1EZ&<:"85[EBJ,'?_7A$_H1\9%X=M: MSNNVTH_-MNM\N<#VH$B)P5O0+F$YE_K))4IJ:DPI-]EEQ]+(,J81:>GJZM+$ M9*>!@X^J(F] 4<[ Z?&G+NDJU"Y\%8&I;WJN=5Y=M8+)\U:>4XK*V3 [IH> MCS;E6JL%6HXS=<3,8C_@].\FP.Y^JGHU%C>%4\&'XBJ>A -9X #ZG@Z)M3]T M7DB$^(.:6MT0K >RC1*=_F[YV *47I1ZK!!5)UD5O"[$&!Z6\\%LSK.^<#G_ M26F8&5*G-&3SB1.4,5 /;(@Y$UYBUH@4+SPAVS3CR_^,D^\<4:'4!,Q(1=M[ M&/39- 3^C9.4XS)D.UN*9=&;BP_D7OR$W+A\,QKM')1 MU,RKE>+4G\[A0WEOT;[,27%7UT'J_IK*,%;U.Y85=^CS!\UPI! M5RX$J6'4F_S@'\&(;WS?[V ?6.T(=9@M&H%AQ/[&"Q'-:]G8%\2TZC%5#IN M3.\F[\VTX,2-#+CG'(Q]LPK&/HHLT 9@J3* ?;H"?;>. 2*2BG!ZO;Z-,$$\$ZN35JT4CEJQ#/8Q/8>Y-L8#-3T_OV:J :5SJ!NHFZ<;[$CBEA0$ M@O,B$TO.+/U\H%-TZNJK]G5I*P5>2A<]D+M(=1__)&OB="W(5+38ED\+"31E M97I?@Q ^!9OI&FDB#T2\"R:>%< L+:)8F MBLL,S7?0;L[N!_%I([\&-P2.J M##_@Z&K%5YWK54_[^^U@?^ X5J[W0SX9?LU*(M>!YO)^ M$2W8I- IFFC4K"PE%1"4&^@@))BAK0I*Y5ZLR1@1?T^G:2;H'OC$I9X$I5"S MEV]39\K+^QV2R<)>L@-(TI.-,R="Q!A!>Y20.'M^^?1O^&M]O7[=_0?/>4FQ$\:<3\ MW;U"A8@Z]X0=#C/M&%D'0A"/.D]SA2!^,S2?HA"^9\ROO]\" MWO0=E@^M )<7$>^W29CKM?3\:?=RC^)Q/XM-&>E/0]"70KZRWF?WC8B^.H]+ M58W+)V=SFU*W5Z?QQJKQ)Z#=RSV*9:KQ)R#H2R%?F6J\;YCXU7EU>[E$L4XT_ 4%?"OF>K&I<'<=[THSWW4/AYM3<:C17(9Q;:<:? M@'8O]RB6:<:?@* OA7QEFG'[^9/OY9['HFIU52\)"ILKM['XD+-41>$%E@ M62EF52V_%D[F\W89.8.J&&P8M0U$ #-]:&1-0AE2&:6XIUX6I%3/+Y^E3'U= MQ4;OD 7P.K%UA&@>> (5D%9V$20@1M>V-F4!VP!8B$N3Q%6"Q8H*ML/-%*ZK M-W!U@=L\K0RO+.422.QV8]#*L'ZU#U]8PZ19JC))9["FS1J4A M82C1/11(28U*[;A;#L[+@I?^X';_,.Q**7O5J=E,NX'T$4C"8CN_W. MM@-AG6L78]-$$!(X8H?\H#&(B" WG?>G3X"!>\3 )0#:K1#;]FC8LPW10922 MP\]4W6%#.]S#B^@ M4 E 3U[V&!Y?6S.)GFI0G5=ZJ_XX!K")UPY6%G.UW0 M2 15T#OP?TKEEP*O;W9G9KT6\H0$?N$T>0F\Z+MPBX%&>+3PDY UXPF(S0 $ MFD2C6[//LVS#-^6-9AM'-=W)(=)(D")5&*&:&P(3FS9CY9"3K@C)O[+_/8JO M0G]PKK%2L>J+^X8Q'-%<*M"#_@^_/Y$E8;2_GR<>2&DLA#7C\\Q+5%3'E8T( M>Y0%&8PGCG4+!#8#)TQWJZF85ZWTKT8 MP9:PZ.(8J^RQG$-A:O#X4X7,Y649K-"43Z=Q.)'Z%<&63%V-K8\$JQ-)^^*VHVE&&; M(*?S8@M>W8>-^5VC>1I0)*$PD=BZR!)92P/".:'R>,;16DB-.JG9L6XT(MM[ M$;LHI3QWQA*GJ$_H"(1JP77AP(Y)&"!6E$(#XQ(9JGF$-TW+Y\T3IAUT!V!N MYZGBY$J1S0N"4/8XO/ZF5RO4!;(O03@\;5T0:D"A^FU[8W.[@,K.P&:\$83I M9+J.<=<\IMMPDD1<]6D+]'FOKZO2>\(&JQ=F\W9CLR'Y=Z^(<\N(7Q^D<6/U M^J-.$%HT66A@_4D*2A*+%I4@3NM25\1CD-%QM)8R1$[,9U=5R5N2(\IE;A^ZL(IFF\2E%<$7I50T2M]?: _V M_#[UO*,-9IQ9NP&6AITC16,7Z"L<+<0("%(IKE"*!0EP"HLM5LN3* R^8VTM M%[R"Y!_'R'<: &NY5 IJLP%4K!VA4( #8]":P'921/?"(^/GKTD2I(. G0%\ MTF9;!>[BO >;\,C&F![O;]\H1Q'@DI3MIVT,V4V=K"ZV)GB6\NQ84^:3!\H/ M@2,(%U"^2E&5#MPDE=@S-E2>@[&52-LVY.:,N<[#N4@.@^RI-=39]Y%([1HG M!OQB9[L5WL1\=PL!R0(VT1&@E<([Q,DU4I1DA1EAY@G.KPHBB<*6 _!F!36 MF%$AJ0/3+-6&.D>);\D-VW.X])^(V+ZLB72J,=%(-%G0CCV?O%$9&)"&A9=) M;8CP"M'Y!.%*%.09"1L$3+5]SZ([A>8?N+^X/^XKB*S2KEUSVE@0,"*V T]0 M[4D&0%]=AI8-2)9L+0KNG =5XRT]*KE3SXO93)$KB37Z,-3:N75"Q#NCF4I$2% MYS1R7BE^9*$AR1S<5+*N**INV7D2ZPF% *[?@)_(5BNJ1;@!=/(OY<5#M>): M4FSL6;O-D37"0+4"4M2RF!#29@"BJA['[E?J=-Q-&Q62@A0R@7P0 M@6S#%#=%_31UO0B:5=V.RUIP.!A= G]/-FHGL)5;P!\KP_F:R+?704O.N^K* MGL;7V+%3$C?#24*B5<:&3>Q-$YS^//82OX8/8%01E:,Q^.#QI% MW+3.DV&[0K!.@G7E,*SMRZ5/=UJ[QDR7 M/4MN*5>B(ZQXFY0Y;IPZ&MCA,3I0^;B$E&FZ?2Z'/KGU.LH?,I[X2$QDL*" MJV]$4MG1FH%V5 :?-^_H+9L(.1]M?IL&(D@XC&0655=7$\![O M.W$ISN/*.;65:Y]&'17RTG@_L$,D> M)B58C_4%QLOU8=_S>LU"$D.K0#=#*TV\X!ESK^N!#!30*CD%HWZ/Y-8&G@O" M/I-N)<]KR:GWKBA"EQ^]/3/GB>PK.,VC,;HU:P%WRD7L_9A\-.I.4V.&FQ;8 M3=\BDKB;;W/653,; J!>8'RJ:Y,DGIQ?",?NU[>&GBAO7,5W+_^U[@/+J+=\ M*K1F=.BP' V&OG>:Z"QHFY-/W7%O'*VN.-7*M=OBY&1P?4[#F[E3QVO'3(%Z M6_UL9MG#SQDN^=TJ'/:09V?FW9,?IHQT&T1DEGCL/K%[7#QPX/F3Q""-:_$A M6QB&6YU>XM3WNSY;+RB?U=Q4PR_TI;QE6=(N?&X:PO*%5J>\XU2QE9A7NC=V M\AKO$UEQI#$)OCZ+.?&O[,O52K'%70DP,T4GHNM>3DIHW#A13<9+]KWNNN"I M6:YN^W/-CGR*-\@$-FEYMJ=?<.RI^]YLSS['/Q_R]R=EW0383-0A!9X(7VUJ MZK H'V-:!=ENN>_3HYHU_0=I+5/F8/ZN42G"&+FBTFC MT<+NCC[IA@397K9HPM2A:^+YC'9&M/IS)'=0XT+ICC[@Q91 G+D_E+6@[J3*8 MR^&8C&&Q=?GB+G/L+7J3F\Z]GHM#SY_5[',W=_=SLYQY!JN5^0Z\=AKO@VIU M,[K=C\1)4'7$Z5V"6^:JGXPF?+%*PRA?^8)<=2M_*W]I4D@YN<]X0^X4T;R\ MB/6FBO#;[6M(1,JH-29HDY,U\%5GTQCS[*="EW#P#D:<64,]<:E)%3U,77;D MI=^WC=,-,8A#_!ED6DSR!-'!S<5BG]/8A@S:CB$=W:;'OHK04TW+VM/H'!S: MUV+$(;T#\RT; MY3VW?E+KPUQ[D&KE03L+R=C2O#>$)]4M]F2WL1:Q>C.S8D* M>]@T+.2;EYODR_,@-_J5Q69B/ZF: B=$\ MJIN 'WFHNG[![3JMG3@\AEY "0^B/4EB&1^<\D93^PZ[B"8=4WX#O,6-6JEF M#M)+F354H>5X.J-M(T<@749):[F:!'QC\458W@/J6PL.)_EMD@$5_LOLDD]V MLQJC3T 4AK,M^KOQWX;X-J;.EVR?YH+E'$9W3(4$Y/9WCHV,9?\.I[A//LWW M!$XK>'IFGQ[*=XCNJ@/( J>&^GW.%\<(:L/EX7J1^[OI$; M@\[9$4-8M?;\!W \[V=$LL$OLN4)=.2F<8,QT/,*@'^LDT M< M01[.&C<>8%*C-".6M4%2>)#<./I!S-+Z,FNR:\8U2,V?UYYJZ'^A1)U+U M;=E#%9RC0!K/I-SDXF3ZFKH,<_*H5 _I*\I*'V$?7LK,MUZ=2+MHREJ()BZ[ MP:M5JN #C@MJ+\5""NOM:V4U\ZHJ3,\ !_@,[!A=Q6 '2P;]%E%5AI4P8??O M1>X6'"C,I>%+OTF.+9-8X;OA5&76(8R 50;>QV5P[KU4K M7+_\808<0&YI=C5S8?;(G/!"D-:J4'82):;GGQX"2*#:!BH&SE^=RK3FC,X% M:6N-K-#S0N63X2/YD;1QJ/ 5Z.L'[.JV_S,)+KV0C:!JQ49$8(-?,;.>JSXH M%G\XDR-:RZ_%5'"EN98K V/I(A?"^W2"R%B\Q$&Q/U0H*T+V,50:AT:F,:M; M]VE.)-&Z_2<:F![,RD+4B0&BC>$ ,,*'JFRR>$O!TI62J0>NZ#%97C,R4$O. M>;WLPVON:ZDPN/6VTAV6NZ_L[)^YXZ'73YR"F- M*=;S8E)9),+ G_!?523[AK,5MYFL;MN^N WJPU Z,I1^A['YVUFYZD<%:H_"N1MO&_Z[26--9-G*V: M="<@1&M*E5"6\5I.=^#>F<#H&,L<>=]UO+0#OK&,EY;@*LDG5:C!/ P";, M) 3]H#Y.BQ 2."?XW+;_&,P@QJ!H?(62N=#E5SY4!GD4T,M4DV-\UWX(RA%F M21$RE(-P!*1N-AH85)+=O-52=78M1CD>!3X*7#-)(C(N!IA(%?2DLL#("6ZS MJZGJ,"PW4:8;1:N9J]5E]MQ#M>-:5#JFBU.P-];K9Q.)$2%U3WZK5?C<]$K& MVQ)@=>NZ1)M!Q4LG+J&0:RHQYL UT@&]D9\5=#-%\W.SIW MDS,QF)SYN;^]I:C16GB6=L&0Z3S!;VS>62,X<25^%0EU*@LV5 M)V5)/_2"_'_.0;A?5D&X>^6[_]3RPJ[1O"=(D@?OMWZCE=+"EAIR2VK&I6_< M6ZQS)OA+X5V,@(5)6#)E"AYJ_[@(>OC"QY=X:8V Z^8NW5)'QEREB(5^$*\ M4RRUCWA] ?K=H"4,H-)MSMV=MN!?0 714N0RG%=D3T0\&?.55RZ34L?)2LQI MB5^::P/N8S45C25/^B.N>/?;1Q=)C%$:"0PV]&5EGPD7R[\^LC2BRU0'A%&& M_"QL10ZW^)$IMLB#3%)"P">J-&ZI9-:Z:!UU1.ODE,AUEL1_@2-SZ(&U9BSH MA#>"W1BZNPT2"YW, 1!4]8A^\;S,![:#/T8R<*]FA#'[\AEYTB35=)&FX9RW MN_'_\JQVVSU!SO48L>*_*(5== B4AQ@['P8R*5#""U$D"S_$["^8*Z$2@AO% MV?T8#Y85QU96)WE=S&I6D*0L$GFS+2"V MI$*C!8HGF83Q&_L10K6>Y8.3$E)"ALHI;,0^H!':J?2.J4Q7< Y\RU4)MX'"\#.34GCE%K#E>4T&>EB4<^)DQXC.&CIV/34\&@SCQC*C P^T#=F(HWI,MCB[*\ MO-W2\G8.BNYRI.Y9V>ZJ$Y$KG9! &XSCL*?P=@^ O>+("L\;NZ _"S+17.H%LD0L0DGL)W!N-9C-#/EGU P* MYP!FPK$QT+V4-$I'G/(ODS@*^D#*\13AS7'%B/"I,MG0#8@PR8N'J"%$'*EB M?7.L,VX^+#W%(9BY2RW+E>DJ5\8 R1_%F$U6V#FS[EMOG7@N.Y?;.G"EU=Z1 M61-G'AD1!5D"8FYAR?@QR.GU=C10Q>)?XR0[1TBG Y]O4"@'PAU?>&,TM9O;>$+/@@Q(L?5&G=;N13SP12<-\=N?0>0F0+9#[PHT M:$M;+82;1WN0HW43_GB6X;/&YBI^]K!' M5]WA(T0.,A0C'2.G?P)S:2J^Q-ZY.#P\(=,/;\%3--IR^*UU2F(K@3.V;,4% MV.X&3<"9Q%'P WXX\;U>/)CJ>1!OP[EQ3NV\R8E;SVWINAMO2$4.?+X<2GX@ M :[<2[:ZL)'E=:SB.#D'L_Z_[( 9ETD9,2@YJY43*FUEN-]Z#L* 72!.CYH! M2?DP-85K;C#PI=0^I^=Q8<0>]N0%S;TN'XL' M0ETGUCF%G^$QV,OU[4P@&J):,6-(R&\:";RIR:A'N=%V0ANRXPAQ9RC="81^ MJD.E)81*2R:Z?"5^B24.U=ZROC<]]3O?#R.)Y$D_&#$<(GA2\). 388"+"]PA MRYMSE\BE/J43:,#F0*G7UPXJ8AWS,CCZ_13(B?3DQ1YQ!6Q)0(7Y/)5A&P(9 ME7Y*>LC5K;4B(ROI(]_;]&KB6N9,L>,T(J7,@6:93FH2; M\V$E2^@^4_A-0F5B/D.4]!!?_O=F??O=6\SU6$)Z4[]6#,:YF8)@=0>F?+DT MA\N.G6E#0M:G%*H2G4W/]20!9\FC%BIE1LJB?A"/R4F#A=OFS-;'W!5<@P8F M'OF@.Q.0WKW82PA_:B@& 79"B?'3LJZ4&.%Z86G')H!PFA0QTSB7#ZJD9<40#;!?W."UU"P% M=*4ZG&"@G0ZEJG&%*2[RJQ<^$$^R]7BX/H[[WWT%U::<< RCIG8 *RZ96@.F9T1IJX:YA>/%(JOGYJV\JA53,E*$X=(= M]%)@T?X%*\EO^_L8<8&#DBIYZ?:.&%JM!RP@ ,>-)CO3^1J7QWER:)E^'OFZ M)(4\0JKVDW "8S^1/G+^&DP6]DQ-6;B2^5ANE6% O8YRKL2PQA"*,:P1G03C MX.1_Y28LK0?'LD0 B".089F@?\@-,K+O-^T(5Z'5XP.-?* M" L0D\DXZX.8EON_!*,/7-L6UERZM_G"="^5+J9SOQ_FFIKBE0.'1U2,)8OY MZ_BU=((-CE$E>3_J8AC&,;?/T#<('-2]F1E&7L^<.^.90=?R(P3SM4+$0:8C MT,N_M7]C94D5#8,_M&' C]GFE8X_X4'0*MHQ*-*[UA_?^9J[P]4J'&:CDC7M M4LG\*U34*CM(6DQXY4BC62WT^A?HQL:^ MK1P=9G,235P3+*T:!>^3VG]3TE$>._!. QZL%U T&GQ@G>I2![<4=JKOD]-4 M C6"!X R7W0?4T^^3'^1X6=D8,(J*-0*Q\@W$@(R$HN /K%U(P "(?$FF._( M5<:7_M23 7,Z_$.T,TYV@OYN0HFA:PL,'J&-Q$8:4H&H0Q6*?%6M@5!JM&Q%/JQ+(Z6)44P3PDV MRH/7GD@@JF>GPB@%)^,<=1WCJ.O#IVU[UM&RPFDH+YUAPR22-#_DVM7F)K^7H M7JNO,7N#B$=PGS[N;N=C??=UY^-CN+I7_NQUS?5R,2HZS\TUBWA*WBZ\8X:? M6UZHZ!Q'2BQ>@I_[N,',HYC10IUJ6%GBZY3#R@[:EE[U5+SL\2<^9$EM?!DW MS5BWJ<2VXX3PQYJ^S"EB?#/T2*J5R1C%8\Y+(F/8NXQ-4T&)<"(SB/)CIGI M%B/21YL-*&QES\Y8$MEMZLX"CRJ//MNW6KY!OJT-\E;_>Q1?A3Y[=;R8UG 8 M2!#)M,P0M\QTZ^9?EC*A^M1=7LHD.^:[H?!)T9S1;Y=?6)"KS+8CSBZ5]^$> MS36MYZ4[5P757=B9/JCKR--7(&I6;I]WZ^);-T#2H!D!%_*P8G?Z"+MEQ]SU MUWX=G%KS/B^UD'<#<^-XDYBXOF5?%.A7#^+/=;/R5"ZF!UXBIRL@A(C#[07J M:6E(8 R9/1A>#?6H (^3_B\)L+NOQW0Y/DYOH\R%_D(YX,R&JG%YS0+^G%@ M+P>6;$UQELQXUD'3YBIH^I"R^:V6S<=DN]%O9>YW?6Z5#SC+L\I\)+*NO-L- M,*AIOCV*Y9WD6+H9LJROK,)(^QA$ Q1](\(I5@W#;G"I!2%_JZ+W630Q*3YU"W, M7/J#TFHN!7--@HNF< MBD^=[NF9:'UM'QW /_#3T0'\H2VZG<]?SD[IU^,]4!2ML\[QT:DX_D1_/6EU MSSKM4_&EW6U_.SIH@^+YTCH\%'MM\?GX]W;WJ'T@]OZLBWWXSEGW&_R& W50 MT9QTVV=M_%FT]O>/NP>MH_TVZ*6S+W4:^;#UAW[+Z5GKK(V_'+7_$'\>=_]G M@S[^[5NW.^D>[[=/:=*P[E8')H(?P_-_BK-NIW6( M3_S>.:65G+;/Q*?C[MD7G,II>Y_7U]C<:&S19/&G-VHF^]WV009M MZK9I\7M_PM=A&2?'W=89+5ITVY_@#[@J6._Q[%WF'6N=G!S^*;Y^@Z7"<_C? MHX,.;^S9\>[>1R#5WL=Y3M!#LZ!XK[GO%!SL1 9"^4-L<8="D/N.2.B@F3Z) M] O0H&QV%!,A2G?Q6P*$F!T.^4H8< MK;=R6%<%1A)RB3F#:\8<.6R'D(*4DN0K!\N%3BK= -0".H*-X]ASRLT(L2/S MJL;9YMFO<1I=V7L%$E]JQ86T"JAC6B^)/1740@!T>R-R@%$FS$SQ S 3,BW# M"4?4'HXOA'N^?3,QU]5_'$'[BV;U?4PTA56 ]9!*:5FV2_)"1%_G4,C:?!/[ MTC,R83 D'9;EK3!$DE=_HV"Y_FZMKLL^[0HOVS2R*KVPXXYC,EQ1GR@WF[VD M803F.(>J;1*:! <6SB"&7M7*K*EQG86N22"?9"8?H3[&LC,L-P/NY>3 :F5. M>J"_#F MZ-%UQ9RZJYL[YA/@:=!CBJD_R?K_5BHOZ35KYZY+R 2DM Q5%HBIB MB%'*0L;.IR)&MK,Q9@/NO5/&W_<2),,DDP4OIDO K'N999IM:-8M/K2 MH-\/O8"N2;.^5("EH329>EUV,:_B3'8TSXG5\9T"A[&C6.C'E$/CJ;GT&>L2 M/Y8DZ"-//6",&#-(GVC*W@-JG/Q/6!'AP\S!>?R5YAUC5)H MI9X[+6/E=;3V)ZEP7U8EP6Z!VQ=/*5G7!?O 6.0Y5[NJ*KLX,:G;X/<$5(0A MNUOK' 'WGCSEFTD0&BB-E,*7?Z- ,_@'IR>M M_<[1YU]?;;ZBWT]:!P?J=X=T>^!*MKOTN9P#?[(.]#YLG9RV=]0/O.;[7^ YGA]=F#^\KMD(5Z;F:-Z,#? HN^7?6GKKB_5LX9_ M=:WUJ8VS3E1 F2X[A%TN;KAQN&U>Q^!+-WC/]K='71L[>GEEZY8HO@$ M#W7KKPK@!."K(Y0*.*/6Z5GW^.CX]U8=??D-/2_:'G=KK#5:2_S2QF );/A; M=UK6Y^:=S7M^IF26#TG 91#LX]YTYP[?OK8X;N!'/[PU2-OY.^(_-ZM]FW15PE]9D?\CE79"%M# M;6#(^M^_"/PAJ'U5<"KKEFTU /]!M7M3M^N>#-P3#"* &9*S3#0^[4]J*:Z, MG9_:V,$KFV^M;NOH[+A[NL/=59Z*U^W"E@)XBQ58*Z'F2;:6 EJF YBJ9E7>]\JY7WO4#>->';]5[KZ'\P<;#UM=WM[+?JXFBC1;<*E!C!%^8KB^=)*8#G:_$.?4CS))Q;QI6]LYSRCNYRU:S\C4MW8S^?=P, M*9A'H8':DN;A=EY+]31^RJR8_/KG6+;-]W. M18"M39"D,?N?I\Q1?$FPWY(Z*^+DB?/FP8GCDF"+28#D M:7SX#:MBDJG8(EF'*FM%&*6_[TO=O/@-7:K^;FXJ2?35FUI":,7KCZN\]>YO MN51I380;$68QU3=-@&:+FV.^UEL],:*.DO7W3F))K6W0Y_&BCY&A=^7 M6'OQ&[I<%=XHJ/ 5KR]3A3==JEC.WXHN2];@D@#LW4G]+=@G7Y'E<55WF?74 MF*>ZFROZ&-5]7\?FQ6_HT61I6OM[?5<8OE; MER954W=:?5E5G@]>7OEN8[.)W>V75%[9C:=>F$W%B3?E'FJK^DJ)X?'NCO65 M;YO_>$#;['V)5'./_JW[#[Q?W-4#]*WOI9.$^SN<^$D0#Q8P<,E[RV ;0(2" M_,TA-PR"=!QZTYT,^QFM]_TPO,E\/PB:<9MZ.JI9WH>(S3'3@^UW:6F=;H/; M#[$! ?85?,H46"QZ',KLYDJ2]SZ3!OCUU=_Z?=\?#E^]&/N@F$+[D/;!WYMU MH#?^\V(-LK+LV"5M^M=(W5RQ_N.P?GF2ZXK[EROS'YH$C?K[=]LOF_%+ MTBH?>,O?;:^X?K',?W@ZO&V^<-8OSXY\X%W?7LG\^3)_>21X*1M>EH^WXOHG M(/-7K+\,F?_ %P\K[E\L\Q^>!%LK._^QN;ZYLO.O(?,?G@Z-E9U?EH_UP+N^ MBNTLD/G+(\%+V?"R#*#'WO*%^1.[K_>.#_Z$#[^U=^W/:2!+^ MG2K^ARGO[993)?,PCN-U'*JPD6UN"5" D\M=75T-8H!9"TFKD>QP?_UUST,/ MP'B=&)SL)978(*11=T\_OJ]G1,ZNA^_;];-KN]&L%PMGP]:P;=?M?QQ4*Z7: MZ[.R>@\?E/49Y.R\V_Q$SJ\NNNUN_]W>Q^O6T-[##TBQ .==,"]B8?VLV?I M!L-/;?O=WCT?1[/3D])K[NT1ZO*I]V[/99-(7G76,Z?-:3CEWD'D!Z>5('I+ M]/N1'T7^7!V:^%YT(/A_V6DU?3^A<^XN3H=\S@3IL'O2]^<4[M1HMZXZ[_9" M/IW!K<[.Z_;G&1_QB$C5R%GYO'Y6[J%NZT2H'CZC#(XTRE[]LM4?#$GCO=UI MPK\A&7;)V6477AA+S7C$#D1 '7;J^?GU[@&-NT.DYS6I4:G2:Y/)FB!*TNXW.@-QTFG:?7%PW M>D/X??B:="^)]")2.]JU<'CK:YOTK[M-F[0&;13VRN[8_4:;M!L?!];.K348 MP'LY]R!;VVX,[ %!J?IP:/?B2-=I#3^1QE7?MJ58* Q*L?W 3(/B'^@^Q<)E MJ]WJ7&VX^U9B))V>;NL7"B'JWW)L2*H3O\(P3[%"LM'-%DC#Z MY:?JT?%;0;KAE'K\OWJF26L,)_()=^0!THGG(] 'E*_@G^KKVM'N9>Z%?L#" M:"&MYWON@OP&J,^>.S/2N&->O-%%MN&>^[1\6Z8@ MDV 0(XEY>RZ-2*UBD;8?"7)T;)$C>'-T8I'#(XL<'Q'TCMJ;5[L6]X)'B_*% M'WO1XI1\9&# CS0$\]U:Y#=TGLP8A".[)2Z]W0AD&"<7??)H/5/4+&V9X:4 MU.7TIU_EGSWRL=4<7K_;JU8J/R>"7P 6LOO?,J\QICV[V0JM*!:6>(4"AC?U MW18'U.Y/LXMU<-^(O$-G!YGS).,QU+\&AK^,V)+,*3A.$C2^:4]#9P8%K')8)?LX8B*!/9DP)^)WC#0AD6?$L CPIV5" M0QYF&&1_QD+&/1*R"0M#-B:1#RH4"\FM$B"3N\O]S!>@ZW@<0A5&W1_$!]92 MUS(D MV8=]^5%G?_2$?NO@=>WXH%HYJ%0M'1+Y7P0@V!V'*'7 ;OT6V.?72FTC$#P\ MVD[JZ3.'1]05+Y)P/E[;?8A58.(I&QTS%_Q=>N@,H)X#\4/!;Q]/00'S#FQO MG*0@[2BDR6"LH4\&S$%>T0,704#6 +>\C"75:/O4$T ID&EIF#7#&/A>"P;7HO+ 2J$."2SL#);48!M\J;].$0?"YO#R"1)%D% M/X5TF^,[X,H\F@&()?G0QS3Q]]A=_.*-1/ 6\2]DBXJ,J"0B+(E]0P9A/P:5 MP6B82]IXT-;.!L+@I\)\.$38#T-O"%TX\]SW;R'+G;RV2 \M6JM5:TN)R@B1 MBTH03DBC6T2 ;L S*&KL^*ZK5 .?(/O\E5(J-]U#!N2NXRO%&208R)7P)L(L M)BTDAA86G$ 06=,Y!H42Q,0G].(HA^*07^'C$"B8-!R('*(032/;Z "\P1 M@B3@(7!DX,!DPWSZJ?<\A[\_],3!L-BY]22OK61)8Q@W10HEM MBX49A0BF&/*RY)KIE)JB+L),#"8A;3J8]@C]'ULD;,(]N!3F%$]*DMI^-H@L MDHO%AAD["UND%V)_Q?&],9=%-8!4P5!OB07P(G2O5);40V9P9)^DL7IQBPN M1<@E\4V-Y2W[(75=M+XW%<2#V16"A@LTVYS>,CDM&<%QIN\ ELKT1%PVA8L7 M9,25'_@C *P*?:79 N8;G=?!(D*QGLBLP]&+P6$%%/*)K[IUL3%<$ ,(Q3<: M@ H6@2YA!(!7QL8(,^[8]Y0'!2S$OMZ+QK)# X1$<-E8J87*Z'J:,R J[\=1 ML2"C5 65F.$42,W0#."F@2[C@T9.K[REO!;V-9UB"="< V9AU% MV=QA/%"!"?7PCY@ZDF9!O@&V0B%,<5#(J-2YA;SCLO%49=A,U=3(1U7+R"\6 M0(O889F<:')F.G$I%M-E0)H5AM$9/LF$N7*!5I:M[PED=/]>G*I9QU96\$ ' M8L72)&O:DR#:JRL$L=N>D<2&52/^CQ;CUX? V7F]6E([)L[KV=Y MO22+6U(QN4C\7,&JK)-M*E''6U*ED:C2P)X(!&]+'E@5%%X"E&"1P2-*:GR7 M9EK#87B(<0;()%IH_H. 45\Y5P4*7F%ETH.<;LBK6]$]06;Y_)[",UD;1)HD MV%AC#H6"R07@+AYE*L]8'E8MJ%5:"#4UNH>RFJ75.5@JD6!JZQS16(/:4*Z- M(L@&%OD/_-%=+"U -J-F:&JCTR*-'J(5X+8>%S/D'G?(9%Q.1P"A8"H=?QY0 M;Z%)T3#T?P?3M>F(N?)2<"+I.\LC% LK0U@F\:-*(M%3-^]4@5?=,@V,$>M. M:;B$AI=(#7F$TZRA,G^6P.RTRB:^B;1RV2.SO)WD&<=CM/T1#UTAJL7"\_-W M8.+/Q=[7D-YCZS E[_EN2#?D,$D@8&*/?%\DJP3N!7 EEDXA2M):7FH"0:9\ M(AF7Y_RYEL)39^SK.PO%PA.U><#*>45RILXD.E4<=$8%R9"U))5C.0NN3<,; M#)9F0),"-]FK6/A"#W_HA>9:-CLVH>'UNL-_9S'4M^&=DZQ M\%S]G&V!E/,2-]YQ4>,R&:X"W%_, 2$KHD/E8LK($G M\*D!)N3E< DN\JK>26-\ARE(O%W:*O"E[1J,P1*$-_+EQ$# [>=J-2E@08XAS]9$G&['JMV1P&!LC@"#80EIBE-ED MV6:R1R7-D(Y&C03[XE4ZF.*0TIG@RMR(TH'46$KH]+;G?ACZ]RQ4C"#V LK' MF:22*3CH.B-P5@_7S?PX@CA5[1^S[RH[@ C"V@-[8,])9E X#CK? MU).4=H-!KW^9E':"[U689&;[)9+OA6*(RS1V$H7NOCY^YAL MD]$#4].:6^G1)?38-&;I);C]88GT:;K/4QE,DADK]6B1!F?&F M$*6074\1F2:TQI-K"U8Z&-Y,I743&5X4^F[I^VXX'OYH.#YK)-=*D&+@[QTU M(+B4 1U)*E9M:YV&\QZ:PT]FCS?B8+52*(L5^)ZG:E(*A-.>$SHYU'$$/2I. M$/L 7/-\X[MPOH1'& A1&.O%59@V1'443KS32U>A7JU2" D."J!49E5+0D65 M9E8I.]G/9-F5Q1]-XQ_@H-EK<>U@]6*]3);#7RFNC4QBV'TF/RHE2Z*]))\J M-]C0G-J*-$>E*@&<@TO8DM2+>"38'W':_RP6Y$X+555V/BU'I4,T MQ!74P!#7$'&Q>JTYDAHTE:=*32U3,56@6#*JPB"4'%4M4T&>ETT+:1H1&1^FH*X3 Z$1=CE3B3?N/3^!ZQ5O MU6Q+[5HLK#&L61Z/ ]VRXAX255WC1Q Y$QX9BQC_TBF1A]GU8#J> M^>/8D?K\[G-<*@GI)!)@,#'C@R06 M1.Y5':%@J*SZ$!LB0;)FIN$\^XPS): 4I=Z3.MH:,SZ04M348H,IFX3,GH>E M1+$^0RPKKB+ RJ0E=Z&\WYPAO3.S42)AW@NUR06YD[R#9!:R?;3"<9?S2GW=)-?DI46.K':YP[N<.Y2[_8M&<#,T$BV0R]E MD_+?Z6;L[Y65U7ZPLN>KLJT.:##LV(,!D9O4NI?9'42X.5.FTO%2NU;5B81U MI:N*$LI.<)V_6$!@##X)P0B(<25*,F(>IA[WH -F'4[:,?]=(#CKP\9YVR87 M=KL]Z#4N6IVK=WN5/?F^UV@VS7L]84@-[%/S M8J,9EVV.F./PHY^Y ME=$AX]%<[F [I7<^'Y,GZK D'#Y>1, <8-L.QD-=/X@%P9 *DQ%EOY=H@G)/@2LU@_7YQF)5N*IB1OK)XAKW[:1(SDRGIZZ#,1/FYS_DD^F,_Q4+, ME5W43WQ6RYDQ M?*PQ>SC[<]>-E)9'KFD8U)SX:&X[31V.+A?RSL191V _( M>M(AP;UI0< D:97^K9\E5^2@1^J5T"ZYP9E&5)EN$BZ"%\]^+%L#<#WAZ0]Z5B04;70UGHN7Z^5+GU(WQXJA>/7.Z\ MP/U[(?HLH?HL0%R)9$[ _!SQD(MEA\KW_ M+!:^!2F^-'9NOI9+[-:I_C6P&^U_;T!X?^&&TG==$?]B'1/;_FMT3-9^W\J/ M[L(W!:@ZW)GY+A5D$/E B;[3]L**%M]??V' /%Q"_L =]0T#N!TG>N%NP]*W MJFWUJ\ETRX$L=1S2+RMZ*OSXD@T)3^T\_-V? 3-&XIQT'8[6?+/68]T#X[X: M4TL?5GV#M5Z!HY]3[U;V$N8LY XUWV65Z18 C]]%NX!\,]V"7"/[1[O@1[N@ M3 ;@(_&4BEFQ\ D==,'NZ(^6P>Y:!HG]U=MD#KZ]CH%Z4SDN5]^4(677_A^( MZUD9_U\/."C_/Y#_ 5!+ P04 " M8(U2:IR3!O," M#P #P &0U M-C0V.&1E>#(Q+FAT;>U7;4^C0!#^;N)_V'#1:")]2RXQE)+0@BV&0@.!]:7^^MOEQ=:JYYG82R[:#V5G=F">>9YAPJJ38&IKZL34#6U_3PVL MP#8U\Z?=KT-U*%K7('A>.3:KC>0+B=68$IB ^SO\;@1(@SEFFI8 M%\ /KFQS(-WAF"V4T]9W3"0 4YR0@92B.2OO4F=-6 ;S!!.9T:726;(^J.V0 M,D:SRC6GA,D%?D!*=VW/88;3E1+@#!7 07? HQGDF73;&CL#*G.U2.T#68VL@I@6T0]@REIAR0LEOWR*4)0?6CSYYNV[<_TD>6,!U)' M*NV9;AB-?6D9P60@=3N= PD,7<\PO=)?8Z@\,E?=UF>^J32+/W*P3=@S3D3+ ME! ]K5X8#9#3[@'GK!T8ZYV+^NZJU#7D7A-9Q55K_N=5#J^I80D3)(>/JMCHBLJ IA_6M M4_[Z(,;%,H4KA<$P17*$TG0+U!L%E+WGP PUO;5!UG8==>\T'?1JW):230\)D";S$4M(.C.>6#-TU7 M?-C07Y#8,$2IV#G^4N0?*:+ON/G/1_0$^"V])=RCUL6.Y_T4B8R;GY7\(DY(Y6/:_-S*_?4IMOK@;(L3+W>6 MQ^3?4$L#!!0 ( "U@C5+&+U]U0@, '\) 0 9#4V-#8X9&5X,C,Q M+FAT;=U6WV_:2!!^CY3_862IU57"8 .I*#&6C.V [QQ QFW:Q\5>8'5XU[*7 MIMQ??[/^T9);Q;6A;<]_Q[,L+*P[BT+?]CWI_ MT#6M7KU$>Z]Q &NZ]#[!=.8NPV4TT>[F0>QK:@,N+]#/I5S2PK:\X .LXT^A M/]'N62KWXU'WBG$-R('M^$0[T*VL4-:J=DLR=CB-8Y;1$A;T'B*1$8SDA,%L,=$*MMMC*&MJ^U_V;,,D MJ,K ZDUMJ[=2I3V5@=G_A2DD%2=5#NYRL?87,2QO(%AX_LK'#RXC?Q:L8S_R M/5B]GX:!"X[K+M\OXF Q@YL@NOWI?"7](G7&4TQA/'SULOSM.PJ)X"5B00J0 M>PJ,)Z+(14$D$QPV)RCHEA:4)VJK\HCHCI6R<5A+(FF&^!+^6(BR"];-$LMM M+\:>2:J7.4GHF(O[@N2:/1@,\.J9[ZX&':NGG.T&HYR(9 MP[?FNQ=B^E=#8]A""$^?A_7UD6F,S#,+( M412K7)W:A3/8T/1YH!S#_9 \DSRDIZMO M2G X/Z)_5*?8%/XC+34-_:^V]*THJO@G=3+%RYS"GP3/+4YUH0.S+A3O%X[( MF::=4I2@R=:>B#ZX?A>N6X.(L3S="J]1YT>5N4FAMN@HEZ&S6OOC]N>[H_=X3I54HEBJE"*[^?':P*:! MD5$<8D]]HC/7-H><[*B^*2CY&Z6@9"D=D\^"I?#"')JP'QI90QJU<[+A(;WP MI!XU)J7_8[-K[J%%Z:WR14/7*'MR)P[9NWVN2Y=?@BBPG_-2!5=?MJHY^ M8^@A.V>1SJJ<^\%L'B.[;[7_1?[VO$Y%*07OP"TI2Y+LCR65LOP>E[\](T_( MZT,^U%NITHVJB!Z^@]#>O(KJN>RI%Q0:JX?7OU!+ P04 " M8(U2NH 8 M#W ' !2&@ $ &0U-C0V.&1E>#,Q,2YH=&WE65M/XT84?H^4_S!*U0JD M7&&WJD*(E(N!J%F"$N_M<6*/DQ&VQ_78">FO[W?&-@DA+%#!]J'[P.+Q.3/? MN7WGC.EUFE)RQ_'FNDD0%V9*GPJ2FY=^BW=H^>SR0 M_J9MRT!H=BW6;*H"CI-ZX]'E]7DEEHLECNKTN];=4LYEPL@RUFGTNYW EV M"$'KY TA.,8G!L/ FMJCB]&@9X\FUVQRP>PKBPVN1M8%L[Y9@\_VZ(N%94A8 M4W;S>3K[W+NVF3UA,VM@5$Z;)Z3V#/RW=. .>@([ZTW[O6MK5IM\&UO?66]@ M$YZ3)G 5H X']4UE$N].ONJE*N9(^)$>AN6+'G29D]#^/TM M$+3J;,26?"58+%92K(6+Z^DD5M=JQ:ML%#KU,_;>2=H]J;,^U[ "D(,- MNP4P7[@+4W$9PMP-2\,D3@73"4]$@#0A S@ (5\D7.%Q M!TLQ4P&J+E&9W".!4#A":QYO2"3@MP+GBG+I?E.-11=H<*9/M4R'0((Y,G;2 M &(A] '%%3&#@YTETRG]V.JO12SR3&"[:6R1(6ZD@X!B'M&P&; M M-,=J@\OA>LD\7ZUU$3G4KT2:"^,LV"[GOB";F$"@YK[42Q(GL0#E M0R5$SZ[4CJ]T"CTJK%CYF=.B6#G"Q;)F1_"1*^#TS!'6G;/DX4*P'E)VFOJ0 M>)YC3GFM]?%('!=$0T=D6N72C_0^NIG> T5)_2#,PD^(&57*3E9D42+KW@ZZ M=P#Z\\"]+7"*Q,/<*Y=H*R+R?],R\B6:8]H??GUE?AWQ8_A%8Q*"8PQ;/9\' M56)2AZ?ZY2K$:'.Q/2GC2)7&8-<45;:2VM0NQ$1H-J(&NBW[70:)A<]-3'.6 MW/JQFK,+O91@ (#1RI<:3)2KH42*Y5R(FMN$824#NEZ/+8+3R-V$L^E[Y,-D3AA\ZE MQ#-!,?[.4N:!Z$X[-J1XEUL4I7&$>&O3/AUD>A M)$74F\X:[%RE2=:6#R)X":_P>VE!8X3W_!149?-B0B% N2< Z"RCYY\=#?>X M,/2QQVA.S=N.>7,H*J^H+R)(Y3AI3%[9LM&A62%0.H$JW9^PEW:PT5\IR Q; M'QW&X<&;R/L]X1PVYBAA!NSPX?1VG(%:",O\PVFZ%OA MY]/VGGSU-0XJEPYX:)L![SF@?30#V@&@S\QGYMIVGRI[:;P;KVU*D\OWS2^7 MGJ;N1_VQ@,;1(A,5ZWNN- O8,L#U*!$FMH^UY@I$3*]<"6A&_P@117EJJG_\ M3SVZ8&KQ5RJ!W&1<&CJ$_[C]\^L1XPW='Z@)2;B?!GT: QTIX*Z)0U%XNDJS@0!]G\KR0-YS%YI:W*?]4Q'+>QXTX'NT MIFK&FQJDJ=, /H)#C#$YUQR\?/U'G(CQ@ZC/BY%F57A$F,J 3\T5.'=^->,. M&:Z4OQ)$("%?Y%?Y."\F$42^V@B\72]55D'\06@1BJ>YM5QZ<=CJ[TX;0_K^ MT,/@X/\6SG5TUCJMLI/F26O_X)U-Z=R]#VN/4%2ZV79F%_J&VNN/+3:PQN/9 M36\PNKX\KS0KYOFF-QP6SU]'0_OJO/*A^6N%]2?3H34URSF$;*4VF(S'O9N9 MU2Y^^:&%^^Z@+ZSEDH$T[>:_#(N#6TV@+UO,_]&2#,Q,BYH=&W% M65UOVD@4?4?B/XQ8[2J1($#2KE:$(/'A-&@I1.#M;A\'>PRCV![78T/97[_G MCNV8$-*DJZ3M0QJ/[YTY]^O<.T[WQOXXZ75OK/ZH5ZUT[;$]L7K6/XV+]MEY MMYD]8KV9"[#N8#;ZS 8?AK/);'Y5^_MF;%LU>L&J%<@-19B(N-<=C3^QA?UY M8EW5MM)-UIT_SM[+L,:X+U?A5%6,#CE0P;B8HZK2BY9/GS4B6) M"K(E3X5)0\M_1:==/GL\D/ZN8\M :#856S97 <=)_L84U-"H7K7-2>P;^:SIP#SV! M7?3G@_[46C1F_TRLSZP_M G/>:M5^O1X4%_%I;UQG8WX1KK5RN*,+0*9K.O, M$7$BO1U+UCSIL*<1_/X: -IG;,S6?"-8+#92;(6+Z^LD5E.UX74V#IVS M2_;6.=H[/V,#KF$%( <[=@=@OG!7HIZ9E=OC*FB%*F$.]N(RA+D[EH9)G JF M$YZ( %E"!G 0KI(N,+C#I9BIA EEJA,[I% *!RA-8]W)!+P.X%S1;5ROZG& MH@LT.-.G4J9#(,$<&3MI +$0^H#BBIC!P>QEZ2$">2.PC0\=/7>P))SY.UCH"(6-_QR*X@L)(X?7],DZYAW2U\A " M.Q,,Z"[7+I M"[*)"01JZ4N])G$2"U ^5$+T[$KM^$JGT*/"BI6?.2V*E2-<+&MV A^Y D[/ M'&%]==8\7 G61\K.4Q\2SW/,!6^TWY^(TX)HZ(A,"S3Z#;WW;J;W0%%2.PBS M\!-B1I6REQ59E,BZUX/N'8'^/'"O!$Z1>)A[U0IM143^?UI&OD1C3.?=K]^9 M7R?\%'[1&(3@&,-6S^=!G9C4X:E^N0HQVE*4)V4WG$D2:8HBB07*N0$UMQC22@=DK1Y;%; M>!JQEWPI?9GLB,*/G4N)9X)B_)VES /1O79L2/%K;E&4QA'BK4W/<1P5NP: M:R0@L\A."ZYPRL>%^:I*<#!>>APXI-X"L MCS2ZHG^\H&BSQ^.MCT))BJ@WG378I4J3K"T?1? 27N'WTH+&"._Y*:C.EL6$ M0H!R3P#094;//SH:[FEAZ&./T9R:MQWSYEA4OJ.^B""5XZ0Q>:5DHV.S0J!T M E6Z/F$O[6"C+RG(#%N?',?AP9O(^P/A'#;F*&$&[/#A]'::@5IS?<_<5#$F M&X1KN,1X(R_S':;H.^'GT_:!?/U['%2M'/%0F0%O.:"]-P/:$:#/S&?FVG:? M*@=IO!^O,J7)Y8?F5RM/4_>C_EA XVB1B8KU/5>:!6P9X'J4"!/;QUI+!2*F M5ZX$-*-_@HBB/#75/_ZG'ETPM?B22B W&9>&#N$_[?SX>L1X0_<':D(2[J=! MG\9 1PJX*Z>X^REC*_@=45;6 PQIF?9E;H[%5>)8%)ZNTFP@0-^GLCR2]]R% MIA;W:?]4Q/*>!PWX'JVIGO&F!FGJ-("/X!!C3,XU1R]?/XD3,7X0]7DQTJP. MCPA3&?"IN0+GSJ]GW"'#C?(W@@@DY*O\*A_GQ22"R%<[@;?;M/CQX;U,Z]^"[VB,4M5ZV MG=F%/J'V!Q.+#:W)9'';'XZG'ZYJK9IYONV/1L7SW^.1?7-5>]?ZM<8&L_G( MFIOE'$*VTAC.)I/^[<+J%+]\T\)#=] 'UFK%0)KW\E]&Q<'M%D[N=9OVB'[, M]T0+#!%RH;%$!=TU)"ZTKNCPC9(N^TX,^;&?\L^)<..AE8.9;<\^=MK15V:N M#NR7EOE7ZS5U,_OYT*G^PF"_RBU#<;F:/P)Z_GG_BQU MFO2G 2R:ORC\!U!+ P04 " M8(U2&U!W>Z8$ =#@ $ &0U-C0V M.&1E>#,R,2YH=&W%5VM/XS@4_5ZI_^$JHQF!U%=XS#(E1$J; -DM394&9OCH M-@ZU-K4SC@MT?_U>YP'= C.+Q Q\*+5SZWO.\;W'CG4>78QLZ]QS7+O9L"(_ M&GFV]ZV]O]&)\/?,&T!2=L-/C)0FJOB5-:G#ED3>,-Y6(NOW,G4, MU7@FE!++^;-[R,_"L/IS'""W^&\2WW:@/BY#*<7CKC M"*( S".X[$P[PPY,O6$!V=P_[+7>"9DS!<<-)I'GPB;(&MJ7WN=:T??!-W7" M@3/VINW@V\B[!F<8:3Q[O=[> Z#GN^Y-JLWV.!<'A5,@E6*2Y3D2TYAT9$P4A065 M% EI LU&R:"D61% @BTXD_1&R#4X'?@J1)RW8+A@-,'%,9EBMQ2")&%S*EO% M>K,UX'?%DG4+LI7,5X0K4.+G&H2KE)8,S7W2-@]V9KNU))K+1B^56U3'ZH9" M)4@L,H5:;.;\3Z2N;R1;R$3DC'":MX/[E*Z;#6=>;*PNM18&$-6'EZOM\PO% M5DWI Z)_\/&5Q;=#=B%"9%65):LT11VQFE*]EP_[*^GW%9-TB4V3:\1;4NA5 ML'K,PYUX]X'K8TD\E$/)M]DPO^P?'!?J_FZZLY(NXUCM2Z(YZ.93A''<0E:6 M:*T%81+%R"3-->V6?DS2% &@<3#L3'R0H0YYJ_A5PCCAI6K OS5=Z/S$^.@ M]]& 01"Z7EA,5Q#*F3;>G$;.9.KUZR\_Y+HMC+XUX;U)0PKMZHM;)S9[F!DM M/G+U1[@16F/(R UMSR0E?[<9SUE,^^16L!A>B:%*>U4=/RCC-LM!$$7!1=_, M[B$7*6;XT"O^#+N;=^',FEXXHY$=>F=!>&UURU%ACM63('"G]?PCH=]%QMZV MZW> \.ONQO8$VQBQHKWKGG[A('K=U<5\-8B=B61H,1EZS)/!+ _I?6MH:>LP=6K^B''*%OJ./C?H(B0$/ZB?GXP(/TAG% M^$R*6Z:O'GB*;M]WM/)W#!UXAK<&22O3QN6>"TQ6DK-\4:[T?Z\H$A@Z-6). M$EAE.*-!TUR5]JPUQ;"W\%U!+ P04 " M8(U2 M"8[/0I$$ "1#0 $ &0U-C0V.&1E>#,R,BYH=&W%5UMSVC@4?F>&_W#& MG7:2&6[.I9L2XQF#3? NQ0PX:?,HC!PT:R2O+$+87[]'O@2:INUV)]OD@2#I MH/-]G\Y%LD;AQ[%MC3S'M>LU*_3#L6=[GYNG)ZT3JUT,<;Y=&H#5#]Q;Z%\- M@G$PZQF?1G[H&7H!ZC6T&U"NJ+0MU[^!>7@[]GK&EBW5JGO1.F?< )*P.]XS M$AJK_%?6M#);$WG'>%.)M-M)U264XX502JR+J5APUPXHMF +-#*QVW[;:4TWM.03FR0M" MB')-<@Q.IJ28B'L"/H]:KX5BX,U"?^@/G- /)A ,(1QY,!CYWA"&_L29#'QG MC--HXMYIO!(R9PZ. M&TQ#SX5#D!6T#YWWE:*O@V_NS/K.Q)LW@\]C[Q:<0:CQG'0Z^Z!_/NM>)-IL MGT,D.*>18H+7:UNF5J!6%!S.-R2!&4V%5"!BV*="HTB&(VWV[HUY]MOE0*Q3 MPG=Z<'%Y#(+#4,@U6,, Q:[*RHHIVLQ2$M$N%UM)4L,V.\T_K+:VLA&ES!WO M*)% ^9(NX7>"&.3N'5]DZ>6IV4!53O"39!"S!--> M=".S#>$*E/BQ2+--0@LTYBEIFF='B^-*,^WF(-N*0ZQL=WW\C',LIW4*Z9V]_ M,CR/R#&$"*R,PWB3)*@CAENB#_LQ "3]:\,D7>.A9!KQ$RGT+D+6:^;YT?+X MD>L^:!X#IB1L?C@]N\S5_=5T%P5=QC$=UD1ST.FI".-XA*R(X4H+PB2*D6(T M:MH-O4R2! %@:='!B LIZI UZC7]L_@Q2G'')UN:#_36$)Z7Z*T"&781# MSD1?G9S^&-NH-Q[/I\[ GUSUC(Z1CZ>.ZU;C3[X;CGK&6>>M ?U@YGJS?+J$ M4,PT\7(U=J9SKUM]^2[9I\KHBQ5>K32DF5U^<2O'9@<]8Q<(7?TQ.S"M,*3D MCC876&S^;#*N"U.7W NL6C^)H71[4W8HE/$IRWX0AL''KID^0"82]/"FD_\9 M=CMKPY>E<@_X5X&U7QW ?VH.<#25#-=3-'C>=+_N1)'8<,7X765P?!@8^$^' M]/^:I@YD^"# 3!5X44>X25$H,&NW6$L5Y9 IS&1=B*NBO 1L?5\UG!6VI@5% M^U0*/#>=^V)_QRBO&)K^EF%-6V"CEK0L@[C=8 MXQ@V*(KQD (H7 0 1 " 0 !A;&]T+3(P,C$P,3,Q M+GAS9%!+ 0(4 Q0 ( "U@C5(2$=.<.!@ -%@ 0 5 " M =X9 !A;&]T+3(P,C$P,3,Q7V-A;"YX;6Q02P$"% ,4 " M8(U2!\NL MJ2-, 'I@0 %0 @ %),@ 86QO="TR,#(Q,#$S,5]D968N M>&UL4$L! A0#% @ +6"-4GO>V=WHI ^+@) !4 ( ! MGWX &%L;W0M,C R,3 Q,S%?;&%B+GAM;%!+ 0(4 Q0 ( "U@C5(TXJ*@ M9X %0W" 5 " ;HC 0!A;&]T+3(P,C$P,3,Q7W!R92YX M;6Q02P$"% ,4 " M8(U2Y%!X)E64 @#&""0 #@ @ %4 MI $ 9#4V-#8X9#$P:RYH=&U02P$"% ,4 " M8(U2Q"V 2Y0^ !^T@$ M$0 @ '5. 0 9#4V-#8X9&5X,3 S-"YH=&U02P$"% ,4 M" M8(U2UWA2CY@3 69 $0 @ &8=P0 9#4V-#8X9&5X M,3 S-2YH=&U02P$"% ,4 " M8(U2:IR3!O," M#P #P M @ %?BP0 9#4V-#8X9&5X,C$N:'1M4$L! A0#% @ +6"-4L8O7W5" M P ?PD ! ( !?XX$ &0U-C0V.&1E>#(S,2YH=&U02P$" M% ,4 " M8(U2NH 8#W ' !2&@ $ @ 'OD00 9#4V M-#8X9&5X,S$Q+FAT;5!+ 0(4 Q0 ( "U@C5(4Y8=20 < %@8 0 M " 8V9! !D-38T-CAD97@S,3(N:'1M4$L! A0#% @ +6"- M4AM0=WNF! '0X ! ( !^Z $ &0U-C0V.&1E>#,R,2YH M=&U02P$"% ,4 " M8(U2"8[/0I$$ "1#0 $ @ '/ II00 9#4V-#8X9&5X,S(R+FAT;5!+!08 #@ . '@# ".J@0 ! end